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Abstract
Carbohydrates have been heavily exploited in the development of new
therapeutic agents. Extensively utilized in nuclear medicine, derivatives such as
[18F]-FDG (13) have gained broad usage in the diagnosis of malignancies. Displaying
high selectivity and favourable pharmacokinetics, carbohydrates have subsequently
been incorporated into peptide-based imaging agents, producing diagnostic probes with
greatly improved physicochemical properties. The efficient radiolabelling of
glycoconjugate-based imaging agents however represents a significant challenge, with
many glycoconjugates prone to degradation under current radiolabelling conditions.
Compatible techniques such as the copper-assited azide-alkyne cycloaddition
(CuAAC) “click” reaction have found usage in the synthesis of radiolabelled
glycoconjugates, linking [18F]-radiolabelled glycosyl azides to alkyne-containing
peptides. The wider application of this approach in the labelling of glycoconjugates
though has been limited by the incongruity of this process with native amino acids, and
peptides or proteins. In this thesis, a methodology for the synthesis of glycoconjugates
amenable to functionalization by the CuAAC “click” reaction is illustrated.
The concise, 5-step production of glc- and gal-sugar azido acids 60 and 65
allowed for the formation of “clickable” glycoconjugates 66-73 in 64-96% yield, linked
to serine, lysine and α-amino containing (Leu, Met, Gln) amino acids. Possessing
β-azides at the anomeric position, the CuAAC “click” reaction of these with alkyne
donors produced the functionalized glycoconjugates 78-87 in 52-85% yield,
representing the first examples of glycosides linked to an amino acid, and derivatized
using the CuAAC “click reaction. Conjugation of glc-sugar azido acid 60 to the
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tripeptide Ac.KPV.NH2 resulted in the glycoconjugate (88), which may be
functionalized by the CuAAC “click” reaction, thus broadening the scope of this
methodology to the labelling of biologically-relevant substrates.
Extension

of this methodology to

the

formation

of linkages

with

carboxyl-containing amino acids was also investigated, with the key synthon 6-azido-6deoxy-1-amino-2,3,4-tri-O-acetyl-β-D-glucose

hydrobromide

(103)

successfully

produced in 8 steps from 1,2;5,6-diisopropylidene-α-D-glucofuranose (93). Amide
coupling at the anomeric amine of 103 by sidechain carboxyl-containing (Asp, Glu)
amino acids produced the “clickable” glycoconjugates 110 and 111 in 60-70% yield.
Subsequent CuAAC “click” reaction with 4-pentyn-1-ol yielded the functionalized
glycoconjugates 112 and 113 in 62-70% yield, the first examples of functionalized
glycoconjugates formed from carboxyl containing amino acids.
Using 6-p-toluenesulfonyl-1,2,3,4-tetra-O-acetyl-D-glucose (114) as a key
synthon, thioether-linked glycoconjugates bearing an anomeric or 6-azido group were
also evaluated. Alkylation of the anomeric azide 6-iodo-6-deoxy-1,2,3-tri-O-acetyl-β-Dglucosyl azide (117; 40% yield in 3 steps from 114), by the thiol-containing amino acid
(HCys) 120 did not yield the desired glycoconjugate (124). Alternatively, glycosylation
of the HCys derivative 130 by the glycosyl donors 6-azido-6-deoxy-1,2,3,4-tetra-Oacetyl-D-glucose

(125)

and

6-azido-6-deoxy-1,2,3-tri-O-acetyl-α,D-glucosyl

trichloroacetimidate (127) yielded the thioether-linked “clickable” glycoconjugate 131,
however this was present as an anomeric mixture.
Subsequently, an efficient method for the formation of thioether-linked
glycoconjugates utilizing the “click” thiol-ene reaction was developed. The maleimide-
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sugar azido acid conjugate 136 was produced from 60 (66% yield), with “click” thiolene reaction with Fmoc.HCys.OMe (130) producing the functionalized derivative 137
(62% yield). CuAAC “click” reaction resulted in the functionalized thioether-linked
glycoconjugates 138, which together with amide-linked examples demonstrated the
versatility of azidosugars in the formation of functionalizable glycoconjugates.
Beyond “clickable” glycoconjugates, a strategy for the formation of
orthogonally-protected Type A and B “clickable” neoglycopeptides was also developed.
Orthogonal protection of the 4-position of a glc-based glycoside yielded the β-azides
155 and 156 (7 steps). Containing bulky protecting groups (Trt, MMTrt, PMB) though,
the development of a superior atom-economical approach was sought, with subsequent
selective TEMPO/PhI(OAc)2 oxidation of the 2,3-OBz diol 154 producing the
orthogonally-protected sugar azido acid 161 (88% yield). Consequently, amide coupling
(164, 50% yield) and 4-OTBS protection (165, 36% yield) yielded key intermediates for
the production of Types A and B “clickable” neoglycopeptides.
The scope of this strategy was subsequently broadened to those bearing
orthogonal protection at the 3-position. Formation of the 6,3-lactone intermediate 166
from 1-azido-1-deoxy-2,3,4-tri-O-acetyl-β-D-glucuronic acid methyl ester (53) and
nucleophillic ring opening, produced the 3-OH glycoconjugate 169 (42% over 3 steps).
Subsequent 3-OTBS protection (66% yield) yielded the orthogonally protected
derivative 170, which alongside 169 represent key intermediates for the production of
Types A and B “clickable” neoglycopeptides. In conjunction with the developed
“clickable” glycoconjugates, these derivatives provide a solid platform for the broader
utilization of the CuAAC “click” reaction in the formation and functionalization of
bioconjugates encompassing carbohydrates.
xxvii | P a g e
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Chapter 1: Introduction

Chapter 1 : Introduction

1.1 Carbohydrates – Definition and Structural Diversity
Carbohydrates, synonymously known as saccharides, are a structurally rich class
of complex molecules. Comprising carbon, hydrogen and oxygen atoms, carbohydrates
exist in many different forms, ranging from linear non-reducing (ketose) and reducing
(aldose) species (Figure 1.1, A and B) consisting of three to nine carbons, to cyclic
hemiacetal-containing species forming five (pentose - furan) or six (hexose - pyran)
membered ring systems (Figure 1.1, C and D).1

Figure 1.1: Examples of non-reducing (D-fructose, A) and reducing (D-glucose, B) linear
carbohydrates, which in solution cyclize to form furan (C) and pyran (D) glycosides respectively.

Bearing multiple hydroxyl groups, carbohydrates form a variety of structural
isomers. For example, cyclic hexoses such as glucose, mannose, allose, galactose, idose
and talose are structural isomers with the chemical formula C6H12O6, resulting from the
1|Page
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alternating stereochemistry of their hydroxyl groups (Figure 1.2). Some examples such
as glucose (glc) and galactose (gal) can be further classified as epimers of eachother,
with these isomers bearing at only one position of the molecule (e.g. C4 in glc/gal,
Figure 1.2).1 Likewise, isomers may also have epimers at multiple stereocentres, with
mannose (C2), allose (C3) and idose (C5) also epimers of glucose (Figure 1.2)

Figure 1.2: Pyran-based isomers of chemical formula C6H12O6.

Formed by the conversion of linear aldoses to cyclic pentoses and hexoses,
epimers of individual isomers including glucose and galactose, may also be produced.
Occurring at the carbon participating in cyclization (or C1), this is known as the
anomeric carbon, with epimers at this position specifically known as anomers.1,2
Differing in the configuration of the proton linked to the anomeric carbon, the
stereochemical assignment of a glycoside is directly relative to its absolute
configuration. In hexose sugars such as D-glucose, the stereochemistry of both the C1
and C5 carbon defines the assignment, with an axial proton at the C5 and an equatorial
proton at the C1 denoting an α-anomer, whilst axial proton at both C1 and C5 carbons
denote a β-anomer.2 The anomeric configuration of many carbohydrates is of great

2|Page

Chapter 1: Introduction

importance, as many carbohydrates exist as multimers of individual saccharides,
including di-, tri-, tetra- and oligosaccharides.3 This can produce isomers of saccharides
conjugated to each other at the same position, such as maltose and cellobiose, which
represent α- and β-isomers of a (1→4) linked disaccharide respectively.2 Additionally,
saccharides can form linkages at a variety of different positions and can also form
glycosidic linkages with a number of different C-, O-, S- and N-acceptors. Hence,
considering the array of structural permutations that carbohydrates may embody, it is of
little surprise that carbohydrates are amongst the most analysed chemical entities, with
their roles in biological systems widely studied.3,4

1.2 Roles of Carbohydrates in Biological Systems
1.2.1 Structural Roles of Carbohydrates
The structural diversity of carbohydrates underlies their importance in a number
of biological functions. Generally speaking, these roles can be divided into three main
categories – structural; cellular signalling and recognition; and energy usage
metabolism.5 In plant, algal, fungal and bacterial species, polysaccharides play an
important role in maintaining cellular structure.6 In green plants and algae, the β(1->4)
glucose polysaccharide cellulose (Figure 1.3, 1) forms a key component of the cell wall,
with chains of cellulose forming large hydrogen bonding networks that provide strength
and stability.7,8 These fibrils of cellulose are often reinforced with other polysaccharide
units, including pectins (Figure 1.3, 2), which are rich in poly-galacturonic acids, and
hemicelluloses such as xylan, which are rich in D-xylose and pentose glycosides. 6,9
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In fungi, their cell walls consists of the β(1->4)-linked N-acetyl-D-glucosamine
polysaccharide chitin (Figure 1.3, 3).10 Aligned in fibrils akin to cellulose, chitin
provides many fungi with strength and flexibility. Interestingly, chitin is also present in
the shells and exoskeletons of many arthropods - including crustacea and insects,11 with
crosslinking by calcium species (primarily CaCO3) in these structures producing chitin
that is much harder and stronger than that in fungal species.10,12 In bacterial species,
peptidoglycan (or murien) forms the principle component of the organism’s cell wall. 13
Consisting of polymeric residues of N-acetylglucosamine and N-acetylmuramic acid
(NAM), peptide chains linked to NAM residues allow for inter-strand cross-linking,
producing a matrix that maintains the strength of the cell wall (Figure 1.3, 4).13

Figure 1.3: Cellulose (1), xylan (2), chitin (3) and murein (4) – important polysaccharides that
maintain the cellular structure of plant (A), algal (B), fungal (C) and bacterial (D) species.14–16

4|Page

Chapter 1: Introduction

In mammalian species, the extracellular matrix that lies between individual cells
is composed of a variety of different glycosylaminoglycans (GAG’s), including
hyaluronic acid and chondroitin sulphate, in addition to dermatan sulphate and keratan
sulphate.3,17 These negatively charged unbranched polysaccharides are constituents of
proteoglycans, core proteins that are heavily glycosylated with polysaccharides.6,18
GAG’s display an uncanny ability to coordinate water molecules, producing a matrix
that can compress and flex when pressure is applied to them.6 Displaying such
flexibility, it is of no surprise that GAG’s form the basis for tissues under constant
loading and stress, including bone cartilage.6,19,20

1.2.2 Carbohydrates in Cellular Signalling, Recognition and Growth
Many carbohydrate-bearing entities hold key positions in the mediation of cellcell recognition processes.21 Glycoconjugates are species where one or multiple
glycosides are linked to a biological molecule via a glycosidic bond, 22 such as
glycoproteins and glycolipids, which are the most abundant forms of glycoconjugates
found in nature.23 Linked to one or multiple glycans (short oligosaccharides of
~3-9 units), glycoproteins play important roles in a number of cellular functions,
including the lubrication and protection of epithelial tissues,24 immunological responses
and defences, cell-cell attachment, and cellular growth and development.25–28

Mucins, a class of 19 highly glycosylated glycoproteins secreted on the surfaces
of epithelial cells, form a major constituent of important bodily lubricants such as saliva
and mucous.29 High in molecular weight (~250-500 kDa), mucins are composed of
oligosaccharide chains attached via O-linked amino acid residues including serine and
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threonine, and to a lesser degree via N-linked asparagine residues.24,29 Mucins are
integral to the body’s defence against external pathogens and key to their role is their
capacity for gelation, whereby they can expand and coat cell surfaces, providing a
physical barrier that both lubricates and protects the cell from pathogens.24,29

Immunoglobins, large Y-shaped proteins that are produced by the immune
system (B cells) to detect and nullify potential pathogens, utilize carbohydrates in their
protective functions.30 Containing two light and heavy polypeptide chains across two
regions (Fab and Fc), the Fc region of an antibody interacts with the Fc receptor of
immune cells - including B lymphocytes, natural killer cells and antigen presenting
cells, eliciting an immune response (Figure 1.4, A), with glycosylation of the Fc region
by D-fucose, in addition to N-acetylglucosamine and neuraminic acid residues essential
for immune activity (Figure 1.4, A).30–32 In contrast, the Fab region of an antibody binds
to a number of different antigens (including pathogens), stimulating an immune
response upon immune cell attachment. Once again glycosylation is important, with the
Fab regions of many natural antibodies having affinity for the disaccharide motif
Gal-(α 1->3)-Gal expressed in a number of bacteria and enveloped viruses, thereby
providing immunity against such pathogens and protecting cells from infection
(Figure 1.4, A).33,34

Interestingly, many pathogens also exploit the carbohydrate binding affinity of
cell surface proteins to avoid detection by the immune system, using cell surface
proteins that bind specific carbohydrate motifs, known as lectins.6 The influenza viral
envelope is coated with membrane-bound glycoproteins including haemagglutinin and
neuraminidase that are crucial in viral entry and propagation (Figure 1.4, B).35,36
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Displaying a high affinity for neuraminic acid residues on the exterior of cell-surface
membranes, influenza haemagglutinin binds to these residues, bringing the viral
envelope within close proximity of a host cell (Figure 1.4, B). Membrane fusion with
the viral envelope induces endocytosis, resulting in viral uptake. Following viral
replication, neuraminidases present on the surface of newly produced virions aid in their
expulsion from the cell. Targeting neuraminic acid residues bound to hemagglutinin and
other cell-surface glycoproteins, cleavage of these residues by neuraminidase triggers
exocytosis, resulting in the release of viral particles that may infect other host cells.37,38

Figure 1.4: Roles of carbohydrate-bearing macromolecules in cellular signaling, recognition and
growth. A: Ig binds disaccharide (Gal(α1->3)Gal) antigens (Fab region) and requires glycosylation
to bind pathogens (Fc region), B: Influenza viruses utilize carbohydrate-binding glycoproteins
hemagglutinin and neuraminidase for viral entry and release. 39

Neuraminic acid residues are also key mediators of cell turnover, coating the
outer surface of red blood cells (RBCs)40,41 and other cells present in the circulatory
system (thrombocytes, leukocytes and hepatocytes, etc.).42–44 Cleavage of these residues
either by serum neuraminidases or by chemical hydrolysis, unmasks galactose residues
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underneath the neuraminic acid. As a marker of cellular aging, these residues attract the
attention of macrophages, which attach to the cells at these residues and subsequently
induce

phagocytosis

(Figure 1.5, A).45,46

Additionally

to

cellular

clearance,

carbohydrates also play important roles in cellular growth, with glycoprotein hormones
such as erythropoietin (EPO) pivotal to the production of red blood cells.47 Heavily
glycosylated with branched saccharide chains, these chains stabilize the protein
structure of EPO, allowing it to bind to the erythropoietin receptor and stimulate the
growth of red blood cells in the bone marrow (Figure 1.5, B).47

Figure 1.5: Roles of carbohydrates in cellular turnover and growth. A – Induction of phagocytosis
of red blood cells (RBCs) following cleavage of neuraminic acid residues from the cell surface.
B - Structure of erythropoietin, bearing heavily glycosylated chains provide structural stability. 48

1.2.3 Carbohydrates in Energy Usage, Storage and Metabolism
The central role of carbohydrates in the regulation of cell structure, recognition
and protection, is matched by their importance in the production and storage of energy.
Glycolysis, a key metabolic process that exists in all organisms, converts glycosides
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into the metabolite pyruvate (Scheme 1.1).5 Enzymatically driven and readily occurring
in the cytosol of cells, glycolysis directly produces two molecules of adenosine
triphosphate (ATP) and reduced nicotinamide adenine dinucleotide (NADH).5

Scheme 1.1: Glycolysis, a key metabolic pathway in the production of free energy from
carbohydrates.5

Both high energy coenzyme molecules, ATP and NADH are the main providers
of chemical energy within a cell.5 In addition, pyruvate molecules produced as a byproduct of glycolysis can be directly fed into the tricarboxylic acid (TCA) cycle in
aerobic organisms, which following enzymatic conversion to oxaloacetate and citrate,
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(in addition to other key intermediate molecules) results in the production of an
additional ~34 molecules of ATP per hexose sugar consumed. Hence the utilization of
carbohydrates provides the most readily accessible source of energy to cells.49,50
In the absence of available glucose, proteins and lipids may also be converted to
glucose in order to meet energy requirements via gluconeogenesis. However, the
catabolism of lipid and protein reserves is energy intensive, with the production of
glucose from these sources resulting in a 33% decrease in available energy.51 Therefore,
a readily accessible stored form of glucose, known as glycogen is utilized. Glycogen,
which is present in muscle tissue and the liver as a network of branched glucose
polysaccharides, is readily formed by the action of the enzyme glycogen synthase.5 In
times of high blood glucose (e.g., postprandial), glycogen synthase can store glucose as
glycogen via chain addition (Scheme 1.2). In contrast, glycogenolysis – the breakdown
of glycogen, can be enacted by the enzyme glycogen phosphorylase, liberating glucose
to curtail low blood glucose levels (Scheme 1.2).5 It is this enzyme in addition to the
hormones insulin and glucagon that modulate the secretion, storage and concentration of
blood glucose.5

Scheme 1.2: Pathways for the production and storage of free glucose, highlighting its production
via gluconeogenesis or glycogenolysis, or its storage as the polysaccharide glycogen. 5
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Beyond the production of free energy from the metabolism of glucose,
carbohydrates play key roles in other metabolic functions. Processes such as xenobiotic
metabolism utilize glucuronidation in the breakdown and excretion of substances that
are foreign to an organism.52,53 The 6-carboxyl derivative of glucose, glucuronic acid is
conjugated to xenobiotic substances in the liver that have been processed by Phase I
metabolism, with glucuronidation representing the most common detoxifying
transformation that takes place under Phase II metabolism (Scheme 1.3).54 Ionisable at
physiological pH, substitution of molecules linked to glucuronic acid following reaction
with uridine diphosphate glucuronate - a carrier of glucuronic acid, produces
metabolites that are significantly more polar, allowing for their excretion in urine or
bile.55 The importance of this process is exemplified in drug metabolism, where the rate
of clearance may have a pronounced influence on the effectiveness of a dosage.53,55

Scheme 1.3: Xenobiotic metabolism, a key process in the metabolism and removal of foreign
substances, including pharmacologically active species.53
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1.3 Carbohydrates in Medicinal Chemistry
The integral role of carbohydrates in such a vast array of biological systems has
attracted the attention of researchers keen to exploit their therapeutic potential. Whilst
beyond the scope of the current discussion, the range of conditions and diseases that are
targeted by carbohydrate-based or containing entities is truly diverse (Figure 1.6). These
range from aminoglycoside and glycopeptide antibiotics such as streptomycin and
vancomycin (5 and 6)56–58 through to cardiac glycosides for the treatment of heart
failure such as digoxin,59 and glycosidase inhibitors for the treatment of influenza (e.g.
Zanamivir (Relenza ®)60 7 and Oseltamivir (Tamiflu

®

(8))

61

and also for diabetes

(e.g. Miglitol (9) and Voglibose (10)).62,63

Figure 1.6: Carbohydrate-based therapeutic agents used as antibiotics (5 and 6), and in the
treatment of influenza (7 and 8) and diabetes (9 and 10).
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In addition to treating the above conditions, carbohydrate-containing species
have also displayed potential in the treatment of a number of malignancies, targeting
glycoproteins upregulated by metastatic cells. Many of these play important roles in
cellular structure and growth, with examples such as the heparan sulphate mimetic
PI-88 (Muparfostat, 11) that inhibits angiogenesis, reaching phase III clinical trials for
the treatment of post-resectional hepatocellular carcinoma (Figure 1.7).64,65

Figure 1.7: Heparan sulphate mimetic PI-88 (11) and pentavalent conjugate vaccine 12, bearing
antigens for tumour-upregulated glycoproteins (MUC-1 – Tn, TF, STn), glycolipids (Globo-H) and
gangliosides (GM2), agents under evaluation for their treatment of malignancies.
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Furthermore, a number of other heavily glycosylated glycoproteins are overexpressed in tumour cells, including a number of mucins.66 MUC-1 is a mucin
glycoprotein that is bound to the apical surface of epithelial cells present in the tissues
of the lungs, stomach and intestines, and represents an excellent tumour marker, with
the targeting of mucins and other markers using tumour associated carbohydrate
antigens (TACAs) representing a promising strategy towards the development of new
anticancer vaccines.66–68 A number of vaccines bearing these antigens have been
developed, with many bearing multiple carbohydrate-based antigens targeting MUC-1
(e.g Tn, TF and STn). Additionally, many of these vaccines also target glycolipids (e.g
Globo-H),

glycophospholipids

and gangliosides (e.g, GM2), which

are

also

overexpressed on the surfaces of a range of cells.68 This work has been pioneered by
Danishefsky and co-workers, who have developed a number of mono, tri and
pentavalent cancer vaccines.69,70 Linked to an immunogenic protein such as keyhole
lymphet haemocyanin (KLH),71 pentavalent vaccines such as 12 (Figure 1.7) have
displayed great promise in providing targeted, selective treatment to specific metastases,
reaching Phase I clinical trials.69,70

1.4 Carbohydrates in Nuclear Imaging
Whilst carbohydrate-based medicines have been developed for the treatment of a
variety of different illnesses, their greatest impact has been in the diagnosis of a number
of different malignancies. In Australia, cancer is a leading cause of mortality and
morbidity accounting for around 30% of deaths in 2011, with approximately 1 in 2 men,
and 1 in 3 women expected to be diagnosed with cancer by the age of 85.72 However,
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whilst a major cause of death in Australia, the actual rate of morbidity from cancer has
decreased over the last thirty years, with 16% fewer people dying from cancer today as
opposed to thirty years ago.72 The survival rate for sufferers of the most common
cancers has also improved dramatically, with 30% more people surviving cancer than
twenty years ago, and the survival rate for sufferers five years after diagnosis rising
by 60%.72 Beyond the development of new and improved cancer therapies, the
improvement in cancer survival can be attributed to three main factors:


A push towards earlier detection of malignancies



The development of tumour-targeting diagnostic probes/imaging agents



More accurate means of detecting malignancies (PET/SPECT)
Greater public awareness of the warning signs and symptoms of particular

cancer types have dramatically decreased the time between occurrence and diagnosis,
resulting in the treatment of cancer in the early stages and limiting the spread and
proliferation of tumours to other tissues.72 However, it can be equally said that the
development of new molecular probes that specifically target tumours has had a
profound impact on the diagnosis of malignancies.73 Incorporating radionuclides linked
to a probe that targets specific features of different malignancies, these probes are
delivered to, and accumulate in the targeted tumour.73 When coupled with techniques
that quantify the radiation emitted by the attached radionuclide, such as Positron
Emission Tomography (PET) or Single Photon Emission Computerized Tomography
(SPECT),74,75 the use of diagnostic probes provides an accurate 3D depiction of the size,
shape and distribution of metastases, allowing for their treatment or removal.76
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1.4.1 18F-Fluorodeoxyglucose ([18F]-FDG)
Of the diagnostic probes developed over the last 40 years, the radiolabelled
glucose derivative [18F]-fluorodeoxyglucose ([18F]-FDG, 13, Figure 1.11) is by far the
most widely used and regarded, revolutionizing the diagnosis of metastatic tumours.77
First described in 1969,78 and developed for nuclear imaging in 1976 at the Brookhaven
National Laboratory,79 [18F]-FDG is fluorinated at the 2-position with radioactive
fluorine-18 (T1/2 = 109 minutes), a positron-emitting radionuclide.80 Taken up by tissues
that maintain a high rate of glucose metabolism, the 2-fluoro group prevents the initial
metabolism by glycolysis, with eventual radioactive decay of fluorine-18 to oxygen-18
allowing for the fast metabolism and clearance of 13 identical to that of naturally
occurring hexoses.81 As metastatic tissues require high quantities of glucose to maintain
their growth, and [18F]-FDG is not metabolised until radioactive decay occurs, the
localization of [18F]-FDG in these tissues ensues. Using PET/SPECT methods, contrast
differences of tissues containing [18F]-FDG to those that don’t (signal to noise ratio) are
quantified to highlight the presence of high glucose-metabolizing tissues, which are
subsequently used to diagnose the presence of malignancies (Scheme 1.4).81

Scheme 1.4: Injection of [18F]FDG into a patient and analysis using Positron Emission Tomography
(PET), allowing for the 3D visualization of the size, shape and distribution of malignancies.
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Whilst the use of [18F]-FDG has significantly improved the diagnosis of a
number of cancer types, for some its use has been rather problematic. As [18F]-FDG
exploits the high glucose metabolism of metastatic tissues, a lack of target selectivity
has been encountered, with this phenomenon primarily observed in tissues that would
normally exhibit a high rate of glucose metabolism.82 This particularly relates to
neuroendocrine tumours of the brain,83,84 gastrointestinal tract85 and pancreas,86 where
the presence of metastatic tissues in close proximity to naturally high glucosemetabolizing tissues has made accurate diagnosis difficult, leading in some cases to
false positives and misdiagnosis.85 Though the use of [18F]-FDG in the diagnosis of
metastases at these sites still bears some clinical significance, efforts have been made to
develop more selective means of tumour diagnosis in these tissues.87

1.4.2 Peptide Imaging Agents
In addition to the exploitation of high glucose metabolism by [ 18F]-FDG in the
diagnosis of malignancies, a large number of non-carbohydrate imaging agents have
also been developed.87 Accompanying the upregulation of cell surface glycans in
tumour cells, a number of different cell-membrane receptors are also upregulated that
promote tumour growth and proliferation.87 Appearing in much larger numbers in
tumour cells compared to healthy cells, these receptors represent good diagnostic
markers for defining the presence and spread of malignancies.87 Consequently, a
number of peptide imaging agents have been developed that target receptors associated
with one or multiple forms of cancer.88 These peptides include mimetics of the
endogenous peptides somatostatin,89,90 α-melanocortin stimulating hormone (α-MSH)91
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and neuropeptide-Y,92 which are associated with, and whose receptors are upregulated
in neuroendocrine, skin and breast cancers respectively (Table 1.1, Entries 1-3).

Table 1.1: Native peptides upregulated in various cancers and their mimics used as diagnostic
probes in nuclear imaging.88

Native Peptide

Tumour/Cancer Type

Probes

Somatostatin

Neuroendocrine, melanoma, breast

Octreoscan®

α-MSH

Melanoma

[111In]DOTA-NAPamide

Neuropeptide Y

Breast

(Cu/DOTA)4]BVD-15

Bombesin/GRP

Lung, colon, glioblastoma, prostate

[99mTc]Bombesin

These

also

include

derivatives

of

exogenous

peptides

such

as

Bombesin (Table 1.1, Entry 4), which is derived from the toad Bombina bombina.93 A
homologue of the mammalian Gastrin-releasing Peptide (GRP), Bombesin binds to
GRP receptors, which are overexpressed in lung, colon and prostate cancer.94,95 Peptide
imaging agents targeting overexpressed receptors have been highly beneficial as
diagnostic tools. Radiolabelled cyclic peptides imcluding

In-111-Octreotide

(Octreoscan®, Mallinckrodt), an octapeptide derivative of somatostatin-14 that shows
high affinity for somatostatin receptors (sst) upregulated in neuroendocrine tumours, has
found broad clinical use.96 However, despite such promise the clinical utility of these
imaging agents has been fraught with a number of challenges. A common problem
encountered with their use is in vivo degradation, with many peptide imaging agents
susceptible to the actions of intracellular proteases.73 Additionally, the reabsorption of
small peptides by glomerular filtration in the kidneys often limits the quantity of
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radiotracer that reaches the desired target, thereby exposing the kidneys to potential
nephrotoxicity, and large doses of radiation.97 Finally, if the utilized imaging agent does
indeed reach the desired target they often suffer from poor tumour retention, which has
the effect of reducing the quality of the diagnostic scan performed by reducing the
signal to noise ratio.98 Considering these issues, in addition to those encountered in the
use of [18F]-FDG, it is evident that their problems with both selectivity and clearance
are balanced by their opposing properties. The high selectivity for metastatic tissues
possessed by peptide imaging agents, in addition to the high tumour retention and
clearance exhibited by [18F]-FDG together impart properties that would be ideal for a
diagnostic agent. Thus, a number of researchers have worked to develop strategies that
would combine these properties of peptide imaging agents and [18F]-FDG.

1.4.3 Glycoconjugation – Improving the Pharmacokinetics of Peptide
Imaging Agents
1.4.3.1 Iodine-125 Radiolabelled Imaging Agents
As a result of their complimentary properties, a number of carbohydratecontaining peptide imaging agents have been developed. These include cyclic
glycoconjugates bearing the peptide motif RGD (Arg-Gly-Asp), that display a high
affinity for the αvβ3 integrin.99 A heterodimeric transmembrane glycoprotein that
mediates cell to cell matrix interactions, αvβ3 is upregulated in metastatic tissues and is
an important mediator of tumour invasion and angiogenesis.100 Initial derivatives of
RGD developed by Wester and co-workers incorporated a cyclic pentapeptide also
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bearing (Lys; K) and tyrosine (Tyr; Y) residues, with the presence of a sugar on the
sidechain εNH2 of the lysine modulating the peptides’ lipophilicity.99 The presence of
the tyrosine residue allowed for radioiodination with iodine-125, producing the
radiolabelled glycosylated RGD derivative 14 (Figure 1.8).99

Figure 1.8: Iodine-125 radiolabelled glycoconjugate imaging agents, based on the cyclo-RGD (14)
and octreotide (15 and 16) peptide scaffolds.99,101–104

The marked reduction in lipophilicity of 14 compared to the non-glycosylated
derivatives inspired the translation of this approach to other diagnostically relevant
peptides. This is demonstrated by the [125I]-labelled derivatives 15 and 16, and the
maltotriose-containing derivative 17, which incorporate the octapeptide somatostatin
derivative Octreotide (Figure 1.8).102 Whilst the lipophilicity of αvβ3 and sst-targeting
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imaging agents 14-17 has been significantly decreased by glycosylation, the use of
iodine-125 as a radionuclide for labelling in these examples limits their usability, with
the long-half life (T1/2 = 59.4 days) and requirement of a tyrosine residue for
introduction being limiting factors.105

1.4.3.2 Fluorine-18 Radiolabelled Imaging Agents
To overcome these hurdles, Wester and co-workers developed a strategy that
allowed for the glycosylation and radiolabelling of peptides with fluorine-18106.
Utilizing a galacturonic acid-derivative linked via the terminal lysine NH2 of the cyclic
peptide (-RGDFK-), acylation with p-nitrophenyl-2-[18F]fluoropropionate ([18F]-NPFP)
resulted in the [18F]-radiolabelled glycoconjugate 18, which is more commonly known
as [18F]GalactoRGD (Figure 1.9).99,107–109 Radiolabelled on the carbohydrate as opposed
to the peptide chain, the shorter half-life of fluorine-18 has led to an increase in the
translation of cyclic-RGD derivatives to the clinic, with [18F]GalactoRGD considered
the “gold standard” for the detection and diagnosis of angiogenesis.108 Furthermore, the
use of the 2-[18F]fluoropropionate method essentially allows for the introduction of
fluorine-18 at any site bearing a free amino group. As a direct result of the success of
[18F]GalactoRGD, p-nitrophenyl-2-[2-[18F]fluoropropionate has also been used to
introduce fluorine-18 into octreotide derivatives, resulting in the [18F]-radiolabelled
derivative 19 (Figure 1.9).76
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Figure 1.9: Fluorine-18 radiolabelled imaging agents 18 and 19 based on the cyclo-RGD and
octreotide peptide scaffolds, with both agents glycosylated and labelled at lysine. 76,109

1.4.3.3 Alternative Methods for the Introduction of Fluorine-18
A variety of different radiofluorination methods exist in addition to the use of
p-nitrophenyl-2-[18F]fluoropropionate (20). For the introduction of fluorine-18 into
derivatives such as 18 and 19, this includes the use of different prosthetic groups (akin
to [18F]-NPFP), and electrophilic and nucleophilic fluorination methods.110 Introducing
a fluorine-18 atom to a respective amine through acylation, the actions of [ 18F]-NPFP
have been mirrored by other [18F]-bearing prosthetic groups, such as N-succinimidyl-4[18F]fluorobenzoate ([18F]-SFB; Figure 1.10, 21). Additionally, prosthetic groups that
label via a different ligation method have also been used, with imidation and alkylation
by

3-[18F]fluoro-5-nitrobenzimidate

([18F]-NFB;

Figure

1.10,

22)

4-[18F]fluorophenacyl bromide ([18F]-FPB; Figure 1.10, 23) are also common.77,106
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Figure 1.10: [18F]-Containing prosthetic groups utilized in the synthesis of 18F-radiolabelled probes.106

The exploitation of these prosthetic groups and their respective conjugative
techniques provides a means for utilizing fluorine-18 in the radiolabelling of peptides
and proteins. However, a major disadvantage of these methods is their synthetic
complexity, with the prosthetic groups described requiring numerous synthetic steps and
long reaction times for their production. Often, these factors result in the isolation of
prosthetic groups containing fluorine-18 in yields much lower than what could be
expected based on the initial amount of radionuclide available, which is also known as
radiochemical yield (Table 1.2).106 Additionally, bar a small number of examples,111–113
the use of nucleophilic and electrophilic radiofluorination methods have largely been
avoided in the development of radiofluorinated peptides. The diversity of reactive
groups present on a peptide limit the use of nucleophilic radiofluorination methods, with
electrophilic radiofluorination also limited by the need for the use of carriers with
agents such as [18F]-F2.106
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Table 1.2: Efficiency of prosthetic groups commonly used in the radiolabelling of peptides and
glycoconjugates with fluorine-18.106

18

# Steps

Time
(min)

RCY(%)

4-nitrophenyl-2-[18F]fluoropropionate

3

90

60

N-succinimidyl-4-[18F]fluorobenzoate

3

30-35

18

Imidation

3- [18F]fluoro-5-nitrobenzimidate

3

45

20-33

Alkylation

4- [18F]fluorophenacyl bromide

3

75

28-40

N-(p-[18F]fluorophenyl)maleimide

4

100

15

Method

Acylation

F Labelling Agent

Hence, considerable research has been undertaken into the further development
of more efficient labelling methods for glycopeptide imaging agents. One method that
has emerged is the labelling of peptides using [18F]-5-fluoro-5-deoxyribose ([18F]-FDR,
24) through oxime linkages. Developed by Xiang-Guo Li and David O’Hagan from the
University of St Andrews, [18F]-FDR is synthesised from a tosylated, protected
furanoside by nucleophilic radiofluorination and deprotection (Scheme 1.5).114 Isolated
in high purity, 24 can be incorporated into peptides bearing an oxime via furan ring
opening, with 95% conversion of 24 to an oxime-linked 18F-radiolabelled glycopeptide
observed (Scheme 1.5).114 Directly labelling the glycoside used prior to peptide
conjugation, this method provides an alternative to the use of prosthetic groups, limiting
the exposure of the radiolabelled glycoconjugate to harsh reaction conditions. One issue
that remains with this method though is the potential formation of cis and trans (E/Z)
isomers from peptide conjugation, a result of labelling via ring opening at the anomeric
carbon of 24.115,116 A relatively minor issue though, the promise of this strategy has
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supported its wider usage in the fluorine-18 radiolabelling of peptides. Beyond this
example though, significant attention is still being paid to approaches that could be
utilized in tthe production radiolabelled glycoconjugates encompassing fluorine-18 and
other radiolabels commonly used in nuclear medicine.

Scheme 1.5: Oxime-linkage method for the synthesis of 18F-radiolabelled glycoconjugates developed
by Li and O’Hagan.114–116
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1.5 The Copper Assisted Azide-Alkyne [3 + 2] Huisgen
Cycloaddition (CuAAC).
1.5.1 Background and Mechanism
One method that has been widely exploited for its labelling potential is the
copper-assisted azide-alkyne [3 + 2] cycloaddition (CuAAC). Initially reported
seperately in 2001 by the groups of Barry Sharpless and Valery Folkin from the Scripps
Research Institute, and Morten Meldal from the Carlsberg Laboratory,117–119 the CuAAC
reaction builds on the Huisgen 1,3-dipolar cycloaddition developed by Rolf Huisgen in
1961 to produce 1,2,3-triazoles from azide and alkyne precursors.120 The catalysis of
this reaction by Cu(I) species results in the selective production of 1,2,3-triazoles
bearing a 1,4-substitution pattern (Scheme 1.6), allowing for the preparation of complex
molecules from fairly simple synthons. The CuAAC reaction is often discussed
alongside other modular ligation methods, with this field of reactions referred to
collectively as “click chemistry”. Subsequently, as the CuAAC is the most popular of
these reactions, it is often described as the quintessential “click” reaction.117

Scheme 1.6: Regioselective comparison of the Huisgen 1,3-dipolar azide-alkyne cycloaddition to the
copper-assisted and ruthenium-assisted azide-alkyne cycloadditions (CuAAC and RuAAC). 118,120,121
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Mechanistically, metallation of an alkyne by Cu(I) ions, results in the Cu-alkyne
intermediate A and the release of a proton (Scheme 1.7). Next, the dissociation of
ligands associated with the Cu(I) ion (not shown) and secondary metallation of an
azide-bearing group to the copper ion via the proximal nitrogen of the azide, result in
the formation of the alkyne-Cu-azide intermediate B (Scheme 1.7). Within close
proximity to each other, the distal nitrogen of the azide group of B undergoes
intramolecular attack of the distal carbon (C2) of the alkyne, resulting in the unusual
six-membered ring intermediate C (Scheme 1.7). Under immense steric strain, a
rearrangement occurs whereby the six-membered ring undergoes ring contraction,
resulting in a 5-membered triazole ring with the Cu(I) bound to the 5-position (D,
Scheme 1.7). Subsequently, exchange between the Cu(I) ion and a proton results in the
formation of a 1,4-substituted-1,2,3-triazole, with recycling of the Cu(I) species into the
catalytic cycle allowing for the propagation of the reaction (Scheme 1.7).122
Alternatively to the CuAAC reaction, the selective formation of 1,5-substituted1,2,3-triazoles

may

also

be

achieved,

with

ruthenium

such as pentamethylcyclopentadienylbis(triphenylphosphine)ruthenium(II)

complexes
chloride

[Cp*RuCl(PPh3)2].121 This variation of the Huisgen 1,3-dipolar cycloaddition is known
as the ruthenium-catalysed azide-alkyne cycloaddition (RuAAC, Scheme 1.6).121 The
rate-limiting steps in both the CuAAC and RuAAC reactions are the specific formation
of the triazole ring, with the transformation of 6-membered energetically unfavourable
metallocycles resulting in a significant increase in reaction kinetics compared to the
Huisgen 1,3-dipolar cycloaddition. In particular, the CuAAC reaction experiences a 107
to 108-fold increase in the overall rate of reaction at room temperature compared to the
uncatalysed reaction.122 Considering that the CuAAC “click” reaction utilizes a catalytic
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quantity of Cu(I) ions, and is susceptible to further rate enhancements through the
modulation of catalyst loading (1-10%) and temperature, the CuAAC “click” reaction
represents a flexible, efficient and quick method for the conjugation of different
chemical entities.122

Scheme 1.7: Proposed mechanism for the formation of 1,4-substituted-1,2,3-triazoles via the
CuAAC “click” reaction.122

1.5.2 Utilization of the CuAAC “Click” Reaction with Carbohydrates
As a result of the convenience of the CuAAC “click” reaction in the conjugation
of small molecules, its use in the development of new carbohydrate-containing entities
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has been extensive.123–125 Azides are widely used in carbohydrate chemistry, with the
first examples of glycosyl azides (glycosides bearing azides at the anomeric position)
produced in 1930, pre-dating both the discovery of the CuAAC “click” reaction and the
Huisgen 1,3-dipolar cycloaddition.126 Subsequently, glycosyl azides comprise the bulk
of the literature utilizing the CuAAC “click” reaction in carbohydrate chemistry, with
their ease of access through anomeric azidonation allowing for their efficient
derivatization with a plethora of alkyne-containing molecules.127 The ability to
efficiently produce diverse libraries has supported their use in medicinal chemistry,
where the utility of this reaction has enabled the production of diverse libraries of
biologically active compounds. This has been illustrated previously by those such as
Poulsen and co-workers, who successfully demonstrated the utility of the CuAAC
“click” reaction in the generation of multiple libraries of sulphonamide-containing
glycoconjugates.128–130 Utilizing CuSO4 and sodium ascorbate to generate Cu(I) from
Cu(II) in situ for catalysis of the “click” reaction, the synthesised glycoconjugates
inhibit

cancer-associated

carbonic

anhydrase

(CA)

enzymes

at

nanomolar

concentrations (Scheme 1.8).128,129

Scheme 1.8: Synthesis of carbonic anhydrase inhibitors by Poulsen and co-workers, utilizing the
CuAAC “click” reaction.128–130

29 | P a g e

Chapter 1: Introduction

Moreover, the use of glycosyl azides and the CuAAC “click” reaction has been
investigated in the development of new glycoconjugation methods with biologically
relevant molecules, including amino acids. Rutjes and co-workers have illustrated the
versatility of glycoconjugates in mimicking linkages found in nature. Linking glycosyl
azide (25) and alkyne-containing amino acids/dipeptides together using the CuAAC
“click” reaction, they have produced triazole-linked glycosylamino acids and
glycopeptides such as 26 (Scheme 1.9).131 Alternatively, triazole-linked glycosylamino
acids utilizing glycosides bearing C-linked alkynes at the anomeric centre have also
been developed. These include the α- and β-acetylenic glucose derivatives 27 and 28,
which were linked to azide-bearing amino acids to produce the triazole-linked
glycosylamino acids 29-32 (Scheme 1.9).131

Scheme 1.9: Synthesis of triazole-containing glycosylamino acids via the CuAAC “click” reaction.131

In addition to these methods that utilize carbohydrates bearing azides or alkynes
directly conjugated to the sugar backbone, a number of examples have been produced
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where these moieties are linked to a respective carbohydrate via a prosthetic group. This
ligation strategy has found particular use in cellular imaging, where glycosides may be
fed to an organism (or cells) and subsequently expressed in cell surface
glycoproteins.132 This work has been pioneered by Carolyn Bertozzi and co-workers,
who have utilized acetylated mannosamine derivatives bearing a 2-linked pentynoyl
group (such as 33) to label Chinese hamster ovary (CHO) cells.133 Taken up by these
cells and converted to alkynylneuraminic acid, these alkynyl-containing species are
incorporated into cell-surface glycoproteins (Scheme 1.10). When cells bearing these
groups are washed with Cu(I) species, a chelating ligand that specifically stabilizes the
Cu(I) oxidation state (TBTA, Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine) and
an azide-bearing fluorescein, the CuAAC “click” reaction ensues. This reaction
produces cells labelled by triazole-linked fluorosceins, that can be visualized using
fluorescence microscopy (Scheme 1.10).133

Scheme 1.10: In vivo CuAAC “click” reaction of Chinese hamster ovary (CHO) cells fed 33,
allowing for their visualization under fluorescence microscopy. 133
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A consideration in the usage of this method, is the impact of Cu toxicity to the
organism, resulting from the potential generation of reactive oxygen species (ROS).134
Accordingly, methods that limit the need for the use of copper catalysis in the formation
of triazoles have been investigated, with the most well known utilizing strained alkynes
in the formation of triazole-linked glycoconjugates. Again pioneered by Carolyn
Bertozzi and co-workers, this approach has been widely used in the labelling of cell
surface glycoproteins.135 The utility of these synthons is exemplified by the work of
Kevin Brindle and co-workers at the University of Cambridge, who have used a strainpromoted “click” approach to label mouse tumour cells.136 Following the injection of a
galactosamine derivative bearing an azide group into live mice, incubation of the mice
and cellular uptake of the probe, resulted in incorporation and externalization of it in
cell-surface glycoproteins.136 Subsequent injection of a strained cyclooctyne derivative
resulted in Cu-free triazole formation, which upon further conjugation allowed for the
visualization of labelled tumour cells by fluorescence microscopy (Scheme 1.11).136

Scheme 1.11: In vivo strain-promoted Cu-free “click” reaction of mouse tumour cells fed an
azidogalactosamine, allowing for their visualization under fluorescence microscopy. 136
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1.5.3 Fluorine-18 Labelling of Carbohydrates utilizing the CuAAC
“Click” Reaction
Based on the utility of the CuAAC “click” reaction in the synthesis of
glycoconjugates, the potential of this method to develop biologically-relevant probes
labelled with fluorine-18 has been evaluated. Initial work in this area by Kim and
co-workers focussed on the production of 18F-radiolabelled derivatives of D-glucose.137
Starting from 2,3,4,6-tetra-O-acetyl-β-D glucopyranosyl azide (25), a CuAAC “click”
reaction with 3-butyn-1-ol was performed, resulting in the 1,4-triazole containing
glycoside 34, Subsequent tosylation of the primary alcohol group (35), radiofluorination
using nBu4N[18F]F and Zemplén deacetylation resulted in the 18F–radiolabelled triazolebearing glycoside 36 in 21% radiochemical yield from 25 (Scheme 1.12).137

Scheme 1.12: Synthesis of 18F-radiolabelled glucose derivative 36 from direct radiofluorination of a
triazole-containing derivative 35.137
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Using SN2 nucleophilic displacement of a tosylate group to introduce
fluorine-18, the synthesis of 36 directly from β-D-glucopyranosyl azide (37) has also
been performed, with the CuAAC “click” reaction of [18F]-4-fluoro-1-butyne (produced
from 4-butyn-1-ol, Scheme 1.13) and 37 resulting in the

18

F-radiolabelled triazole-

bearing glycoside 36 in 30% radiochemical yield (Scheme 1.13).137 This efficiency of
the CuAAC “click” radiofluorination has also been replicated in our research group,
using

2-deoxy-2-N-acetyl-3,4,6-tri-O-acetyl-β-D-glucopyranosyl

azide

and

[18F]-4-fluoro-1-butyne, resulting in the isolation of the desired radiolabelled glycoside
in 22% radiochemical yield (unoptimised).138 In comparison to the acylation and
imidation methods previously described, the radiochemical yield gained for 36
represents a decrease from those previously observed, with the high volatility of
[18F]-4-fluoro-1-butyne (b.p 45°C) believed to be a major contributor to these results.
Thus, the use of less volatile alkynes is key to the utilization of this methodology for
18

F-radiolabelling.

Scheme 1.13: Synthesis of 18F-radiolabelled glucose derivative 36 from CuAAC “click” reaction of
azido sugar 37 with a 18F-fluorinated alkyne.137
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The strategy described above allows the labelling of sugar molecules, but is not
amenable to the 18F-radiolabelling of peptide-based molecular probes. Furthermore, the
efficiency of this method in the

18

F-radiolabelling of the protected azido sugar 25 or

unprotected azido sugar 37 is much lower than that observed in the production of
[18F]FDG (~50% RCY).79 Because of this, alternative methods that utilize the CuAAC
“click” reaction in the synthesis of

18

F-radiolabelled glycoconjugates for use as

molecular probes have been evaluated.

1.5.4 Fluorine-18 Labelled Glycoconjugates Synthesised using the
CuAAC “Click” Reaction
Following in the footsteps of probes such as [18F]FDG, in which fluorine-18 is
introduced by nucleophilic displacement of a mannosyl triflate, methods that utilize
glycosides radiolabelled in this way have been investigated.139 The versatility of the
CuAAC “click” reaction as a ligation method has resulted in the development of
[18F]-radiolabelled glycoconjugates linked via a triazole at the anomeric centre of the
glycoside. Initially developed by Olaf Prante and co-workers, preliminary nucleophilic
radiofluorination of 2-trifluoromethanesulfonyl-3,4,6-tri-O-acetyl-β-D-mannopyranosyl
azide (38) using K[18F]F and Kryptofix 2.2.2 resulted in the production of 2-[18F]-2deoxy-β-D-glucopyranosyl azide (39) in 71% radiochemical yield (Scheme 1.14).139 An
azide-bearing derivative of [18F]FDG, deprotection of the acetyl groups followed by
CuAAC “click” reaction with an Fmoc-protected L-propargylglycine resulted in the
production of the

18

F-radiolabelled glycosylamino acid 40 in 60% radiochemical yield

from 39 (Scheme 1.14).139
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Scheme 1.14: Synthesis of

18

F-radiolabelled triazole-containing glycosylamino acid 40 in 60%

radiochemical yield via the CuAAC “click” reaction. 139

The production of 39 and its subsequent conjugation via the CuAAC “click
reaction provided impetus for the further utilization of this methodology in the synthesis
of [18F]-labelled glycoconjugate probes. Building on this work, Prante and co-workers
utilized 39 to glycosylate and radiolabel a propargylglycine-bearing cyclic
RGD-containing peptide, producing the radiolabelled derivative 41, which in addition to
other [18F]-glycosylated derivatives have been evaluated for their diagnostic potential in
the quantification of angiogenesis (Figure 1.11).140,141 In addition, this methodology has
been extended to the development of probes targeting neurotensin receptor 1 (NST1), a
G-protein coupled receptor upregulated in a number of tumour types, including those of
the breast, lung, pancreas and prostate.142 Examples of probes developed include those
containing both peptidic and non-peptidic scaffolds, with the non-peptidic derivative 42
(Figure 1.11) displaying low nanomolar affinity for NST1, and 70-fold selectivity for
this receptor over the related neurotensin receptor 2 (NST2).142
Such has been the worth of this method in the development of radiolabelled
glycoconjugates, that it has been adopted by researchers investigating other biological
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targets. Schibli and co-workers have utilized 39 and the CuAAC “click” reaction to
target the folate receptor.143A membrane-anchored protein that binds folic acid as its
natural substrate, the folate receptor is upregulated in a variety of different tumour types
in addition to a number of autoimmune and inflammatory diseases, positioning it well
as a diagnostic target.143 Subsequently, the CuAAC “Click” reaction of 39 with a
propargylglycine-bearing folate derivative, resulted in the [18F]-glycosylated derivative
43 (Figure 1.11), which showed high affinity for the folate receptor.
Beyond the production of diagnostic probes (such as 43), the CuAAC “click”
reaction has also been used in the evaluation and analysis of glycoprotein interactions.
This is exemplified by the group of Benjamin Davis at the University of Oxford, who
have selectively synthesised proteins bearing fluorosugars. Incorporating non-natural
amino acids (such as L-homopropargylglycine (Hpg)) into proteins,144 these residues
may participate in the CuAAC “click” reaction in mild conditions, with linkage at these
sites providing a mechanism for the production of [18F]-radilabelled glycoproteins. This
is illustrated by the triazole-linked glycoprotein 44, that was formed by the CuAAC
“click” reaction of 39 and the protein SsβG, a beta-glycosidase derived from the
hyperthermophilic bacteria Sulfoolbus solfataricus (Figure 1.11).144
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Figure 1.11:

18

F-containing glycopeptides radiolabelled using 39 and the CuAAC “click”

reaction.140–144

The utilization of azide-bearing [18F]-labelled sugars such as 39 have resulted in
the development of diagnostically-relevant [18F]-labelled glycoconjugate probes.
However, the current methodology for the synthesis of the required fluorosugars (39),
and ligation to the desired peptide or protein using the CuAAC “click” reaction, present
some challenges. Firstly, access to 39 from a commercially-available starting material in
high yield is difficult, with the production of the precursor 38(β-anomer) from
D-mannose yielding only 8.2% yield over 5 synthetic steps (Scheme 1.15).139 Much of
this is due to the need for the use of an orthogonal protection strategy, allowing for the
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selective conversion of the mannosyl triflate derivative 38(β-anomer) into the glucosyl
fluoride.139 Also, the requirement of a β-azide that can undergo the CuAAC “click”
reaction significantly lowers the efficiency of this process, with the presence of a
pentafluorophenyl (Pfp) group in 46 and 47 prior to azidonation significantly decreasing
the selectivity of this reaction, producing both α- and β-anomers of 48 (Scheme 1.15).

Scheme 1.15: Synthesis of 2-OTf-containing derivative 38 from D-mannose, a key precursor in the
synthesis of 2-[18F]fluoro-2-deoxy-β-D-glucopyranosyl azide (39).139

However, one of the largest issues with the current methodology is the need for
an alkyne group in the macromolecule or peptide to be labelled. Whilst in the previously
described examples 41-43 this approach is used efficiently, it isn’t really appropriate for
use in the synthesis of larger peptides and proteins. As illustrated by the work of Davis
and co-workers (44), in order to introduce an alkyne-bearing amino acid changes to the
peptide or protein of interest at specific positions in the amino acid sequence are
required.144 This represents both a synthetic and structural challenge, as the introduction
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of the required alkyne-containing amino acid must be performed in a way that is
synthetically efficient. Also, it is important that the modifications made do not alter the
structural characteristics of the peptide or protein in question, maintaining the biological
activity of the probe.

1.5.5 Alternative Strategies for the Fluorine-18 Labelling of
Glycoconjugates using the CuAAC “Click” Reaction
Considering the potential complications of this approach and how these may
affect the broader utilization of this strategy, the development of an alternative method
to the labelling of glycoconjugates via the CuAAC “click” reaction is warranted. We
propose that an alternative methodology that utilizes azide-bearing glycosides that can
be readily conjugated to proteinogenic amino acids would be advantageous. Containing
an azide group, these glycosides would by definition be azidosugars. If a number of
azidosugars were produced that contained different functional groups forming linkages
with amino acids (such as carboxylic acids, amines, leaving groups, etc), these could be
incorporated into peptides or conjugates (Scheme 1.16). The use of a protecting group
strategy utilizing acetyl protecting groups would allow for the installation of the
required azide groups, in addition to amino acid coupling. Simple and easily installed,
these groups also have the benefit of being easily cleaved in the cellular environment,
due to pH and the presence of intracellular esterases.145
These glycoconjugates could thus be described as being “clickable,” with the
corresponding free azide group of the glycoside available for use in the CuAAC “Click”
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reaction. In conjunction with alkynes akin to the previously discussed [18F]-4-fluoro-1butyne, this could be utilized to produce

18

F-radiolabelled glycoconjugates

(Scheme 1.16).137 This represents a methodology that allows for the introduction of
fluorine-18 into a glycoconjugate in the final step, an important feature when working
with radioisotopes with short half lives. Also, as non-proteinogenic amino acids are not
required, it allows for the use of unmodified native peptides and proteins that may
display ideal radiopharmaceutical properties, thus limiting the need for the installation
of prosthetic groups (such as alkynes) for conjugation (Scheme 1.16).

Scheme 1.16: Comparison of methods that may be used to produce 18F-radiolabelled glycosylamino
acids using the CuAAC “click” reaction. A: Previously described strategy developed by Prante and
co-workers, B: Postulated method using “clickable” glycosylamino acids radiolabelled by a
[18F]-fluoroalkyne using the CuAAC “click” reaction.

Therefore, in order to produce

18

F-radiolabelled glycoconjugates of this form,

“clickable” glycosylamino acids consisting of an azidosugar linked to an amino acid
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must be produced. However, an evaluation of the relevant literature has highlighted a
clear lack of structures of this form. Of those previously synthesised, many are etherlinked conjugates between azidosugars and hydroxyl-containing amino acids, including
serine, threonine, tyrosine and hydroxylproline, and as demonstrated by the
threonine-linked derivatives 49 and 50 (Figure 1.12).146,147

Figure

1.12:

Threonine-linked

glycosylamino acids.

derivatives

50

and

51,

examples

of

“clickable”

146,147

Interestingly, the formation of glycoconjugates between azidosugars and other
amino acids used in the synthesis of glycoconjugates, including serine (Ser; via
ester linkages), lysine (Lys), aspartic acid (Asp), glutamic acid (Glu) and cysteine (Cys)
be performed. Also, the majority of “clickable” glycoconjugates previously synthesized
either pre-date the development of the CuAAC “click” reaction, or instead have been
used

as

precursors

in

the

synthesis

of

other

glycoconjugates,

including

N-acetylglycosylamino acids.146,147 Thus, there lies the opportunity to develop and
synthesise a host of “clickable” glycosylamino acids and demonstrate the applicability
of the CuAAC “click” reaction in their further derivatization. Conjugated together via
ester linkages initially, before being utilized in the formation of conjugates formed
through more stable amide and thioether linkages, the synthesis of these derivatives
could then be extended to other glycopeptides, neoglycopeptides and glycoconjugates.
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The development of this approach would further expand the use of the CuAAC “click”
reaction in the production 18F-radiolabelled glycoconjugates for nuclear imaging.

1.6

Project Aims
The CuAAC “click” reaction represents a useful method for the synthesis of 18F-

radiolabelled

glycoconjugates.

Utilizing

“clickable”

glycosylamino

acids

glycopeptides, this method would allow for the efficient production of a range of

and
18

F-

radiolabelled diagnostic probes. In order to evaluate this approach, azidosugars that can
ligate to a number of different proteinogenic amino acids must be developed and
optimised (Scheme 1.17). Subsequent ligation would produce the desired “clickable”
glycoconjugates, which would be open to evaluation with the CuAAC “click” reaction
(Scheme 1.17). The success of this process may then be ported to the synthesis of
“clickable” glycopeptides and neoglycopeptides, paving the way for the development of
18

F-radiolabelled glycoconjugates for use as probes in nuclear imaging (Scheme 1.17).

Therefore, the specific aims of this project were:
1.

To synthesise a range of different azidosugars (sugar azido acids and
azidoglucopyranosyl amines) that could form linkages with proteinogenic
amino

acids

commonly

used

in

bioconjugation

(serine,

lysine,

aspartic/glutamic acid, homocysteine, etc.) (Goal 1, Scheme 1.17).
2.

To synthesise a range of “clickable” glycoconjugates bearing ester, amide and
thioether linkages to various amino acid residues (Goal 2, Scheme 1.17).
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3.

To demonstrate the utility of the synthesised glycoconjugates in the
CuAAC “click” reaction (Goal 3, Scheme 1.17).

4.

To extend this methodology towards the synthesis of glycopeptides and
neoglycopeptides that may be functionalized via the CuAAC “click” reaction
(Goal 4, Scheme 1.17).
In Chapter 2, 3 and 4, the synthesis and functionalization of “clickable”

glycoconjugates will be discussed. These chapters will focus on examples linked to
serine, lysine and α-amino groups (Chapter 2), aspartic acid and glutamic acid
(Chapter 3) and homocysteine (Chapter 4). In Chapter 5, the development of methods
toward the synthesis and functionalization of “clickable” neoglycopeptides will also be
discussed.

Scheme 1.17: General scope of the synthesis and functionalization of “clickable” glycoconjugates
performed in this project.
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Chapter 2 : Synthesis and Functionalization of
Serine, Lysine and α-Amino Linked “Clickable”
Glycoconjugates.

Carbohydrates that can be incorporated into peptides and functionalized using the
CuAAC “click” reaction have a wide range of potential applications. In the following
chapter, the synthesis and functionalization of serine, lysine and α-amino linked
“clickable” glycoconjugates will be described. Conjugates of sugar azido acids linked
to proteinogenic amino acids are useful compounds that can be incorporated into
peptides

and

are

also

freely

available

for

functionalization

using

the

CuAAC “click” reaction.

2.1 Synthetic Rationale
Azidosugars are highly amenable to the CuAAC “click” reaction. If the same
azidosugars could also be coupled to amino acid residues then they would have great
potential for use in the synthesis and labeling of glycopeptides.139 However, currently
there is limited literature precedence on the development of azidosugars that can both
couple to amino acids or peptides, and also be free to undergo the CuAAC “click”
reaction. Hence, a methodology that provides a comprehensive, wide-ranging approach
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towards the introduction (and labeling) of carbohydrates into linear and/or cyclic
peptides would be highly advantageous.
Previously in our research group, work had been performed towards the
development of acid-labile cytotoxic isatin prodrug models for conjugation to the cancer
relevant protein plasminogen activator inhibitor-2 (PAI-2), whereby the acid-labile
prodrug was tethered by a carboxylic acid group to a Nα/C-protected lysine
residue.148,149 Conjugates that are tethered together through an amide linkage hold a
distinct advantage over those formed through other methods, particularly due to their
strength and chemical resistance under a wide variety of conditions, and ease of
synthesis through peptide coupling conditions.150 Whilst conjugates to lysine may be
linked via its Nε-sidechain, it could be envisaged that amino acid residues containing
chemically inert sidechains may also form amide linkages, through coupling to
carboxylic acid containing moieties through their terminal α-amino group (Scheme 2.1).
Moreover, using this coupling strategy could result in conjugates with other amino acid
residues commonly used as linkers in peptide conjugation and labeling, including ester
linkages when coupled to the amino acids serine or threonine.
Therefore, if a glycosyl coupling partner that included a carboxylic acid group
(uronic acid); such as a sugar azido acid was employed, and coupled to a variety of
different proteinogenic amino acids, this could produce a library of “clickable”
glycoconjugates that could be employed in the CuAAC “click” reaction (Scheme 2.1).
The synthesis and functionalization of conjugates of this type would provide further
insight into the feasibility of this approach in producing glycoconjugates that could find
future utility in the synthesis and labeling of glycopeptides (Scheme 2.1).
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Scheme 2.1: Proposed scheme for the synthesis of "clickable" glycoconjugates.

2.2 Initial Synthetic Targets
2.2.1 Conjugate Criteria
In order to synthesize a library of diverse “clickable” glycoconjugates, it was
recognized that a few key design principles were required. The synthetic approach
undertaken should be:


Divergent in nature, allowing for the production of a variety of different
“clickable” glycosyl-amino acids from one or two precursor molecules, and;
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Synthetically efficient, with easy installation and access to the azide and
carboxylic acid functional groups required for coupling and the CuAAC
reaction.

Whilst not a definitive requirement, it was also decided that the glycosides used
would be pyran-based (6-membered ring). By using a pyran ring as a scaffold, it would
ultimately leave the 6-position as the most synthetically viable site for the introduction
of the required carboxyl group. This is an attractive option, allowing the carboxyl group
to be introduced via oxidation of a 6-OH group. Alternatively, it would be highly
advantageous to utilize uronic acid precursors in which the carboxylic acid is already
installed if possible. If the azido group of the sugar azido acid was installed at the
anomeric centre, and ester protecting groups such as acetyl (OAc) groups were utilized,
this would provide a versatile, stereoselective method for the synthesis of sugar azido
acids. Additionally, this methodology would be portable, and hence could be used in the
synthesis of sugar azido acids based on different glycosyl isomers (Scheme 2.2).

Scheme 2.2: Key design principles required in the synthesis of "clickable" glycoconjugates, utilizing
a uronic acid precursor.
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2.2.2 Synthetic Approaches
Based on the criteria described in section 2.2.1, a review of sugar azido acids
reported in the literature was undertaken. To date, all sugar azido acids previously
synthesized can be classified into one of four different stereochemical isomer classes;
glc,151 gal,152 manno153 or allo153 (Figure 2.1), with a β-configuration at the anomeric
position the most common. Of these, sugar azido acids based on D-glucuronic acid were
the most prominent, with multiple methods previously used in the synthesis of
D-glucuronic acid based derivatives with either α- or β-stereochemistry present at the
anomeric centre. Hence, commercially available D-glucuronic acid was employed as the
scaffold for the synthesis of the sugar azido acids described herein.

Figure 2.1: Examples of sugar azido acids previously reported in the literature.151–153
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The selection of D-glucuronic acid-based derivatives was further rationalized by
the prominent role of D-glucuronic acid in living systems, such as glucuronidation
described in Chapter 1.53 D-Glucuronic acid is also present as a constituent in a number
of different biologically relevant glycosaminoglycans, including hyaluronic acid and
chondroitin sulfate, where they are important constituents in connective tissues such as
cartilage.19
D-Galacturonic was chosen as a second scaffold for the synthesis of sugar azido
acids. Varying only by the axial stereochemistry of the hydroxyl group attached to the
C4 position of the pyran ring, D-galacturonic was selected as it was thought that this
distinction would not affect the further functionalization of the molecule, but would
impart a stereochemical difference into the “clickable” glycoconjugates. Furthermore,
akin to D-glucuronic acid, D-galacturonic acid displays a variety of roles in nature,
particularly as a structural element of plant gums such as pectin.154 D-Galacturonic acid
is present in many different food stuffs, thus it is likely that conjugates containing
D-galacturonic acid would be well tolerated if used in nuclear imaging agents in the
future.155 In addition to D-glucuronic acid and D-galacturonic acid, D-mannuronic acid
was also considered as a sugar azido acid scaffold. However, the axial stereochemistry
at the C2 position on the pyran ring increased the potential risk of side reactions due to
the closer proximity of the C2 hydroxyl group to the carboxylate group. Hence no SAAs
based on mannuronic acid were synthesized herein.
In selecting an approach for the synthesis of the required glc- and gal- sugar
azido acids, three potential methodologies were considered (Scheme 2.3). The first of
these, described by Von Roedern et al.,156 was the synthesis of 1-azido-2,3,4,-tri-Oacetyl-β-D-glucuronic acid methyl ester (53) from the corresponding 1,2,3,4-tri-O51 | P a g e
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acetyl-β-D glucuronic acid methyl ester (52) (Pathway A, Figure 2.4). Utilizing
glucuronolactone (51) as a precursor, this pathway was deemed not suitable in this
instance due to the long duration/low yielding nature of the process. Also, this method
would not be able to be ported to the synthesis of a gal-based sugar azido acid.

Scheme 2.3: Three potential pathways en route to the synthesis of sugar azido acids based on the
Glc scaffold.156–158
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An alternate strategy previously developed by D’Onofrio et al.,158 that was
considered

also

commenced

from

a

previously

synthesized

precursor,

β-D-glucopyranosyl azide (37, Scheme 2.3 Pathway 2), where selective protection of
the primary 6-OH, peracetylation of the remaining 2-,3- and 4-OH groups (54),
followed by the one pot selective deprotection of a silyl ether and oxidation of the
primary 6-OH, resulted in the required SAA. However, the utilization of the
CrO3/H2SO4 reaction cocktail in the one-pot deprotection/oxidation of 54 posed some
safety concerns,158 reducing the scalability of the synthesis considerably.
Instead, a strategy whereby the target SAAs were synthesized from Dglucuronic/or galacturonic starting materials was employed (Scheme 2.3, Pathway 3).
Utilizing cheap, readily available precursor molecules of D-glucuronic and
D-galacturonic acid, this methodology would allow for the stereoselective introduction
of an azido group at the anomeric position, with β-stereochemistry. Furthermore, this
concise four step synthesis allows for the utilization of a number of different protecting
groups for the 6-carboxyl group, including the methyl protecting group utilized by
Von Roedern et al.,156 and other commonly used protecting groups such as the ethyl,
allyl, tert-butyl or benzyl groups;159 providing versatility in the deprotection procedure
that would yield the required sugar azido acids.
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2.3 Synthesis of Glc- and Gal-Sugar Azido Acids.
2.3.1 Synthesis of 1-Azido-2,3,4-tri-O-acetyl-β-D-glucuronic acid (60)
For the production of glc- and gal- sugar azido acids, protection of both the
secondary hydroxyl groups and the carboxylic acid was required. Based on the protocol
reported by Bergeon et al.,160 D-glucuronic acid (55) was peracetylated using I2 as a
Lewis acid, with slow, cold addition of methanol resulting in the cleavage of the
intermediate anhydride, which after recrystallization produced 56 in 58% yield
(Scheme 2.4).

Scheme 2.4: Synthesis of peracetylated glucuronic acid allyl ester 57 from D-glucuronic acid.

Analysis of the 1H NMR spectrum highlighted the β-configuration of the OAc
group at the anomeric centre, with a doublet at 5.79 ppm (J = 7.6 Hz) indicative of a
shielded proton of α- or axial anomeric configuration. Subsequently, the free carboxylic
acid of 56 was protected using the method of Tosin et al. to form an allyl ester.157 The
allyl ester was chosen over other options due to its stability under both acidic and basic
conditions. Furthermore, the selective deprotection of an allyl ester in the presence of an
azido group would allow for the efficient production of the required glc- sugar azido
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acid. Installation of the allyl ester began with the formation of a glucuronyl chloride
from 56, utilizing oxalyl chloride and catalytic DMF. Substitution of the glucuronyl
chloride with allyl alcohol, followed by scavenging of the alcohol proton by pyridine,
resulted in the peracetylated glucuronic acid allyl ester 57 in 93% yield over two steps
(Scheme 2.4).157 In the 1H NMR spectrum, multiplets at 5.89 ppm and 5.37 ppm
integrating for one and two protons respectively, and

a doublet at 4.61 ppm

(J = 6.1 Hz) integrating for two protons were consistent with the allyl group in 57.
Accordingly, with 57 in hand the synthesis of the β-azidosugar 59 was
investigated. In comparison to tin (IV) chloride-catalyzed azidonation reactions
presented in the literature in the formation of the previously described β-azide 25,157 it
was identified that variations in the coordinating group at the C6 position of the
protected glycoside (OAc group versus COOMe) could result in a noticeable decrease in
the yield of product. Therefore, an alternate strategy employing a two-step process was
initially used. Firstly, acid-catalyzed bromination of the anomeric centre of 57 using
33% HBr in acetic acid, produced the α-brominated compound 58 in 67% yield
(Scheme 2.5).

Scheme 2.5: Synthetic pathways towards the production of the protected sugar azido acid 59.
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In the following reaction in dichloromethane, the anomeric OAc group of 57
dissociates, producing an oxocarbenium intermediate (Scheme 2.6). Stabilization of this
intermediate produces an anomeric-centred carbocation, which in the presence of a
bromide undergoes nucleophilic substitution. Formation of the α-bromo compound 58 is
highly favoured, due to hyperconjugation resulting from the orbital overlap present
between the lone pair of electrons of the ring oxygen, and the anti-bonding orbital of the
anomeric carbon (Scheme 2.6). α-Bromo compound 58 was then subjected to
nucleophilic substitution at the anomeric centre employing NaN3, producing the sugar
azido acid 59 in 68% yield (Scheme 2.5). The use of a polar aprotic solvent such as
DMF allowed the nucleophilic substitution to proceed smoothly without the formation
of potentially hazardous side products. This is in contrast to the use of CH2Cl2, which
when used with ionic azides is known to result in the production of diazidomethane – a
highly unstable, shock sensitive species.161 To this end, the use of NaN3 in chlorinated
solvents during azidonation reactions was completely avoided in this work.

Scheme 2.6: Proposed alternative mechanistic pathway for the synthesis of 1-azido-2,3,4-tri-Oacetyl-β-D-glucuronic acid allyl ester (59).
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Whilst this methodology produced the required protected sugar azido acid 59,
the yield for this product proved to be significantly less than that expected (44% versus
~70% as described in the literature).157 Furthermore, the sensitivity of the intermediate
α-bromo compound 58 to degradation hindered the scalability of this process. Hence,
the procedure of Tosin et al. was utilized (Scheme 2.5, pathway B), where the azido
group was directly introduced to 57, using TMSN3 as a soft azide donor and catalyzed
by tin(IV) chloride (Figure 2.8).157 Workup and subsequent recrystallization generated
the fully protected sugar azido acid 59 in 63% yield (Scheme 2.5). Mechanistically,
tin(IV) chloride forms a coordinate complex with the carbonyl oxygen of the carboxylic
acid

and

that

of

the

anomeric

OAc

group.

This

coordination

induced

neighbouring-group participation from the carbonyl of the OAc group attached to the
C2 of the pyran ring results in the formation of a carbocation-containing acetal
intermediate, and the release of an acetate ion (Scheme 2.7). The axial stereochemistry
of the acetal intermediate allowed for the SN2 nucleophilic substitution at the anomeric
centre with the azide anion, forming the required β-sugar azido-acid 59.

Scheme 2.7: Mechanism for the SnCl4-catalyzed azidonation that formed 59.151
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The 1H and

13

C NMR spectra of 59 highlight the distinct difference in electron

density surrounding the anomeric centre, with a doublet (J = 9.1 Hz) in the 1H NMR at
4.71 ppm and a singlet in the 13C NMR at 88.3 ppm respectively, with the correlation of
these signals confirmed by a 2D gHSQC NMR experiment. These appear noticeably
upfield from those signals for the peracetylated precursor 57 (5.79 ppm and 91.6 ppm
respectively), and are indicative of the inductive electron-withdrawing effects of the
anomeric OAc group in 59, which deshields the nuclei of H1 and C1. Even further
upfield from the H1 doublet in the 1H NMR spectrum of 59 is a doublet representing the
H5 proton (4.14 ppm, J = 9.8 Hz). The difference between these protons (~0.6 ppm) and
their relative positions was a consistent feature of the 1H NMR spectra of all derivatized
sugar azido acids synthesised in this project.
The protected sugar azido acid 59, was then subjected to deprotection, in order
to yield the required 1-azido-2,3,4-tri-O-acetyl-β-D-glucuronic acid (60). The utilization
of the allyl ester allowed for the selective “unmasking” of the carboxylic acid through
mild palladium(0)-catalyzed deallylation. Mechanistically, when in the presence of
Pd(0) catalysts such as Pd(PPh3)4 the allyl ester is cleaved, forming a free carboxylate
and Pd-π complex between the catalyst and the liberated allene. In the presence of a
“scavenger” molecule such as pyrrolidine, piperidine or morpholine, the allene is
sequestered from the catalyst, which is reintegrated into the catalytic cycle, producing
the free carboxylic acid product (Scheme 2.8).157
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Scheme 2.8: Catalytic cycle for the deprotection of allyl esters. 162

Hence, using this approach and the methodology of Tosin and co-workers, the
allyl ester of 59 was deprotected, to form the target sugar azido acid 60. Utilizing
Pd(PPh3)4 as a catalyst and pyrrolidine as an allyl scavenger, 60 was synthesized in 66%
yield (Scheme 2.9).157

Scheme 2.9: Synthesis of 1-azido-2,3,4-tri-O-acetyl-β-D-glucuronic acid 60.

In comparison to the literature, this yield was somewhat less than that previously
achieved (83-93%) when performed on the same scale.151,157 Furthermore, this yield
proved inconsistent when synthesized on larger scales, with yields ranging from
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49-66%. Considering the catalyst (Pd(PPh3)4) used, the high loading of catalyst
(10 mol%) and the proposed mechanism of this reaction, one likely reason for these
variances is the potential side reaction of the starting material with triphenylphosphine
(PPh3) leached from the catalyst. In the presence of PPh3, the azide at the anomeric
centre of 59 can undergo a Staudinger reduction, resulting in the release of N2 gas and
upon aqueous work-up the formation of triphenylphosphine oxide and a sugar amino
acid derivative (Scheme 2.10).

Scheme 2.10: Proposed mechanism of the Staudinger reduction that occurs in the synthesis of 60.

The leaching of PPh3 from the catalyst is supported by the presence of signals in
both the 1H and

13

C NMR spectrum between 7.40 and 7.80 ppm, respectively in a

number of the crude reaction samples of 60, which are indicative of the presence of an
aromatic ring, of which PPh3 or O=PPh3 are the only potential contributors in this
protocol. In addition, signals of m/z 301 present in the low resolution electrospray
ionization mass spectrum (LR-ESIMS) of the reaction mixture are indicative of
O=PPh3 + Na. To combat the potential interference of PPh3 in this reaction, freshly
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recrystallized Pd(PPh3)4 was used, and removal of the catalyst was performed via
filtration over a thick pad of celite, to prevent any leaching. Whilst no amine formation
was detected in the worked-up solution, the following approach to the use of catalyst
resulted in generally higher yields of 60, compared to when no recrystallization of the
catalyst was performed. In this manner, starting initially from D-glucuronic acid,
1-azido-2,3,4-tri-O-acetyl-β-D-glucuronic acid (60) was successfully synthesized in a
total yield of 23% over four steps.

2.3.2 Synthesis of 1-Azido-2,3,4-tri-O-acetyl-β-D-galacturonic acid (65)
Based on the convenient synthesis of 60 from D-glucuronic acid, it was
envisaged that this methodology would prove quite useful in the synthesis of 1-azido2,3,4-tri-O-acetyl-β-D-galacturonic acid (65). Hence, the synthesis of this sugar azido
acid initiated with the peracetylation of commercially available D-galacturonic
monohydrate. Utilizing the protocol developed by Vogel and co-workers, acetic
anhydride and perchloric acid were employed to produce 1,2,3,4-tetra-O-acetyl-α-Dgalacturonic acid (61) in 35% yield (Scheme 2.11).163 Mechanistically, the perchloric
acid-catalyzed protocol proceeds in a comparable manner to the use of I2 in the
acetylation of D-glucuronic acid, with an in depth examination of the literature
illustrating the similarities in yield when either method is used to synthesise 61.164 The
α-stereochemistry of the anomeric centre is highlighted by the 1H NMR spectrum of 61,
where a doublet integrating to one proton at 6.47 ppm indicates the deshielded,
equatorial nature of H1. Furthermore, the small coupling constant of J = 2.9 Hz
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emphasizes the small dihedral angle that exists between H1 and H2 when H1 is in the
equatorial position.

Scheme 2.11: Synthesis of peracetylated allyl ester 62 from D-galacturonic acid monohydrate.

The presence of α-stereochemistry at the anomeric centre of 61 is in stark
contrast to the β-stereochemistry present in the D-glucuronic acid derivative 56. To
understand and reason this difference further, a brief conformational analysis was
undertaken using the molecular modeling program ChemBio3D 11. Using the AM1
semi-empirical level of theory, the heat of formation (ΔHf) for both α- and β-anomers of
56 and 61 was calculated (Figure 2.2).

Figure 2.2: Heat of formation (ΔHf) of the α- and β- anomers of 56 and 61, calculated using
ChemBio3D 11.0.
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Interestingly, there were noticeable differences between the different uronic
acids, with the β-anomer of 56 calculated to have a ΔHf 11.4 kcal/mol less than its
counterpart α-anomer. This is indicative of the greater stability of the β-anomer, as seen
by the resulting ratio of the β-anomer of 56. In contrast, the calculated ΔHf values for
the respective anomers of 61 show negligible differences between them (0.1 kcal/mol,
Figure 2.2), suggesting an even likelihood of the formation of both α- and β-anomers.
Considering the low yield of 61 and the use of recrystallization in its isolation, it is
entirely possible that the production of the β-anomer of 61 could have occurred in equal
quantities to the isolated α-anomer.
With 61 in hand, the free carboxylic acid could be protected. Utilizing the
protocol optimised in the synthesis of 57, the peracetylated galacturonic acid allyl ester
derivative 62 was synthesized via the acid chloride intermediate in 85% yield
(Scheme 2.11). Similarly to the previously synthesized 57, signals in the 1H NMR
spectrum at 5.75 ppm (1H), 5.15 ppm (2H) and 4.70 ppm (2H) were indicative of the
presence of the allyl ester. Subsequently, 62 was subjected to azidonation at the
anomeric centre. Based, on the experience gained during the synthesis of 59, the
peracetylated galacturonic acid allyl ester 62 was subjected to reaction under
TMSN3/SnCl4 conditions. Interestingly though, compared to the moderate yielding
synthesis of 59, an initial reaction attempted over 4 hours yielded the anticipated
product 64 in only 18% yield.

Increasing reaction time to 20 hours only mildly

increased the yield of product (29%), with no further gains in yield observed after
72 hours of reaction time.
Mechanistically, the α-stereochemistry of the parent molecule appeared to
impede the kinetics of this reaction, as a result of the large distance between the OAc
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group at the C1 position, and the carbonyl group of the allyl ester (Scheme 2.12).
Hence, when SnCl4 is dissolved in dichloromethane and in the presence of 62, it instead
preferentially forms an interaction between the carbonyl group of the allyl ester, and the
oxygen of the pyran ring. This interaction can destabilize the pyran ring, leading to ringopening at the anomeric centre, resulting in the formation of a C1-centred carbocation
intermediate. Mutarotation of the C-C bond between C1 and C2, and subsequent ring
closing of this intermediate results in the formation of the β-anomer of 62, which can
undergo OAc elimination, neighbouring group participation and nucleophilic
substitution to form the protected sugar azido acid 64 (Scheme 2.12).151

Scheme 2.12: Mechanism for the synthesis of 64 from 62 in the presence of SnCl 4.165

As a consequence of the inefficiencies present in this process, it was determined
that the synthesis of the α-bromo intermediate en route to 64 would provide the most
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viable procedure towards the synthesis of 1-azido-2,3,4-tri-O-acetyl-β-D-galacturonic
acid (see Scheme 2.6). Furthermore, the oxocarbenium transition state is formed
independent of the stereochemistry present at the anomeric centre.

Scheme 2.13: Synthesis of 1-azido-2,3,4-tri-O-acetyl-β-D-galacturonic acid (65)

Hence, the peracetylated allyl ester 62 was subject to bromination utilizing the
conditions

developed

in

the

preparation

of

58

(33% HBr/Acetic

acid

in

dichloromethane), resulting in the α-bromo compound 63 in 66% yield. Next, 63 was
subjected to NaN3 azidonation, producing the β-azide derivative 64 in 70% yield
(Scheme 2.13, pathway B). The structure of 64 was confirmed using 2D NMR
spectroscopy, with the gCOSY spectral plot displaying correlations between the H5 and
H4, H4 and H3, and H2 and H1 (Figure 2.3). The axial stereochemistry of the proton at
the anomeric centre of 64 was identified using the NOESY spectral plot, where through-
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space correlations between the H1 and H3 of 64 were detected. Hence, the azido group
present at the anomeric centre possessed β-stereochemistry (Figure 2.3).

Figure 2.3: The gCOSY (left) and NOESY (right) 2D 1H NMR spectral plots for 64.

Subsequently, the carboxylic acid group was unmasked through the
Pd-catalyzed deprotection of the the allyl ester of 64, producing 1-azido-2,3,4-tri-Oacetyl-β-D-galacturonic acid (65) in 67% yield (Scheme 2.13).157 This was evident by
the 1H and

13

C NMR spectra of 65, where the disappearance of signals from the allyl

group of 64 highlighted the deallylation. Therefore, the novel, target sugar azido acid 65
was synthesized from D-galacturonic acid monohydrate in 9% over 5 steps. Comparable
in yield to the synthesis of the glc sugar azido acid 60, this synthesis allowed for the
timely, scalable synthesis of SAAs without the need of chromatography. Thus,
sufficient material for the synthesis of a library of “clickable” glycoconjugates was
procured.
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2.4 Synthesis of “Clickable” Glycoconjugates
2.4.1 Synthesis of Sidechain-linked Derivatives (66-69)
With the key glc- and gal- sugar azido acids 60 and 65 in hand, our attention
turned to the synthesis of “clickable” glycosyl amino acids. Initially, the synthesis of
conjugates formed through the coupling of our synthesized sugar azido acids with serine
was targeted, with Boc.Ser.OMe selected as the protected serine donor. The general
reactivity of primary alcohols in peptide coupling conditions, positioned serine ideally
as a coupling amino acid in the development of “clickable” glycoconjugates. The
formation of serine-linked glycoconjugates was also validated by the importance and
prevalence of serine glycosylation in the production of biologically important
glycoconjugates.166

Hence,

utilizing

a

classical

Steglich

N,N’-1,3-dicyclohexylcarbodiimide (DCC)-based esterification protocol, Boc.Ser.OMe
was coupled to the glc- sugar azido acid 60, successfully producing the novel serinebased “clickable” glycosyl amino acid 66 in 80% yield (Scheme 2.14).167

Scheme 2.14: Synthesis of serine-based “clickable” glycoconjugates 66 and 67.
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Mechanistically, in the presence of a non-nucleophilic base such as DMAP, the
free carboxylic acid of 66 reacts with the carbodiimide of DCC to form an activated
ester (Scheme 2.15). Driven by electron donation into the pyridine ring, DMAP can
subsequently attack the activated ester resulting in the acyl iminium intermediate and
the displacement of dicyclohexylurea as a by-product. Relatively unstable, the acyl
imminium intermediate is subsequently prone to nucleophilic substitution by the
hydroxyl group of the Boc.Ser.OMe sidechain, resulting in the formation of desired
ester product 66 (Scheme 2.15). Subsequently, the success of this procedure was
mirrored by its use in the synthesis of the novel gal-based sugar azido acid 67, which
was produced from Boc.Ser.OMe and 65 in 64% yield (Scheme 2.14).

Scheme 2.15: Mechanism of the synthesis of esters using a Steglich DCC/DMAP coupling approach.
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The 1H NMR spectra of both 66 and 67 highlighted the presence of signals each
integrating for 2 protons at 4.58 and 4.47 ppm,

respectively, with both of these

indicative of the CH2 protons adjacent to the ester on serine. This is in comparison to
the corresponding protons in the parent amino acid (Boc.Ser.OMe, 3.80 - 3.95 ppm),
which are more shielded due to the presence of the adjacent hydroxyl group. In addition,
the 13C NMR spectra of 66 and 67 highlighted the formation of the esters in each, with
signals at 173.2 and 167.8 ppm in 60 and 65 replaced by signals at 165.9 and 165.0 ppm
in 66 and 67. Furthermore, the LR-ESIMS of both 66 and 67 highlighted signals at
m/z 639, indicative of a [M + Na]+ signal. As far as the novelty of 66 and 67, both of
these compounds represent the first examples of “clickable” glycoconjugates produced
from sugar azido acids and amino acids.
Considering the ease in using the DCC/DMAP coupling protocol, this
methodology was utilized in the synthesis of conjugates containing protected lysine
amino acids. In comparison to the previous serine-based examples however, the
synthesis of these conjugates proved less efficient using this protocol, with the coupling
of glc- sugar azido acid 68 to Ac.Lys.OMe.HCl yielding only 31% after 48 hours
(Table 2.1). It is likely that the poor solubility of the lysine donor in dichloromethane, in
addition to the reduced nucleophilicity of the primary amine of the lysine sidechain with
respect to the serine hydroxyl group, significantly impeded the progress of the reaction.
These conclusions are further illustrated by the significant quantity of DCC-activated
ester that was left unreacted as observed by TLC. Hence, in an attempt to improve the
efficiency of this reaction, a modified procedure was employed utilizing
hydroxybenzotriazole (HOBt) as an activator and DIPEA as a base in DMF.150,168 This
procedure resulted in a significant improvement in reaction time and yield, producing
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the novel glc- and gal- lysine-based conjugates 68 and 69 in 75% and 60% yield,
respectively (Table 2.1).

Table 2.1: Reaction conditions for the synthesis of lysine-based “clickable” glycoconjugates
68 and 69

An important constituent of coupling reagents such as N,N,N′,N′-Tetramethyl-O(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU), N,N,N′,N′-TetramethylO-(1H-benzotriazol-1-yl)uranium tetrafluoroborate (TBTU) and (benzotriazol-1-yl)tripyrrolidinophosphonium hexafluorophosphate (PyBOP); HOBt in the presence of a
DCC-activated ester will displace N,N’-dicyclohexylurea and form an unstable HOBtactivated ester. The sidechain -NH2 group of Ac.Lys.OMe.HCl is a suitable nucleophile,
and in the presence of this activated ester will displace HOBt, undergoing coupling to
form the amide-linked conjugates 68 or 69 (Scheme 2.16).150
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Scheme 2.16: Mechanism of the synthesis of amides using a DCC/HOBt coupling approach.

The identity of both 68 and 69 were confirmed by their HR-ESIMS with signals
at m/z 552.1918 and 552.1935 (calculated for C21H31N5O11Na [M + Na]+: 552.1918)
indicative of the desired products. Furthermore, the NMR spectra of glc-68 and gal-69
highlighted the contrasting stereochemistry at the C4 position between these conjugates,
and the steric consequences that result from this variation. In the 1H NMR spectrum of
68, two matching signals present at 3.40 ppm and 3.15 ppm each displaying an
integration of 1H are present (Figure 2.4). A gCOSY 2D NMR experiment of 68
suggested that both of these protons were those of the CH2 group bound directly to the
amide bond formed during the coupling reaction (Hε).
The different chemical environments of the two geminal protons are potentially
indicative of hydrogen bond stabilization resulting from the neighbouring amide bond.
It is possible that under the conditions of the 1H NMR experiment performed (CDCl3,
25°C) the proton of the newly-formed amide nitrogen of 68 may be in close proximity
to the C4-linked oxygen of the pyran ring. Though the amide itself is an sp2 hybridized
system, if this were the case the proton would be in close enough proximity to the ring71 | P a g e
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bound oxygen at the 4-position to form a pseudo six-membered ring. Whilst the
presence of this interaction is completely speculatory, if present the ring would display a
configuration close to that of a “chair,” with the stability of this interaction effectively
limiting the rotation by the C-C bond at the C5 position (Figure 2.4).

Figure 2.4: 1H NMR spectrum of 68, highlighting the pseudo 6-membered ring formed through
hydrogen bonding, inducing rigidity at the C4 position.

In contrast, the 1H NMR spectrum of 69 displays two asymmetrical signals –
two multiplets at 3.25-3.49 ppm integrating for the two hydrogens bound to Cε
(Figure 2.21). The axial C4 stereochemistry of 69 produces a “cis” configuration in the
C-C bond linking the C4 and C5 of the pyran ring, resulting in a shorter relative
distance between the C4-OAc group and the C5-amide linkage. When aligned in a
manner akin to that described for the 1H NMR of 68 (CDCl3, 25°C), it can be speculated
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that the amide proton of 69 is facing in an opposing direction to the ring-bound oxygen
at the 4-position. The greater distance between these groups would limit their
interaction, and thus likelihood of forming a hydrogen bond. Hence, near-free rotation
of the C-C bond present at the C5 would occur, resulting in a greater degree of chemical
equivalence for the Cε compared to the corresponding protons in 68 (Figure 2.5).

Figure 2.5: 1H NMR spectrum of 69, highlighting the chemical equivalence of the two protons
bound to Cε, allowing for bond rotation at the C5 position.
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2.4.2 Synthesis of Leucine, Methionine and Glutamine α-Amino linked
Derivatives (70-73)
Based on the success of coupling 60 and 65 to lysine and serine residues, this
methodology was next applied to the coupling of amino acid residues via their α-amino
group. Leucine (Leu), methionine (Met) and glutamine (Gln) were selected as ideal
coupling amino acids, with these residues comprising a range of sidechain functional
groups that are resistant to coupling conditions (aliphatic chain, thioether and amide). In
addition to this trait, the synthesis of derivatives including glutamine, leucine and
methionine would be highly advantageous, as previous studies have highlighted the
utility of these amino acids in targeting of amino acid transport.169–172
Glutamine has been targeted primarily for magnetic resonance imaging of
tumour cells,173,174 with some studies utilizing fluorinated derivatives of glutamine in
the metabolic imaging of tumour cells.175 Leucine has been investigated for ultrasonic
imaging of tumour angiogenesis as part of the cell binding tripeptide arginine-arginineleucine.176 Methionine (Met) is the most widely used [11C]-labelled amino acid in
clinical PET imaging,170,177 with derivatives also labelled with fluorine-18 under current
investigation for use in the imaging of tumours.169,171,178 The linkage of these amino
acids to either 60 or 65 would generate a novel class of N-α-linked “clickable”
glyococonjugates that could be evaluated potentially in the development of
radiolabelled glycoconjugates formed using the CuAAC “click” reaction.179
Contrasting the previously used DCC and DCC/HOBt coupling protocols in the
syntheses of 66-69, HBTU was selected as the coupling reagent. Possessing milder
reactivity than carbodiimide-based coupling reagents such as DCC and DIC, HBTU and
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related coupling reagents (HATU, TBTU, HCTU) display a lower propensity to induce
racemization in the coupling amino acid residue – an important attribute considering the
position of the unhindered α-amino group adjacent to the stereocentre of the amino
acid.150 Hence, using HBTU in the presence of DIPEA in DMF, attempts were
undertaken to couple glc-sugar azido acid 60 to H.Leu.OMe.HCl, producing the novel
conjugate 70 in 84% yield (Figure 2.22). This method was extended to the synthesis of
the novel gal- sugar azido acid leucine conjugate 71, which was produced from 65 and
H.Leu.OMe.HCl in 78% yield (Scheme 2.17).

Scheme 2.17: Synthesis of leucine-based “clickable” glycoconjugates 70 and 71

The presence of doublets at 6.70 and 6.82 ppm in the 1H NMR spectra of 70 and
71, respectively is indicative of the amide-bond formed during the coupling procedure,
with further signals at 4.57 and 4.70 ppm correlating to the proton at the α-carbon of the
leucine each integrating for one proton (Figure 2.6).
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Figure 2.6: 1H NMR spectra of leucine-based “clickable” glycoconjugates 70 and 71, highlighting
the deshielded amide nitrogen and proton of the α-carbon of leucine

Following on from the efficient coupling of H.Leu.OMe.HCl to 60 and 65, this
procedure was extended to the coupling of glc- sugar azido acid 60 with
H.Met.OMe.HCl and H.Gln.OtBu.HCl, producing the glycosyl amino acids 72 and 73
in 95% and 96% yields, respectively (Scheme 2.18).
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Scheme 2.18: Synthesis of “clickable” glycoconjugates 72 and 73.

Containing thioether and amide functional groups, the coupling of both
H.Met.OMe.HCl and H.Gln.OtBu.HCl were both well tolerated under the conditions
used, with clean coupling occurring. This is verified by the

13

C NMR spectrum of 72,

where a signal at 165.7 ppm indicates coupling of the carboxylic acid to form an amide
bond (Figure 2.7). In the

13

C NMR spectrum of 73, coupling was verified by the

presence of a signal at 167.5 ppm, with a downfield signal 174.9 ppm highlighting the
shielding effect imposed on the carbonyl carbon by the α-amino group as opposed to the
amide present on the sidechain (Figure 2.8).

Figure 2.7: 13C NMR spectrum of methionine-based “clickable” glycoconjugate 72, highlighting the
shielded carbonyl signal resulting from amide bond formation.
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Figure 2.8: 13C NMR spectrum of glutamine-based “clickable” glycoconjugate 73, highlighting the
shielded signal resulting from amide bond formation in comparison to the sidechain amide bond
carbonyl.

2.5 Synthesis of Functionalized Glycoconjugates
2.5.1 Optimisation of CuAAC “Click” Reaction Conditions
With the production of “clickable” glycoconjugates 66-73 successfully achieved,
efforts were subsequently made to demonstrate the versatility of the CuAAC “click”
reaction towards this class of compounds. In order to optimize reaction conditions for
all “click” reactions to be performed, the previously synthesized allyl ester intermediate
59 was utilized as an azide bearing glycoside, with the cheap and widely available 3butyn-1-ol used as an alkyne donor. Using varying quantities of different copper salts
(CuSO4, Cu(OAc)2) and sodium ascorbate,131,180 different solvent conditions, reaction
times and the use of copper-stabilizing additives (e.g TBTA),181 the CuAAC “click”
reaction between 59 and 3-butyn-1-ol was successfully optimized, producing the
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triazole-containing glycoconjugate 74 in 88% yield after 24 hours of reaction time
(Table 2.2, Entry F).
Table 2.2: Optimization of CuAAC “Click” reaction conditions, producing the triazole-bearing
functionalized glycoconjugate 74.

TLC monitoring of the reaction mixture highlighted the formation of a spot at
significantly reduced Rf (0.18, 1:1 Hexane: EtOAc), which was indicative of

the

formation of a more polar product than the starting material, due to the presence of the
terminal alcohol present on the alkyne.

It is interesting to note that during our

evaluation of different reaction conditions, the utilization of the known additive TBTA
provided some increase in reaction yield, but was not ultimately used further (Table 2.2,
Entry E). This is a result of the extra purification required to isolate 74 from the reaction
mixture in the presence of TBTA, which during chromatographic isolation co-eluted
with the product. In addition to visualization using TLC, the formation of 74 was
highlighted in the 1H NMR spectrum, where the presence of a singlet at 7.74 ppm was
79 | P a g e

Chapter 2: Serine, lysine and α-amino linked “clickable” glycoconjugates

indicative of the proton present at the 5’-position of the newly-formed triazole ring
of 74, with multiplets at 2.92 and 3.87 ppm each integrating for two protons indicative
of the CH2 groups linked to the triazole and hydroxyl groups, respectively (Figure 2.9).

Figure 2.9: 1H NMR spectrum of the functionalized triazole-bearing glycoconjugate 74.

Following on from the formation of 74, the CuAAC “click” reaction was further
evaluated against a variety of alkyne donors. In the presence of 4-pentyn-1-ol, 59 and its
respective gal-analogue 64 underwent successful “click” reaction, producing the
triazole-bearing glycoconjugates 75 and 76 in 84% and 80% yields, respectively
(Scheme 2.19). Compared to 74, the 1H NMR spectrum of 75 was quite similar except
for the presence of a multiplet at 1.95ppm, which was indicative of the central CH2
group of the ligated alkyne. This too was represented in the 1H NMR spectrum of 75
at 1.95 ppm. Following on from these examples, 59 was subjected to CuAAC “click”
reaction with phenylacetylene, producing the glycoconjugate 77 in 85% yield
(Scheme 2.19). A very different alkyne donor to those used in the production of 74-76,
the formation of the triazole was distinguished in the 1H NMR by a signal at 8.08 ppm,
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with the deshielding of the triazole proton compared to 74-76 likely due to the
deshielding effect of the neighbouring phenyl ring.

Scheme 2.19: Synthesis of triazole-bearing functionalized glycoconjugates 75-77.

2.5.2 Synthesis of Functionalized Glycoconjugates (78-87)
With reaction conditions for the CuAAC “click” reaction optimized, the
functionalization of “clickable” glycoconjugates was undertaken. Initially evaluating
sidechain-linked derivatives, the serine-based glc “clickable” glycoconjugate 66,
CuAAC “click” reaction with 3-butyn-1-ol resulted in the functionalized glycoconjugate
78 in 62% yield (Scheme 2.20). Similarly to 59 and 64, this was extended to 4-pentyn1-ol, where “click” reaction with 66 and the gal serine-based “clickable” glycoconjugate
67 resulted in the production of functionalized glycoconjugates 79 and 80 in 58% and
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69% yield, respectively (Scheme 2.20), with LR-ESIMS of 79 and 80 (m/z 653,
molecular formula C26H38N4O14 + Na) confirming their production. Similarly, the glc
and gal lysine-based “clickable” glycoconjugates 68 and 69 were subjected to the
CuAAC “click” reaction. In the presence of 3-butyn-1-ol, “click” reaction with 68
resulted in the production of the functionalized glycoconjugate 81 in 70% yield
(Scheme 2.20). The presence of a singlet in the 1H NMR spectrum of 81 at 7.87 ppm
was indicative of triazole formation. Subsequently, 68 and 69 were subject to the
CuAAC “click” reaction in the presence of 4-pentyn-1-ol, producing the functionalized
glycoconjugates 82 and 83 in 63% and 75% yields, respectively (Scheme 2.20).

Scheme 2.20: Synthesis of triazole-bearing functionalized glycoconjugates 78-83.
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As a result of the successful production of functionalized glycoconjugates 78-83,
our focus turned to the synthesis of analogues derived from the previously synthesized
α-amino derivatives 70-73. Beginning with the glc and gal-linked leucine derivatives 70
and 71, in the presence of 4-pentyn-1-ol both of these underwent CuAAC “click”
reaction to produce the triazole-bearing functionalized glycoconjugates 84 and 85 in
80% and 75% yield, respectively (Scheme 2.21).

HR-ESIMS of both 84 and 85

displayed molecular ions of m/z 579.2271 and 579.2273 respectively, which
corresponded to a molecular formula of C24H36N4O11 + Na (579.2278) confirming the
formation of the desired products.

Scheme 2.21: Synthesis of triazole-bearing functionalized glycoconjugates 84 and 85

Subsequently, the CuAAC “click” reaction was extended to the methionine and
glutamine-based derivatives 72 and 73, whereby reaction with 4-pentyn-1-ol under the
previously

optimized

conditons

produced

the

triazole-bearing

functionalized

glycoconjugates 86 and 87 in 85% and 63% yields, respectively (Scheme 2.22).
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Scheme 2.22: Synthesis of triazole-bearing functionalized glycoconjugates 86 and 87

The 1H NMR spectra of 86 and 87 displayed the presence of signals at 7.63 ppm
and 8.15 ppm, both indicative of the triazole protons present in 86 and 87. Furthermore,
a desielded signal at 2.86 ppm in the 1H NMR spectrum of 86 is indicative of a CH2
adjacent to an aromatic ring, indicative of the Hα protons introduced into 86 post “click”
reaction (Figure 2.10). These protons are readily distinguished from the more shielded
Hβ, and the more deshielded Hγ protons of 86 (Figure 2.10).

Figure 2.10: 1H NMR spectrum of the functionalized glycoconjugate 86, highlighting the formation
of the triazole ring.
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2.6

Towards

the

Synthesis

and

Functionalization

of

“Clickable” Glycopeptides
2.6.1 Synthesis of Sugar Azido Acid-Ac.Lys-Pro-Val.NH2
Considering the success achieved in the synthesis and functionalization of
“clickable” glycoconjugates 78-87, the methodology was next investigated for
expansion to the production and functionalization of “clickable” glycopeptides. Hence,
in order to evaluate this possibility, our focus turned to the replication of this
methodology on a small peptide system. In evaluating a peptide for coupling, it was
recognized that a few key criteria would be important in selecting the peptide,
including:


Relevance to bioconjugation



Contains a number of different functional groups that would be stable to the
condition of the CuAAC “click” reaction

With these criteria in mind, an analysis of the literature was undertaken to discover a
suitable candidate for this study. During this investigation, the protected tripeptide
analogue Ac.Lys-Pro-Val.NH2 (Ac.KPV.NH2) (Figure 2.11) drew considerable
attention. Forming the C-terminus of the naturally-occurring peptide α-melanocortin
stimulating hormone (α-MSH) (Figure 2.11), Ac.KPV.NH2 and its parent peptide have
been found to display anti-inflammatory and antimicrobial activities, with Ac.KPV.NH2
displaying activity comparable to the parent α-MSH.100,182,183 Furthermore, in respect to
the compatibility of Ac.KPV.NH2, the variety of functional groups it encompasses
aligned

well
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those

present

in
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functionalized

“clickable”
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glycoconjugates, suggesting that the peptide would be stable to the CuAAC “click”
reaction conditions previously optimized.

Figure 2.11: Primary structure of α-melanocortin stimulating hormone (α-MSH), and Nα-acetyl
lysine-proline-valinamide (Ac.KPV.NH2), a tripeptide analogue of the C-terminus of α-MSH

Therefore, in order to evaluate the CuAAC “click” reaction on a small
glycopeptide, the glc- sugar azido acid 60 was coupled to the commercially available
tripeptide Ac.Lys-Pro-Val-NH2.HCl, which in the presence of HBTU and DIPEA in
DMF produced the β-azide containing glycopeptide 88 in 53% yield (Scheme 2.23).

Scheme 2.23: Synthesis of Ac.KPV.NH2-based “clickable” glycopeptide 88
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Evaluation of the 1H NMR spectrum of 88 showed clear evidence of the desired
coupled product, with a signal 6.83 ppm indicative of the sidechain NH2 of the lysine of
Ac.KPV.NH2.HCl (Figure 2.35). Furthermore, two multiplets integrating for one proton
each at 3.38 and 3.05 ppm indicate splitting of the two geminal protons present on the
Cε of the lysine of the peptide – a result of their significantly different ”environments”
resulting from hydrogen bond stabilization (Figure 2.12). The correlations between
these protons – similarly to the previously synthesized “clickable” glycoconjugate 68,
were exemplified in a gCOSY 2D NMR experiment of 88, displaying a clear three-bond
coupling between the geminal protons linked to the Cε of the lysine of
Ac.KPV.NH2.HCl and the neighbouring NH (Figure 2.13).

Figure 2.12: 1H NMR spectrum of the glc-Ac.KPV.NH2-based “clickable” glycopeptide 88,
highlighting the pseudo 6-membered ring formed through hydrogen bonding, and three-bond
coupling correlation.
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Figure 2.13: 2D

1

H NMR gCOSY experiment of the glc-Ac.KPV.NH2-based “clickable”

glycopeptide 88, highlighting the pseudo 6-membered ring formed through hydrogen bonding, and
three-bond coupling correlation.

With the synthesis and isolation of 88 achieved, the functionalization of the
azide-bearing glycopeptide is expected to be straightforward. However, the production
of 89 using the CuAAC “click” reaction was not performed due to time restraints.
(Figure 2.24).
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Scheme 2.24: Postulated synthesis of the glc-Ac.KPV.NH2-based functionalized glycopeptide 89

Herein, the synthesis and functionalization of a range of sidechain and α-amino
linked glycoconjugates utilizing the CuAAC “click” reaction, has been described.
Furthermore, the synthesis of the biologically-relevant glycopeptide 88 has provided an
opportunity for the production of functionalized glycopeptides (such as 89) via the
CuAAC “click” reaction. In chapter 3, the synthesis and functionalization of “clickable”
glycoconjugates will be further discussed, encompassing sidechain carboxyl-containing
amino acids.
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Chapter 3 : Synthesis and Functionalization of
Sidechain-Linked “Clickable” Glycoconjugates

As illustrated in Chapter 2,”clickable” glycoconjugates represent a class of
molecules that can be readily incorporated into biologically-active peptides, whilst
retaining free handles for use in the CuAAC “click” reaction. In this chapter, the
development of sidechain-linked “clickable” glycoconjugates will be examined.

3.1 Synthetic Rationale
In Chapter 2, the development of serine and lysine sidechain and leucine,
methionine and glutamine α-amino linked “clickable” glycoconjugates, and their
functionalization using the CuAAC “click” reaction, highlighted the potential of these
species for utilization in the labelling of biologically-active peptides. Exploiting ester
and amide-coupling chemistry in the preparation of these conjugates,150 this platform
methodology allows for the conjugation of sugar azido acids to a variety of different
compatible amino acid residues used in bioconjugation, as highlighted by the synthesis
of the “clickable” glycopeptide 88. This strategy is highly advantageous in the synthesis
of conjugates with free hydroxyl and amino groups, however it would also be useful to
expand this methodology to other amino acid residues used in labeling and
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bioconjugation. These include those bearing sidechain carboxyl groups, such as aspartic
acid and glutamic acid.
Carboxyl-containing amino acid residues can be readily coupled to a
glycosylamine to give rise to stable amide linkages formed using peptide-coupling
chemistry. Hence, in consideration of the research detailed in Chapter 2, if a
methodology utilizing amide coupling was developed to form conjugates between
carboxylic acid-containing amino acids and azido glycosylamines, such analogues
would be examples of amide-linked “clickable” glycoconjugates. Analogous to the
glucuronic acid derivatives 66-73 described in Chapter 2, these conjugates would be
amenable to the CuAAC “click” reaction, allowing for their use in the labelling and
conjugation of biologically-active peptides (Scheme 3.1).

Scheme 3.1: Proposed synthesis of sidechain carboxyl-linked "clickable" glycoconjugates.

3.2 Synthetic Approach
It was recognized that the pronounced reactivity of the anomeric and 6-positions
of a pyranoside would favour azidonation or amination/conjugate formation, compared
to other positions on the pyran ring. Using a simple glycosyl precursor containing a
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suitable leaving group (Ts, etc) at the 6-position, in stallation of an azide moiety via SN2
nucleophilic substitution would be highly favourable. Such 6-azidonated glycosides
may then be subjected to reduction, producing an amine at the 6-position that could be
coupled to carboxylic acid-containing derivatives to produce 6-amide linked sugar
derivatives.146,184 Accordingly, a second azide group could be introduced at the
anomeric centre, resulting in 6-linked azido sugar derivatives that may be amenable to
the CuAAC click reaction (Scheme 3.1).
Conversely, an azide could be introduced at the 6-position of a relevant
furanoside or pyranoside, and left available for utilization in the CuAAC reaction, with
the introduction of an amine at the anomeric position, and subsequent protection and
coupling of a sidechain carboxyl-containing amino acid would produce anomeric
amide-linked conjugates (Scheme 3.1).185,186 The literature precedence for the synthesis
of 6-azidoglycosylamines, endorses this strategy in the production of sidechain-linked
“clickable” glycoconjugates (Scheme 3.1).

3.3 - Synthesis and Functionalization of Anomeric-linked
“Clickable” Glycoconjugates
Thus, to further extend the library of “clickable” glycoconjugates to those linked
via an acidic sidechain or α-carboxyl group, derivatives linked via the anomeric centre
were investigated. As mentioned, an evaluation of the literature showed precedence for
the preparation of glycoconjugates based upon glucopyranosylamines, including those
bearing azide groups at a variety of different positions on the pyran ring.187,188
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Stereoselective amination of the anomeric centre of pyranoside has been thoroughly
investigated, with the early work of Likhosherstov and coworkers utilizing either
ammonium carbonate, ammonium bicarbonate and ammonium carbamate in the
production of β-glucopyranosylamines.189 As a result, the tandem use of azidosugars
encompassing an anomeric amine, such as the azidoglucopyranosylamines prepared by
Garcia Fernandez and coworkers, have been used to great effect, providing synthons
(such as 90) that can readily undergo reaction at the anomeric centre, whilst maintaining
an additional handle for derivatization (Scheme 3.2).188

Scheme 3.2: Further derivatization of an azidoglucosylamine (90) previously described by Garcia
Fernandez and Co-workers.188

In the current context, azidoglucopyranosylamines can be accessed concisely
from the known precursor 6-azido-1,2-α-D-glucofuranose (96), with protecting group
manipulation providing synthons that can be coupled to both an acidic sidechain or
α-carboxyl containing amino acid derivatives, and be available for use in the CuAAC
“click” reaction (Scheme 3.3). Furthermore, the convergent nature of this approach
allows for the utilization of a variety of different amino acid protecting group strategies,
making such molecules amenable to further amino acid coupling (Scheme 3.3).
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Scheme 3.3: Approach towards the synthesis of amide-linked “clickable” glycoconjugates linked at
the anomeric position.

3.3.1 Synthesis of Key β-Azidoglycosylamine Intermediate 103
As a starting point for the production of amide-linked “clickable”
glycoconjugates, the synthesis of the known 6-azido-1,2-isopropylidene-α-Dglucofuranose (96) was initiated. Starting from the commercially available, 1,2:5,6-diisopropylidene-α-D-glucofuranose (93), cleavage of the primary acetonide under mild
70% acetic acid was effected, resulting in the production of 1,2-isopropylidene-α-Dglucofuranose (94) in 90% yield (Scheme 3.4), which was confirmed by 1H and
13

C NMR spectroscopy.190 Subsequently, 94 was subjected to standard tosylation

conditions, with selective tosylation of the primary 6-OH resulting in the production of
6-p-toluenesulfonyl-1,2-isopropylidene-α-D-glucofuranose

(95)

in

73%

yield

(Scheme 3.4). The presence of two doublets at 7.79 and 7.33 ppm (J = 7.9 Hz) in the 1H
NMR spectrum, each integrating for two protons is indicative of the formation of the
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mono-tosylated product, with the LR-ESIMS spectrum of 95 highlighting a signal at m/z
397, which was indicative of the product. The selectivity observed is a result of the
steric hinderance encountered by the 3- and 5-OH groups, with the additional freedom
of rotation experienced by the primary 6-OH providing a greater level of selectivity
towards the 6-OH of 94.

Scheme 3.4: Synthesis of 6-azido-1,2-isopropylidene-α-D-glucofuranose (96).

With 95 in hand, a modified procedure of Fleet et al. was trialled in the
production of 96.191 SN2 nucleophilic substitution of the 6-tosyl group by NaN3 in DMF
resulted in the requisite 6-azido-1,2-isopropylidene-α-D-glucofuranose (96) in 74%
yield (Scheme 3.4). This was confirmed in the 1H NMR spectrum of 96, where
disappearance of the aromatic protons of 95 indicated substitution with the azide group
(Figure 3.1). Furthermore, the HR-ESIMS displayed a signal of m/z 280.0710 of
chemical formula C9H15N3O5+ Cl (280.0700), which was indicative of the formed
product.
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Figure 3.1: 1H NMR spectrum of 6-azido-1,2-isopropylidene-α-D-glucofuranose (96).

Following the successful production of 96, our focus next shifted to the
synthesis of the key 6-azido-β-D-glucopyranosylamine intermediate 118. Conversion of
the furan ring to a pyran ring initially began with cleavage of the 1,2-isopropylidene
group, using 80% acetic acid at 80°C, to yield the lactol intermediate 97 (Scheme 3.5).
Subsequently, the glycoside was subject to prolonged heating in a saturated solution of
NH4HCO3 at 40°C over four days. In this aqueous solution, it is proposed that the
furanose intermediate underwent interconversion to its respective reducing sugar, which
in the presence of NH3 (formed from the decomposition of NH4HCO3) resulted in the
formation of the aminal intermediate 98. Driven forward by the abstraction of dissolved
CO2 from the solution, 98 could then cyclize through the 5-OH of the reducing sugar,
forming the pyranose carbamate ammonium salt 99 (Scheme 3.5). Indeed, the potential
presence of this intermediate was suggested by the presence of a signal in the
LR-ESIMS of the reaction mixture (m/z 265). Key to the formation of 99 was the
maintenance of a saturated NH4HCO3 solution at precisely 40°C, with dissolved NH3
and CO2 gas essential for the reaction. Furthermore, if heated above 50°C, significant
dimerization to form the bisglycosylamine compound 100 (m/z 409, M + NH4+) was
observed (Scheme 3.5).
97 | P a g e

Chapter 3: Sidechain and α-carboxyl linked “clickable” glycoconjugates

Scheme 3.5: Proposed mechanism for the production of 99 utilizing an NH4HCO3-promoted
anomeric amination.

Following lyophilisation, the ammonium salt 99 was subjected to protection of
the anomeric amine using diethyl (ethoxymethylene)malonate, which as an excellent
Michael acceptor that readily underwent nucleophilic substitution, liberating CO2, NH3
and EtOH to produce the required enamine-protected 6-azido-β-D-glucopyranosylamine
101 in 53% yield from 6-azido-1,2-isopropylidene-α-D-glucofuranose (Scheme 3.6).
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Scheme 3.6: Synthesis of enamine-protected 6-azido-β-D-glucopyranosylamine 101.

Evaluation of the 1H and

13

C NMR spectra of 101 (Figure 3.2, A and B) were

inconclusive in their identification of the stereochemistry at the anomeric centre, with
only the 13C NMR spectrum displaying an upfield signal at 91.6 ppm suggesting that the
stereochemistry around the anomeric centre of 101 may be beta (β-). The sole
β-stereochemistry present at the anomeric carbon of 101 was however confirmed by a
NOESY 2D 1H NMR experiment, highlighting correlations between the H1 and H5 of
101, suggesting they are both axially configured (Figure 3.3).

Figure 3.2: A: 1H NMR spectrum of 101, highlighting signals indicating H1 and H3, B: 13C NMR
spectrum of 101, highlighting the downfield C1 carbon.
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Figure 3.3: NOESY 2D 1H NMR experiment of 101, showing weak H1/H5 correlation.

Following the installation and protection of the required anomeric β-amine, 101
was then subject to peracetylation of the free 2-,3- and 4-OH groups under standard
Ac2O/pyridine conditions, yielding the fully protected glycoside 102 in 92% yield
(Scheme 3.7). Subsequently, the anomeric enamine of 102 was cleaved under aqueous
Br2, unmasking the anomeric amine, which was stabilized as a hydrobromide salt,
producing 103 in 73% yield (Scheme 3.7).

Scheme 3.7: Synthesis of the 6-azido-2,3,4-tri-O-β-D-glucopyranosylamine hydrobromide salt 103.
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In the presence of Br2, the enamine 102 is subject to Markovnikov addition
across the double bond, resulting in the formation of an iminium intermediate
(Scheme 3.8). The presence of water in the reaction mixture drives nucleophilic
substitution of the imine, which following proton transfer results in the formation of a
α-hydroxy intermediate. Subsequently, the presence of bromide ions in situ from the
initial use of Br2 drive the formation of an aldehyde, resulting in the production of the
desired ammonium hydrobromide salt 103 (Scheme 3.8). Whilst the synthesis of the
corresponding hydrochloride salt (90) of 103 has previously been detailed,188 the use of
Br2 represents a more readily accessible, safer option compared to the Cl2 gas
previously utilized.

Scheme 3.8: Proposed mechanism for the formation of 103 through enamine cleavage mediated by
wet Br2.
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The formation of 103 was indicated in the

13

C NMR spectrum, where the

disappearance of the signal for the methylene carbon of 102, and the shielding of the
anomeric carbon from 95.2 ppm in 102 to 79.1 ppm in 103 due to the unmasking of the
free amine, verified the cleavage of the anomeric protecting group (Figure 3.4).

Figure 3.4:

13

C NMR spectra of 102 and 103, highlighting the deprotection of the anomeric

enamine.

3.3.2 Synthesis of Boc-protected Amino Acids 108 and 109
With the required 6-azido-β-D-glucopyranosylamine 103 in hand, our focus now
shifted to the synthesis of amino acids that could be coupled with 103. Considering the
widespread use of both aspartic and glutamic acid residues in the synthesis of
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bioconjugates,192 it was decided that conjugates between 103 and protected aspartic and
glutamic acid residues would be synthesised to broaden the scope of our current studies.
Hence, the synthesis of both protected aspartic acid and glutamic acid
derivatives was performed, with the known Boc.Asp.OMe (108) and Boc.Glu.OMe
(109) chosen. Starting from the Boc-N-protected benzyl ester derivatives 104 and 105,
using our own developed method methyl iodide and K2CO3 were employed to protect
the α-carboxylic acid group of 104 and 105, with successful esterification producing
Boc.Asp(OBn).OMe (106) and Boc.Glu(OBn).OMe (107) in 85% and 92% yields,
respectively (Scheme 3.9). Subsequently, reduction of the sidechain benzyl ester
protecting groups of 106 and 107 produced the required Boc.Asp.OMe (108) and
Boc.Glu.OMe (109) in 84% and 86% yields, respectively (Scheme 3.9).

Scheme 3.9: Synthesis of Boc.Asp.OMe (108) and Boc.Glu.OMe (109).
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3.3.3

Synthesis

of

Sidechain

Carboxyl-linked

“Clickable”

Glycoconjugates 110 & 111
With our key building blocks synthesized, coupling between these protected
amino acids 108 and 109 commenced. Utilizing HBTU as a coupling reagent in the
presence of DIPEA, Boc.Asp.OMe (108) was successfully coupled to 103, with reaction
over 24 hours resulting in the “clickable” glycoconjugate 110 in 74% yield
(Scheme 3.10).

Scheme 3.10: Synthesis of sidechain carboxyl-linked “clickable” glycoconjugates 110 and 111.

In the 1H NMR spectrum of 110, the presence of a deshielded doublet at
6.55 ppm with coupling of 9.0 Hz was suggestive of a proton present on an amide
nitrogen, indicative of the amide bond formed through the coupling (Figure 3.5, A).
Furthermore, evaluation of a gCOSY experiment of 110 displays a correlation between
this signal and a multiplet at 5.26 ppm, representing the three bond coupling present
between H1 and the anomeric-linked NH (Figure 3.5, B). In addition to these, signals at
3.74 and 1.44 ppm integrating for three and nine protons respectively, and a signal in
the

HR-ESIMS

of

m/z

582.2029

representing

a

chemical

C22H33N5O12+Na (582.2023), definitively illustrated the production of 110.
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Figure 3.5: 1H NMR spectrum (A) and gCOSY 2D 1H NMR experiment (B) of the sidechain
carboxyl-linked “clickable” glycoconjugate 110, highlighting the correlation between the H1 and
NH resulting from amide bond formation.

The success achieved in the formation of 110 was subsequently extended to the
coupling of Boc.Glu.OMe. Reaction of 103 with under HBTU-mediated coupling
conditions resulted in the production of the Glu-linked “clickable” glycoconjugate 111
in 79% yield (Scheme 3.10). Similarly to 110, the presence of a deshielded doublet at
6.85 ppm in the 1H NMR spectrum of 111 was indicative of the proton bound to the
anomeric amide nitrogen, with a gCOSY experiment of 111 showing a correlation
between the NH proton and a multiplet at 5.31 ppm representing the H1 proton. In the
13

C NMR spectrum of 111, a signal at 172.7 ppm was indicative of the carbon of an
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amide linkage, indicative of the coupling of 100 and 106. Furthermore, the HR-ESIMS
displayed a signal of m/z 596.2204 representing a chemical formula of
C23H35N5O12+Na (596.2180), indicative of the desired product. Examples of sidechain
carboxyl-linked “clickable” glycoconjugates, 110 and 111 represent the first instances
of sidechain carboxyl-linked “clickable” glycoconjugates described.

3.3.4

Synthesis

of

Functionalized

Sidechain

Carboxyl-linked

Glycoconjugates 112 & 113
With the production of carboxyl sidechain-linked “clickable” glycoconjugates
110 and 111 successfully achieved, our attention now turned to their functionalization
via the CuAAC “click” reaction. Utilizing the conditions previously described in
Chapter 2 for the functionalization of “clickable” glycoconjugates 66-73, aspartic acid
derivative 110 was subject to the CuAAC “click” reaction with 4-pentyn-1-ol.
Subsequently, after work up and flash column chromatography the functionalized
derivative 112 was isolated, in 70% yield (Scheme 3.11).

Scheme 3.11: Synthesis of functionalized sidechain carboxyl-linked “clickable” glycoconjugates
112 and 113 through the CuAAC “click” reaction.
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An evaluation of the 1H NMR spectrum of 112 illustrated the formation of the
desired triazole-bearing product, with a singlet at 7.54 ppm ascribed to the triazole
proton (Figure 3.6). Interestingly, two signals at 4.55 ppm and 4.61 ppm were
suggestive of the H6/H6’ protons adjacent to the triazole ring, with the electron-rich
nature of the neighbouring triazole ring deshielding these protons by approximately
1.1 ppm compared to the parent glycoconjugate 110 (Figure 3.5). Furthermore,
HR-ESIMS of 112 displayed a signal of m/z 666.2621, which was indicative of the
product with a molecular formula of C27H41N5O13 + Na (666.2599).

Figure 3.6: 1H NMR spectrum (4.0 ppm – 8.0 ppm) of functionalized glycoconjugate 112,
highlighting the formation of a 1,4-substituted triazole.

Subsequently, following on from the successful production of 112, the glutamic
acid derivative 111 was also subjected to the CuAAC “click” reaction with
4-pentyn-1-ol, which up on work up and isolation yielded the functionalized derivative
113 in 62% yield (Scheme 3.11). Similarly to 112, a downfield singlet in the 1H NMR
spectrum of 113 at 7.72 ppm was indicative of the desired product, representing the
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triazole proton. Furthermore, a more deshielded doublet at 4.31 ppm was ascribed to the
H6/6’ protons of 113, with the HR-ESIMS of 113 displaying a signal for the desired
product of m/z 680.2793, corresponding to the formula C28H43N5O13+ Na (680.2755).
To summarize, the synthesis of the azidoglucosylamine 103 has provided access
to the development of “clickable” glycoconjugates 110 and 111 through amino acids
coupled to sidechain-carboxyl groups. Further derivatization of these glyconjugates
utilizing the CuAAC “click” reaction has broadly extended the uility of this
methodology beyond the ester and amide-linked conjugates produced in chapter 2. In
chapter 4, the extension of this approach to the synthesis and functionalization of
thioether-linked “clickable” glycoconjugates will be discussed.
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Chapter 4 : Synthesis and Functionalization of
Thioether-linked “Clickable” Glycoconjugates

Chapters 2 and 3 detailed the development of ester and amide linked azido
sugar amino acid derivatives attached through either sidechain groups such as NH2,
OH or COOH, or via the N-terminus. These ”clickable” glycoconjugates could be
readily incorporated into biologically-active peptides, whilst retaining free handles for
use in the CuAAC “click” reaction. In this chapter, the development of thioether-linked
“clickable” glycoconjugates will be presented.

4.1 Synthetic Rationale
In Chapters 2 and 3, the synthesis of “clickable” glycoconjugates exploiting
amide-coupling chemistry was highlighted. Demonstrating the coupling of sugar azido
acids to a variety of different amino acid residues (e.g. Ser, Lys, Asp and Glu), the
following approach provides a highly advantageous method for the synthesis of
bioconjugates. However, beyond the following amide and ester-linked examples, there
are a number of different conjugate types that are incompatible with this approach.
These include thioesters formed through the coupling of thiol-containing amino acids
such as cysteine or homocysteine to carboxylic acids, which are less stable than their
corresponding esters.193 Thioesters are susceptible to degradation under acidic or basic
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conditions and prone to substitution in the presence of stronger oxygen and nitrogenbased nucleophiles. Although their use has been widely applied in areas of peptide and
ligation chemistry, such as native chemical ligation,193,194 the lability of these linkages
has made their use in the development of stable bioconjugates unsuitable.
In contrast, thioethers represent linkages which provide excellent chemical
stability under a range of different conditions. Widely accessible through alkylation,
they have been commonly used in the developments of conjugates with thiol or alcoholcontaining amino acids.195 If a class of azidosugars were developed that had the capacity
to form thioether linkages, these could produce glycoconjugates with amino acids such
as cysteine and homocysteine. Comparable to the examples described in Chapter 2 and
Chapter 3, these glycoconjugates would be “clickable,” and could therefore be utilized
to functionalize biologically-active peptides via “click” chemistry (Scheme 4.1).

Scheme 4.1: Proposed synthesis of thioether-linked "clickable" glycoconjugates.

4.2 Initial Synthetic Approach
Building upon the earlier strategies that produced “clickable” glycoconjugates
bearing azides at the anomeric (Chapter 2) and 6-position (Chapter 3) of the glycoside,
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respectively, a divergent synthetic strategy that could produce both of these types of
glycoconjugates was initially undertaken. Using a simple precursor such as D-glucose
would allow for the introduction of the required azide moiety. Also, the presence of a
suitable leaving group would allow for the installation of a thioether-linkage through
alkylation. A p-toluenesulfonyl (tosyl; Ts) group, when utilized in a fully-protected
glycoside (such as 114, Figure 4.3), provides a strategy whereby an azide moiety can be
introduced into the molecule by a number of different ways (Scheme 4.2, pathway A).

Scheme 4.2: Pathways towards the synthesis of thioether-linked “clickable” glycoconjugates.

Akin to examples described in chapter 2 (cf earlier synthesis of 58 and 63,
section 2.3), bromination of the anomeric acetate of 114 using HBr in acidic conditions
could be utilized to produce an anomeric α-bromide intermediate (115). Based on Hard
Acid Soft Base (HSAB) theory, both the anomeric α-bromide and OTs groups represent
soft leaving groups. The bromide of 115 however is a better leaving group than the
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6-OTs moiety, with this judgement based on the pKa of the conjugate acid of each
leaving group (pKa: HBr = -9, TsOH = -2.8). As a result of this difference, in the
presence of NaN3 selective SN2 nucleophilic substitution of the anomeric centre of 115
would be favoured, resulting in the production of the β-azide 116. Subsequently, the
replacement of the stable 6-OTs of 116 with a more labile leaving group (e.g. halide Br, I) would produce a glycoside that could be alkylated to yield thioether-linked
glycoconjugates (Figure 4.2, pathway A). This judgement is based on the soft nature of
a thiol nucleophile, with a softer leaving group (for example, pKa HI = -10), more likely
to undergo nucleophilic substitution in the presence of a relatively soft nucleophile.
Alternatively to this approach, the tosyl group of 114 could be subjected to directly
nucleophilic substitution in the presence of NaN3, resulting in the production of the
6-azidonated glycoside 125. The subsequent introduction of an anomeric leaving group
would allow for the formation of the desired glycoconjugates through glycosylation
chemistry (Scheme 4.2, pathway B).

4.3 Attempted Synthesis of 6-Thioether-linked “Clickable”
Glycoconjugates
4.3.1 Synthesis of 6-Iodo-2,3,4-tri-O-acetyl-β-D-glucosyl azide (117)
With the following options available, the synthesis of thioether-linked
“clickable” glycoconjugates initially focused on the synthesis of derivatives
incorporating amino acids linked to the glycoside at the 6-position. The lack of a
stereocentre at the 6-position of these glycosides would remove problems regarding
113 | P a g e
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stereoselectivity in these conjugates, and the potential formation of epimers during
alkylation. Hence, D-glucose was initially subject to p-tosylation at the 6-position using
p-touenesulfonyl chloride and pyridine, with the subsequent addition of acetic
anhydride resulting in the acetylation of the remaining alcohols, producing
6-p-toluenesulfonyl-1,2,3,4-tetra-O-acetyl-D-glucose

(114,

Scheme

4.3)

in

40% yield.196 The moderate yield of this reaction is a direct result of the lack of
selectivity of the p-tosylation step, which in comparison to the previously synthesized
furanose p-tosylate 95 is much less hindered. The inefficiency of this process however,
was offset by the high scalability and simple purification of this process, in addition to
the divergent nature of the synthesis to be performed from this key intermediate.
With 114 in hand, installation of the anomeric β-azide to produce the required
6-p-toluenesulfonyl-β-D-glucosyl azide 116 was undertaken. In comparison to the
synthesis of β-azides previously described in chapter 2, SnCl4-mediated azidonation was
not considered, due to the likely cleavage of the tosyl group in the presence of the tin
catalyst. Hence, 114 was instead subjected to anomeric α-bromination conditions by
reaction with 33% w/v HBr/AcOH in dichloromethane producing the anomeric bromide
intermediate 115 (Scheme 4.3). Under subsequent SN2 nucleophilic azidonation using
sodium azide in DMF, 6-p-toluenesulfonyl-2,3,4-tri-O-acetyl-β-D-glucopyranosyl azide
was isolated in 65% yield over the two steps (116, Scheme 4.3).
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Scheme 4.3: Synthesis of 6-iodo-2,3,4,tri-O-acetyl-β-D-glucopyranosyl azide (117).196

The production of 116 was confirmed by the 1H NMR spectrum, where a
shielded doublet at 4.56 ppm (J = 9.8 Hz) indicated the introduction of a β-azide into
the molecule. Whilst in its own right the p-tosyl group represents a good leaving group,
it was believed that the stability of this group (compared to more labile, soft leaving
groups) would prevent the formation of 124 under mild alkylating conditions. Hence,
the introduction of a more labile leaving group was investigated. A halide, such as an
iodo group, would be more inclined to undergo elimination in the presence of a suitable
nucleophile, negating the requirement for stronger basic conditions to drive alkylation.
Furthermore, it is possible that nucleophilic substitution of the iodo group could be
favoured over the dimerization of the alkylating thiol, a common side reaction in the
presence of base. Hence, utilizing classical Finkelstein iodination conditions employing
4.0 equivalents of sodium iodide in acetone,196 the p-tosyl containing azidosugar 116
was iodinated at the 6-position, to produce 6-iodo-2,3,4-tri-O-acetyl-D-glucosyl azide in
62% yield (117, Scheme 4.3). In the 1H NMR spectrum of 117, the disappearance of
two doublets at 7.80 ppm and 7.36 ppm were indicative of substitution of the tosyl
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group, with a more shielded signal at 3.60 ppm in the

13

C NMR spectrum of 117

indicative of the formation of a C-I bond at the 6-position.

4.3.2 Synthesis of Thiol-bearing Amino Acid Boc.HCys.OtBu (120)
With the requisite carbohydrate building block in hand, the synthesis of the
thiol-containing amino acid was attempted, with the homocysteine (HCys) derivative
N-tertbutoxycarbonyl-L-cysteine-t-butyl ester (Boc.HCys.OtBu) chosen as the thiolcontaining amino acid. Starting from L-homocystine, Boc-protection of the α-amino
groups using aqueous Na2CO3 yielded 118 in 90% (Scheme 4.4), which in the presence
of an excess of t-butyl-2,2,2-trichloroacetimidate yielded the t-butyl diester 119 in
near-quantitative yield (Scheme 4.4).197 Subsequently, the disulfide bond of 119 was
reduced to the thiol using n-tributylphosphine, yielding Boc.HCys.OtBu in 85% yield
(120, Scheme 4.4), with an analysis of the 1H NMR spectrum of 120 highlighting a new
triplet at 1.55 ppm (J = 5.7 Hz) that was indicative of the free thiol group present in 120.

Scheme 4.4: Synthesis of Boc.HCys.OtBu (120) from L,L-homocystine.178,197
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4.3.3

Attempted

Alkylation

of

6-Iodo-2,3,4-tri-O-acetyl-β-D-

glucosyl azide (117)
With the 6-iodosugar 117 and Boc.HCys.OtBu in hand, efforts were made
towards the alkylation of thioether-containing amino acids. In endowing 117 with a
better leaving group in our attempts to form thioether–linked “clickable”
glycoconjugates, it was recognized that the iodo group may be susceptible to cleavage
under the alkylation conditions proposed. This premise was based on the previous work
of Murphy and co-workers, who en route to the production of glc, gal and manno
iminosugars 121-123 produced the hex-5-enopyranosides from 6-iodopyranosides, with
DBU catalysis resulting in HI elimination (Scheme 4.5).198

Scheme 4.5: Proposed mechanism for the elimination of hydrogen iodide from 121-123 in the
presence of a non-nucleophillic base.

Considering that the reported conditions in the glc example (121) required much
higher temperatures to induce elimination (reflux, >110°C)198 than the conditions we
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proposed, it was believed that the competing process of alkylation would occur
favorably with an amino acid containing a good nucleophile. Hence, alkylation of
Boc.HCys.OtBu by 117 was attempted, utilizing a range of different non-nucleophilic
bases to catalyse alkylation. However, under these conditions the formation of the
desired product (124) was not observed, with the azidosugar side product 121 instead
procured in moderate quantities (Table 4.1, Entries 1-3).
Table 4.1: Attempted alkylation of 6-iodo-2,3,4-tri-O-acetyl-β-D-glucopyranosyl azide (117) by
Boc.HCys.OtBu (120).

Comparison of the 1H NMR spectra of 117, Boc.HCys.OtBu and the crude
reaction mixture when Cs2CO3 was used as the alkylating base (Figure 4.1, A-D
respectively), highlighted the degradation of 117 and the near-quantitative conversion of
Boc.HCys.OtBu to the dimerized precursor (Boc.HCys.OtBu)2 (Figure 4.1). This also
was clearly illustrated by LR-ESIMS, with a signal of m/z 603 (M + Na) indicative of
Boc.HCy.OtBu dimerization. The disappearance of signals from 3.0-4.0 ppm in A
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ascribed to the H5 and H6/H6’ protons of 117, the downfield shift of a CH2 signal (120)
to ~2.75 ppm in B, and the appearance of methine protons between 4.5-5.0 ppm in C,
are indicative of the elimination of HI from 117, the reformation of (Boc.HCys.OtBu)2
(119) and the formation and isolation of the unwanted glc hex-5-enepyranoside 121
(Figure 4.1, D).

Figure 4.1: Comparison of the 1H NMR spectrums of 117 (A), Boc.HCys.OtBu (120, B) and the
crude alkylation reaction mixture (C), highlighting reformation of (Boc.HCys.OtBu)2 (119) and the
glc hex-5-enepyranoside 121 (D).
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Based on the observed dimerization of 120, it is the plausible that the bases used
in the attempted alkylations were too strong for the thiol-containing amino acid used.
The pKa values for NEt3 (~10.45), DBU (~12) and Cs2CO3 (~10.3) are all much higher
than that of the thiol of the amino acid used (~8.5), thus it is likely that in solution the
thiol of 120 may have been more readily present as a thiolate. A good nucleophile, it is
possible (but speculatory) that the presence of this species may have encouraged
nucleophilic attack of the thiol of another amino acid in solution, resulting in the
observed dimerized amino acid.
Interestingly, TLC analysis of the reaction mixture highlighted the presence of
significant quantities of the starting iodide (117), with 25-35% recovered across the
three approaches used. Whilst the undesired hex-5-enopyranoside (121) was also
isolated in significant quantities, its rate of formation was much slower compared to the
dimerization of 120, which was observed over 4-6 hours of reaction time compared to
the 48 hours for the HI elimination. The lack of desired product formed, in addition to
the slow rate of by-product formation and the presence of significant quantities of
starting material, suggested that lower temperature would not inhibit elimination.
Thus, a base-free alternative approach using the halide scavenger Ag2O was
trialled to catalyze the alkylation of Boc.HCys.OtBu by 117. Exhibiting a strong affinity
for halides, it was believed that Ag2O would act to promote the alkylation without
promoting side product formation through proton scavenging.199 However, whilst this
methodology was effective in preventing the formation of the side product 121, after
stirring for 4 days in the presence of 4.0 equivalents Ag2O in DMF no reaction was
observed (Table 4.1, entry 4). To further evaluate this reaction, the reaction time was
extended to 8 days, and THF was utilized as a reaction solvent. Similarly though, this
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non-reaction proved unsuccessful, with only a trace amount of 121 detected (Table 4.1,
Entry 5). Thus, after multiple attempts to produce 6-thioether-linked “clickable”
glycoconjugates, the synthesis of these was discontinued, and focus shifted to the
synthesis of conjugates linked to the anomeric position of a pyranoside.

4.4 Synthesis of Anomeric Thioether-linked “Clickable”
Glycoconjugate 131
Akin to the carboxyl-linked glycoconjugates synthesized in Chapter 3, attempts
to produce thioether-linked derivatives through linkages at the anomeric centre were
investigated. Utilizing the previously synthesized acetyl protected 6-tosyl bearing
glycoside 114, SN2 nucleophilic substitution with an azide donor (such as NaN3) would
produce an azidosugar such as 125 that could be directly glycosylated (using SnCl4 or
BF3.OEt2). Alternatively, the introduction of a better leaving group (e.g bromide,
trichloroacetimidate, etc.) at the anomeric centre, would provide a better glycosyl donor
that could undergo steroselective glycosylation.200 If a thiol-containing glycosyl
acceptor such as cysteine or homocysteine were utilized, these molecules would
represent anomeric thioether-linked “clickable” glycoconjugates, and thus would be
amenable to further functionalization using the CuAAC “click” reaction.
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4.4.1

Synthesis

of

6-Azido-2,3,4-tri-O-acetyl-α-D-glucopyranosyl

trichloroacetimidate (127)
The synthesis of the target thioether-linked glycoconjugates commenced using
6-p-toluenesulfonyl-1,2,3,4-tetra-O-acetyl-D-glucopyranose (114) as a key synthon. In
the presence of NaN3 in DMF, and under mild heating over 24 hours, 114 was
converted into the requisite 6-azido-6-deoxy-1,2,3,4-tetra-O-acetyl-D-glucopyranose
(125) in 57% yield (Scheme 4.6), as a ~1:1 mixture of α- and β-anomers. Compared to
previous azidonations discussed in this work, the yield of 125 was somewhat reduced
due to the competing azidonation of the anomeric centre of 114, as opposed to the
p-tosyl group. The formation of this side product was initially indicated by TLC
analysis, with LR-ESIMS of the reaction mixture displaying a signal of m/z 379
(M + Na) indicative of the side product. As a result, additional recrystallization from
EtOAc/Hexane following chromatography was required to yield spectroscopically pure
125, the structure of which was confirmed from the 1H NMR spectra, where the loss of
two doublets at 7.80 and 7.36 ppm (J = 8.2 Hz), indicated the loss of the p-tosyl group.
This was further confirmed by the LR-ESIMS of 125, where a value of m/z 396 was
indicative of the desired product plus sodium (C14H19N3O9Na).

Scheme 4.6: Synthesis of 6-azido-6-deoxy-1,2,3,4-tetra-O-acetyl-D-glucose 125.
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In order to evaluate glycosylation at the anomeric centre, a suitable glycosyl
donor was required. As mentioned previously (section 2.3), anomeric acetates have been
known for their susceptibility to glycosylation under Lewis acid catalysis – utilizing
SnCl4 and BF3.OEt2.200 However, the potential formation of epimers in using these
methods limits their favourability in these reactions. Alternatively, glycosyl
trichloroacetimidates represent a class of compounds that have historically been used as
glycosyl donors. Developed by Schmidt and co-workers,201 the versatility of these
glycosyl donors to undergo stereoselective glycosylation using Lewis acids such as
TMSOTf, in the presence of a range of O- and S-acceptors has validated their
widespread use in chemical glycosylation.202 Considering the breadth of literature into
anomeric glycosylation via both of these methodologies, they were both evaluated in the
production of the target anomeric-linked glycosyl azides.
Therefore, with peracetylated 6-azidoglycoside 125 in hand the synthesis of the
desired azidosugar bearing an α-trichloroacetimidate at the anomeric position was
initiated. Commencing from 125, selective deacetylation at the anomeric position using
hydrazine acetate resulted in the lactol intermediate 126 in 75% yield (Scheme 4.7).
This isolated intermediate was then subjected to reaction with trichloroacetonitrile and
DBU, producing the desired α-trichloroacetimidate bearing compound 127, isolated
solely as the α-anomer in 78% yield (Scheme 4.7).146
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Scheme 4.7: Synthesis of α-trichloroacetimidate bearing azidosugar 127.146

Confirmation of the formation of 127 was highlighted by the 1H NMR spectrum,
where a singlet at 8.76 ppm corresponded to the imidate proton present on the
trichloroacetimdate (Figure 4.2). Furthermore, a doublet at 6.63 ppm (J = 3.7 Hz)
signified the equatorial H1 proton of 127, suggesting a small dihedral angle between
H1 and H2, indicative of the α-stereochemistry of the trichloroacetimidate present at
the anomeric position, with no signal indicating the presence of the β-anomer observed
(Figure 4.2).146

Figure 4.2: 1H NMR spectrum of 127, highlighting the small coupling constant (J = 3.7 Hz) between
the H1 and H2 protons, indicative of the α-stereochemistry present in 127.
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4.4.2 Synthesis of Fmoc.HCys.OMe (130)
With the trichloroacetimidate 127 inhand, our attention tuned to the required
thiol-containing amino acid. Previously utilizing Boc.HCys.OtBu (120), it was
recognized that the acid-sensitive Boc and tBu protecting groups would not be
compatible with the current Lewis acid-catalysed strategy. Therefore as an alternative, a
homocysteine derivative protected with groups compatible with Lewis acid-mediated
glycosylation conditions (Fmoc, OMe groups) was chosen for use in this strategy. Thus,
commencing from L,L-homocystine, esterification using thionyl chloride (SOCl2) in dry
methanol resulted in the formation of the dimethyl ester dihydrochloride derivative 128
in near quantitative yields (Scheme 4.8).203

Scheme 4.8: Synthesis of Fmoc.HCys.OMe (130) from L,L-homocystine. 203

The α-amino groups of 128 were subsequently protected using Fmoc-Cl in
aqueous K2CO3, yielding the protected derivative (Fmoc.HCys.OMe)2 (129) in
74% yield (Scheme 4.8). Finally, disulfide bond reduction of 129 utilizing Zinc
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dust/TFA conditions, resulted in the isolation of the requisite thiol-containing amino
acid Fmoc.HCys.OMe (130) in 71% yield respectively (Scheme 4.8), with 1H and
13

C NMR spectra in accordance with those previously described elsewhere.203

4.4.3 Synthesis of Thioether-Linked “Clickable” Glycoconjugate 131
With both the glycosyl donors 125 and 127, and the amino acid acceptor 130
prepared, the synthesis of the desired thioether-linked glycoconjugate was attempted. As
previously discussed in section 2.3, the utilization of contrasting non-stereoselective and
steroselective Lewis acid-mediated glycosylation strategies was trialled. In the first
instance, the anomeric acetate-bearing azidosugar 125 was subjected to SnCl4-mediated
glycosylation by Fmoc.HCys.OMe (130). As a result, the target compound 131 was
synthesised, as ~2:1 α- to β-anomeric mixture in 51% yield (Scheme 4.9).

Scheme 4.9: Synthesis of thioether-linked “clickable” glycoconjugate 131 from anomeric
acetate 125.

Isolable individually by flash column chromatography, both α- and β-anomers of
131 displayed m/z values of 707 (C32H36N4O11S+Na), which were both indicative of the
desired product plus sodium. The 1H NMR spectra for both α- and β-anomers of 131
also highlighted their differing conformations (Figure 4.3). For the α-anomer, a
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deshielded doublet at 6.35 ppm (J = 3.6 Hz) was indicative of the equatorial H1 proton,
with the small coupling constant between the H1 proton and the neighbouring axial
H2 proton highlighting their “cis” configuration (Figure 4.3, A). Comparably, in the
1

H NMR spectrum of the β-anomer of 131, the presence of a doublet (J = 9.9 Hz) at

4.51 ppm was indicative of the H1 proton (Figure 4.3, B), with the larger coupling
constant highlighting the “trans” relationship that exists between the axial H1 and H2
protons (Figure 4.3, B).

Figure 4.3: 1H NMR spectra for both α- and β-anomers (A and B) of the thioether-linked
“clickable” glycoconjugate 131.

Additionally, variations between the signals for the Hγ of the amino acid portion,
and H6/H6’ protons of the pyran ring portion of 128 highlighted the different anomeric
configurations. In the β-anomer, two multiplets each integrating for one proton at
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2.69 ppm and 2.79 ppm represented the geminal Hγ protons (Figure 4.12, B). The
different signals for each proton in the β-anomer of 131 indicated that in the 1H NMR
conditions utilized (CDCl3, 25°C) these geminal protons may be in different chemical
environments. Considering the adjacent 2-OAc group, it is possible that one of these
protons may be sterically hindered by this neighbouring group, with the β-configuration
of the thioether at the anomeric centre placing one of these protons in close proximity to
the neighbouring ring-bound oxygen. Such hinderance would limit free rotation of the
C-S bond, resulting in the diastereotopic signals observed in the 1H NMR spectrum of
131(Figure 4.4). This phenomenon is specific to the β-anomer of 131, as the
corresponding protons of the α-anomer do not display the same divergence (Figure 4.3,
A). The non-stereoselective synthesis of 131 represents the second instance where a
thiol-containing amino acid has been utilized in the glycosylation of an azidosugar,
producing thioether-linked “clickable” glyococnjugates.204

Figure 4.4: Proposed steric hinderance between the amino acid Hγ methylene protons and
neighbouring acetate group of 131, resulting in different chemical environments for the two H γ
protons in the 1H NMR spectrum (CDCl3, 25°C) of 131.

With the non-stereoselective production of 131 successfully achieved, efforts to
replicate these results utilizing a steroselective strategy were attempted. As with the
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previously described glycosylation, Lewis acid catalysis provided the best opportunity
to catalyse this glycosylation, with TMSOTf widely used for such a procedure.205 In the
presence of a trichloroacetimidate (such as the synthesised 127), coordination of the
imidate by TMSOTf results in the elimination of trichloroacetamide (Scheme 4.10).
Equilibration between the formed oxocarbenium ion, and the formation of a stable
anomeric carbocation, results in neighbouring group participation by the 2-OAc group,
forming a stable acetal intermediate (Scheme 4.10). Subsequently, in the presence of an
O- or S-containing acceptor the anomeric centre is susceptible to nucleophilic
substitution, with the α-stereochemistry of the acetal intermediate favouring the
stereoselective formation of a β-substituted product (Scheme 4.10).

Scheme 4.10: Proposed mechanism for the stereoselective formation of β-glycosides from an
α-trichloroacetimidate.

In respect to the proposed mechanism for glycosylation, the resonance
stabilization of the oxocarbenium ion provides an opportunity for glycosylation to occur
via either an SN1-mediated mechanism (kinetic control - direct glycosylation) or an
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SN2-mediated mechansm (thermodynamic control - neighbouring group participation),
potentially producing both α- and β-anomers of the desired glycoconjugates.200,206
Whilst the potential formation of both anomers was a concern, previous literature had
highlighted that the selective formation of azido-β-thioglycosides via this methodology
was feasible, with Gouin and co-workers successfully utilizing 127 and TMSOTf to
produce the β-thioglycoside 132 en route to tethering fluorescein to heptyl
α-D-mannosides.207 This work highlights the importance of reaction temperature in
stereoselectively producing β-thioglycosides via this methodology, suggesting that a
reaction temperature of less than -20°C would be sufficient to maintain kinetic control,
and thus produce the desired β-glycoconjugate.

Scheme 4.11: Synthesis of azido-β-thioglycoside 132 performed by Gouin and co-workers.207

Thus, based on this literature precedence the stereoselective synthesis of
thioether-linked 131 was attempted. After being thoroughly dried under vacuum, 127
and Fmoc.HCys.OMe (130) were subjected to TMSOTf catalysis in dichloromethane.
After 1 hour at -20°C, subsequent work up resulted in the isolation of the desired
glycoconjugate 131 in a moderate yield of 38% (Scheme 4.12). Monitored by TLC,
unfortunately the appearance of two spots at Rf 0.23 and Rf 0.30 (2:1 Hexane:EtOAc)
represented the presence of both α-and β-anomers, with the 1H and 13C spectra of these
samples in agreement with those previously produced using SnCl4.
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Scheme

4.12:

Synthesis

of

thioether-linked

“clickable:

glycoconjugate

131

from

α-trichloroacetimidate 127.

The stringent requirement of moisture and oxygen-free conditions made the
synthesis of 131 via this method precarious, with the TMSOTf used in each reaction
highly susceptible to degradation. Forming triflic acid as a by-product, it is likely that
this occurred in both these instances, with the presence of spots on the baseline of the
TLC of each reaction suggesting the degradation of the trichloroacetimidate 127,
contributing to the moderate yields gained for 131. In regards to the lack of
stereoselectivity observed, it is likely that in our hands at -20°C, neighbouring group
participation was not favoured, leading to ambivalent nucleophilic substitution of the
anomeric centre. Additionally, whilst 127 was stable when stored under argon at less
than 0°C, it was noticed over time the trichloroacetimidate was susceptible to
degradation, particularly during reaction set up. Considering the issues with this
synthetic strategy, and our shortcomings in the stereoselective production of 131, the
focus of our efforts shifted to the development of a broader methodology for the
"formation of “clickable” glycoconjugates between azidosugars and thiol-containing
amino acids and peptides, and thus the functionalization of 131 by the CuAAC “click”
reaction was not attempted.
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4.5 Synthesis of Thioether-linked “Clickable” Glycoconjugate
138 Using a “Click” Thiol-ene Approach
As described, problems were encountered in the attempted production of
anomeric and 6-thioether linked derivatives (124 and 131), and it was also recognised
that these strategies may not be so well suited for use in the formation of higher
glycoconjugates. Challenges in producing 124 and 131 including reactivity,
stereoselectivity and protecting group orthogonality could be overcome to yield
thioether-linked glycoconjugates encompassing a single amino acid.

It is unlikely

however whether this would be true for the synthesis of thioether-linked peptides or
proteins. This is particular relevant in regards to protecting group orthogonality, as
many glycosylating reagents (including SnCl4/TMSOTf) are not compatible with acidsensitive protecting groups. Additionally, reduction-labile protecting groups may
compete with the 6-azido group during depotection, thus further limiting the access of
produced synthons to solid or solution phase peptide synthesis. Furthermore, as many
proteins and peptides require specific aqueous pH environments to maintain structure
(and function) it is likely that the aciditiy of reagents could interfere with the coupling
peptide or protein. Considering these arguments, a methodology that allowed for the
ligation of azidosugars to thiol-containing peptides or proteins in benign conditions
would be highly advantageous.
Thus, an evaluation of the literature was undertaken to identify methods that
could be utilized to readily produce “clickable” glycoconjugates between azidosugars
and thiol-containing peptides or proteins. One such method that has grown in use for the
labelling and tagging of peptides containing thiol groups is the thiol-ene reaction.
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Encompassing the anti-Markovnikov addition of a free thiol group to an alkene, the
result of this reaction is a saturated thioether.208,209 Mechanistically, the thiol-ene
reaction can proceed via either an ionic or radical reaction mechanism. Under the ionic
reaction conditions, the reaction is often performed in a buffered solvent at pH 6.5-7.5.
At this pH, the thiol group may disproportionate to form the respective thiolate anion,
which in the presence of an alkene will undergo addition, forming the desired thioether
(Scheme 4.13, A).208 Alternatively to this, in the presence of a suitable radical initiator a
thiyl radical may instead be produced from a thiol. In the presence of an alkene, antiMarkovnikov addition across the double bond ensues, resulting in the formation of a
thioether containing a stabilized secondary radical. In the propagation phase of the
reaction, this radical can go on to form an additional sulfanyl radical, producing the
desired thioether (Scheme 4.13, B). 208

Scheme 4.13: Ionic (A) and radical (B) mechanisms for the synthesis of thioethers via the
thiol-ene reaction.208
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The use of relatively pH-netural, environmentally benign conditions in the ionic
thiol-ene reaction have promoted its widespread use in synthetic biology.210 The
utilization of maleimides as alkene donors drastically increases the reaction rate for the
formation of thiol-enes, with these reactions finding widespread usage in the labelling
of thiol-containing bioconjugates. As a result of its speed and efficiency in the
formation of thioethers, the thiol-ene reaction is often referred to as a “click” reaction,
and is often discussed alongside the CuAAC “click” reaction utilised in this work.208
Examples such as the previously discussed development of [18F]-FDR by O’Hagan and
co-workers (Chapter 1, Scheme 1.5), have illustrated the utility of this method in the
formation of bioconjugates. Utilizing a maleimide-containing hydroxylamine to attach
to the thiol-containing tripeptide glutathione (γ-Glu-Cys-Gly), subsequent oxime
formation resulted in the labelling of the bioconjugate with [18F]-FDR.114
Beyond the usage of an oxime in this example, an abundance of literature for the
introduction of maleimides into macromolecules using amide-coupling chemistry exists,
linking maleimides through linkers bearing an amine or carboxylic acid.210 As described
in chapter 2, the glc- and gal-sugar azido acids 60 and 65 were extensively derivatized
using amide-coupling chemistry (Chapter 2, Pg 66-76), displaying broad scope for their
usage in the synthesis of “clickable” glycoconjugates. Bearing these considerations in
mind, if a maleimide bearing a free amine was produced and linked to a SAA using
amide-coupling chemistry, this molecule could be subjected to the “click” thiol-ene
reaction. The resulting thioether-linked “clickable” glycoconjugates could then be
further derivatized at the free azide by the CuAAC “click” reaction (Scheme 4.14).
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Scheme 4.14: Approach towards the synthesis and functionalization of thioether-linked “clickable”
glycoconjugates utilizing the thiol-ene “click” reaction.

4.5.1 Synthesis of Maleimide-Sugar Azido Acid-linked Derivative 136
Thus, in order to synthesise glycoconjugates of this form, the synthesis of a
maleimide bearing an amine-containing linker was required. An ethylenediamine-based
linker was chosen for conjugation between the maleimide and sugar azido acid, with the
short distance between the two limiting the likelihood of any issues due to linker
folding. Additionally, the lack of cleavable functional groups on the linker would allow
for the use of the glycoconjugate in a broad range of acidic or basic conditions. To form
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the maleimide, N-Boc-ethylenediamine (133) was subject to reaction with maleic
anhydride in diethyl ether in the presence of triethylamine. Subsequent refluxing in
acetone with Ac2O followed by workup, resulted in the isolation of the desire
N-Boc-ethylenediamine maleimide 134 in 50% yield (Scheme 4.15).211 With the desired
maleimide core isolated, the Boc protecting group of 134 was subject to deprotection
under standard TFA/dichloromethane conditions. Stirring for 1 hour, solvent
evaporation followed by trituration with diethyl ether resulted in the isolation of 135 as
a TFA salt in 95% yield (Scheme 4.15).211 The isolation of 135 was confirmed by the
1

H NMR spectrum, where the disappearance of a signal from 1.42 ppm integrating for

nine protons was indicative of the cleavage of the Boc protecting group, with both
1

H and

13

C NMR spectra for 135 consitent with those previously described in the

literature.211

Scheme 4.15: Synthesis of ethylenediamine maleimide 135.

With 135 in hand, our focus now shifted to the formation of the maleimide-sugar
azido acid glycoconjugate 136. Considering that the previously synthesised 131 was a
glc-based derivative, it seemed fitting that the glc-sugar azido acid 60 should be used in
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the formation of the required conjugate. Thus, under standard DCC/HOBt coupling
conditions in acetonitrile, 60 was subjected to reaction with maleimide linker 135, with
work up and flash column chromatography resulting in the isolation of the maleimidelinked azido sugar 136 in a respectable 66% yield (Scheme 4.16).

Scheme 4.16: Synthesis of maleimide-SAA linked derivative 136.

In the 1H NMR spectrum of 136, the presence of a broad signal at 6.86 ppm
accounting for one proton was indicative of the amide proton formed during the
reaction, with a signal in the HR-ESIMS at m/z 490.1204 representing the desired
product plus sodium (C18H21N5O10 + Na; 490.1186). Interestingly, the signals
representing the hydrogens on the carbon adjacent to the amide bond in 136 are not split
as they are in previous conjugates bearing CH2 groups adjacent to the amide (68 and
88), with these protons forming a multiplet at 3.43 ppm. It is possible (but speculatory)
that in the conditions of the 1H NMR (CDCl3, 25°C) the amide NH moiety present in
136 may hydrogen bond with either of the ketones of the maleimide, forming a sevenmembered interaction that places both of these protons into identical chemical
environments. The plausibility of this argument is justified by both the planarity and the
α,β-unsaturated nature of the maleimide present in 136.
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4.5.2 Thiol-ene “Click” Reaction of Maleimide-linked Derivative 136
and Fmoc.HCys.OMe (130).
With the maleimide-linked derivative 136 synthesised, its derivatization using
the “click” thiol-ene reaction was subsequently evaluated. Instead of using a protected
peptide (such as reduced L-glutathione), Fmoc.HCys.OMe (130) would instead be used
to develop a methodology that could be used on protected thiol-bearing peptides. In
addition to the ready availability of the homocysteine derivative 130, it was believed
that the pKa of the thiol group of L-homocysteine (pKa 8.57) would provide a good
comparison to the thiol groups present in other thiol-containing amino acids and
peptides, such as L-cysteine (pKa 8.14) and reduced L-glutathione (pKa 9.2).212–214
Thus, reaction between 136 and Fmoc.HCys.OMe (130) was trialled in a
1:1 acetonitrile:water solution. Monitored by LR-ESIMS, after complete consumption
of 136 (3 hours) the solvents were evaporated, with purification by flash column
chromatography yielding thioether-linked glycoconjugate 137 as a mixture of
diastereomers in 61% yield (Scheme 4.17).

Scheme 4.17: Synthesis of thioether-linked “clickable” glycoconjugate 137 by “click” thiol-ene
reaction of 136 and Fmoc.HCys.OMe (130).
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Whilst compound 137 was similar to the previously synthesized 131 in being a
mixture of diastereomers, their presence in 137 was tolerated. This was because this
strategy was targeted at the functionalization of thiol-containing peptides and proteins,
with the relative chemistry of the linkage to the maleimide unlikely to affect the higher
function and structure of peptides or proteins conjugated. The formation of 137 was
supported by signals in the positive and negative ion modes of the LR-ESIMS of m/z
861 and 873, with these masses represented the product (C38H42N6O14S) plus sodium
and chloride, respectively. Furthermore, in the

1

H NMR spectrum of 137, the

disappearance of a signal from ~6.7 ppm ascribed to the maleimide methine protons
highlights the formation of the glycoconjugate, illustrating the change in hybridization
of the alkene carbons from Sp2 in 136 to Sp3 in 137.
Interestingly in the 1H NMR spectrum, the signals representing the CH2 protons
adjacent to the amide linking the succinimide in 137 have different chemical shifts of
~3.35 ppm (Hβ) and ~3.71 ppm (Hα). This directly compares to the starting
maleimide-sugar azido acid 136, where these protons are represented by a single twoproton multiplet (3.44 ppm). It is likely that the difference in the signals for these
protons in the 1H NMR spectra of 136 and 137 may be due to the planarity of the
maleimide in 136 versus the less planar succinimide in 137. Lacking symmetry in the
succinimide of 137, the less planar succinimide ketones provide different chemical
environments for the two geminal protons, resulting in two different signals in the
1

H NMR spectrum of 137. (Figure 4.5).
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Figure 4.5: Comparison between the chemical shift for Hβ protons in the 1H NMR spectra of 136
and 137, highlighting the effect of planarity and symmetry in the maleimide of 136 versus the
succinimide of 137.

4.6

Functionalization

of

Thioether-linked

“Clickable”

Glycoconjugate 137
With the production of the “clickable” glycoconjugate 137 through the ‘click”
thiol-ene

reaction

successfully

achieved,

our

attention

now

turned

to

its

functionalization via the CuAAC “click” reaction. Utilizing the reaction conditions
previously optimized for 74 in Chapter 2, reaction of 137 with 4-pentyn-1-ol resulted in
the production of the functionalized thioether-linked glycoconjugate 138 in 76% yield,
as a mixture of diastereomers (Scheme 4.17). The production of 138 was supported by
LR-ESIMS of the isolated product, where a signal of m/z 946 calculated for a chemical
formula C43H50N6O15S + Na was indicative of the desired compound. Additionally,
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signals at 7.87 ppm in the 1H NMR spectrum and 120.2 ppm and 148.4 ppm in the
13

C NMR spectrum of 138 were characteristic of the formed triazole ring.

Scheme 4.18: Synthesis of the functionalized maleimide-linked glycoconjugate 136.

Alongside the previously synthesised “clickable” glycoconjugate 131, 137
represents one of the first examples of a thioether-linked glycoconjugate that may be
functionalized via the CuAAC “click” reaction. Thus in this chapter the synthesis of
thioether-linked glycoconjugates formed by azidosugars and thiol-containing amino
acids (HCys) was performed. Furthermore, the development of a methodology for the
synthesis and functionalization of thioether-linked glycconjugates using the “click”
thiol-ene reaction has also been described, allowing for its further use in the formation
of glycoconjugates with thiol-containing peptides. In Chapter 5, the development of
strategies towards the synthesis and functionalization of neoglycopeptides by the
CuAAC “click” reaction will be discussed.
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Chapter 5 : Strategies Towards the Synthesis
and Functionalization of “Clickable”
Neoglycopeptides

As illustrated in chapters 2, 3 and 4, the development of new carbohydrate
molecules that can be readily incorporated into biologically-active peptides, and
comprise functional groups that allow for further conjugation are greatly warranted.
This chapter will focus on the development of sugar azido acid-containing
neoglycopeptides; key intermediates in the production of “clickable” neoglycopeptides.

5.1 Synthetic Rationale
In earlier chapters, a broad range of azidosugars were conjugated to a range of
different proteinogenic amino acids, to produce a library of different “clickable”
glycoconjugates that were amenable to further functionalization via the CuAAC “click”
reaction. To this end, the examples described thus far have been of azidosugars linked to
the sidechain, α-amino group or carboxyl group of an amino acid. Hence, if these
“clickable” glycoconjugates were to be incorporated into a peptide (such as in the
KPV-glycopeptide derivative 88), the azidosugar would be external to the amino acid
sequence of the synthesized peptide.
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In the development of new peptidomimetics and glycoconjugates, keen interest
has been shown in the imbedding of glycosides, including azidosugars, into the primary
structure of both linear and cyclic peptides. Kessler and co-workers have illustrated this,
producing a number of different neoglycopeptides – glycopeptides whereby the
glycoside has been integrated into the peptide’s primary structure in an ‘unnatural’
fashion.156,215–217 Examples of linear neoglycopeptides include the sugar amino acid
(SAA)-containing Leu-Enkephalin analogues 139 and 140, where a native Gly-Gly
dipeptide motif was replaced with a sugar amino acid (Figure 5.1), with both of these
analogues evaluated for their biological activity in a guinea pig ileum assay.156

Figure 5.1: Leu-Enkephalin neoglycopeptide analogues 139 and 140, containing sugar amino acids
(in red) -mimicking a Gly-Gly dipeptide motif.156

In addition, a number of SAAs have been incorporated into cyclic peptides,
giving rise to different peptide secondary structures based on the differing substitution
patterns of NH2 and COOH groups present in the glycosides used. These include SAA’s
that impart linear (2,5-substituted, Figure 5.2, A) and flexible β-turn (1,6-substituted,
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Figure 5.2, B) conformations to cyclic peptides, and more restricted β-turn
(1,5-substituted, Figure 5.2, C), γ-turn (2,3 substituted, Figure 5.2, D) and homoproline
peptide conformations (Figure 5.2, E).156

Figure 5.2: Conformations induced by differing substitution patterns of various sugar amino acids
embedded into cyclic peptides.156

Based on these structural differences, a number of neoglycopeptides exploring
these different motifs have been synthesised. In particular, much focus of their potential
has been centred on biologically-derived scaffolds, with those such as the cyclic
tetradecapeptide hormone somatostatin widely targeted.156,215,217,218 Subsequently, the
synthesis of a number of cyclic petpide SAA derivatives displaying desirable biological
activities has been achieved, including the furanosyl SAA-containing derivative 141
(present in a homoproline conformation), which displayed IC50 values of 31 µM and 25
µM against the drug-sensitive rat hepatoma carcinoma cell line Clone 2, and the
multidrug resistant subclone Clone 2(10 x 80)T1, respectively (Figure 5.3).215
Furthermore, the flexible β-turn containing cyclic neoglycopeptide 142 has also
displayed great potential, (Figure 5.3), exhibiting inhibitory activity at an IC 50 of

145 | P a g e

Chapter 5: Towards fuctionalized neoglycopeptides

150 nM when displacing the receptor bound radioligand [125I]-Tyr11-somatostatin-14 in
AtT20 epithelial-like tumour cell membranes.156

Figure 5.3: Cyclic neoglycopeptide derivatives 141, 142 and 143, as sugar amino acid (red)
containing analogues of somatostatin.156,215,217

In addition to these examples, the synthesis of glycoside-containing analogues of
somatostatin has been extended to neoglycopeptides bearing other β-turn inducing
glycosides, including the glu-sugar azido acid 60 previously synthesised in Chapter 2
(Figure 5.3, 141).156 From a synthetic perspective, sugar azido acids such as 60 and 65
are more readily accessible than the SAAs utilized in the cyclic somatotastatin
derivatives 141 and 142, and hence show great promise as synthons in the production of
substituted neoglycopeptides.156
However, as seen in both the synthesis of sugar azido acids 60 and 65 in
chapter 2, and in the synthesis of azidosugars in Chapters 3 and 4, selective substitution
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of a secondary alcohol in a pyran based glycoside represents a significant challenge.
Current protecting group strategies limit the selective substitution of secondary alcohols
in glc-pyran ring systems, with the 2-, 3- and 4-positions of the pyran ring possessing
comparable reactivity.

In order to selectively substitute these different positions,

lengthy, atom uneconomical chemical manipulations are required.218 Hence, the
development of an orthogonal protecting group strategy that could be used to selectively
derivatize the secondary alcohols at either the 2-, 3- or 4-positions of a pyran ring would
be highly advantageous.
If these pyranosides are also incorporated an accessible amine and carboxylic
acid (Scheme 5.1), they would additionally be compatible with amino acid coupling.
This would produce neoglycopeptides that could be functionalized such that they can
participate in the CuAAC “click” reaction (Scheme 5.1). Bearing such a handle for
derivatization, these so-called “clickable” neoglycopeptides could be utilized to
introduce a variety of different functional groups. These would provide an evaluation of
the use of functionalized neoglycopeptides as molecular scaffolds, in addition to
expanding the utility and chemical space surrounding the structure and function of
linear and cyclic peptides (Scheme 5.1).

Scheme 5.1: Proposed approach towards the synthesis of "clickable" neoglycopeptides.
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5.2 Initial Synthetic Strategy
5.2.1 Synthetic Criteria
A number of different synthetic pathways could be employed to yield glycosides
bearing handles capable of further ligation. One purported strategy is to synthesize and
incorporate sugar diamino acids (SDAs), as previously described by Wittmann et al.
(Figure 5.4, 144 & 145) and Gervay-Hague et al. (Figure 5.4, 146).219–221

Figure 5.4: Sugar diamino acids (SDAs) reported by Wittmann et al. and Gervay-Hague et al.219–221

Containing an accessible amine and carboxylic acid substituted primarily at the
1-,2- and 6-positions of the glycoside, these sugar amino acids also possess an
additional amine or azide handles that can be further functionalized (Figure 5.4). Hence,
these synthons represent an expansion of sugar amino acids that are amenable to amide
coupling, and hence may be utilized to form either linear or cyclic neoglycopeptides.
The may also participate in the CuAAC “click” reaction either directly, or through
further chemical manipulation.
Synthetically though, SDA analogues such as 144 and 145 are far from trivial to
prepare, requiring 10 and 8 steps, respectively from an advanced intermediate.219
Furthermore, the additional steps required to convert 144 and 145 to synthons that
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contain a group available for use in the CuAAC “click” reaction, further decreases the
feasibility of this approach. However, the greatest barrier to the successful use of these
molecules is the limitation of the use of an azide as a “handle” for functionalization,
which requires a rigorous orthogonal protecting group strategy in order to be introduced
in the presence of another protected amine. Alternatively, an approach that allows for
the late-stage introduction of a handle - potentially by a linker, would provide efficient
access to a glycoside that can be introduced into linear or cyclic peptides and
functionalized. Furthermore, this approach allows for the interchangeable usage of
different handles (in this case, azide vs. alkyne), providing wider flexibility to the
synthesis. Thus, an approach employing the late-stage derivatization was developed
(Scheme 5.2).
Based on the previous employment of a pyran-based sugar azido acid core
(60 and 65), and its use in the somatostatin analogue 145,156 it was believed that the
same core bearing an anomeric β-azide and 6-COOH would provide the easiest access
to the targeted glc-sugar azido acid. Allowing for the introduction of the required handle
at either the 2, 3- or 4-OH group of the glc-sugar azido acid, it was apparent that the
4-position of the glycoside would provide the most easily accessible site for substitution
through an orthogonal protecting group strategy, and hence was initially targeted.
Adjacent to the primary 6-OH group on the pyran ring, both the 4-OH and 6-OH may be
protected together as an acetal from a simple glycosyl azide (Scheme 5.2), with
subsequent protection of the remaining 2,3-OH groups and deprotection of the acetal
producing a 4,6-diol. This intermediate can be selectively protected using a sterically
bulky protecting group (e.g. TBDPS, trityl, etc.) at the primary 6-OH, producing a free
4-OH group (Scheme 5.2, Step A). Further protecting group manipulation would allow
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for the protection of the 4-OH group, with deprotection, oxidation of the primary 6-OH
and orthogonal deprotection of the 4-OH yielding a mono-hydroxylated glc-sugar azido
acid (Scheme 5.2, Step B).
Considering the potential length of this synthetic strategy, it was recognized that
the coupling of this intermediate to an amino acid, producing a glycoconjugate that
could be further derivatized using standard ester coupling conditions, also represented a
key synthetic target (Scheme 5.2, Step C). Producing “clickable” neoglycopeptides that
are structurally different to those previously studied (e.g.Type A, Scheme 5.2), the free
β-azide of this target molecule would be available for functionalization via the CuAAC
“click” reaction. As well as being a synthon in the production of Type A “clickable”
neoglycopeptides, the orthogonal protection of the 4-OH group would provide an
approach towards the synthesis of neoglycopeptides linked at the anomeric and
6-positions, similar to those previously described (Scheme 5.2, Step D).156 Tandem
reduction/amide coupling of the β-azide would yield a neoglycopeptide which following
selective deprotection and functionalization of the 4-position would yield a “clickable”
neoglycopeptide (Type B, Scheme 5.2).
Synthetic approaches towards the development of both Type A and B
neoglycoconjugates would have different biological purposes. If Type A derivatives of
biologically-active neoglycopeptides were developed bearing different substitution
patterns (i.e, 2,6-, 3,6- or 4,6-), the effect of peptide conformation on biological activity
could be evaluated. These studies could serve as a guide, providing a platform for the
replacement of the ester linkage with a more stable linkage (i.e amide). Also, if the
neoglycoconjugate synthesised bears relevance to nuclear imaging, the anomeric
β-azide could be utilized for radiolabelling via the CuAAC “click” reaction. In regards
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to Type B neoglycoconjugates, a synthetic approach for derivatives of this form will
allow for the evaluation of cyclic peptides as nuclear imaging agents, again via labelling
using the CuAAC “click” reaction. Examples of cyclic peptide derivatives that could be
produced include labelled derivatives of the somatostatin mimics 141-143. Hence, in the
current study our focus was on developing a synthetic strategy to both of these key
synthetic targets, that would allow for the future synthesis of Type A and Type B
“clickable” neoglycopeptides (Scheme 5.2).

Scheme 5.2: Key strategy towards the development of "clickable" neoglycopeptides.
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5.3 Synthesis of Orthogonally-protected Glycoconjugates
5.3.1 Initial Pathway Towards 4-Protected Sugar Azido Acids
En route to the synthesis of our key intermediate glc-sugar azido acid, the
preparation of a glycoside with a selectively unmasked 4-OH group in the presence of
2,3-OH protection was required. Hence, our synthesis of this target glycoside was
initiated from D-glucose, where peracetylation yielded the known penta-acetylated
glycoside 147 in 96% yield (Scheme 5.3).222

Scheme 5.3: Synthesis of 2,3,4,6-tetra-O-β-D-glucopyranosyl azide (148) from D-glucose.

Obtained as a white solid, evaluation of the 1H NMR spectrum of 147
highlighted two doublets at 6.31 ppm (J = 3.9 Hz) and 5.72 ppm (J = 8.2 Hz) indicative
of the α- and β-anomers, respectively. Equally integrating for 0.5 protons, this suggests
an equal abundance of both anomers present. Subsequently, the penta-acetate 147 was
then subject to anomeric azidonation, under previously utilized SnCl4/TMSN3
conditions. After 20 hours, subsequent work up yielded the known 2,3,4,6-tetra-Oacetyl-β-D-glycopyranosyl azide (148) in 79% yield (Scheme 5.3).153 Compared to the
SnCl4-mediated azidonation discussed in Chapter 2 (for compound 59), the longer time
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period utilized here allows for epimerization of the anomeric α-acetate, with the
presence of the 6-OAc providing a coordination site for SnCl4 with a much closer
proximity than that described previously for the β-azido glucuronic acid allyl ester 59.
The presence of a signal in the 1H NMR at 4.66 ppm was indicative of the anomeric
H1, with the downfield position of the signal indicative of shielding effects of the azide
group, and a coupling constant of J = 8.8 Hz indicative of the trans stereochemistry that
exists between the H3 and the β-H1 protons. This was consistent with data for 148
previously reported.223
With 148 in hand, our focus shifted to the regioselective formation of the
4,6-benzylidene acetal, which is a key requirement of our orthogonal faprotection
strategy. In order to install our acetal, 148 was subjected to classical Zemplen
deacetylation conditions,224 with stirring in the presence of NaOMe dissolved in
methanol yielding the β-D-glucopyanosyl azide intermediate 149 (Scheme 5.4).
Subsequent heating of 149 under vacuum (~250 mbar) at 60°C for 4 hours in the
presence of benzylidene dimethyl acetal and p-toluenesulfonic acid resulted in the
formation of the requisite 4,6-benzylidene acetal, which upon isolation following flash
column chromatography yielded 150 in 62% as a white solid (Scheme 5.4).158,225

Scheme 5.4: Synthesis of 4,6-benzylidene-β-D-glucopyranosyl azide (150).
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Mechanistically, in the presence of a catalytic quantity of p-TsOH a methoxy
group of benzylidene dimethyl acetal is protonated. Subsequently, the primary 6-OH of
149 may undergo nucleophilic attack of the α-carbon of benzylidene dimethyl acetal,
resulting in the elimination of methanol and the proton of the primary alcohol. The
remaining methoxy group can then be protonated, with nucleophilic substitution by the
neighbouring 4-OH resulting in the elimination of a second molecule of MeOH, proton
and the desired benzylidene acetal 150 (Scheme 5.5).

Scheme 5.5: Mechanism for the acid catalysed formation of the 4,6-benzylidene acetal 150.

Producing an acetal only between the 4- and 6- positions, the regioselectivity of
this reaction is a result of their direct proximity, with the acetal forming a 6-membered
ring displaying a geometric chair arrangement. This is exemplified by a 2D NOESY
NMR experiment of 150, where the proton situated on the α-carbon (5.55 ppm) present
in the acetal shows a clear correlation with the H4 proton (3.56 ppm) present on the
pyran ring, in addition to a H6 proton (Figure 5.5).
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Figure 5.5: 2D NOESY experiment highlighting correlations between the acetal CH, and H4 and
H6 in 150.

With the required acetal installed, the remaining 2-OH and 3-OH were subjected
to protection. Considering the later introduction of our handle, multiple protecting group
conditions were trialled to achieve the requisite 4,6-diol, with p-methoxybenzyl ethers
(PMB) and benzoyl ester (Bz) protecting groups both utilized. Removed under
concentrated acid, hydrogenolysis or oxidative conditions, the PMB ether allows for the
introduction of our requisite handle through standard alkylation conditions, permitting
the use of stronger hydride bases (NaH, KH).159 Conversely, the benzoyl ester is highly
susceptible to base hydrolysis, a distinct disadvantage compared to the PMB ether,
requiring the use of trichloroacetimidate chemistry to install the required handle at the
4-OH. However, benzoyl esters display high compatibility to the reduction of anomeric
β-azides to produce an amine, maintaining β-stereochemistry through neighbouring
group participation, whilst PMB may be cleaved under such conditions.159
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Thus to evaluate both of these protecting group strategies, the 2,3-OH groups of
150 were protected. Using p-methoxybenzyl chloride (PMB-Cl) in the presence of
tetrabutylammonium iodide (TBAI) as an activator, and NaH as base, the novel
2,3-OPMB protected derivative 151 was synthesized in 77% yield (Scheme 5.6). This
was confirmed by the LR-ESIMS spectrum of 151, where a signal at m/z 556
(C29H31N3O7 + Na) represented the desired product plus sodium. Similarly, 150 was
protected with benzoyl chloride (BzCl) in the presence of pyridine, with subsequent
recrystallization yielding the novel 2,3-OBz protected derivative 152 in 81% yield
(Scheme 5.6). The benzoyl protection of the 2,3-OH’s of 150 was highlighted in the
1

H NMR spectrum, where signals at 5.81 ppm and 3.88 ppm were indicative of the H3

and H2 protons of 152. These signals are in direct contrast to the corresponding protons
in 150 (3.46 ppm, H3; 3.25 ppm, H2) with the benzoyl protecting group delocalizing the
electrons of the oxygen at the 2- and 3-position significantly, reducing the shielding
effect imparted on the neighbouring protons.

Scheme 5.6: Synthesis of 2,3-protected-4,6-diol derivatives 153 and 154.
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With 151 and 152 in hand, the acetals of both were exposed to acidic
deprotection conditions to unmask the 4-OH group. Initially, (-)-camphorsulphonic acid
(CSA) was utilized in the deprotection of 151, with stirring in MeOH/CH2Cl2 (1:1) over
24 hours resulting in cleavage of the acetal, to produce the 2,3-OPMB-4,6-diol 153 in
67% yield (Scheme 5.6). Deprotection of the acetal was signified by the disappearance
of a signal in the 1H NMR spectrum of the product 153 at 5.56 ppm, indicative of the
axial proton present on the carbon linking the 4-OH and 6-OH. Subsequently, cleavage
of the acetal of 152 was also performed under acidic conditions, with catalytic
p-toluenesulfonic acid in MeOH/CH2Cl2 (4:1) producing the requisite diol 153 in
73% yield after 3 hours. (Scheme 5.6) Though benzoyl esters are more prone to
cleavage in acidic pH than PMB ethers,159 it was recognized that the catalytic use of a
stronger acid such as p-TsOH, compared to CSA (pKA -2.5 vs. 0.9),212 would reduce
the reaction time required for diol cleavage, limiting the formation of cleaved-ester
by products. It must be noted though that TLC analysis of the formation of 154 also
showed the slow cleavage of the benzoyl esters after 3 hours of reaction time.
With both diols 153 and 154 synthesized, efforts were next made to selectively
install the required 6-OH protecting group. For this purpose, protecting groups based on
the triphenylmethyl (trityl -Trt) group were chosen, due to their steric bulk, ease of
introduction and wide availability. Hence, using the PMB-protected diol 153 trials were
initiated, with the use of Trt-Cl, NEt3 and DMAP over 48 hours resulting in the
formation of the 6-OTrt derivative 155 in 31% yield (Scheme 5.7).
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Scheme 5.7: Synthesis of 6-protected glycosides 155 and 156.

Utilizing a catalytic quantity of DMAP as an activator, the formation of a tritylDMAP intermediate ensued. In the presence of NEt3 as a proton scavenger, nucleophilic
substitution of this intermediate by the 6-OH group of 153 resulted in the formation of
the desired 6-OTrt protected 155, albeit in low yield. Thus, considering that this
protection strategy may later be utilized in the 6-OH protection of the 2,3-OBz diol 154,
efforts were made to improve this selective protection without requiring stronger basic
conditions. Subsequently, the more-activated trityl donor 4-methoxytriphenyl chloride
(MMTrt-Cl) was used in place of Trt-Cl, which under the previously used NEt3/DMAP
conditions yielded the 6-OMMTr-protected derivative 156 in 61% yield (Scheme 5.7).
The isolation of 156 was evidenced by the 1H NMR spectrum, whereby overlapping
signals at 3.77 and 3.80 ppm accounted for the protons of the trityl-bound methoxy
group and the p-methoxy groups of the PMB protecting groups present at the 2- and 3OH’s respectively (Figure 5.8).
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Scheme 5.8: 1H NMR spectrum of 156, highlighting overlapping signals at 3.77 and 3.80 ppm that
indicates the PMB and MMTr-methoxy groups, respectively.

Interestingly, LR-ESIMS of 156 highlighted a signal at m/z 740 (C42H43N3O8Na;
[M + Na+]) in a spectroscopically-pure sample of 156. Representing the molecular ion
for this compound, this signal shows only ~25% intensity compared to the highest
intensity signal present, highlighting the weak ionizability of the compound in the mass
spectrometer. The MMTr-protecting group added significant mass to the overall
compound, which when taken into account alongside the PMB groups introduced at the
2- and 3- positions, accounted for a 245% increase in the molar mass of 156 from the
4,6-acetal intermediate 150 (Scheme 5.9). Furthermore, in order to produce our requisite
sugar azido acid bearing handles capable of further derivatization, it would require at
least four additional synthetic steps, which alongside the six steps to produce 156 from
D-glucose, signified a lengthy, atom-uneconomical synthesis (Scheme 5.9). Thus, based
on these findings, alternate pathways towards our target glycoside were sought.
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Scheme 5.9: Original synthetic pathway highlighting additional synthetic steps from 156 required
to produce the desired sugar azido acid target.

5.3.2. Improved Pathway Towards 4-Protected Sugar Azido Acids
In the development of a new strategy for the synthesis of orthogonally-protected
sugar azido acids, a number of approaches were evaluated. One approach included the
selective reduction of the benzylidene acetal of either 151 or 152, unmasking the 6-OH.
This approach is effectively highlighted in the recently published work of Bera and
Linhardt, whereby the 4-OH derivative 158 was produced en route to the synthesis of
unnatural heparosan and chondroitin building blocks (Scheme 5.10).226 Synthesised in
7 steps from phenyl-4,6-benzylidene-1-thio-β-D-glucopyranoside (157), this work
demonstrates the usage of a 2,3-OBz protecting group strategy in addition to the
selective reductive opening of a benzylidene acetal. Oxidation of the 6-OH group to the
carboxylic acid, and one-pot azidonation/4-deprotection result in the desired sugar azido
acid bearing a free 4-OH group. This work represents a concise route to sugar azido

160 | P a g e

Chapter 5: Towards fuctionalized neoglycopeptides

acids that can be derivatized with a handle and coupled to produce numerous
glycoconjugates (Scheme 5.10).

Scheme 5.10: Synthesis of 1-azido-2,3-O-benzoyl-β-D-glucuronic acid methyl ester (158) from
phenyl-4,6-benzylidene-1-thio-β-D-glucopyranoside (157) published by Bera and Linhardt.226

Reflecting on our previous endeavours, there are clear distinctions between these
two approaches – namely, the selective reduction of the benzylidene acetal and the
timing of the introduction of the requisite anomeric β-azide. Whilst an attractive and
noteworthy concept, the selective benzylidene reduction could potentially complicate
the synthesis, with Bera and Linhardt highlighting that the removal of a 4-PMB group
would require orthogonal protection of the carboxylic acid.226 Whilst more than
adequate in this example, our requirement for coupling to the carboxylic acid would
result in additional protection and deprotection steps. Instead, an approach that could
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adapt the previously attempted synthesis of 4-OH bearing sugar azido acids would be
highly advantageous.
Considering the synthesis of the 2,3-OBz diol 154, it was recognized that a
strategy where the required carboxylic acid could be produced selectively in the
presence of a 4-OH would be optimal. Requiring minimal protecting group
manipulation, the carboxylic acid could then be coupled to an amino acid with a free
amine. Subsequently, the 4-OH could then be coupled to another amino acid bearing a
free carboxylic acid, to produce a Type A “clickable” neoglycopeptide. Alternatively,
the 4-OH group could be orthogonally protected, allowing for the coupling of another
amino acid at the anomeric position following reduction of the azide to an amine (See
Scheme 5.2). Indeed, previous studies by Van Den Bos and co-workers have
highlighted the efficiency of oxidants such as TEMPO and bisacetoxyiodobenzene
(PhI(OAc)2) in the selective oxidation of the primary alcohol of pyranosides carboxylic
acids.

227

Encompassing a broad range of differently pyranosides bearing different

mono- and dihydroxylated substitution patterns, these include a number of 4,6-OH
bearing derivatives, such as 159 and 160 (Scheme 5.11).

Scheme 5.11: Examples of selective oxidation of a primary alcohol present on a pyran-based
glycoside previously described by Van Den Bos and coworkers.227
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Affording selective oxidation in the presence of a 4-OH in glucosyl-based
examples, 159 and 160 show that the TEMPO/PhI(OAc)2 oxidation system can tolerate
a variety of different protecting groups at the 2- and 3-positions, including benzyl and
benzoyl groups.227 In relation to the previously synthesised 154, it was believed that this
methodology could be utilized to produce a sugar azido acid that would also possess a
4-OH free for further protection or derivatization, en route to the production of
“clickable” neoglycopeptides. Therefore, 154 was subjected to TEMPO/PhI(OAc)2
oxidation condition, with stirring in CH2Cl2/H2O (2:1).227 After 45 minutes, workup and
purification by flash column chromatography resulted in the isolation of the partiallydeprotected sugar azido acid 161 in 88% yield (Scheme 5.12).

Scheme 5.12: TEMPO/BAIB-mediated oxidation of diol 154 to form the sugar azido acid 161.

The oxidation of 154 to form the sugar azido acid 161 was monitored by TLC,
with the formation of a spot (solvent, 1:1 EtOAc/Hexane + 5% AcOH) much lower on
the TLC plate (Rf 0.28) highlighting the transformation of 154 to the more polar
carboxylic acid. Furthermore, the 1H NMR spectrum of 161 highlights the presence of
five protons between 3.0 – 6.0 ppm as opposed to the seven protons observed in 154,
indicative of the oxidation of the primary 6-OH to form a carboxylic acid (Figure 5.6).
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Figure 5.6: Comparison of the 1H NMR spectra of 154 (A) and 161 (B), highlighting the loss of two
protons (A – H6/H6’) through oxidation, resulting in the sugar azido acid (B).

Utilizing a catalytic quantity of TEMPO, the reaction is initiated by an excess of
PhI(OAc)2, resulting in the production of a piperidinium N-oxide intermediate
(Scheme 5.13, A). In the presence of 154, the piperidinium N-oxide is subject to
nucleophilic substitution by the alcohol, resulting in the formation of a dihydroxylamine
intermediate (Scheme 5.13, B). Deprotonation at the C6 position of 154 drives the
oxidation of the primary alcohol, resulting in the production of an intermediate
aldehyde, in addition to a hydroxylamine derivative (Scheme 5.13, C).
The biphasic solvent conditions present in the reaction are ideal for aldehyde
hydration, resulting in the formation of a geminal diol intermediate (Scheme 5.13 D).
Concurrently, the disproportionation of the hydroxylamine derivative back to TEMPO
allows for its further usage in the catalytic cycle (Scheme 5.13, E). Secondary initiation
of TEMPO by PhI(OAc)2 resulted in the reformation of the piperidinium N-oxide
intermediate (Scheme 5.13, F). Finally, nucleophilic substitution by one of the geminal
diols resulted in the production of a second dihydroxylamine intermediate, which
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following oxidation yielded the desired carboxylic acid 161 (Scheme 5.13, G). It is
likely that the tight transition state at the 6-OH, the steric bulk provided by the
neighbouring 3-OBz group present on 154 and the mild/short reaction conditions
utilized, significantly reduced the susceptibility of the 4-OH group of 154 to
oxidation.228–234

Scheme 5.13: Proposed mechanism for the oxidation of primary alcohols to carboxylic acids
utilizing the TEMPO/PhI(OAc)2 oxidation protocol.
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5.3.3 Synthesis of 4-Orthogonally Protected Intermediate 165
With access to the key intermediate sugar azido acid 161 achieved, our focus
turned to the formation of a hydroxyl-bearing glycoconjugate, the first key synthetic
target of this project. Orthogonal protection of the 4-OH of 161 prior to amino acid
coupling would likely deliver the highest yielding approach to this target, providing
future access to Type A and B neoglycopeptides. The presence of both an alcohol and
carboxylic acid group in 161 though raises questions regarding protecting group
selectivity, with the greater acidity of the carboxylic acid in comparison to the 4-OH of
161 likely to favour carboxyl protection rather than alkylation. This is exemplified by
the selective methylation of 161 by MeI and K2CO3 in DMF, which produced the ester
162 in 64% yield, with this molecule displaying 1H and

13

C NMR spectral data

corresponding with those previously reported (Scheme 5.14).226

Scheme 5.14: Synthesis of previously reported glucuronic acid methyl ester 162.226

Hence, as the presence of a 4-OH would be highly advantageous in the future
production of Type A neoglycopeptides, direct coupling of 161 to a respective amino
acid was performed prior to the protection of the 4-OH group. As a requirement of this
strategy, suitably carboxyl-protected amino acids were required for coupling to the
carboxylic acid group of 161. As a result, L-alanine (Ala) was chosen as our model-
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coupling amino acid, with its simplicity in being N- or C-protected, and its minimal
sidechain steric bulk making it ideal for the development of a broader strategy. Utilizing
thionyl chloride in dry MeOH, the carboxylic acid of L-alanine was methylated,
producing the carboxyl-protected derivative L-alanine methyl ester hydrochloride
(H.Ala.OMe.HCl; 163) in near quantitative yield (Scheme 5.15). The 1H and 13C NMR
spectral data for 163 were consistent with those previously reported.235,236

Scheme 5.15: Synthesis of L-alanine methyl ester hydrochloride (163). 235,236

With both 161 and our requisite amino acid in hand, coupling and protection was
initiated. Utilizing the coupling reagent HBTU and 2.1 equivalents of DIPEA,
H.Ala.OMe.HCl (163) was coupled to 161, selectively producing the novel
glycopeptide 164 in 50% yield (Scheme 5.16).

Scheme 5.16: Synthesis of alanine-sugar azido acid glycoconjugate 164 via amide coupling.

An evaluation of the 1H NMR spectrum of 164, highlighted the presence of a
doublet at 7.13 ppm (J = 6.9 Hz) integrating for one proton, which was indicative of the
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amide nitrogen formed during coupling (Figure 5.7, A). Furthermore, when analysed
with respect to a 2D gCOSY 1H NMR experiment of 164, correlations were observed
between this signal and a triplet at 4.62 ppm (J = 7.5 Hz) integrating for one proton.
Further correlations with a signal at 1.55 ppm highlighted sequential 3-bond couplings
between the amide NH, Hα and Hβ of the coupled amino acid in 164 (Figure 5.7, B). The
first key objective of this project, to our knowledge the synthesis of 164 represents the
first example of a glycoconjugate formed by the selective coupling of a sugar azido acid
bearing a hindered alcohol.

Figure 5.7: 1H NMR experiment (A) and 2D gCOSY experiment (B) of glycoconjugate 164.
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Following the success encountered in producing the coupled product, efforts
were undertaken to protect the 4-OH group of 164, and thus complete the second key
objective of this project. Mindful of the need for an orthogonal protecting group, the
tert-butyldimethylsilyl (TBS) group was chosen. Displaying favourable stability to
reduction, and removed using mildly acidic conditions or through the use of fluoride
donors such as tetrabutylammonium fluoride (TBAF),159 TBS-protection of 164 would
provide access to the required neoglycopeptide, with selective deprotection unmasking
the 4-OH group in order to introduce our handle for derivatization. Hence, 164 was
subjected to TBS protection, with stirring in the presence of TBS-Cl and imidazole in
DMF overnight resulting in the isolation of the 4-OTBS derivative 165 in 36% yield
(Scheme 5.17).

Scheme 5.17: Synthesis of the orthogonally-protected glyconjugate 165.

The low yield gained for 165, was likely a result of the bulky nature of the TBS
protecting group, with the surrounding benzoyl esters and linked amino acid hindering
the approach of the active TBS-imidazole intermediate. Furthermore, the relative
distance between the amide carbonyl of 164 and its corresponding 4-OH allows for
hydrogen bonding, stabilizing the hydroxyl group and thus decreasing its
nucleophilicity. As a result, even with an excess of TBS-Cl (2 eq.) and imidazole (4 eq.)
present, protection of the 4-OH group of 164 would still have been highly unfavourable.
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The formation of 165 was highlighted in the TLC by a dramatic increase in Rf (0.85,
1:1 Hexane:EtOAc) from 164, with TBS protection greatly decreasing the polarity of
the molecule. The effect of protecting the 4-OH group of 164 was also highlighted in
the 1H NMR spectrum, where the signal representing the H4 proton of 165 shifted
downfield (~0.3 ppm) compared to the corresponding proton in 164 (Figure 5.8).
Attachment of the TBS group in 165 delocalizes electron density present on the 4-bound
oxygen to the electropositive silicon atom of the TBS group, which as a result deshields
the neighbouring H4, increasing the chemical shift (Figure 5.8). The second key
objective of this project, the synthesis of 165 represents an important milestone in the
development of Type B “clickable” neoglycopeptides.

Figure 5.8: Comparison of the 1H NMR spectra of 164 (A) and 165 (B), highlighting the deshielding
effect on the H4 of 165 through TBS-protection.
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5.3.4 Synthesis of the 3-Orthogonally Protected Intermediate 170
Building on the production 164 and 165 towards the development of “clickable”
neoglycopeptides, it was recognised that the development of derivatives that could be
functionalised at alternate positions of the glycoside would also be highly advantageous.
Increasing the structural diversity of analogues, the development of differentlysubstituted derivatives may also deliver a more concise route in the development of
neoglycopeptides that may be functionalized by the CuAAC “click” reaction.
The development of a more efficient approach was of particular importance,
considering that the production of 165 from D-glucose required seven synthetic steps.
Of these steps, the synthesis of the benzylidene acetal 150 and the low yielding
production of the 4-OTBS glycoconjugate 165, stood out as those that would limit the
scalability of this methodology. The use of p-toluenesulfonic acid, the same acid used to
catalyze the acetals’ deprotection, made scaling up the production of 150 quite
problematic, with the steric hinderance imposed by surrounding groups in 164 making
the production of 165 highly unfavourable.
Hence, in continuing on with the use of a sugar azido acid scaffold, an
evaluation of the relevant literature was undertaken in order to develop an alternate
route to development of orthogonally-protected neoglycopeptides that could be further
functionalized by the CuAAC “click” reaction. During this process, a re-evaluation of
the

work

of

Tosin

et

al.

highlighted

acids (such as 53) can undergo intramolecular
6,3-lactones (Scheme 5.18, 166).157,237
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Scheme 5.18: Conversion of 1-azido-2,3,4-tri-O-acetyl-β-D-glucuronic acid methyl ester (53) to the
6,3-lactone 166 reported by Tosin et al.157,237

In the presence of a strong nucleophilic base such as LiOH, global deprotection of
the protected sugar azido acid 53 takes place, resulting in a glucuronic acid intermediate
(Scheme 5.19). Present in an equatorial “chair” conformation, heating (85°C) results in
conversion to a “half-chair” conformation, where the 3-OH and 6-COOH are more
confined “axial” geometry relative to one another. In the presence of Ac2O, the
formation of a mixed anhydride with the carboxyl group occurs. Prone to nucleophilic
substitution from the 3-OH group, lactonization occurs, with the remaining 2- and 4-OH
acetylated to yield the requisite protected 6,3-lactone product (Scheme 5.19).

Scheme 5.19: Mechanism for the formation of 6,3-lactone 53 from 166, utilizing saponification and
chair conformation interconversion.
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Whilst not initially obvious, the importance of this conversion lies in the
susceptibility of 6,3-lactones to nucleophilic attack, with Tosin et al. subjecting 166 to
attack by weak nucleophiles such as allyl alcohol and aniline, producing the ester and
amide derivatives 167 and 168 (Scheme 5.20).157,237 As a result of ring opening of the
lactone, the 3-positions of both products 167 and 168 bear free-hydroxyl groups that
may be further protected, alkylated or glycosylated (Scheme 5.20).157,237

Scheme 5.20: Nucleophilic substitution of the 6,3-lactone 164, resulting in the ester and amide
derivatives 167 and 168 that bear unprotected 3-OH groups.157,238

In relation to the previously synthesised 4-OH-bearing intermediate 164, it could
be envisaged that if an amino acid bearing an unprotected α-amino group, such as the
previously used H.Ala.OMe.HCl (163), was reacted with 166, it may generate a
respective glycoconjugate bearing a free 3-OH group (Scheme 5.21). Such a
glycoconjugate would provide a mechanism for the production of Type A “clickable”
neoglycopeptides linked to amino acids by the 3- and 6-positions. Additionally,
protection of the 3-OH with a TBS-group akin to 165 would provide an orthogonally
protected glycoconjugate that could be utilized as a key synthon in the development of
Type B “clickable” neoglycoconjugates (Scheme 5.21).
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Scheme 5.21: Proposed synthesis of glycoconjugates bearing a free 3-OH group from the 6,3-lactone
166, towards the synthesis of “clickable” neoglycopeptides.

With this in mind, efforts were undertaken to produce the requisite 3-OH and
3-OTBS protected glycoconjugates, with the synthesis of the peracetylated azido
glucuronic acid methyl ester 53, the precursor molecule to the 6,3-lactone 166, first
targeted. Glucuronolactone (51) was utilized as starting material, with initial stirring in
the presence of triethylamine in MeOH for 3 hours resulting in esterification and
expansion of the furan ring of glucuronolactone to a pyran ring. Subsequently, workup
followed by the addition of Ac2O and NaOAc, and stirring at room temperature for
8 days resulted in the formation of the peracetylated methyl ester derivative 52, which
was isolated by recrystallization in 38% yield (Scheme 5.22).
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Scheme

5.22:

Synthesis

of

1,2,3,4-tetra-O-acetyl-β-D-glucuronic

acid

methyl

ester

(52)

from glucuronolactone.
1

H and

13

C NMR spectra for 52 synthesised were identical to those previously

reported.156 Though produced in low yield due to the concurrent formation of the
α-anomer of 52, the scalability of this reaction (>10 g product) and easy work up made
it ideal for producing our requisite azidosugar. Hence, with 52 in hand, the β-azido
group was introduced at the anomeric position. Using the TMSN3/SnCl4 conditions, the
required 1-azido-2,3,4-tri-O-acetyl-β-D-glucuronic acid methyl ester (53) was
synthesised, isolated in 81% yield (Scheme 5.23), with 1H and

13

C NMR spectra, and

LR-ESIMS data consistent with those previously described.156

Scheme 5.23: Synthesis of 1-azido-2,3,4-tri-O-acetyl-β-D-glucuronic acid methyl ester (53).156

With the production of the required peracetylated precursor 53 achieved, efforts
were made to produce the desired 3-OH glycoconjugate 169. Initially, saponification of
the acetyl groups and methyl ester were performed under base hydrolysis, with
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neutralization and lyophilisation, followed by heating in Ac2O at 85°C producing the
desired 6,3-lactone intermediate 166. The formation of this intermediate was confirmed
by TLC (Rf 0.45, 1:1 Hexane:EtOAc), with further evaluation of the crude 1H NMR
spectrum of 166 (Figure 5.9, A) highlighting the presence of two signals at 2.18 and
2.10 ppm each integrating for 3 protons. Furthermore, signals in the 13C NMR spectrum
(Figure 5.9, B) at 169.0 and 168.9 ppm corresponding to the carbonyl carbons of the
acetyl esters highlighted the presence of only two ester groups in 166.

Figure 5.9: 1H (A) and 13C (B) NMR spectra of the crude 6,3-lactone 166, highlighting the presence
of 2 acetyl protecting groups at the 2- and 4- positions.

Consequently, the 6,3-lactone 166 was subjected to nucleophilic substitution,
utilizing H.Ala.OMe.HCl (163). Under stirring in dichloromethane, the addition of a
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slight excess of triethylamine (1.2 equivalents) neutralised the hydrochloride salt of 163,
liberating the α-amino group as a nucleophile. The subsequent nucleophilic attack of the
lactone resulted in ring-opening, producing the desired 3-OH-bearing glycoconjugate
169 in 42% yield from 53 (Scheme 5.24).

Scheme 5.24: Synthesis of 3-OH bearing glycoconjugate 169 via ring-opening of the 6,3-lactone 166.

The 1H NMR spectrum of 167 highlighted the formation of the amide linkage
from ring-opening of the lactone, with a doublet at 6.93 ppm (J = 7.5 Hz) integrating for
one proton indicative of the amide hydrogen (Figure 5.34). The formation of the amide
bond was further established in the

13

C NMR spectrum, where a signal at 165.9 ppm

represented the carbonyl formerly constituting the lactone, bound to the α-amino group
of the protected alanine (Figure 5.10). This signal appeared slightly shielded compared
to that representing the same carbon in 166, the result of this carbon being bound to the
comparatively less electronegative nitrogen atom, rather than the oxygen atom present
in the lactone. The synthesis of 169 represents the first reported use of a 6,3-lactone, and
only the second reported usage of lactone ring-opening in the preparation of
glycoconjugates between a glycoside and a proteinogenic amino acid.239 Furthermore,
169 represents a key intermediate in the production of Type A “clickable”
glycoconjugates.
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Figure 5.10: 1H and 13C NMR spectra of the 3-OH glycoconjugate 169, highlighting the formation
of an bond resulting from the nucleophilic ring-opening of 164 by H.Ala.OMe.HCl.

With the synthesis of 169 successfully completed, the 3-OH of 169 was
subjected to TBS-protection. Utilizing TBS-Cl (2.0 equivalents) and imidazole
(4.0 equivalents), the 3-OTBS glycoconjugate 170 was isolated in 66% yield
(Scheme 5.25). Comparably to the previously synthesised 4-OH glycoconjugate 165, it
is likely that the higher yield gained in the production of 170 is a result of the reduced
steric hindrance present on the adjacent 2- and 4-positions, with the less-bulky acetyl
groups allowing sufficient access to the 3-OH group by the TBS-imidazole reactive
intermediate.
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Scheme 5.25: Synthesis of the orthogonally-protected glycoconjugate 170.

The production of 170 was confirmed by the 1H NMR spectrum, where the
presence of singlets at 0.81 and 0.05 ppm integrating for nine and six protons
respectively, were indicative of the tert-butyl and methyl protons of the TBS group.
Furthermore, these signals correlated to two signals in the

13

C NMR spectrum of 170

at -4.6 and -4.9 ppm, both indicative of carbons linked to a silicon atom. A key
intermediate in the production of Type B “clickable” glycoconjugates, the synthesis of
170 from glucuronolactone represents a more concise and higher yielding approach to
their production (8.5% over 6 steps), compared to the synthesis of 165 from D-glucose
(4.4% over 9 steps). Nonetheless, the synthesis of 165 and 170 from D-glucose and
glucuronolactone described in this chapter, have laid the foundation for the synthesis
and development of Type A and Type B “clickable” neoglycocopeptides.
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6.1 Conclusions
6.1.1 “Clickable” Glycoconjugates
The CuAAC “click” reaction has greatly impacted on the synthesis and
development of new bioconjugates.240Allowing for the rapid and stereoselective
production of conjugates based on the 1,4-substituted triazole motif, until recently apart
from metabolically incorporated azido sugars, the utilization of this ligation method in
the synthesis and functionalization of bioconjugates incorporating carbohydrates has
been limited.

133,136

In the study discussed herein, the scope and variety of

glycoconjugates that can be formed between azidosugars and proteinogenic amino acids
- and thus can participate in the CuAAC “click” reaction, has been significantly
broadened. As a result, a number of glycoconjugates linked via ester (A, Scheme 6.1),
amide (B and C, Scheme 6.1) and thioether linkages (D, Scheme 6.1) have been
developed and further functionalized using the CuAAC “click” reaction.
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Scheme 6.1: The diversity of “clickable” glycoconjugates synthesised from azidosugars, and
functionalized using the CuAAC “click” reaction that have been described in the current study.

Building on the successful production of glc- and gal-sugar azido acids 60 and
65 from uronic acid precursors in Chapter 2, the variety of ester (66 and 67), sidechain
(68 and 69) and α-amide (70-73) linked glycosyl azides produced highlighted the
versatility of these molecules as scaffolds in the formation of glycoconjugates that can
be functionalized using the CuAAC “click” reaction. This point was further
demonstrated by the synthesis of the azide-bearing glycopeptide 88 as a key “click”
precursor, promoting the use of this strategy in the synthesis and labelling of
biologically-relevant peptides.
In Chapter 3, the synthesis of “clickable” glycoconjugates linked via the
sidechain or α-carboxyl group of an amino acid was investigated, with the conversion of
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the azidoglucofuranose derivative 96 to the key intermediate azidoglucosylamine (102)
achieved. Subsequently, the synthesis of amide-linked glycoconjugates 110 and 111
through the coupling of 102 to the sidechain (Asp, Glu) groups of protected amino acids
was also performed, along with their functionalization via the CuAAC “click” reaction.
The synthesis and functionalization of 110 and 111 further demonstrated the versatility
of azidosugars in forming amide-linked glycoconjugates with amino acids. In doing so,
the development of glycoconjugates of this design has broadly extended the scope of
this methodology to the formation of glycoconjugates between azidosugars and amino
acids or peptides that bear a free sidechain-carboxyl group.
Moving on from amide-linked examples, in chapter 4 the synthesis of thioetherlinked “clickable” glycoconjugates was also explored. In doing so, the challenges that
exist in the production of thioether-linked conjugates with glycosides were highlighted.
The individual reactivity of positions on a pyran-based glycoside (as illustrated in the
attempted synthesis of 124), in addition to issues with stereoselectivity and scalability
(131), significantly hindered the feasibility of producing glycoconjugates with
individual thiol-containing amino acids. To address this issue, the development of the
maleimide derivative 135 and the formation of glycoconjugate 136 by the “click” thiolene reaction provided a concise method for the synthesis of thioether-linked “clickable”
glycoconjugates. Utilizing the glc-sugar azido acid 60, the divergent nature of this
synthesis added to the advantages that sugar azido acids possess in the formation of
glycoconjugates that can be further derivatized by the CuAAC “click” reaction,
endorsing their use in the development of glycoconjugates through the “click”
thiol-ene reaction.
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6.1.2 Functionalized Neoglycopeptides
In chapter 5, the development of a strategy towards the production of “clickable”
neoglycopeptides based on sugar azido acids was also described. The development of an
orthogonal protecting group strategy leading to the synthesis of the glycoconjugate 165
was achieved (Scheme 6.2). Starting from D-glucose, an initial methodology utilizing
acetal, p-methoxybenzyl, trityl and 4-methoxytrityl-protecting groups proved highly
atom uneconomical. Revision of this methodology to utilize benzoyl protecting groups
and selective TEMPO/BAIB oxidation conditions resulted in the partially protected
glc-sugar azido acid derivative 164. Amide coupling followed by TBS protection
subsequently yielded the desired orthogonally-protected 165.

Scheme 6.2: The synthesis of orthogonally-protected glycoconjugates 165 and 170 from simple
precursors (D-glucose; 165, and glucuronolactone; 170).

Bearing a TBS protecting group at the 4-postion, the potential formation of
differently-substituted derivatives, in addition to the efficiency of the synthesis of 163
(4.4% over 9 steps) validated the investigation of an alternate method that may lead to
the production of Type A and B “clickable” neoglycocpeptides. Subsequently, the
design and synthesis of the orthogonally-protected glycoconjugate 170 was achieved,
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with 170 instead bearing a TBS group at the 3-postion of the glycoconjugate
(Scheme 6.2, 8.5% over 6 steps). Utilizing glucuronolactone (51), the formation of the
key glycoconjugate 169 through nucleophilic substitution of a 6,3-lactone (166)
represents a unique approach to the formation of glycoconjugates, providing a concise,
atom economical route to a key intermediate in the production of Type A and B
“clickable” neoglycopeptides. The orthogonal protecting group strategies developed for
the creation of 165 and 170 provides a mechanism for their further derivatization, which
following protecting group manipulation would allow for their functionalization with a
plethora of different functional groups.

6.2 Future Directions
6.2.1 Improved Access to Sugar Azido Acids From Protected
Derivatives
Key to the synthesis of “clickable” glycoconjugates performed in this study was
the use of azidosugars, with sugar azido acids (such as the glc-sugar azido acid 60)
shown to be exceedingly versatile in forming a variety of different linkages - directly or
indirectly, with proteinogenic amino acids. One obvious drawback though in the
production of sugar azido acids of this form is their scalability. This is predominantly a
result of the utilization of allyl ester protection, as illustrated by the SAA precursors 59
and 64. Both requiring Pd(0)-catalyzed de-allylation to produce the glc and gal-SAA’s
60 and 65, the large quantities of catalyst (10 mol% loading) used in these processes is
enough to limit their large scale production purely on economic grounds. However, the
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competing reduction of the β-azide present in 60 and 65 by PPh3 that has leached from
the catalyst is a much greater limitation, with the high variability in the quality of
Pd(PPh3)4 that may be procured commercially reducing the consistency of yields
obtained in the production of sugar azido acids.
Thus, in order to scale up the synthesis of sugar azido acids and make their
utility in the development of radiolabelled glycoconjugates more viable, an alternative
strategy that doesn’t require the use of allyl esters or Pd(0) catalysis in their production
would be required. Considering the ease and scale in which the methyl ester derivative
53 was produced, an approach that used molecules of this form to produce sugar azido
acids would be ideal. Generally cleaved under basic conditions akin to acetyl groups,
reagents such as trimethyltin(IV) hydroxide have emerged as a mild alternative in the
cleavage of methyl esters. This work has been pioneered by Nicolaou and co-workers,
proving highly efficient and selective in the cleavage of methyl esters in the presence of
acetyl groups.241 The development of such a strategy would have far reaching
implications beyond the scope of our studies, generally improving accessibility to
uronic acids for use in the development of biologically active molecules.

6.2.2 Extension of the Synthesis of “Clickable” Glycoconjugates to
Carboxyl and Thiol-containing Peptides
In chapter 2, the synthesis of the neoglycopeptide 88 represented a key
milestone in the development of glycoconjugates that may be derivatized by the
CuAAC “click” reaction for the development of radiolabelled glycoconjugates.
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Following on from the synthesis and functionalization of “clickable” glycoconjugates
66-73, the production of 88 provided a substrate for the porting of this method to small,
biologically-active peptides. The further functionalization of 88 to form 89 would
illustrate the power of the CuAAC “click” reaction in the further derivatization of
glycocopeptides. In chapters 3 and 4, the formation of “clickable” glycoconjugates
bearing thiol or carboxyl-containing amino acids was also achieved. In comparison
though, the formation of glycoconjugates through these linkages was not extended to
thiol or carboxyl-containing peptides. In order to validate the use of the CuAAC “click”
reaction in the synthesis and labelling of glycoconjugates formed through these
linkages, the methods developed in this project should be extended to peptides bearing
these functional groups. Comparable to Ac.KPV.NH2 utilized in chapter 2, the synthesis
of “clickable” glycoconjugates linked to small biologically-active tripeptides via an
amide or thioether linkages would provide a good platform for the further utilization of
conjugates linked in this manner.
For amide-linked glycopeptides, the tripeptide motif LDV (H-Leu-Asp-Val-OH,
171) represents a great example of a small peptide that could be utilized for this
function. Commonly known as the Fibronectin Adhesion Motif, LDV motifs form key
interactions with the α4β1 integrin, which has clinical implications in the promotion of
tumour cell migration, invasion and metastasis.100,242,243 In addition to its biological
relevance, the LDV motif bears both sidechain and terminal carboxyl groups, which
through protecting group manipulation could be used to highlight the formation of
“clickable” glycopeptides linked via either carboxyl group (Scheme 6.3). Additionally,
the previously discussed thiol-containing peptide reduced-glutathione (172) would be
ideally suited in validating the synthesis of “clickable” thioether-linked glycopeptides.
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This is a result of its widespread use as model thiol-containing peptide in bioconjugate
chemistry – particular when used in tandem with the “click” thiol-ene reaction, in
addition to its important roles as an antioxidant in biological systems.244

Scheme 6.3: The tripeptides Fibronectin Binding Motif (LDV; 171) and reduced-Glutathione (172),
potential model peptides in the synthesis of amide and thioether-linked “clickable” glycopeptides.

6.2.3 Synthesis of “Clickable” Neoglycopeptides
In

chapter

5,

the

successful

development

of

orthogonally-protected

glycoconjugates 165 and 170 was described. Bearing TBS protecting groups at the
3- and 4-positions, the basis for their production was to broaden the utility of sugar
azido acids as molecular scaffolds in the synthesis of neoglycoconjugates. Considering
that the general theme of this project was to develop glycoconjugates that were

188 | P a g e

Chapter 6: Conclusions and FutureDirections
amenable to the CuAAC “click” reaction, it seems appropriate that this ligation method
could be applied to the functionalization of these neoglycopeptides formed from these
precursors.
If the 4- and 3-OH bearing derivatives 164 and 169 were subject to standard
DCC/DMAP-mediated esterifcation, this would produce derivatives joined via an ester
linkage (Scheme 6.4). As Type A “clickable” neoglycopeptides, these derivatives could
then be further derivatized using the CuAAC “click” reaction. Alternatively, the 4- and
3-OTBS derivatives 165 and 170 could be subjected to tandem azide reduction/amide
coupling, to produce neoglycopeptides linked at the position (Scheme 6.4). The TBS
groups of these derivatives are susceptible to selective cleavage by nucleophilic fluoride
donors such as tetrabutylammonium fluoride (TBAF), which would unmask a free
alcohol that could be derivatized (Scheme 6.4). Employing trichloroacetimidate
chemistry akin to that used in the production of 128, azide-containing handles could be
readily introduced, producing Type B “clickable” neoglycopeptides (Scheme 6.4). The
utilization of this methodology would also allow for the functionalization of
neoglycopeptides with a variety of different groups bearing a trichloroacetimidate,
additional glycosides (such as 127). This could subsequently be ported to the
development of a wider range of functionalized neoglycopeptides.
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Scheme 6.4: Proposed synthetic strategy for the synthesis of Type A and B “clickable”
neoglycopeptides from 164 and 169.

6.2.4 Development and Synthesis of Radiolabelled Glycoconjugates
Using the CuAAC “Click” Reaction
With the development of “clickable” glycoconjugates achieved, the next step
would be to examine this approach in the synthesis of radiolabelled glycoconjugatebased molecular probes. In line with previous studies,137 a strategy utilizing fluorine-18
as a radiolabel would represent the most viable approach to producing radiolabelled
glycoconjugates. Such probes would be generated by the CuAAC “click” reaction of
glycoconjugates to fluorine-18 containing species, with the subsequent purification of
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these probes occurring prior to injection. This would limit the possiblilty of copper
toxicity, a problem encountered in in vivo CuAAC “click” imaging approaches such as
live or whole cell imaging.
Such derivatives would require cold standards, analogues of the radiolabelled
compound containing fluorine-19, that provide a comparison for the radiolabelled
derivative during purification.84

During our investigation into the production of

“clickable” glycoconjugates based on the glc-sugar azido acid 60, the synthesis of
fluorinated derivatives for the purpose of producing cold standards was explored. Using
the methodology of Yin and co-workers,245 the fluorinated glycoconjugates 173 and 174
were produced from the allyl ester 59, and the methionine derivative 72 in 58% and
49% yields, respectively (Scheme 6.5). These examples confirm the viability of
fluorinated glycoconjugates of this form, validating the development of different
[18F]-radiolabelled glycoconjugates using the CuAAC “click” reaction.

Scheme 6.5: Synthesis of fluorinated glycoconjugates 173 and 174.

In order to utilize this strategy in the development of radiolabelled
glycoconjugates, the synthesized analogues must target biological function up-regulated
in malignancies. Targets that may be suitable for this strategy include amino acid
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transporters such as the neutral large amino acid transporter LAT-1 and the neutral
small amino acid transporter ASCT-2.246,247 Key mediators of kinase signalling
pathways such as PI3K, PKB and mTOR, these amino acid transporters coordinate
cellular growth, metabolism and proliferation, and have been found to be up-regulated
in metastases such as glioblastoma and non-small cell lung cancer (LAT-1).248
Previously evaluated using radiolabelled derivatives of methionine171,178 and
glutamine,175 the development of carbohydrate-containing derivatives of these
analogues (such as 72, 73, 111 & 131) would probe both the effect of glycosylation on
uptake of these amino acids, in addition to the pharmacokinetics of their excretion.
In addition, the small scale nature of these conjugates would allow for the
fine-tuning of radiofluorination conditions. This would subsequently allow for the
extension of this methodology to more complex systems, including the formation of
[18F]-radiolabelled glycoconjugates with peptides currently used in the evaluation of
metastasis. These include those containing the RGD tripeptide motif targeting
angiogenesis, those linked to the somatostatin analogue octreotide targeting
neuroendocrine tumours, and full derivatives of α-MSH targeting melanoma. Herein,
the foundation for the incorporation and utilization of azidosugars into a variety of
peptides and other biomolecules has been laid. There is great scope for future work in
this area, as azidosugars can be incorporated into a wide range of molecules (e.g. amino
acids, peptides, proteins and lipids), and functionalised with a variety of different
groups (e.g. with fluorophores, radiolabels).
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7.1 Chemical Procedures
7.1.1 General Experimental
All reactions were performed in standard glassware, acetone washed and oven
dried prior to use. Solvents and reagents used were purchased from Sigma Aldrich
Chemical Company (St Louis, MO, USA), Ajax Fine Chemicals (Taren Point, NSW),
Thermofisher Scientifc (Waltham, MA, USA), Acros (Geel, Belgium), Alfa Aesar
(Ward Hill, MA, USA), Carbosynth (Berkshire, UK) or Bachem (Bubendorf,
Switzerland), and used as supplied. All solvents used were of analytical reagent (AR)
grade or higher except for Hexane which was of LR grade, and was distilled for purity
prior to use. The term petroleum spirit specifically refers to the solvent of the same
name with a boiling point range of 40-60°C. The removal of large quantities of solvent
in vacuo was carried out using Buchi and Heidolph rotary evaporators, at temperatures
ranging from 35-65°C. When required, removal of trace quantities of solvent and drying
in vacuo were performed using a CustomBlown Glassware high-vacuum manifold
(Sydney, Australia), equipped with a JAVAC high vacuum pump.
Sonication of reaction mixtures and solutions was performed using a Soniclean
250HT ultrasonic bath (Thebarton, Victoria). Celite (Celite 545, particle size 0.020.1 mm, Merck, Germany) was used to fliter out metal catalysts from reaction mixtures.
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4Å molecular sieves (Sigma Aldrich) were used to dry reaction solvents, and Amberlite
IR-120 or Dowex 50W cationic exchange resins (Sigma Aldrich) were utilized to
neutralize basic aqueous solutions. All reactions were performed under an atmosphere
of N2 or argon where possible. In particularly sensitive dry/inert reaction conditions,
acetonitrile, CH2Cl2 and DMF used were supplied as pre-dried reagents. All melting
points were acquired using a Reichert and Buchi melting point apparati, standardised
with (3,4-dimethoxyphenyl)acetic acid. All temperatures are recorded in °C, and are
reported uncorrected.

7.1.2 Chromatography
All thin layer chromatography (TLC) was performed using Merck Silica Gel 60
F254 aluminium backed plates. In general, all TLC plates used were stained to enhance
visulaization using either vanillin, potassium permanganate, cerium molybdate or
ninhydrin dips. For those bearing aromatic substituents, fluorescence was detected by
exposure to ultraviolet (UV) light at a wavelength of (λ) 254 nm. Flash column
chromatography was performed using DavisilTM Silica Gel 60 (40-63 μm mesh) under
air pressure. All eluents used for chromatographic purposes are indicated, with solvent
proportions used given in volume: volume (v: v) ratios.

7.1.3 Nuclear Magnetic Resonance (NMR) Spectroscopy
Nuclear magnetic resonance (NMR) spectra for all samples were acquired on a
Varian VNMRS PS54 500 MHz spectrometer, with proton (1H) for all samples, and
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carbon (13C) spectra for novel samples obtained at 500 MHz and 125 MHz,
respectively. All spectra were obtained using a 5 mm PFG AutoX DB probe, at an
operating temperature of 25.0 °C. Unless specifically stated, all samples subjected to
NMR spectroscopy were dissolved in deuterated solvents, including chloroform
(CDCl3), methanol (CD3OD), dimethylsulfoxide (d6-DMSO), acetonitrile (CD3CN) or
water (D2O). Each provided internal references in 1H and

13

C NMR spectra at δ 7.26

ppm and 77.0 ppm (CDCl3), 3.31 ppm and 49.00 ppm (CD3OD), 3.50 ppm and 39.52
ppm (d6-DMSO) 1.94 and 1.32 ppm (CD3CN) and 4.79 ppm (D2O,

1

H only),

respectively. Chemical shifts of peaks in NMR spectra are expressed in ppm with peak
multiplicities reported as either singlets (s), doublets (d), triplets (t) or multiplets (m).
Spectral data are assigned in the following format; (1H/13C NMR) (δ ppm) (m, iH, cc
Hz, a) where m = multiplicity, i = integration, cc = coupling constant and a =
assignment. All 1H and

13

C NMR spectral assignments were assigned based on a

combination of comparisons with literature data, 2D NMR spectral data, and using
computer-aided identification methods.

7.1.4 Mass Spectrometry
Electrospray ionisation (ESI) mass spectra were obtained using both a
Micromass Platform LCZ spectrometer and a Shimadzu Tandem LCMS-2010 liquid
chromatograph mass spectrometer. For the majority of samples, High Resolution
Electrospray Ionisation Mass Spectra (HRESI-MS) were performed on a Waters XEVO
G2 Quadrapole Time-Of-Flight (Q-TOF) mass spectrometer, with leucine enkephalin
(LeuEnk) used as an internal standard.
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7.1.5 Chemical and Spectral Illustrations/Calculations
All figures, schemes and tables were drawn using ChemBioDraw Ultra
versions 10.0-13.0

(CambridgeSoft/PerkinElmer,

representations of 1D 1H and

13

Waltham,

MA,

USA).

All

C NMR spectra, and 2D gCOSY/NOESY experiments

were analysed and displayed using either MestReNova NMR Lite (Santiago, Chile) or
ACD NMR Labs 12.00 (Toronto, Canada). All heat of formation ΔHf calculations were
performed using ChemBio3D Ultra 11.00 (PerkinElmer) using the AM1 (semiempirical) level of theory. The following non-IUPAC structural abbreviations were used
in the illustration of synthesised compounds:
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7.2 Chapter 2 Experimental Data:
1,2,3,4-tetra-O-acetyl-β-D-glucuronic acid (56)
According to the method of Bergeon et al.,160 a round bottom
flask containing D-glucuronic acid (55, 3.01 g, 15.50 mmol)
was added acetic anhydride (50 mL), and the resulting
suspension was chilled to 0°C. Solid I2 (0.215 g, 0.847 mmol) was added portionwise to
the mixture, which was then allowed to stir at 0°C for 2 hours before being allowed to
gradually warm to room temperature. After 5 hours, the reaction mixture was cooled
back to 0°C, and dry MeOH (20 mL) was added dropwise to the solution, and allowed
to stir overnight. The crude reaction mixture was then evaporated to dryness,
resuspended in CH2Cl2 (50 mL) and washed sequentially with 0.1 M Na2S3O3 solution
(2 x 20 mL) and brine (20 mL). The organic phases were combined, dried and
evaporated, before recrystallization from Hexane/EtOAc yielded 56 as a white solid.
(3.70 g, 58%), M.p. 153-155°C (lit. 154 155°C)249 1H NMR (500 MHz, CDCl3) δ 5.79
(d, 1H, J = 7.6 Hz, H1), 5.29 (m, 2H, H3/H4), 5.13 (m, 1H, H2), 4.24 (m, 1H, H5),
2.11-2.02 (4s, 12H, CH3, 4 x OAc). 13C NMR (CDCl3, 125 MHz): 170.2 (C=O, OAc),
169.9 (C=O, OAc), 169.5 (C=O, OAc), 169.1 (C=O, OAc), 91.5 (C1), 72.7 (C5), 72.1
(C4), 70.4 (C3), 68.9 (C2), 20.9 (CH3, OAc), 20.7 (CH3, OAc), 20.6 (CH3, OAc), 20.6
(CH3, OAc). LRMS (ESI): m/z 361 [M - H],- HRMS (ESI): m/z calculated for
C14H17O11 [M – H]-: 361.0771; Found 361.0774.
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1,2,3,4-Tetra-O-acetyl-β-D-glucuronic acid allyl ester (57)
According to the method of Tosin et al.,157 a solution of 56
(4.65 g, 12.84 mmol) dissolved in dry CH2Cl2 (120 mL) was
chilled to 0°C. Under an argon atmosphere, oxalyl chloride
(1.2 mL, 1.68 g, 13.23 mmol) and DMF (0.60 mL) were added, and the reaction mixture
was allowed to stir at 0°C for 30 minutes, before being allowed to warm to room
temperature. After 2 hours, the reaction mixture was cooled back down to 0°C, and in a
separate dry round bottom flask, a solution of allyl alcohol (1.00 mL, 0.854 g,
14.70 mmol), pyridine (3 mL)

and CH2Cl2 (20 mL) stirring in the presence of

4Å molecular sieves was prepared. The solution containing the alcohol and pyridine
was added dropwise to the reaction mixture, and allowed to stir at 0°C for 30 minutes
before being warmed to room temperature. After a further 3 hours, the reaction mixture
was diluted with CH2Cl2, before being quenched with sat. NaHCO3 solution (100 mL).
The organic phases were washed with cold 0.1 M HCl (100 mL) and brine (50 mL),
before being dried and evaporated. The resultant milky residue was triturated with
petroleum spirit and left in the freezer overnight, to produce 57 as a waxy white solid.
(4.81 g, 93%), M.p. 97-99°C (lit. 95-97°C)157 Rf 0.77 (1:1 Hexane:EtOAc.). 1H NMR
(500 MHz, CDCl3) δ 5.89 (m, 1H, CH2-CH=CH2), 5.79 (d, 1H, J =7.7 Hz, H1),
5.37 - 5.26 (m, 4H, CH2-CH=CH2, H3 and H4), 5.15 (dd, 1H, J = 8.7 Hz, H2), 4.61 (m,
2H, CH2-CH=CH2), 4.20 (d, 1H, J = 9.4 Hz, H5), 2.12-2.02 (4s, 12H, CH3, 4 x OAc).
13

C NMR (125 MHz, CDCl3) δ 170.1 (C=O, OAc), 170.0 (C=O, OAc), 169.5 (C=O,

OAc), 169.1 (C=O, OAc), 166.3 (C=O), 131.2 (CH2-CH=CH2), 119.8 (CH2-CH=CH2),
91.6 (C1), 73.2 (C5), 72.1 (C4), 70.4 (C2), 69.1 (C3), 67.0 (CH2-CH=CH2), 21.0 (CH3,
OAc), 20.7 (CH3, OAc), 20.7 (CH3, OAc), 20.6 (CH3, OAc). LRMS (ESI): m/z 425
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[M + Na]+ HRMS (ESI): m/z calculated for C17H22O11Na [M + Na]+ : 425.1060;
Found 425.1050.

1-Bromo-2,3,4-tri-O-acetyl-α-D-glucuronic acid, allyl ester (58)
A solution of 57 (0.531 g, 1.33 mmol) dissolved in dry CH2Cl2
(2 mL) was chilled to 0°C. 33% w/v HBr in AcOH (4 mL) was added
dropwise to the solution, and upon addition the reaction mixture was
allowed to gradually warm to room temperature under constant stirring. After 3 hours,
the reaction mixture was diluted with CH2Cl2 (10 mL), and washed with H2O (5 mL),
ice cold sat. NaHCO3 solution (5 mL) and brine (5 mL). The organic phases were then
dried and evaporated, producing 58 as an orange oil that was used used without further
purification.

(0.355 g, 67%), Rf 0.24 (3:1 Hexane:EtOAc). 1H NMR (500 MHz,

CDCl3) δ 6.65 (d, 1H, J = 4.1 Hz, H1), 5.91 (m, 1H, CH2-CH=CH2), 5.61 (1H, t,
J = 9.9 Hz, H3), 5.35 (m, 2H, CH2-CH=CH2), 5.24 (t, 1H J = 10.1 Hz, H4), 4.86 (dd,
1H, J = 10.0 Hz, 4.1 Hz, H2), 4.62 (m, 3H, CH2-CH=CH2/H5), 2.12-2.01 (3s, 9H, CH3,
3 x OAc).

13

C NMR (CDCl3, 125 MHz): δ 169.7 (C=O, OAc), 169.6 (C=O, OAc),

169.2 (C=O, OAc), 166.0 (C=O), 130.8 (CH2-CH=CH2), 119.9 (CH2-CH=CH2), 85.4
(C1), 72.1 (C5), 70.3 (C4), 69.3 (C3), 68.5 (C2), 67.0 (CH2-CH=CH2), 20.6 (CH3,
OAc), 20.6 (CH3, OAc), 20.5 (CH3, OAc). LRMS (ESI): m/z 423; 425
[M + H]+Br79; Br81
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1-Azido-2,3,4-tri-O-acetyl-β-D-glucuronic acid, allyl ester (59)
Method A: 58 (0.355 g, 0.85 mmol) was dissolved in dry DMF
(3 mL), and the solution was cooled to 0°C. NaN3 (0.250 g,
3.84 mmol) was added portion wise to the mixture, and allowed to
stir at 0°C for 30 minutes, after which it was allowed to warm to room temperature.
After 3 hours, the reaction mixture was diluted with H2O (5 mL), with the aqueous
phase extracted with EtOAc (3 x 25 mL). The organic phases were dried and
evaporated, with recrystallization from EtOAc/Hexanes producing 59 as a fluffy white
solid. (0.223 g, 68%)
Method B: According to the method of Tosin et al

157

57 (4.00 g, 9.95 mmol) was

dissolved in dry CH2Cl2 (100 mL) under an atmosphere of argon. TMS-N3 (3.30 mL,
2.89 g, 25.09 mmol) was added, and the resultant mixture was cooled to 0°C. SnCl4
(0.60 mL, 1.34 g, 5.14 mmol) was added slowly to the cooled mixture and allowed to
stir at 0°C for 15 minutes, after which the mixture was warmed to room temperature.
After 4 hours, the mixture reaction mixture was diluted with CH2Cl2 (50 mL), and
extracted with sat. NaHCO3 solution (2 x 50 mL) and brine (50 mL). The organic phase
was dried and evaporated, with recrystallization from EtOAc/Hexanes yielding 59 as a
fluffy

white

solid.

(2.43

g,

63%),

M.p.

132-133°C,

Rf

0.81

(1:1 Hexane:EtOAc).1H NMR (500 MHz, CDCl3) δ 5.91 (m, 1H, CH2-CH=CH2), 5.365.26 (m, 4H, CH2-CH=CH2/ H3/H4), 4.97 (m, 1H, J = 9.5 Hz, 8.6 Hz, H2), 4.71 (d, 1H,
H1), 4.63 (m, 2H, CH2-CH=CH2), 4.14 (d, 1H, J = 9.8 Hz, H5), 2.08-2.01 (3s, 9H, CH3,
3 x OAc). 13C NMR (CDCl3, 125 MHz): 170.2 (C=O, OAc), 169.4 (C=O, OAc), 169.3
(C=O, OAc), 166.1 (C=O), 131.2 (CH2-CH=CH2), 119.9 (CH2-CH=CH2), 88.3 (C1),
74.6 (C5), 72.2 (C4), 70.7 (C2), 69.3 (C3), 67.0 (CH2-CH=CH2), 20.7 (CH3, OAc), 20.7
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(CH3, OAc), 20.6 (CH3, OAc). LRMS (ESI): m/z 408 [M + Na]+ HRMS (ESI): m/z
calculated for C15H19N3O9Na [M + Na]+: 408.1019; Found 408.1039.

1-Azido-2,3,4-tri-O-acetyl-β-D-glucuronic acid (60)
According to the method of Tosin et al,157 59 (0.510 g,
1.33 mmol) was dissolved in dry ACN (7 mL), and the reaction
mixture was cooled to 0°C. To this solution, Pd(PPh3)4 (0.155 g,
0.132 mmol) was added, and the mixture was immersed in an atmosphere of argon.
Pyrrolidine (0.12 mL, 1.34 mmol) was then added dropwise, and the reaction mixture
was allowed to warm gradually to room temperature. After 1 hour, the reaction mixture
was filtered through Celite, with the filtrate evaporated to dryness. The residue was redissolved in EtOAc (20 mL), before extraction with H2O (2 x 20 mL). The aqueous
phase was collected and acidified to pH 2 using Amberlite IR-120 resin, and
subsequently extracted with EtOAc (3 x 40 mL). The organic phase was dried and
evaporated, with the residue allowed to sit under high vacuum overnight, producing 60
as a yellow foam. (0.303 g, 66%), 1H NMR 500 MHz, CD3OD) δ 5.36 (t, 1H,
J = 9.4 Hz, H3), 5.19 (t, 1H, H4), 5.02 (d, 1H, J = 8.8 Hz, H1), 4.91 (t, 1H, J = 9.3 Hz,
H2), 4.33 (d, 1H, J = 10.0 Hz, H5), 2.07-2.01 (3s, 9H, CH3, 3 x OAc).

13

C NMR

(CDCl3, 125 MHz): 173.2 (C=O, COOH), 172.5 (C=O, OAc), 172.4 (C=O, OAc), 172.4
(C=O, OAc), 87.5 (C1), 74.7 (C5), 72.9 (C4), 71.2 (C2), 69.9 (C3), 20.3 (CH3, OAc),
20.3 (CH3, OAc), 20.2 (CH3, OAc). LRMS (ESI): m/z 344 [M - H]- HRMS (ESI):
m/z calculated for C12H14N3O9 [M - H]-: 344.0730; Found 344.0746.
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1,2,3,4-Tetra-O-acetyl-α-D-galacturonic acid (61)
According to the method of Vogel et al.,163 a round bottom flask
containing D-galactouronic acid (4.032 g, 19 mmol) was added
acetic anhydride (25 mL), and the resulting suspension was chilled
to 0°C. 70% perchloric acid (0.20 mL) was added dropwise over a 5 minute period, with
the mixture allowed to gradually come to room temperature over a 30 minute period.
After stirring at room temperature for 3 hours, the reaction mixture was cooled back to
0°C, and dry MeOH (6 mL) was added dropwise to the solution. The reaction mixture
was the diluted with H2O (20 mL), and subsequently extracted with CHCl3 (3 x 50 mL).
The organic phases were dried (MgSO4), filtered and evaporated to dryness, producing a
white residue which following recrystallization with EtOAc/Heptane produced 61 as a
white solid. (2.46 g, 35%), M.p (103-105 °C) 1H NMR (500 MHz, CDCl3) δ 6.47 (d,
1H, J = 2.9 Hz. H1), 5.84 (t, 1H, H4), 5.38 (t, 1H, J = 2.8 Hz, H3), 5.33 (dd, lH,
J = 9.5 Hz, 11.0 Hz, H2), 4.76 (d, 1H, J = 1.5 Hz, H5), 2.15-1.99 (4s, 12H, CH3,
4 x OAc). 13C NMR (CDCl3, 125 MHz): 170.4 (C=O, OAc), 170.2 (C=O, OAc), 170.1
(C=O, OAc), 169.1 (C=O, OAc), 168.6 (C=O), 89.5 (C1), 70.5 (C5), 68.7 (C4), 67.3
(C3), 66.2 (C2), 20.8 (CH3, OAc), 20.8 (CH3, OAc), 20.7 (CH3, OAc), 20.6 (CH3,
OAc). LRMS (ESI): m/z 361 [M – H]- HRMS (ESI): m/z calculated for C14H17O11
[M - H]-: 361.0771; Found 361.0778.

1,2,3,4-Tetra-O-acetyl-α-D-galacturonic acid, allyl ester (62)
A solution of 61 (4.65 g, 12.84 mmol) dissolved in dry CH2Cl2
(120 mL) was chilled to 0°C. Under an argon atmosphere, oxalyl
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chloride (1.2 mL, 1.68 g, 13.23 mmol) and DMF (0.60 mL) were added, and the
reaction mixture was allowed to stir at 0°C for 30 minutes, before being allowed to
warm to room temperature. After 2 hours, the reaction mixture was cooled back down
to 0°C, and in a separate dry round bottom flask, a solution of allyl alcohol (1.00 mL,
0.854 g, 14.70 mmol), pyridine (3 mL) and CH2Cl2 (20 mL) stirring in the presence of
4Å molecular sieves was prepared. The solution containing the alcohol and pyridine
was added dropwise to the reaction mixture, and allowed to stir at 0°C for 30 minutes
before being warmed to room temperature. After a further 3 hours, the reaction mixture
was diluted with CH2Cl2, before being quenched with sat. NaHCO3 solution (100 mL).
The organic phases were washed with cold 0.1 M HCl (100 mL) and brine (50 mL),
before being dried and evaporated. The resultant milky residue was triturated with
petroleum spirit and left in the freezer overnight, to produce the novel 62 as an off-white
solid. (4.38 g, 85%), M.p. 82-85°C Rf 0.80 (1:1 Hexane:EtOAc.). 1H NMR (500 MHz,
CDCl3) δ 6.41 (d, 1H, J = 2.4 Hz, H1), 5.75 (m, 2H, CH2-CH=CH2/H4), 5.28 (m, 2H,
H2/H3), 5.19 (dd, 2H, J = 10.3 Hz, 17.1 Hz, CH2-CH=CH2, 4.70 (m, 1H, H5), 4.56 (m,
2H, CH2-CH=CH2), 2.07-1.91 (4s, 12H, CH3, 4 x OAc). 13C NMR (125 MHz, CDCl3) δ
170.1 (C=O, OAc), 169.8 (C=O, OAc), 169.8 (C=O, OAc), 168.8 (C=O, OAc), 165.9
(C=O), 132.1 (CH2-CH=CH2), 120.0 (CH2-CH=CH2), 89.8 (C-1), 70.9 (C-5), 68.8 (C4),
67.2 (C3), 66.7 (C2), 66.0 (CH2-CH=CH2), 20.4 (CH3, OAc), 20.2 (CH3, OAc), 20.1
(CH3, OAc), 20.1 (CH3, OAc). LRMS (ESI): m/z 425 [M + Na]+ HRMS (ESI):
m/z calculated for C17H22O11Na [M + Na]+: 425.1060; Found 425.1063.
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1-Bromo-2,3,4-tri-O-acetyl-α-D-galacturonic acid, allyl ester (63)
A solution of 62 (2.113 g, 5.24 mmol) dissolved in dry CH2Cl2
(6 mL) was chilled to 0°C. 33% w/v HBr in AcOH (14 mL) was
added dropwise to the solution, and upon addition the reaction
mixture was allowed to gradually warm to room temperature under constant stirring.
After 3 hours, the reaction mixture was diluted with CH2Cl2 (50 mL), and washed with
H2O (50 mL), ice cold sat. NaHCO3 solution (50 mL) and brine (50 mL). The organic
phases were then dried and evaporated, producing 63 as an orange oil that was used
used

without

further

purification

(1.494

g,

66%),

R f 0.21

(3:1

Hexane:EtOAc.).1H NMR (500 MHz, CDCl3) δ 6.78 (d, 1H, J = 3.3 Hz, H1), 5.86 (m,
2H, CH2-CH=CH2/H4), 5.46 (dd, 1H, J = 3.0 Hz, 9.5 Hz, H3), 5.32 (dd, 2H, J = 10.2
Hz, 17.3 Hz, CH2-CH=CH2), 5.11 (dd, 1H, J = 2.9 Hz, 9.5 Hz, H2), 4.90 (m, 1H, H5),
4.65 (m, 2H, CH2-CH=CH2), 2.14-2.01 (3s, 9H, CH3, 3 x OAc). 13C NMR (125 MHz,
CDCl3) δ 170.1 (C=O, OAc), 169.9 (C=O, OAc), 169.6 (C=O, OAc), 165.2 (C=O),
130.9 (CH2-CH=CH2), 120.3 (CH2-CH=CH2), 87.4 (C1), 72.6 (C5), 68.1 (C4), 67.8
(C3), 67.3 (C2), 66.8 (CH2-CH=CH2), 20.8 (CH3, OAc), 20.7 (CH3, OAc), 20.6 (CH3,
OAc). LRMS (ESI): m/z 423; 425 [M + H]+Br79; Br81

1-Azido-2,3,4-tri-O-acetyl-β-D-galacturonic acid, allyl ester (64)
Method A: 62 (1.00 g, 2.48 mmol) was dissolved in dry CH2Cl2
(30 mL) under an atmosphere of argon. TMS-N3 (0.83 mL,
0.727 g, 6.31 mmol) was added, and the resultant mixture was
cooled to 0°C. SnCl4 (0.15 mL, 0.335 g, 1.29 mmol) was added slowly to the cooled
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mixture and allowed to stir at 0°C for 15 minutes, after which the mixture was warmed
to room temperature. After 20 hours, the mixture reaction mixture was diluted with
CH2Cl2 (20 mL), and extracted with sat. NaHCO3 solution (2 x 20 mL) and brine
(20 mL). The organic phases were combined, dried and evaporated, with
recrystallization from EtOAc/Hexanes yielding 64 as an off-white solid. (0.274 g, 29%)
Method B: 63 (1.494 g, 3.54 mmol) was dissolved in dry DMF (10 mL), and the
solution was cooled to 0°C. NaN3 (1.036 g, 15.98 mmol) was added portion wise to the
mixture, and allowed to stir at 0°C for 30 minutes, after which it was allowed to warm
to room temperature. After 3 hours, the reaction mixture was diluted with H2O (10 mL),
with the aqueous phase extracted with EtOAc (3 x 50 mL). The organic phases were
dried and evaporated, with recrystallization from EtOAc/Hexanes producing 64 as an
off-white solid. (1.006 g, 70%), M.p. 113-114°C Rf 0.84 (1:1 Hexane:EtOAc.).1H NMR
(500 MHz, CDCl3) δ 5.87 (m, 1H, CH2-CH=CH2), 5.76 (m, 1H, H4), 5.32 (dd, 2H,
J = 10.4 Hz, 17.1 Hz, CH2-CH=CH2), 5.18 (t, 1H, J = 9.0 Hz, H2), 5.10 (m, 1H, H3),
4.68-4.64 (m, 3H, CH2-CH=CH2/H1), 4.43 (m 1H, H5), 2.11-1.99 (3s, 9H, CH3,
3 x OAc). 13C NMR (125 MHz, CDCl3) δ 170.1 (C=O, OAc), 169.9 (C=O, OAc), 169.4
(C=O, OAc), 165.2 (C=O), 131.2 (CH2-CH=CH2), 120.1 (CH2-CH=CH2), 88.6 (C1),
74.3 (C5), 70.6 (C4), 68.2 (C3), 67.8 (C2), 66.8 (CH2-CH=CH2), 20.9 (CH3, OAc),
20.7 (CH3, OAc),

20.6 (CH3, OAc). LRMS (ESI): m/z 408 [M + Na]+

HRMS (ESI): m/z calculated for C15H19N3O9Na [M + Na]+: 408.1019; Found 408.1024
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1-Azido-2,3,4-tri-O-acetyl-β-D-galacturonic acid (65)
64 (0.511 g, 1.33 mmol) was dissolved in dry ACN (7 mL), and
the reaction mixture was cooled to 0°C. To this solution,
Pd(PPh3)4 (0.155 g, 0.132 mmol) was added, and the mixture was
placed under an atmosphere of argon. Pyrrolidine (0.12 mL, 1.34 mmol) was then added
dropwise, and the reaction mixture was allowed to warm gradually to room temperature.
After 1 hour, the reaction mixture was filtered through Celite, with the filtrate
evaporated to dryness. The residue was re-dissolved in EtOAc (20 mL), before
extraction with H2O (2 x 20 mL). The aqueous phase was collected and acidified to
pH 2 using Amberlite IR-120 resin, and subsequently extracted with EtOAc
(3 x 40 mL). The organic phase was dried and evaporated, with the residue placed under
high vacuum overnight, producing 65 as a yellow foam. (0.308 g, 67%).1H NMR (500
MHz, CDCl3) δ 5.78 (m, 1H, H4), 5.16 (t, 1H, J = 8.5 Hz, H2), 5.12 (t, 1H, J = 8.5 Hz,
H3, 4.71 (d, 1H, J = 8.8 Hz, H1), 4.44 (m, 1H, H5), 2.10, 2.09, 1.99 (3s, 9H, CH3, 3 x
OAc).

13

C NMR (125 MHz, CDCl3) δ 170.1 (C=O, OAc), 170.0 (C=O, OAc), 169.4

(C=O, OAc), 167.8 (C=O), 88.4 (C1), 74.0 (C5), 70.5 (C4), 68.0 (C3), 67.7 (C2), 20.7
(CH3, OAc), 20.6 (CH3, OAc), 20.5 (CH3, OAc). LRMS (ESI): m/z 344 [M - H]HRMS (ESI): m/z calculated for C12H14N3O9 [M - H]-:344.0730; Found 344.0736.
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Nα-(tert-Butoxycarbonyl)-O-(1-azido-2,3,4-tri-O-acetyl-β-D-glucuronoyl)-L-serine
methyl ester (66)
A solution of 60 (0.141 g, 0.41 mmol) and Boc.Ser.OMe
(0.092 g, 0.41 mmol) in dry CH2Cl2 (10 mL) was cooled
to 0°C. DCC (0.170 g, 0.81 mmol) and DMAP (0.010 g,
0.08 mmol) were added, and the solution stirred at room
temperature for 24 hours. Upon completion, the reaction mixture was filtered, and the
filtrate was diluted with CH2Cl2 (10 mL). The organic phase was washed with sat.
NaHCO3 solution (10 mL) and brine (10 mL), and dried and evaporated. The resulting
residue was purified using flash column chromatography (2:1 Hexane: EtOAc) to
produce 66 as a white solid. (0.172 g, 80%), M.p. 112-114°C Rf 0.18
(2:1 Hexane:EtOAc.).1H NMR (500 MHz, CDCl3) δ 5.40 (bs, 1H, NH), 5.26 (m, 2H,
H3/H4), 4.96 (t, 1H, J = 8.7 Hz, H2), 4.73 (d, 1H, J = 8.1 Hz, H1), 4.58 (m, 2H, Hβ),
4.41 (m, 1H, Hα), 4.16 (d, 1H, J = 8.7 Hz, H5), 3.78 (s, 3H, OCH3), 2.08-2.02 (3s, 9H,
CH3, 3 x OAc), 1.45 (s, 9H, Boc-H).

13

C NMR (125 MHz, CDCl3) δ 170.1, (C=O,

OAc), 169.9, (C=O, OAc), 169.6, (C=O, OAc), 169.3 (C=O, COOCH3), 165.9 (C=O),
155.3 (C=O, Boc), 88.1 (C1), 80.6, (C(CH3)3), 74.3 (C5), 72.0 (C4), 70.5 (C3), 69.1
(C2), 66.0 (Cβ), 53.1 (OCH3), 52.8 (Cα), 28.4 (C(CH3)3), 20.7 (CH3, OAc), 20.7 (CH3,
OAc), 20.6 (CH3, OAc). LRMS (ESI): m/z 569 [M + Na]+
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Nα-(tert-Butoxycarbonyl)-O-(1-azido-2,3,4-tri-O-acetyl-β-D-galacturonoyl)-Lserine methyl ester (67)
A solution of 60 (0.142 g, 0.410 mmol) and
Boc.Ser.OMe (0.095 g, 0.430 mmol) in dry CH2Cl2
(10 mL) was cooled to 0°C. DCC (0.170 g, 0.810 mmol)
and DMAP (0.011 g, 0.080 mmol) were added, and the
solution stirred at room temperature for 24 hours. Upon completion, the reaction
mixture was filtered, and the filtrate was diluted with CH2Cl2 (10 mL). The organic
phase was washed with sat. NaHCO3 solution (10 mL) and brine (10 mL), and dried and
evaporated. The resulting residue was purified using flash column chromatography
(2:1 Hexane: EtOAc) to produce 66 as a colourless oil. (0.138 g, 64%),
Rf 0.22 (2:1 Hexane:EtOAc). 1H NMR (500 MHz, CDCl3) δ 5.69 (s, 1H, H4), 5.38 (d,
1H, J = 7.3 Hz, NH), 5.16 (t, 1H, J = 8.7 Hz, H2), 5.08 (dd, 1H, J = 3.0 Hz, 10.3 Hz,
H3), 4.64 (d, 1H, J = 8.7 Hz, H1), 4.55 (m, 1H, Hα), 4.47 (m, 2H, Hβ), 4.38 (m, 1H,
H5), 3.76 (s, 3H, OCH3), 2.07-1.98 (3s, 9H, CH3, 3 x OAc), 1.43 (s, 9H, CH3, Boc).
13

C NMR (125 MHz, CDCl3) δ 170.2 (C=O, OAc), 170.0 (C=O, OAc), 169.8 (C=O,

OAc), 169.4 (C=O, COOCH3), 165.0 (C=O), 155.4 (C=O, Boc), 88.5 (C1), 80.6
(C(CH3)3), 74.0 (C5), 70.4 (C3), 68.0 (C4), 67.9 (C2), 66.1 (Cβ), 53.1 (OCH3), 52.9
(Cα), 28.5 (C(CH3)3), 20.8 (CH3, OAc), 20.8 (CH3, OAc), 20.7 (CH3, OAc).
LRMS (ESI): m/z 569 [M + Na]+
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Nα-(Acetyl)-Nε-(1-azido-2,3,4-tri-O-acetyl-β-D-glucuronoyl)-L-lysine methyl ester
(68)
Method A: A solution of 60 (0.140 g, 0.40 mmol)
and Ac.Lys.OMe.HCl (0.100 g, 0.41 mmol) in dry
CH2Cl2 (10 mL) was cooled to 0°C. DCC
(0.171 g, 0.81 mmol) and DMAP (0.16 g,
0.13 mmol) were added, and the solution was allowed to stir at room temperature for
24 hours. Upon completion, the reaction mixture was filtered, and the filtrate was
diluted with CH2Cl2 (10 mL). The organic phase was washed with sat. NaHCO3
solution (10 mL) and brine (10 mL), and dried and evaporated. The resulting residue
was purified using flash column chromatography (1:2 Hexane: EtOAc) to produce 68 as
a light yellow oil. (0.67 g, 31%).
Method B: 60, (0.141 g, 0.41 mmol) Ac.Lys.OMe.HCl (0.100 g, 0.41 mmol), DCC
(0.175 g, 0.815 mmol) and HOBt (0.077 g, 0.528 mmol) were dissolved in DMF
(5 mL), and the solution was cooled to 0°C. DIPEA (0.075 mL, 0.056 g, 0.446 mmol)
was added dropwise to the solution, and the reaction mixture was allowed to warm to
room temperature and stir for 24 hours. Upon completion, the reaction mixture was
filtered, and the filtrate was diluted with EtOAc (20 mL), and extracted with H2O
(5 mL). The organic phase was dried and evaporated, with the following residue
purified by flash column chromatography (1:2 Hexane: EtOAc) to produce 68 as a light
yellow solid. (0.163 g, 75%), M.p 145-148°C, Rf 0.16 (1:2 Hexane:EtOAc).1H NMR
(500 MHz, CDCl3) δ 6.76 (bs, 1H, NH), 6.70 (bs, 1H, NH), 5.31 (t, 1H, J = 9.5 Hz,
10.0 Hz, H4), 5.17 (t, 1H, J = 9.5 Hz, 10.0 Hz, H3), 4.95 (t, 1H, J = 9.2 Hz, H2), 4.83
(d, 1H, J = 8.9 Hz, H1), 4.61 (m, 1H, CHα), 4.05 (d, 1H, J = 10.1 Hz, H5), 3.73 (s, 3H,
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OCH3), 3.40 (m, 1H, CHε), 3.15 (m, 1H, CHε), 2.09-2.01 (4s, 12H, CH3,
NHAc/3 x OAc), 1.79 (m, 1H, CHβ), 1.72 (m, 1H, CHβ), 1.55 (m, 2H, CHδ), 1.35 (m,
2H, CHγ).

13

C NMR (125 MHz, CDCl3) δ 173.1 (C=O, NHAc), 170.5 (C=O, OAc),

170.3 (C=O, OAc), 169.9 (C=O, OAc), 169.4 (C=O, COOCH3), 166.2 (C=O), 88.1
(C1), 74.6 (C5), 72.1 (C4), 70.8 (C3), 69.5 (C2), 52.5 (OCH3), 52.2 (CHε), 38.7 (CHα),
31.9 (CHδ), 29.1 (CHβ), 23.1 (CH3, NHAc), 22.4 (CHγ), 20.8 (CH3, OAc), 20.7 (CH3,
OAc), 20.7 (CH3, OAc). LRMS (ESI): m/z 552 [M + Na]+ HRMS (ESI): m/z calculated
for C21H31N5O11Na [M + Na]+: 552.1918; Found 552.1918.

Nα-(Acetyl)-Nε-(1-azido-2,3,4-tri-O-acetyl-β-D-galacturonoyl)-L-lysine methyl ester
(69)
65 (0.141 g, 0.41 mmol) Ac.Lys.OMe.HCl
(0.100 g, 0.42 mmol), DCC (0.176 g, 0.817 mmol)
and HOBt (0.079 g, 0.530 mmol) were dissolved
in DMF (5 mL), and the solution was cooled to
0°C. DIPEA (0.075 mL, 0.056 g, 0.446 mmol) was added dropwise to the solution, and
the reaction mixture was allowed to warm to room temperature and stir for 24 hours.
Upon completion, the reaction mixture was filtered, and the filtrate was diluted with
EtOAc (20 mL), and extracted with H2O (5 mL). The organic phases were combined,
dried and evaporated, and the residue purified by flash column chromatography
(1:2 Hexane: EtOAc) to produce 69 as a light yellow oil. (0.130 g, 60%), M.p. 154156°C (decomp.), Rf 0.18 (1:2 Hexane:EtOAc.). 1H NMR (500 MHz, CDCl3) δ 6.63 (t,
1H, J = 6.2 Hz NH), 6.37 (d, 1H, J = 7.7 Hz, NH), 5.81 (m, 1H, H4), 5.14 (m 2H,
H3/H2), 4.74 (m, 1H, H1), 4.54 (m, 1H, Hα), 4.34 (m, 1H, H5), 3.74 (s, 3H, OCH3),
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3.32-3.25 (m, 2H, CHε), 2.10 -1.98 (4s, 12H, CH3, NHAc/3 x OAc), 1.83 (m, 1H, CHβ),
1.70 (m, 1H, CHβ), 1.58 (m, 2H, CHδ), 1.37 (m, 2H, CHγ).

13

C NMR (125 MHz,

CDCl3) δ 173.0 (C=O, NHAc), 170.3 (C=O, OAc), 169.9 (C=O, OAc), 169.8 (C=O,
OAc), 169.4 (C=O, COOCH3), 165.4 (C=O), 88.4 (C1), 76.8 (C4), 75.4 (C5), 70.4 (C3),
67.8 (C2), 52.4 (OCH3), 52.0 (CHε), 38.7 (CHα), 31.7 (CHδ), 29.2 (CHβ), 23.1 (CH3
NHAc), 22.4 (CHγ), 20.7 (CH3, OAc), 20.7 (CH3, OAc), 20.5 (CH3, OAc).
LRMS (ESI): m/z 552 [M + Na]+ HRMS (ESI): m/z calculated for C21H31N5O11Na
[M + Na]+: 552.1918; Found 552.1935

N-(1-Azido-2,3,4-tri-O-acetyl-β-D-glucuronoyl)-L-leucine methyl ester (70)
60 (0.173 g, 0.50 mmol), H.Leu.OMe.HCl (0.136 g,
0.74 mmol) and HBTU (0.379 g, 1.00 mmol) were dissolved
in DMF (5 mL), and the solution was cooled to 0°C. DIPEA
(0.10 mL, 0.074 g, 0.55 mmol) was added dropwise to the
solution, and the reaction mixture was allowed to warm to room temperature and stirred
for 24 hours. Upon completion, the reaction mixture was filtered, and the filtrate was
diluted with EtOAc (20 mL), and extracted with H2O (5 mL). The organic phase was
dried and evaporated, and the residue purified by flash column chromatography
(3:1 Hexane: EtOAc) to produce 71 as a white solid. (0.199 g, 84%), M.p. 122-124°C,
Rf 0.72 (1:1 Hexane:EtOAc.). 1H NMR (500 MHz, CDCl3) δ 6.70 (d, 1H, J = 8.4 Hz,
NH), 5.28 (t, 1H, J = 9.4 Hz, H4), 5.15 (t, 1H, J = 9.8 Hz, H3), 4.96 (t, 1H, J = 9.1Hz,
H2), 4.79 (d, 1H, J = 8.9 Hz, H1), 4.57 (m, 1H, Hα), 4.04 (d, 1H, J = 10.1 Hz, H5), 3.74
(s, 3H, OCH3), 2.08 – 2.01 (3s, 9H, CH3, 3 x OAc), 1.69 - 1.64 (m, 3H, Hβ/Hγ), 0.95 (m,
6H, CH3, 2 x Hδ). 13C NMR (125 MHz, CDCl3) δ 172.8 C=O (COOCH3), 169.8 (C=O,
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OAc), 169.4 (C=O, OAc), 169.2 (C=O, OAc), 165.5 (C=O), 87.9 (C1), 74.2 (C5), 71.9
(C4), 70.6 (C3), 69.1 (C2), 52.4 (Cα), 50.4 (OCH3), 41.2 (Cβ), 24.8 (Cγ), 22.8 (Cδ), 21.8
(Cδ), 20.6 (CH3, OAc), 20.5 (CH3, OAc), 20.5 (CH3, OAc). LRMS (ESI): m/z 495
[M + Na]+ HRMS (ESI): m/z calculated for C19H24N4O10Na [M + Na]+: 495.1703;
Found 495.1697.

N-(1-Azido-2,3,4-tri-O-acetyl-β-D-galacturonoyl)-L-leucine methyl ester (71)
65 (0.173 g, 0.50 mmol), H.Leu.OMe.HCl (0.137 g,
0.75 mmol) and HBTU (0.380 g, 1.00 mmol) were dissolved in
DMF (5 mL), and the solution was cooled to 0°C. DIPEA
(0.10 mL, 0.074 g, 0.55 mmol) was added dropwise to the
solution, and the reaction mixture was allowed to warm to room temperature and stir for
24 hours. Upon completion, the reaction mixture was filtered, and the filtrate was
diluted with EtOAc (20 mL), and extracted with H2O (5 mL). The organic phase was
dried and evaporated, with the following residue purified by flash column
chromatography (2:1 Hexane: EtOAc) to produce 71 as a clear oil. (0.184 g, 78%),
Rf 0.65 (1:1 Hexane:EtOAc.). 1H NMR (500 MHz, CDCl3) δ 6. 82 (d, 1H, J = 7.6 Hz,
NH), 5.83 (m, 1H, H4), 5.17 (m, 2H, H2/H3), 4.70 (m, 2H, H1/Hα), 4.33 (m, 1H, H5),
3.75 (s, 3H, OCH3), 2.11 – 1.99 (3s, 9H, CH3, 3 x OAc), 1.69 – 1.60 (m, 3H, Hβ/ Hγ),
0.95 (m, 6H, CH3, 2 x Hδ).

13

C NMR (125 MHz, CDCl3) δ 172.9 (C=O, COOCH3),

170.0 (C=O, OAc), 169.6 (C=O, OAc), 169.3 (C=O, OAc), 164.9 (C=O), 88.4 (C1),
75.4 (C5), 70.4 (C3), 67.7 (C2), 67.6 (C4), 52.5 (OCH3), 50.4 (Cα), 41.4 (Cβ), 24.8 (
Cγ), 22.9 (Cδ), 20.7 (CH3, OAc), 20.5 (CH3, OAc), 20.4 (CH3, OAc). LRMS (ESI): m/z
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495 [M + Na]+ HRMS (ESI): m/z calculated for C19H24N4O10Na [M + Na]+: 495.1703;
Found 495.1696

N-(1-Azido-2,3,4-tri-O-acetyl-β-D-glucuronoyl)-L-methionine methyl ester (72)
60 (0.342 g, 1.01 mmol), H.Met.OMe.HCl (0.302 g,
1.51 mmol) and HBTU (0.764 g, 2.00 mmol) were
dissolved in DMF (15 mL), and the solution was cooled to
0°C. DIPEA (0.20 mL, 0.148 g, 1.1 mmol) was added
dropwise to the solution, and the reaction mixture was allowed to warm to room
temperature and stirred for 24 hours. Upon completion, the reaction mixture was
filtered, and the filtrate was diluted with EtOAc (50 mL), and extracted with H2O (5
mL). The organic phase was dried and evaporated, with the following residue purified
by flash column chromatography (2:1 Hexane: EtOAc) to produce 72 as a fluffy white
solid. (0.461 g, 95%), M.p. 106-107°C, Rf 0.71 (1:1 Hexane:EtOAc.).1H NMR
(500 MHz, CDCl3) δ 7.14 (bs, 1H, NH), 5.27 (t, 1H, J = 9.5 Hz, H3), 5.16 (t, 1H,
J = 9.8 Hz, H4), 4.97 (t, 1H, J = 9.6 Hz, H2), 4.78 (d, 1H, J = 9.8Hz, H1), 4.68 (m, 1H,
Hα), 4.02 (d, 1H, J = 9.8 Hz, H5), 3.78 (s, 3H, OCH3), 2.54 (t, 2H, J = 7.3 Hz, Hγ),
2.19 (m, 2H, Hβ), 2.13 (s, 3H, S-CH3), 2.09-2.02 (3s, 9H, CH3, 3 x OAc).

13

C NMR

(125 MHz, CDCl3) δ 171.8 (COOCH3), 169.9 (C=O, OAc), 169.6 (C=O, OAc), 169.3
(C=O, OAc), 165.7 (C=O), 87.9 (C1), 74.2 (C5), 71.7 (C4), 70.5 (C3), 69.1(C2), 52.7
(Cα), 51.2 (-OCH3), 31.2 (Cβ), 29.7(Cγ), 20.7 (CH3, OAc), 20.6 (CH3, OAc), 20.6 (CH3,
OAc), 15.4 (SCH3). LRMS (ESI): m/z 513 [M + Na]+ HRMS (ESI): m/z calculated for
C18H26N4O10SNa [M + Na]+: 513.1267; Found 513.1273.
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N-(1-Azido-2,3,4-tri-O-acetyl-β-D-glucuronoyl)-L-glutamine tert-butyl ester (73)
60 (0.173 g, 0.50 mmol), H.Glu.OtBu.HCl (0.179 g,
0.75 mmol) and HBTU (0.376 g, 0.99 mmol) were
dissolved in DMF (5 mL), and the solution was cooled to
0°C. DIPEA (0.10 mL, 0.074 g, 0.55 mmol) was added
dropwise to the solution, and the reaction mixture was allowed to warm to room
temperature and stir for 24 hours. Upon completion, the reaction mixture was filtered,
and the filtrate was diluted with EtOAc (20 mL), and extracted with H2O (5 mL). The
organic phase was dried and evaporated, with the following residue purified by flash
column chromatography (1:3 Hexane: EtOAc) to produce 73 as an off-white solid.
(0.254 g, 96%), M.p. 129-130°C, Rf 0.24 (1:3 Hexane:EtOAc.). 1H NMR (500 MHz,
CDCl3) δ 7.24 (d, 1H, J = 7.7 Hz, NH), 5.31 (t, 1H, J = 9.5 Hz, H3), 5.18 (t, 1H, J = 9.6
Hz, H4), 4.98 (t, 1H, J = 9.4 Hz, H2), 4.82 (d, 1H, J = 9.0 Hz, H1), 4.45 (m, 1H, Hα),
4.02 (d, 1H, J = 9.9 Hz, H5), 2.35 - 2.28 (m, 2H, Hγ), 2.20-1.90 (m, 2H, Hβ), 2.09 - 2.02
(3s, 9H, CH3, 3 x OAc), 1.48 (s, 9H, OtBu).13C NMR (125 MHz, CDCl3) δ 174.9
(CONH2), 170.6 (COOtBu), 170.2 (C=O, OAc), 169.7 (C=O, OAc), 169.2 (C=O, OAc)
167.5 (C=O), 87.9 (C1), 83.0 (C(CH3)3), 74.2 (C5), 71.6 (C4), 70.6 (C3), 69.5(C2), 51.8
(Cα), 38.6 (Cγ), 31.3 (Cβ), 27.9 (C(CH3)3), 20.8 (CH3, OAc), 20.5 (CH3, OAc), 20.5
(CH3, OAc). LRMS (ESI): m/z 552 [M + Na]+ HRMS (ESI): m/z calculated for
C21H31N5O11Na [M + Na]+: 552.1918; Found 552.1922.
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1-(4’-(2”-Hydroxyethyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetyl-β-D-glucuronic
acid allyl ester (74)
Method A: To a round bottom flask containing 59
(0.100 g, 0.260 mmol), 3-butyn-1-ol (0.034 mL,
0.037 g, 0.52 mmol), CuSO4.5H2O (0.013 g,
0.052 mmol) and sodium ascorbate (0.010 g, 0.052 mmol) was added a 3:1 solution of
ACN:H2O, (0.500 mL), with the solution stirred vigorously under an atmosphere of
nitrogen at room temperature for 8 hours. Upon completion, the reaction mixture was
diluted with CH2Cl2 (5 mL), and extracted with H2O (1 mL), then brine (1 mL).
Subsequent drying (MgSO4) of the organic phase, and evaporation in vacuo resulted in a
residue which was purified by flash column chromatography (1:3 Hexane: EtOAc) to
yield 74 as a light yellow oil. (0.044 g, 37%).
Method B: As for Method A, except that a solution of 1:1 nBuOH: H2O was instead
used, and the reaction mixture was stirred at 40°C for 4 hours. Work up and purification
by flash column chromatography yielded 74 as a light yellow oil. (0.058 g, 49%).
Method C: To a round bottom flask containing 59 (0.100 g, 0.260 mmol), 3-butyn-1-ol
(0.067 mL, 0.073 g, 1.04 mmol), CuSO4.5H2O (0.013 g, 0.052 mmol) and sodium
ascorbate (0.021 g, 0.104 mmol) was added a 1:1 solution of nBuOH:H2O, (0.500 mL),
with the solution stirred vigorously under an atmosphere of nitrogen at room
temperature for 8 hours. Upon completion, the reaction mixture was diluted with
CH2Cl2 (5 mL), and extracted with H2O (1 mL), then brine (1 mL). Subsequent drying
(MgSO4) of the organic phase, and evaporation in vacuo resulted in a residue which was
purified by flash column chromatography to yield 74 as a light yellow oil.
(0.061 g, 52%)
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Method D: As for Method C, except that CuOAc2.H2O (0.010 g, 0.052 mmol) was used
instead of CuSO4.5H2O. Work up and purification by flash column chromatography
yielded 74 as a light yellow oil. (0.065 g, 55%)
Method E: As for Method D, except that the additive TBTA (0.028 g, 0.052 mmol) was
added to the reaction mixture. Work up and purification by flash column
chromatography yielded 74 as a light yellow oil. (0.071 g, 60%)
Method F: To a round bottom flask containing 59 (0.100 g, 0.260 mmol), 3-butyn-1-ol
(0.070 mL, 0.075 g, 1.06 mmol), CuOAc2.H2O (0.011 g, 0.056 mmol) and sodium
ascorbate (0.022 g, 0.110 mmol) was added a 1:1 solution of nBuOH:H2O, (0.500 mL),
with the solution stirred vigorously under an atmosphere of nitrogen at room
temperature for 24 hours. Upon completion, the reaction mixture was diluted with
CH2Cl2 (5 mL), and extracted with H2O (1 mL), then brine (1 mL). Subsequent drying
(MgSO4) of the organic phase, and evaporation in vacuo resulted in a residue which was
purified by flash column chromatography to yield 74 as a light yellow solid
(0.104 g, 88%), M.p. 116-118°C, Rf 0.29 (1:3 Hexane:EtOAc.). 1H NMR (500 MHz,
CDCl3) δ 7.74 (s, 1H, Triazole-H), 5.93-5.86 (m, 2H, H1/CH2=CH-CH2), 5.48-5.25 (m,
5H, H4/H3/H2/CH2=CH-CH2), 4.61 (m, 2H, CH2=CH-CH2), 4.35 (d, 1H, J = 9.8 Hz,
H5), 3.87 (m, 2H, CH2-CH2-OH), 2.92 (m, 2H, CH2-CH2-OH), 2.04-1.98 (3, 9H, CH3,
3 x OAc). Exchangeable OH not detected. 13C NMR (125 MHz, CDCl3) δ 169.9 (C=O,
OAc), 169.5 (C=O, OAc), 169.2 (C=O, OAc), 165.7 (C=O), 147.9 (Triazole), 130.9
(CH2-CH=CH2), 120.6 (Triazole), 120.0 (CH2-CH=CH2), 88.1 (C1), 74.9 (C5), 71.8
(C4), 70.3 (C3), 69.1 (C2), 67.1 (CH2-CH=CH2), 61.5 (CH2-CH2-OH), 29.1
(CH2-CH2-OH),

20.6

(CH3,

LRMS (ESI): m/z 478 [M + Na]+
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OAc),

20.6

(CH3,

OAc),

20.3

(CH3, OAc).
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1-(4’-(3”-Hydroxypropyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetyl-β-D-glucuronic
acid allyl ester (75)
To a round bottom flask containing 59 (0.101 g,
0.261 mmol), 4-pentyn-1-ol (0.097 mL, 0.087 g,
1.04

mmol),

CuOAc2.H2O

(0.010

g,

0.052 mmol) and sodium ascorbate (0.021 g, 0.104 mmol) was added a 1:1 solution of
nBuOH:H2O, (0.500 mL), with the solution stirred vigorously under an atmosphere of
nitrogen at room temperature for 24 hours. Upon completion, the reaction mixture was
diluted with CH2Cl2 (5 mL), and extracted with H2O (1 mL), then brine (1 mL).
Subsequent drying (MgSO4) of the organic phase, and evaporation in vacuo resulted in a
residue which was purified by flash column chromatography to yield 75 as a white
solid.

(0.114 g, 84%), M.p. 114-116°C, Rf 0.27 (1:3 Hexane:EtOAc). 1H NMR

(500 MHz, CDCl3) δ 7.69 (s, 1H, Triazole-H), 5.95-5.84 (m, 2H, H1/CH2=CH-CH2),
5.48-5.27 (m, 5H, H4/H3/H2/CH2=CH-CH2), 4.63 (m, 2H, CH2=CH-CH2), 4.37 (d, 1H,
J = 9.8 Hz, H5), 3.67 (m, 2H, CH2-CH2-CH2-OH), 2.85 (m, 2H, CH2-CH2-CH2-OH),
2.05 (s, 6H, CH3, 2 x OAc), 1.93 (m, 2H, CH2-CH2-CH2-OH), 1.88 (s, 3H, CH3, OAc).
Exchangeable OH not detected.

13

C NMR (125 MHz, CDCl3) δ 169.9 (C=O, OAc),

169.5 (C=O, OAc), 169.1 (C=O, OAc), 165.7 (C=O), 130.9 (Triazole C), 147.9 (CH2CH=CH2), 120.0 (Triazole C), 119.9 (CH2-CH=CH2), 85.5 (C1), 74.9 (C5), 72.0 (C4),
70.1 (C3), 69.1 (C2), 67.1 (CH2-CH=CH2), 61.6 (CH2-CH2-CH2-OH), 31.7 (CH2-CH2CH2-OH), 22.0 (CH2-CH2-CH2-OH), 20.6 (CH3, OAc), 20.6 (CH3, OAc), 20.2 (CH3,
OAc). LRMS (ESI): m/z 492 [M + Na]+ HRMS (ESI): m/z calculated for
C20H27N3O10Na [M + Na]+: 492.1594; Found 492.1580.
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1-(4’-(3”-Hydroxypropyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetyl-β-D-galacturonic
acid allyl ester (76)
To a round bottom flask containing 64
(0.101 g,
(0.097 mL,

0.261
0.087

mmol),
g,

4-pentyn-1-ol
1.04

mmol),

CuOAc2.H2O (0.010 g, 0.052 mmol) and
sodium ascorbate (0.020 g, 0.099 mmol) was added a 1:1 solution of nBuOH:H2O,
(0.500 mL), with the solution stirred vigorously under an atmosphere of nitrogen at
room temperature for 24 hours. Upon completion, the reaction mixture was diluted with
CH2Cl2 (5 mL), and extracted with H2O (1 mL), then brine (1 mL). Subsequent drying
(MgSO4) of the organic phase, and evaporation in vacuo resulted in a residue which was
purified by flash column chromatography to yield 76 as a light yellow oil. (0.109 g,
80%), Rf 0.30 (1:3 Hexane:EtOAc.). 1H NMR (500 MHz, CDCl3) δ 7.73 (s, 1H,
Triazole-H), 5.89-5.83 (m, 3H, CH2-CH=CH2/H1/H3), 5.56 (t, 1H, J = 10.0 Hz, H2),
5.30 (m, 3H, CH2-CH=CH2/H4), 4.68-4.61 (m, 3H, CH2-CH=CH2/H5), 3.68 (m, 2H,
CH2-CH2-CH2-OH), 2.85 (m, 2H, CH2-CH2-CH2-OH), 2.02 (s, 6H, CH3, 2 x OAc), 1.95
(m, 2H, CH2-CH2-CH2-OH), 1.89 (s, 3H, CH3, OAc). Exchangeable OH not detected.
13

C NMR (125 MHz, CDCl3) δ 169.8 (OAc), 169.6 (OAc), 169.2 (OAc), 164.7 (OAc),

147.8 (Triazole C), 130.8 (CH2-CH=CH2), 120.2 (Triazole C), 119.7 (CH2-CH=CH2),
85.9 (C1), 74.8 (C5), 70.4 (C4), 68.1 (C3), 67.6 (C2), 66.7 (CH2-CH=CH2), 61.5 (CH2CH2-CH2-OH), 31.7 (CH2-CH2-CH2-OH), 21.9 (CH2-CH2-CH2-OH), 20.6 (CH3, OAc),
20.5 (CH3, OAc), 20.2 (CH3, OAc). LRMS (ESI): m/z 492 [M + Na]+ HRMS (ESI):
m/z calculated for C20H27N3O10Na [M + Na]+: 492.1594; Found 492.1597.
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1-(4’-Phenyl-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetyl-β-D-glucuronic acid allyl ester
(77)
To a round bottom flask containing 59
(0.101 g,
(0.115 mL,

0.261

mmol),

0.107

g,

pheylacetylene
1.04

mmol),

CuOAc2.H2O (0.010 g, 0.052 mmol) and
sodium ascorbate (0.021 g, 0.104 mmol) was added a 1:1 solution of nBuOH:H2O,
(0.500 mL), with the solution stirred vigorously under an atmosphere of nitrogen at
room temperature for 24 hours. Upon completion, the reaction mixture was diluted with
CH2Cl2 (5 mL), and extracted with H2O (1 mL), then brine (1 mL). Subsequent drying
(MgSO4) of the organic phase, and evaporation in vacuo resulted in a residue which was
purified by flash column chromatography (2:1 Hexane: EtOAc) to yield 75 as a light
yellow solid (0.108 g, 85%), M.p 207-210 °C (decomp.) Rf 0.25 (2:1 Hexane:EtOAc.).
1

H NMR (500 MHz, CDCl3) δ 8.08 (s, 1H, Triazole-H), 7.82 (d, 2H, J = 7.3 Hz,

Ar-H2/H6), 7.34-7.44 (m, 3H, Ar-H3/H4/H5), 6.00 (d, 1H, J = 8.2 Hz, H1), 5.90 (m,
1H, CH2=CH-CH2), 5.52 (m, 2H, CH2=CH-CH2), 5.43-5.25 (3t (overlapping), 3H,
J = 9.0 Hz, 9.9 Hz, H4/H3/H2), 4.63 (m, 2H, CH2=CH-CH2), 4.37 (d, 1H, J = 9.7 Hz,
H5), 2.04 (2s, 6H, CH3, 2 x OAc), 1.87 (s, 3H, CH3, OAc).

13

C NMR (125 MHz,

CDCl3) δ 170.4 (C=O, OAc), 169.9 (C=O, OAc), 169.5 (C=O, OAc), 166.1 (C=O),
131.4 (CH2-CH=CH2), 130.4 (Triazole C), 129.5 (Ar-C), 129.2 (Ar-C), 126.5 (Ar-C),
120.6 (Triazole C), 118.6 (CH2-CH=CH2), 86.1 (C1), 75.6 (C5), 72.6 (C4), 70.5 (C3),
69.6 (C2), 67.6 (CH2-CH=CH2), 21.2 (CH3, OAc), 21.2 (CH3, OAc), 20.8 (CH3, OAc).
LRMS (ESI): m/z 486 [M - H]- HRMS (ESI): m/z calculated for C23H24N3O9 [M - H]-:
486.1514; Found 486.1512.

220 | P a g e

Chapter 7: Experimental
Nα-(tert-Butoxycarbonyl)-O-(1-(4’-(2”-hydroxyethyl)-1’,2’,3’-triazol-1’-yl)-2,3,4tri-O-acetyl-β-D-glucuronyl)-L-serine methyl ester (78)
To a round bottom flask containing 66
(0.143 g, 0.261 mmol), 3-butyn-1-ol
(0.067 mL, 0.073 g, 1.04 mmol),
CuOAc2.H2O (0.010 g, 0.052 mmol) and
sodium ascorbate (0.022 g, 0.110 mmol) was added a 1:1 solution of nBuOH:H2O,
(0.500 mL), with the solution stirred vigorously under an atmosphere of nitrogen at
room temperature for 24 hours. Upon completion, the reaction mixture was diluted with
CH2Cl2 (5 mL), and extracted with H2O (1 mL), then brine (1 mL). Subsequent drying
(MgSO4) of the organic phase, and evaporation in vacuo resulted in a residue which was
purified by flash column chromatography (1:3 Hexane: EtOAc) to yield 78 as a light
yellow

solid.

(0.100

g,

62%),

M.p.

146-148°C

Rf

0.20

(1:3

Hexane:EtOAc.).1H NMR (500 MHz, CDCl3) δ 7.74 (s, 1H, Triazole-H), 5.88 (d, 1H,
J = 8.9 Hz, (H1), 5.47-5.33 (m, 4H, H4/H3/H2/NH), 4.55 (m, 2H, Hβ), 4.37 (m, 2H,
Hα/H5), 3.92 (m, 2H, CH2-CH2-OH), 3.75 (s, 3H, OCH3), 2.96 (t, 2H, J = 6.9 Hz, CH2CH2-OH), 2.10-1.89 (3s, 9H, CH3, 3 x OAc), 1.44 (s, 9H, Boc-H). Exchangeable OH
not detected.

13

C NMR (125 MHz, CDCl3) δ 169.7, 169.7, 169.5 (C=O, OAc), 169.1

(C=O, COOCH3), 165.4 (C=O), 155.6 (C=O, Boc), 149.4 (Triazole C), 118.6
(Triazole C), 88.6 (C1), 80.6(C-CH3), 74.9 (C5), 71.7 (C4), 70.2 (C3), 69.0 (C2), 66.0
(Cβ), 62.7 (CH2-CH2-OH), 53.0 (OCH3), 52.7 (Cα), 34.0 (CH2-CH2-OH), 28.3 (C-CH3),
20.5 (CH3, OAc), 20.5 (CH3, OAc), 20.2 (CH3, OAc). LRMS (ESI): m/z 639 [M + Na]+
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Nα-(tert-Butoxycarbonyl)-O-(1-(4’-(3”-hydroxypropyl)-1’,2’,3’-triazol-1’-yl)-2,3,4tri-O-acetyl-β-D-glucuronyl)-L-serine methyl ester (79)
To a round bottom flask containing
66

(0.144 g,

0.262

mmol),

4-pentyn-1-ol (0.097 mL, 0.087 g,
1.04 mmol), CuOAc2.H2O (0.010 g,
0.052 mmol) and sodium ascorbate (0.020 g, 0.099 mmol) was added a 1:1 solution of
nBuOH:H2O, (0.500 mL), with the solution stirred vigorously under an atmosphere of
nitrogen at room temperature for 24 hours. Upon completion, the reaction mixture was
diluted with CH2Cl2 (5 mL), and extracted with H2O (1 mL), then brine (1 mL).
Subsequent drying (MgSO4) of the organic phase, and evaporation in vacuo resulted in a
residue which was purified by flash column chromatography (1:3 Hexane: EtOAc) to
yield 79 as a light yellow solid. (0.096 g, 58%), M.p 174-176°C, Rf 0.16 (1:3
Hexane:EtOAc.). 1H NMR (500 MHz, CDCl3) δ 7.64 (s, 1H, Triazole-H), 5.88 (d, 1H,
J = 8.7 Hz, H1), 5.44 (m, 2H, H4/H3), 5.33 (m, 2H, H2/NH), 4.59 (m, 1H, Hα), 4.52
(dd, 1H, J = 3.7 Hz, 11.4 Hz, Hβ), 4.40 (dd, 1H, J = 2.6 Hz, 11.2 Hz, Hβ), 4.31, (d, 1H,
J = 9.9 Hz, H5), 3.76 (s, 3H, OCH3), 3.68 (m, 2H, CH2-CH2-CH2-OH), 2.85 (t, 2H,
J = 7.2 Hz, CH2-CH2-CH2-OH), 2.10, 2.05 (2s, 6H, CH3, 2 x OAc), 1.95 (t, 2H, J = 6.7
Hz, CH2-CH2-CH2-OH), 1.88 (s, 3H, CH3, OAc), 1.44 (s, 9H, Boc). Exchangeable OH
not detected.

13

C NMR (125 MHz, CDCl3) δ 169.9 (C=O, OAc), 169.9 (C=O, OAc),

169.7 (C=O, OAc), 169.1 (C=O, COOCH3), 165.6 (C=O), 155.5 (C=O, Boc), 148.6
(Triazole C), 119.6 (Triazole C), 85.6 (C1), 81.1(C-CH3), 75.1 (C5), 72.1 (C4), 70.2
(C3), 69.2 (C2), 66.0 (Cβ), 61.8 (CH2-CH2-CH2-OH), 53.1 (OCH3), 52.9 (Cα), 31.8
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(CH2-CH2-CH2-OH), 28.5 (C-CH3), 22.2 (CH2-CH2-CH2-OH), 20.7 (CH3, OAc), 20.7
(CH3, OAc), 20.3 (CH3, OAc). LRMS (ESI): m/z 653 [M + Na]+

Nα-(tert-Butoxycarbonyl)-O-(1-(4’-(3”-hydroxypropyl)-1’,2’,3’-triazol-1’-yl)-2,3,4tri-O-acetyl-β-D-galacturonyl)-L-serine methyl ester (80)
To a round bottom flask containing
67

(0.143 g,

0.261 mmol),

4-pentyn-1-ol (0.097 mL, 0.087 g,
1.04 mmol), CuOAc2.H2O (0.010 g,
0.052 mmol) and sodium ascorbate (0.020 g, 0.099 mmol) was added a 1:1 solution of
nBuOH:H2O, (0.500 mL), with the solution stirred vigorously under an atmosphere of
nitrogen at room temperature for 24 hours. Upon completion, the reaction mixture was
diluted with CH2Cl2 (5 mL), and extracted with H2O (1 mL), then brine (1 mL).
Subsequent drying (MgSO4) of the organic phase, and evaporation in vacuo resulted in a
residue which was purified by flash column chromatography (1:3 Hexane: EtOAc) to
yield 76 as a light yellow oil. (0.114 g, 69%), Rf 0.22 (1:3 Hexane:EtOAc.).
1

H NMR (500 MHz, CDCl3) δ 7.78 (bs,1H, Triazole-H) 5.87 (m, 2H, H3/H4), 5.58 (t,

1H, J = 9.9 Hz, H2), 5.47 (d, 1H, J = 7.0 Hz, NH), 5.35 (d, 1H, J = 10.3 Hz, H1), 4.67
(m, 1H, H5), 4.59 (m, 1H, Hα), 4.48 (d, 1H, J = 9.7 Hz, Hβ), 3.78-3.73 (m,
5H,OCH3/CH2-CH2-CH2-OH), 2.86 (m, 2H, CH2-CH2-CH2-OH), 2.21 (s, 3H, CH3,
OAc), 2.04 (s, 3H, CH3, OAc), 1.97 (m, 2H, CH2-CH2-CH2-OH), 1.90 (s, 3H, CH3,
OAc), 1.46 (s, 9H, Boc-H). Exchangeable OH not detected.

13

C NMR (125 MHz,

CDCl3) δ 169.9 (C=O, OAc), 169.7 (C=O, OAc), 169.6 (C=O, OAc), 169.1 (C=O,
COOCH3), 164.6 (C=O), 155.2 (C=O, Boc), 148.3 (Triazole C), 120.0 (Triazole C),
85.9 (C1), 80.5 (C(CH3)3), 74.6 (C4), 70.2 (C5), 67.8 (C3), 67.6 (C2), 66.1 (Cβ), 61.5
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(CH2-CH2-CH2-OH), 52.9 (OCH3), 52.7 (Cα), 31.6 (CH2-CH2-CH2-OH), 28.2
(C(CH3)3), 22.0 (CH2-CH2-CH2-OH), 20.6 (CH3, OAc), 20.5 (CH3, OAc), 20.2 (CH3,
OAc). LRMS (ESI): m/z 653 [M + Na]+

Nα-(Acetyl)-Nε-(1-(4’-(2”-hydroxyethyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetylβ-D-glucuronyl)-L-lysine methyl ester (81)
To

a

containing

round
68

bottom

flask

(0.138 g,

0.261

mmol), 3-butyn-1-ol (0.067 mL,
0.073 g, 1.04 mmol), CuOAc2.H2O
(0.010 g, 0.052 mmol) and sodium ascorbate (0.022 g, 0.110 mmol) was added a
1:1 solution of nBuOH:H2O, (0.500 mL), with the solution stirred vigorously under an
atmosphere of nitrogen at room temperature for 24 hours. Upon completion, the reaction
mixture was diluted with CH2Cl2 (5 mL), and extracted with H2O (1 mL), then brine
(1 mL). Subsequent drying (MgSO4) of the organic phase, and evaporation in vacuo
resulted in a residue which was purified by flash column chromatography (EtOAc) to
yield 81 as a light yellow oil (0.110 g, 70%). Rf 0.05 (1:3 Hexane:EtOAc.).
1

H NMR (500 MHz, CDCl3) δ 7.87 (s,1H, Triazole-H) 6.71 (bs, 1H, NH), 6.55 (d, 1H,

J = 7.5 Hz, NH), 5.94 (d, 1H, J = 9.5 Hz, H1), 5.58 (t, 1H, J = 9.5 Hz, H4), 5.49 (t, 1H,
J = 9.5 Hz, H3), 5.37 (t, 1H, J = 9.4 Hz, H2), 4.59 (m, 1H, CHα), 4.23 (d, 1H,
J = 10.0 Hz, H5), 3.93 (m, 2H, CH2-CH2-OH), 3.74 (s, 3H, OCH3), 3.34 (m, 1H, CHε),
3.11 (m, 1H, CHε), 2.98 (m, 2H, CH2-CH2-OH), 2.11-2.03 (3s, 9H, CH3, 2 x OAc,
NHAc), 1.88 (s, 3H, CH3, OAc), 1.77 (m, 1H, CHβ), 1.68 (m, 1H, CHβ), 1.53 (m, 2H,
CHδ), 1.34 (m, 2H, CHγ). Exchangeable OH not detected. 13C NMR (125 MHz, CDCl3)
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δ 173.0 (C=O, NHAc), 170.6 (C=O, OAc), 170.0 (C=O, OAc), 169.7 (C=O, OAc),
169.2 (C=O, COOCH3), 165.6 (C=O), 148.3 (Triazole C), 120.6 (Triazole C), 85.1
(C1), 75.3 (C5), 72.0 (C4), 70.2 (C3), 69.1 (C2), 61.2 (CH2-CH2-OH), 52.5 (OCH3),
51.7 (CHε), 38.6 (CHα), 32.2 (CHδ), 28.8 (CHβ), 28.3 (CH2-CH2-OH), 23.1(NHAc),
22.1 (CHγ), 20.7 (CH3, OAc), 20.5 (CH3, OAc), 20.2 (CH3, OAc). LRMS (ESI): m/z
622 [M + Na]+ HRMS (ESI): m/z calculated for C25H37N5O12Na [M + Na]+: 622.2336;
Found 622.2360.

Nα-(Acetyl)-Nε-(1-(4’-(3”-hydroxypropyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetylβ-D-glucuronyl)-L-lysine methyl ester (82)
To a round bottom flask
containing

68

(0.137 g,

0.261 mmol), 4-pentyn-1-ol
(0.097 mL,

0.087

g,

1.04 mmol), CuOAc2.H2O (0.010 g, 0.052 mmol) and sodium ascorbate (0.020 g, 0.099
mmol) was added a 1:1 solution of nBuOH:H2O, (0.500 mL), with the solution stirred
vigorously under an atmosphere of nitrogen at room temperature for 24 hours. Upon
completion, the reaction mixture was diluted with CH2Cl2 (5 mL), and extracted with
H2O (1 mL), then brine (1 mL). Subsequent drying (MgSO4) of the organic phase, and
evaporation in vacuo resulted in a residue which was purified by flash column
chromatography (EtOAc) to yield 82 as a light yellow oil. (0.101 g, 63%), Rf 0.07
(1:3 Hexane:EtOAc.). 1H NMR (500 MHz, CDCl3) δ 7.79 (s,1H, Triazole-H) 6.77 (bs,
1H, NH), 6.47 (bs, 1H, NH), 5.99 (d, 1H, J = 9.5 Hz, H1), 5.62 (t, 1H, J = 9.5 Hz, H4),
5.50 (t, 1H, J = 9.5 Hz, H3), 5.39 (t, 1H, J = 9.4 Hz, H2), 4.58 (m, 1H, CHα), 4.27 (d,
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1H, J = 10.0 Hz, H5), 3.73 (s, 3H, OCH3), 3.67 (m, 2H, CH2-CH2-CH2-OH), 3.34 (m,
1H, CHε), 3.11 (m, 1H, CHε), 2.86 (m, 2H, CH2-CH2-CH2-OH), 2.11-2.02 (3s, 9H, CH3,
2 x OAc, NHAc), 1.94 (m, 2H, CH2-CH2-CH2-OH), 1.88 (s, 3H, CH3, OAc), 1.77
(m, 1H, CHβ), 1.68 (m, 1H, CHβ), 1.53 (m, 2H, CHδ), 1.34 (m, 2H, CHγ). Exchangeable
OH not detected.

13

C NMR (125 MHz, CDCl3) δ 173.0 (C=O, NHAc), 170.7 (C=O,

OAc), 170.0 (C=O, OAc), 169.9 (C=O, OAc), 169.0 (C=O, COOCH3), 165.8 (C=O),
149.8 (Triazole C), 120.1 (Triazole C), 85.1 (C1), 75.4 (C5), 72.2 (C4), 70.1 (C3), 69.2
(C2), 61.4 (CH2-CH2-CH2-OH), 52.4 (OCH3), 51.8 (CHε), 38.6 (CHα), 32.1 (CHδ), 31.6
(CH2-CH2-CH2-OH), 28.5 (CHβ), 28.4 (CH2- CH2-CH2-OH), 23.0 (NHAc), 22.2 (CHγ),
20.7 (CH3, OAc), 20.5 (CH3, OAc), 20.2 (CH3, OAc). LRMS (ESI): m/z 636 [M + Na]+
HRMS (ESI): m/z calculated for C26H39N5O12Na [M + Na]+: 636.2493; Found
636.2520.

Nα-(Acetyl)-Nε-(1-(4’-(3”-hydroxypropyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetylβ-D-galacturonyl)-L-lysine methyl ester (83)
To a round bottom flask
containing

69

(0.137 g,

0.261 mmol), 4-pentyn-1-ol
(0.097 mL, 0.087 g, 1.04
mmol), CuOAc2.H2O (0.010 g, 0.052 mmol) and sodium ascorbate (0.020 g, 0.099
mmol) was added a 1:1 solution of nBuOH:H2O, (0.500 mL), with the solution stirred
vigorously under an atmosphere of nitrogen at room temperature for 24 hours. Upon
completion, the reaction mixture was diluted with CH2Cl2 (5 mL), and extracted with
H2O (1 mL), then brine (1 mL). Subsequent drying (MgSO4) of the organic phase, and
evaporation in vacuo resulted in a residue which was purified by flash column
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chromatography (EtOAc) to yield 83 as a light yellow oil. (0.121 g, 75%), Rf 0.05
(1:3 Hexane:EtOAc.). 1H NMR (500 MHz, CDCl3) δ 7.73 (s, 1H, Triazole-H), 6.47 (t,
1H, J = 6.2 Hz NH), 6.23 (d, 1H, J = 7.7 Hz, NH), 5.94 (m, 2H, H4/H3), 5.65 (m 1H,
H2), 5.33 (d, 1H, J = 9.9 Hz, H1), 4.57-4.51, (m, 2H, H5/Hα), 3.72 (s, 3H, OCH3), 3.68
(m, 2H, CH2-CH2-CH2-OH), 3.23 (m, 2H, Hε), 2.87 (m, 2H, CH2-CH2-CH2-OH), 2.10
(s, 3H, CH3, NHAc), 2.01 (s, 6H, CH3, 2 x OAc), 1.95 (m, 2H, CH2-CH2-CH2-OH) 1.88
(s, 3H, CH3, OAc), 1.81 (m, 1H, CHβ), 1.68 (m, 1H, CHβ), 1.50 (m, 2H, CHδ), 1.32 (m,
2H, CHγ). Exchangeable OH not detected. 13C NMR (125 MHz, CDCl3) δ 172.9 (C=O,
NHAc), 170.3 (C=O, OAc), 169.7 (C=O, OAc), 169.2 (C=O, OAc), 169.1 (C=O,
COOCH3), 164.9 (C=O), 148.4 (Triazole-C), 119.9 (Triazole-C), 85.7 (C1), 76.1 (C4),
70.8 (C5), 67.7 (C2), 67.5 (C3),61.5 (CH2-CH2-CH2-OH), 52.4 (OCH3), 51.9 (CHε),
38.7 (CHα), 31.9 (CH2-CH2-CH2-OH), 31.7 (CHδ), 29.0 (CHβ), 23.0 (CH3 NHAc), 22.5
(CHγ), 22.0 (CH2-CH2-CH2-OH), 20.6 (CH3, OAc), 20.5 (CH3, OAc), 20.2 (CH3,
OAc).

LRMS (ESI): m/z 636 [M + Na]+

HRMS

(ESI):

m/z

calculated

for

C26H39N5O12Na [M + Na]+: 636.2493; Found 636.2493.

N-(1-(4’-(3”-Hydroxypropyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetyl-β-Dglucuronoyl)-L-leucine methyl ester (84)
To a round bottom flask containing 70 (0.123 g,
0.261 mmol), 4-pentyn-1-ol (0.097 mL, 0.087 g,
1.04

mmol),

CuOAc2.H2O

(0.010

g,

0.052 mmol) and sodium ascorbate (0.020 g,
0.099 mmol) was added a 1:1 solution of nBuOH:H2O, (0.500 mL), with the solution
stirred vigorously under an atmosphere of nitrogen at room temperature for 24 hours.
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Upon completion, the reaction mixture was diluted with CH2Cl2 (5 mL), and extracted
with H2O (1 mL), then brine (1 mL). Subsequent drying (MgSO4) of the organic phase,
and evaporation in vacuo resulted in a residue which was purified by flash column
chromatography (1:2 Hexane: EtOAc) to yield 84 as a light yellow solid. (0.116 g,
80%), M.p. 132-133°C, Rf 0.10 (1:2 Hexane:EtOAc.). 1H NMR (500 MHz, CD3OD) δ
8.10 (s, 1H, triazole-H), 6.16 (d, 1H, J = 8.9 Hz, H1), 5.62-5.44 (2t (overlapping), 2H,
J = 9.2 Hz, H4/H3), 5.39 (t, 1H, J = 9.7 Hz, H2), 4.46 (m, 2H, H5/Hα), 3.67 (s, 3H,
OCH3), 3.57 (m, 2H, CH2-CH2-CH2-OH), 2.79 (m, 2H, CH2-CH2-CH2-OH, 2.05 (s, 3H,
CH3, OAc), 2.00 (2s, 6H, CH3, 2 x OAc), 1.87 (m, 2H, CH2-CH2-CH2-OH), 1.65-1.59
(m, 3H, Hβ/Hγ), 0.90 (m, 6H, 2 x CH3, Hδ). Exchangeable OH not detected.

13

C NMR

(125 MHz, CD3OD) δ 172.7 (C=O, COOCH3), 170.3 (C=O, OAc), 169.8 (C=O, OAc),
169.1 (C=O, OAc), 167.0 (C=O), 148.4 (Triazole C), 121.3 (Triazole C), 5.3 (C1), 75.4
(C5), 72.6 (C4), 70.5 (C3), 69.4 (C2), 60.7 (CH2-CH2-CH2-OH),

51.6 (Cα), 50.9

(OCH3), 40.1 (Cβ), 31.9 (CH2-CH2-CH2-OH) 24.7 (Cγ), 22.1 (Cδ), 21.5 (CH2-CH2-CH2OH), 20.7 (Cδ’), 19.5 (CH3, OAc), 19.3 (CH3, OAc), 18.9 (CH3, OAc). LRMS (ESI):
m/z 579 [M + Na]+, HRMS (ESI): m/z calculated for C24H36N4O11Na [M + Na]+:
579.2278; Found 579.2271.

N-(1-(4’-(3”-Hydroxypropyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetyl-β-Dgalacturonoyl)-L-leucine methyl ester (85)
To a round bottom flask containing 71
(0.122 g,

0.261 mmol),

4-pentyn-1-ol

(0.097 mL, 0.087 g, 1.04 mmol), CuOAc2.H2O
(0.010 g, 0.052 mmol) and sodium ascorbate
(0.020 g, 0.099 mmol) was added a 1:1 solution of nBuOH:H2O, (0.500 mL), with the
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solution stirred vigorously under an atmosphere of nitrogen at room temperature for 24
hours. Upon completion, the reaction mixture was diluted with CH2Cl2 (5 mL), and
extracted with H2O (1 mL), then brine (1 mL). Subsequent drying (MgSO4) of the
organic phase, and evaporation in vacuo resulted in a residue which was purified by
flash column chromatography (1:2 Hexane: EtOAc) to yield 85 as a light yellow oil.
(0.109 g, 75%), Rf 0.12 (1:2 Hexane:EtOAc.). 1H NMR (500 MHz, CDCl3) δ 7.68 (s,
1H, Triazole-H), 6.72 (d, 1H, J = 8.4 Hz, NH), 5.95 (m, 2H, H4/H3), 5.65 (t, 1H, J = 9.7
Hz, H2), 5.36 (d, 1H, J = 10.1 Hz, H1), 4.62 (m, 1H, Hα), 4.59 (m, 1H, H5), 3.76 (t, 2H,
J = 6.0 Hz, CH2-CH2-CH2-OH), 3.69 (s, 3H, OCH3), 2.88 (t, 2H, J = 7.1 Hz, CH2-CH2CH2-OH), 2.32 (t, 2H, J = 2.1 Hz, 7.3 Hz, CH2-CH2-CH2-OH) 2.13 – 1.88 (3s, 9H, CH3,
3 x OAc), 1.65 – 1.55 (m, 3H, Hβ/ Hγ), 0.94 (m, 6H, 2CH3, Hδ). Exchangeable OH not
detected. 13C NMR (125 MHz, CDCl3) δ 172.7 (C=O, COOCH3), 169.6 (C=O, OAc),
169.1(C=O, OAc), 169.1(C=O, OAc), 164.5 (C=O), 148.4 (Triazole-C), 119.9
(Triazole-C) 85.7 (C1), 76.2 (C4), 70.7 (C5), 67.7 (C2), 67.5 (C3), 61.5 (CH2-CH2-CH2OH), 52.5 (OCH3), 50.5 (Cα), 41.1 (Cβ), 31.7 (CH2-CH2-CH2-OH), 24.9 (Cγ), 22.8 (Cδ),
22.0 (Cδ’) 21.7 (CH2-CH2-CH2-OH), 20.5 (CH3, OAc), 20.5 (CH3, OAc), 20.2 (CH3,
OAc). LRMS (ESI): m/z 579 [M + Na]+ HRMS (ESI): m/z calculated for
C24H36N4O11Na [M + Na]+: 579.2278; Found 579.2274.

N-(1-(4’-(3”-Hydroxypropyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetyl-β-Dglucuronoyl)-L-methionine methyl ester (86)
To a round bottom flask containing 72
(0.129 g,
(0.097 mL,
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0.261 mmol),
0.087

g,

4-pentyn-1-ol
1.04

mmol),
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CuOAc2.H2O (0.010 g, 0.052 mmol) and sodium ascorbate (0.020 g, 0.099 mmol) was
added a 1:1 solution of nBuOH:H2O, (0.500 mL), with the solution stirred vigorously
under an atmosphere of nitrogen at room temperature for 24 hours. Upon completion,
the reaction mixture was diluted with CH2Cl2 (5 mL), and extracted with H2O (1 mL),
then brine (1 mL). Subsequent drying (MgSO4) of the organic phase, and evaporation in
vacuo resulted in a residue which was purified by flash column chromatography (1:3
Hexane:EtOAc.) to yield 86 as a white solid. (0.128 g, 85%), M.p. 132-133°C Rf 0.10
(1:3 Hexane:EtOAc.). 1H NMR (500 MHz, CDCl3) δ 7.63 (s, 1H, Triazole-H), 7.06 (d,
1H, J = 7.6 Hz, NH), 5.94 (d, 1H, J = 9.5 Hz, H1), 5.55 (t, 1H, J = 9.7 Hz, H3), 5.48 (t,
1H, J = 9.7 Hz, H4), 5.35 (t, 1H, J = 9.7 Hz, H2), 4.64 (m, 1H, Hα), 4.23 (d, 1H,
J = 10.0 Hz, H5), 3.73 (s, 3H, OCH3), 3.68 (t, 2H, J = 7.2 Hz, CH2CH2CH2OH), 2.86 (t,
2H, J = 7.3 Hz, CH2CH2CH2OH), 2.51 (t, 1H, J = 7.2 Hz, Hγ), 2.19-2.15 (m, 2H, Hβ),
2.09-2.04 (2s, 9H, CH3, 3 x OAc), 2.04-1.99, (m, 2H, CH2CH2CH2OH), 1.89 (s, 3H,
SCH3). Exchangeable OH not detected.

13

C NMR (125 MHz, CD3OD) δ 173.1

(COOCH3), 171.4 (C=O, OAc), 171.0 (C=O, OAc), 170.2 (C=O, OAc), 168.2 (C=O),
149.9 (Triazole-C), 122.6 (Triazole-C), 86.3 (C1), 76.4 (C5), 73.6 (C2), 71.6 (C4), 70.5
(C3), 61.8 (CH2-CH2-CH2-OH), 53.0 (Cα), 52.6 (-OCH3), 33.0 (Cβ), (CH2-CH2-CH2OH) 31.0 (Cγ), 22.7 (CH2-CH2-CH2-OH), 20.7 (CH3, OAc), 20.5 (CH3, OAc), 20.1
(CH3, OAc), 15.2 (SCH3). LRMS (ESI): m/z 597 [M + Na]+ HRMS (ESI):
m/z calculated for C23H34N4O11SNa [M + Na]+: 597.1842; Found 597.1857.
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N-(1-(4’-(3”-Hydroxypropyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetyl-β-Dglucuronoyl)-L-glutamine tert-butyl ester (87)
To a round bottom flask containing 73
(0.137 g,
(0.097 mL,

0.260 mmol),
0.087

g,

4-pentyn-1-ol
1.04

mmol),

CuOAc2.H2O (0.010 g, 0.052 mmol) and
sodium ascorbate (0.020 g, 0.099 mmol) was added a 1:1 solution of nBuOH:H2O,
(0.500 mL), with the solution stirred vigorously under an atmosphere of nitrogen at
room temperature for 24 hours. Upon completion, the reaction mixture was diluted with
CH2Cl2 (5 mL), and extracted with H2O (1 mL), then brine (1 mL). Subsequent drying
(MgSO4) of the organic phase, and evaporation in vacuo resulted in a residue which was
purified by flash column chromatography (EtOAc) to yield 76 as a light yellow foam.
(0.101 g, 63%), Rf 0.05 (1:3 Hexane:EtOAc.). 1H NMR (500 MHz, CD3OD) δ 8.4 (d,
1H, J = 7.8 Hz, NH), 8.15 (s, 1H, Triazole-H), 6.16 (d, 1H, J = 8.4 Hz, H1), 5.58 (m,
2H, H3/H4), 5.37 (t, 1H, J = 8.9 Hz, H2), 4.45 (d, 1H, J = 10.0 Hz, H5), 4.27 (m, 1H,
Hα), 3.58 (m, 2H, CH2-CH2-CH2-OH), 2.79 (m, 2H, CH2-CH2-CH2-OH), 2.34-2.26 (m,
2H, Hγ), 2.16-1.93 (m, 2H, Hβ), 2.05, 2.00 (s, 6H, 2x OAc), 1.89-1.86 (m, 2H, CH2CH2-CH2-OH),1.83 (s, 3H, OAc), 1.43 (s, 9H, OtBu). Exchangeable OH not detected.
13

C NMR (125 MHz, CDCl3) δ 177.6 (CONH2), 171.7 (C=O, OAc), 171.4 (C=O,

OAc), 171.4 (C=O, OAc), 170.4 (COOtBu), 168.3 (C=O), 149.6 (Triazole-C),
122.6 (Triazole C), 86.2 (C1), 83.3 (C(CH3)3), 76.3 (C5), 73.4 (C2), 71.7 (C4), 70.6
(C3), 61.8 (CH2-CH2-CH2-OH), 54.0 (Cα), 33.0 (CH2-CH2-CH2-OH) 33.0 (Cγ), 31.3
(Cβ), 28.2 (C(CH3)3), 22.6 (CH2-CH2-CH2=OH), 20.8 (CH3, OAc), 20.5 (CH3, OAc),
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20.1 (CH3, OAc).LRMS (ESI): m/z 636 [M + Na]+ HRMS (ESI): m/z calculated for
C26H39N5O12Na [M + Na]+: 636.2493; Found 636.2501

Nα-Acetyl-Nε-(1-azido-2,3,4-tri-O-acetyl-β-D-glucuronoyl)-L-lysine-L-proline-Lvalinamide (88)
60

(0.041

g,

0.119 mmol),

Ac.Lys.Pro.Val.NH2.HCl

(0.050

g,

and

HBTU

0.178 mmol)

were

0.119

(0.068 g,

mmol)

dissolved in DMF (1 mL), and the solution was cooled to 0°C. DIPEA (0.228 mL, 0.017
g, 0.131 mmol) was added dropwise to the solution, and the reaction mixture was
allowed to warm to room temperature and stir for 24 hours. Upon completion, the
reaction mixture was diluted with EtOAc (5 mL), and extracted with H2O (2 x 1 mL).
The organic phase was dried and evaporated, with the following residue purified by
flash column chromatography (EtOAc) to produce 88 as a light yellow foam (0.049 g,
53%), Rf 0.29 (EtOAc.). 1H NMR (500 MHz, CDCl3) δ 6.89 (m, 2H, NH2), 6.83 (m,
1H, NH), 6.44 (m, 1H, NH), 5.98 (m, 1H, NH), 5.27 (m, 2H, H3/H4), 4.97 (m, 1H, H2),
4.78 (d, 1H, J = 8.8 Hz, H1), 4.75 (m, 1H, CαPro), 4.47 (m, 1H, CαLys), 4.31 (t, 1H,
J = 6.1 Hz, CαVal), 4.04 (m, 1H, H5), 3.80 (m, 1H, CδPro), 3.67 (m, 1H, Cδ’Pro), 3.38
(m, 1H, CεLys), 3.05 (m, 1H, Cε’Lys), 2.16 (m, 1H, HβVal), 2.11 (m, 2H, HβLys), 2.071.99 (4s, 12H, CH3, 3 x Ac/NHAc), 1.72 (m, 2H, HβPro), 1.50 (m, 2H, HδLys), 1.38 (m,
2H, HγPro), 1.25 (m, 2H, HγLys), 0.95 (2q, 6H, J = 6.5 Hz, 2 x CH3).

13

C NMR

(125 MHz, CDCl3) δ 173.9 (C=O, CONH2), 172.5 (C=O, NHAc), 171.8 (C=O, CONH),
170.6 (C=O, CONH), 170.1 (C=O, OAc), 170.1 (C=O, OAc), 169.6 (C=O, OAc), 166.4

232 | P a g e

Chapter 7: Experimental
(C=O), 88.3 (C1), 75.2 (C5), 72.2 (C4), 70.7 (C2), 69.6 (C3), 61.0 (CαLys), 58.4
(CαVal), 50.9 (CαPro), 47.9 (CεLys), 38.9 (CδPro), 32.2 (CβPro), 31.2 (CβVal), 29.5
(CγLys), 28.7 (CδLys), 25.5 (CβLys), 23.3 (CH3, NHAc), 22.1 (CγPro), 20.9 (CH3,
OAc), 20.8 (CH3, OAc), 20.7 (CH3, OAc), 19.5 (CγVal), 18.0 (CγVal). LRMS (ESI):
m/z 733 [M + Na]+

7.3 Chapter 3 Experimental Data:
1,2-Isopropylidene-α-D-glucofuranose (94)
According to the method of Monrad and Madsen,190 a round
bottom

flask

containing

1,2:5,6-di-isoproylidene-α-D-

glucofuranose (93, 5.00 g, 19.2 mmol) was added a solution of
70% acetic acid (80 mL), and the reaction was stirred at room
temperature for 24 hours. Upon completion, the solvent was evaporated in vacuo, with
addition of water (50 mL) and azeotropic distillation resulting in 94 as a flaky white
solid. (3.82 g, 90%), M.p. 157-160°C (Lit. 157-160°C )190 1H NMR (500 MHz, D2O) δ
5.90 (d, 1H, J = 3.7 Hz, H1), 4.58 (d, 1H, J = 3.7 Hz, H3), 4.20 (d, 1H, J = 2.0 Hz,
H2), 3.98 (dd, 1H, J = 2.5, 9.0 Hz, H4), 3.80 (m, 1H, H5), 3.70 (ddd, 1H J = 1.3 Hz, 2.7
Hz, 12.0 Hz, H6), 3.53 (ddd, 1H, J = 1.3 Hz, 6.0 Hz, 12.1 Hz, H6’), 1.41 (s, 3H, CH3),
1.26 (s, 3H, CH3).

13

C NMR (125 MHz, D2O) δ 113.5 (CH(CH3)2), 105.6 (C1), 85.3

(C4), 80.6 (C2), 74.5 (C3), 69.3 (C5), 64.4 (C6), 26.4 (CH3), 26.0 (CH3). LRMS (ESI):
m/z 255 [M + Cl]- HRMS (ESI): m/z calculated for C9H16O6Cl [M + Cl]-: 255.0635;
Found 255.0625.
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6-p-Toluenesulfonyl-1,2-isopropylidene-α-D-glucofuranose (95)
To a round bottom flask containing 94 (3.00 g, 13.62 mmol)
was added pyridine (30 mL), and the mixture was cooled to
0°C. Under stirring, p-toluenesulfonyl chloride (3.12 g,
16.34 mmol) was added to the solution portionwise, with the
reaction mixture allowed to warm to room temperature and stir for an additional 18
hours. Upon completion, the reaction mixture was evaporated in vacuo. The resulting
slurry was subject to recrystallization from ethanol, to produce 95 as an amorphous
white solid. (3.77 g, 73%), Rf 0.29 (1:1 Hexane:EtOAc.).1H NMR (500 MHz, CDCl3) δ
7.79 (d, 2H, J = 7.9 Hz, Ar-H), 7.33 (d, 2H, J = 7.9 Hz, Ar-H), 5.88 (m, 1H, H1), 4.50
(m, 1H, H2), 4.34 (m, 1H, H3), 4.28 (d, 1H, J = 9.5 Hz, H4), 4.19 (m, 1H, H5), 4.11
(m, 1H, H6), 4.01 (m, 1H, H6’), 2.43 (s, 3H, Ar-CH3), 1.45 (s, 3H, CH3), 1.29 (s, 3H,
CH3).

13

C NMR (125 MHz, CDCl3) δ 148.9 (Ar-C1), 145.1 (Ar-C4), 130.0

(Ar-C3/C5), 128.0 (Ar-C2/C6), 111.9 (CH(CH3)2), 105.1 (C1), 85.1 (C4), 79.3 (C2),
74.7 (C3), 72.4 (C5),

67.6

(C6),

26.8

(CH3),

26.2

(CH3),

21.6

(Ar-CH3).

LRMS (ESI): m/z 409 [M + Cl]-

6-Azido-6-deoxy-1,2-isopropylidene-α-D-glucofuranose (96)
To a round bottom flask containing 95 (3.00 g, 8.01 mmol), was
added NaN3 (2.08 g, 32.04 mmol). The solids suspended in
DMF (30 mL), and stirred under an argon atmosphere at 40°C
for 72 hours. Upon completion, the reaction mixture was diluted
with ethyl acetate (50 mL), and washed with water (2 x 25 mL). Subsequently, the
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aqueous phases was washed with ethyl acetate (3 x 50 mL), and the combined organic
fractions were dried (MgSO4) and evaporated in vacuo. Flash column chromatography
(2:1 Hexane: EtOAc) of the mixture yielded the product 96 as a fine white solid,
(1.46 g, 74%), M.p. 98-99°C (Lit. 104°C)250 Rf 0.45 (1:1 Hexane:EtOAc.). 1H NMR
(500 MHz, CDCl3) δ 5.94 (d, 1H, J = 7.6 Hz, H1), 4.53 (d, 1H, J = 3.7 Hz, H3), 4.36
(m, 1H, H2), 4.15 (m, 1H, H5), 3.80 (dd, 1H, J = 2.3 Hz, 6.6 Hz, H4), 3.59-3.54 (m,
2H, H6/H6’), 3.30 (bs, 1H, OH), 3.13 (bs, 1H, OH), 1.49 (s, 3H, CH3), 1.32 (s, 3H,
CH3).

13

C NMR (125 MHz, CDCl3) δ 112.0 (CH(CH3)2), 104.9 (C1), 85.2 (C4), 79.7

(C2), 75.3 (C3), 6943 (C5), 54.0 (C6), 26.8 (CH3), 26.2 (CH3). LRMS (ESI): m/z 280
[M + Cl]- HRMS (ESI): m/z calculated for C9H15N3O5Cl [M + Cl]-: 280.0700;
Found 280.0710.

6-Azido-6-deoxy-1-amino-N-(2’,2’-diethoxycarbonylvinyl)-β-D-glucose (101)
In a round bottom flask, 96 (1.00 g, 4.08 mmol) was
dissolved in 80% acetic acid (20 mL). The mixture
was heated to 80°C, and stirred for 18 hours. After
this period, the reaction mixture was cooled to room temperature, and the solvent
removed in vacuo using water as an azeotrope. The resulting oil was then re-dissolved
in a saturated solution of NH4HCO3 (50 mL), and stirred at 40°C for a further 4 days.
Additional solid NH4HCO3 (2 g) was added to the reaction mixture every 24 hours to
maintain saturation. Upon completion monitored using LR-ESIMS, the reaction mixture
was evaporated to half volume at 20°C and then subject to lyophilisation overnight. The
resultant

foam

was

resuspended

in

MeOH

(10

mL),

and

diethyl

ethoxymethylenemalonate (1.24 mL, 1.32 g, 6.12 mmol) was added and allowed to stir
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at room temperature for 48 hours. Upon completion, the reaction mixture was
evaporated to dryness, and the residue subject to column chromatography (45:5:3
EtOAc/EtOH/H2O), producing 101 as a colourless oil. (0.809 g, 53%), Rf 0.54 (45:5:3
EtOAc/EtOH/H2O). 1H NMR (500 MHz, CD3OD) δ 9.40 (m, 1H, NH), 8.22 (d, 1H,
J = 13.7 Hz, CH=C), 4.57 (t, 1H, J = 8.3 Hz, H1), 4.28-4.10 (2q, 4H, J = 7.0 Hz, 2 x
CH2CH3), 3.62 (m, 1H, H3), 3.57 (m, 1H, H4), 3.49-3.31 (m, 4H, H6/H6’/H2/H5), 1.28
(t, 6H, J = 7.1 Hz, CH2CH3).

13

C NMR (125 MHz, CDCl3) δ 168.1 (C=O), 166.3

(C=O), 158.5 (CH=C), 91.6 (CH=C), 88.2 (C1), 77.3 (C4), 76.7 (C5), 73.2 (C2), 70.4
(C3), 59.7 (C6), 51.1 (CH2CH3), 13.3 (CH2CH3). LRMS (ESI): m/z 409 [M + Cl]HRMS (ESI): m/z calculated for C14H22N4O8Cl [M + Cl]-: 409.1126; Found 409.1120.
Data gained in the production of this compound was not consistent with that published
elsewhere.187

6-Azido-6-deoxy-1-amino-N-(2’,2’-diethoxycarbonylvinyl)-2,3,4-tri-O-acetyl-β-Dglucose (102)
To a round bottom flask containing 101 (0.400 g,
1.07 mmol), was added acetic anhydride (10 mL)
and pyridine (10 mL), and the reaction mixture was
stirred at room temperature for 2 hours. Upon completion, the reaction mixture was
evaporated to dryness, with flash column chromatography (2:1 Hexane: EtOAc) of the
crude mixture producing 102 as a white solid. (0.491 g, 92%), M.p. 88-91°C, Rf 0.75
(1:1 Hexane:EtOAc.).1H NMR (500 MHz, CDCl3) δ 9.22 (m, 1H, NH), 7.94 (d, 1H, J =
13.7 Hz, CH=C), 5.29 (t, 1H, J = 9.3 Hz, H3), 5.06 (t, 1H, J = 9.5 Hz, H2), 5.04 (t, 1H,
J = 9.5 Hz, H4), 4.59 (t, 1H, J = 8.5 Hz, H1) 4.26-4.18 (2q, 4H, J = 7.1 Hz, 2 x
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CH2CH3), 3.77 (m, 1H, H5), 3.38 (m, 2H, H6/H6’), 2.08-2.03 (3s, 9H, CH3, 3 x OAc),
1.30 (t, 6H, J = 7.1 Hz, CH2CH3). 13C NMR (125 MHz, CDCl3) δ 170.1 (C=O, OAc),
169.6 (C=O, OAc), 169.4 (C=O, OAc), 167.6 (C=O), 165.5 (C=O), 157.2 (CH=C), 95.2
(CH=C), 86.9 (C1), 75.0 (C5), 72.4 (C3), 70.5 (C2), 69.2 (C4), 60.4 (CH2CH3), 60.2
(CH2CH3), 50.8 (C6), 20.6 (CH3, OAc), 20.6 (CH3, OAc), 20.5 (CH3, OAc), 14.4
(CH2CH3), 14.2 (CH2CH3).

LRMS (ESI): m/z 523 [M + Na]+ HRMS (ESI):

m/z calculated for C20H28N4O11Na [M + Na]+: 523.1652; Found 523.1663.

6-Azido-6-deoxy-1-amino-2,3,4-tri-O-acetyl-β-D-glucose hydrobromide (103)
In a round bottom flask, 100 (0.300 g 0.60 mmol) was
dissolved in CH2Cl2 (5 mL) and cooled to 0°C. Br2 (0.060 mL,
0.186 g, 1.16 mmol) was then added dropwise, followed by
the addition of H2O (0.20 mL) and the reaction mixture was stirred at 0°C for 1 hour.
Upon completion, the reaction mixture was evaporated in vacuo, resulting in an orange
residue. Subsequent trituration and storage of the residue at -20°C overnight in diethyl
ether (5 mL) resulted in the isolation of 103 as an orange solid. (0.181 g, 73%),
1

H NMR (500 MHz, CD3OD) δ 5.36 (t,1H, J = 9.5 Hz, H3), 5.12 (m, 2H, H2/H4) 5.02

(m, 1H, H1), 4.09 (m,1H, H5), 3.60 (m, 1H, H6), 3.42 (m, 1H, H6’), 2.09-1.98 (3s, 9H,
3 x OAc).

13

C NMR (125 MHz, CD3OD) δ 171.4 (C=O, OAc), 171.3 (C=O, OAc),

171.1 (C=O, OAc), 80.5 (C1), 76.3 (C5), 73.6 (C3), 71.3 (C2), 69.5 (C4), 51.6 (C6),
20.6 (CH3, OAc), 20.5 (CH3, OAc), 20.4 (CH3, OAc). LRMS (ESI): m/z 331
[M + H-Br]+
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N-(tert-Butoxycarbonyl)-4-benzyl-L-aspartic acid, methyl ester (106)
To a round bottom flask containing BocAsp.(OBn).OH (104,
0.648 g, 2.00 mmol) and THF (10 mL) was added K2CO3
(1.106 g, 8.00 mmol), and the solution was allowed to cool to
0°C under stirring. MeI (0.182 mL, 0.415 g, 3.00 mmol) was added dropwise to the
solution, and stirred for 30 minutes at 0°C, before warming to room temperature. After
18 hours, the reaction was diluted with THF (10 mL), and washed with sat. NaHCO3
solution (10 mL) and brine (10 mL). The organic phases were dried (MgSO4) and
evaporated in vacuo, with recrystallization from EtOH/Hexanes producing 106 as a
white

solid.

(0.576

g,

85%),

M.p

64-66°C.

(Lit.

61-62°C)251

Rf

0.90

(1:1 Hexane:EtOAc.). 1H NMR (500 MHz, CDCl3) δ 7.35 (m, 5H, Ar-H), 5.49 (d, 1H,
J = 7.6 Hz, NH), 5.13 (s, 2H, CH2Ph), 4.59 (m, 1H, Hα), 3.70(s, 3H, OCH3), 3.03 (dd,
1H, J = 3.6 Hz, 16.7 Hz, Hβ),2.86 (dd, 1H, J = 3.6 Hz, 16.7 Hz, Hβ’), 1.44 (s, 9 H,
Boc-H). 13C NMR (125 MHz, CDCl3) δ 171.7 (C=O, OBn), 171.1 (C=O, OBn), 155.8
(C=O, Boc), 135.6 (Ar-C1), 128.8 (Ar-C), 128.6 (Ar-C), 128.5 (Ar-C), 80.4 (CCH3),
67.0 (CH2Ph), 52.9 (Cα), 50.2 (OCH3), 37.1 (Cβ), 28.5 (CCH3). LRMS (ESI): m/z 360
[M + Na]+ HRMS (ESI): m/z calculated for C17H23NO6Na [M + Na]+: 360.1423; Found
360.1430.

N-(tert-Butoxycarbonyl)-5-benzyl-L-glutamic acid, methyl ester (107)
To a round bottom flask containing BocGlu.(OBn).OH
(105, 0.671 g, 1.99 mmol) and THF (10 mL) was added
K2CO3 (1.106 g, 8.00 mmol), and the solution was
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allowed to cool to 0°C under stirring. MeI (0.182 mL, 0.415 g, 3.00 mmol) was added
dropwise to the solution, and stirred for 30 minutes at 0°C, before warming to room
temperature. After 18 hours, the reaction was diluted with THF (10 mL), and washed
with sat. NaHCO3 solution (10 mL) and brine (10 mL). The organic phases were dried
(MgSO4) and evaporated in vacuo, with recrystallization from EtOH/Hexanes producing
107 as a white solid. (0.644 g, 92%), M.p. 42-45°C (Lit 38-41°C),252 Rf 0.85 (1:1
Hexane:EtOAc.). 1H NMR (500 MHz, DMSO-d6) δ 7.39 - 7.28 (m, 5H, Ar-H), 5.09 (s,
2H, CH2Ph), 4.02 - 3.90 (m, 1H, Hα), 3.62 (s, 3H, OCH3), 2.47 - 2.42 (m, 2H, Hγ), 2.02
- 1.94 (m, 1H, Hβ), 1.86 - 1.76 (m, 1H, Hβ), 1.37 (s, 9 H, Boc-H). 13C NMR (125 MHz,
DMSO-d6) δ 172.6 (C=O), 172.1 (C=O), 155.5 (C=O, Boc), 136.2 (Ar-C1), 128.4 (ArC), 128.0 (Ar-C), 127.9 (Ar-C), 78.3 (CCH3), 65.5 (CH2Ph), 52.6 (Cα), 51.8 (OCH3),
29.9 (Cγ), 28.1 (Cβ), 25.9 (CCH3). LRMS (ESI): m/z 374 [M + Na]+ HRMS (ESI):
m/z calculated for C18H25NO6Na [M + Na]+: 374.1580; Found 374.1572.

N-(tert-Butoxycarbonyl)- L-aspartic acid, methyl ester (108)
To a round bottom flask containing 106 (0.400 g, 1.19 mmol)
dissolved in THF (10 mL), 10% palladium on carbon (0.100 g)
was added. The reaction mixture was placed under an
atmosphere of H2 gas, and stirred for 18 hours. Upon completion, the H2 atmosphere
was removed, and the reaction mixture was filtered through a pad of Celite, with the pad
washed with EtOAc (4 x 20 mL). Subsequent evaporation to dryness of the filtrate
resulted in the isolation of 108 as an off-white solid. (0.248 g, 84%), M.p. 80-82°C
(Lit. 79-81°C).253 1H NMR (500 MHz, CD3OD) δ 4.48 (m, 1H, Hα), 3.71 (s, 3H,
OCH3), 2.80-2.72 (m, 1H, Hβ), 1.43 (s, 9H, Boc-H).
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172.7 (C=O, COOH), 172.1 (C=O, COOCH3), 156.3 (C=O, NHBoc), 79.4 (C(CH3)3),
51.5 (Cα), 50.1 (OCH3), 30.1 (Cγ), 35.8 (Cβ), 27.2 (C(CH3)3). LRMS (ESI): m/z 270 [M
+ Na]+ HRMS (ESI): m/z calculated for C10H17NO6Na [M + Na]+: 270.0954; Found
270.0962.

N-(tert-Butoxycarbonyl)- L-glutamic acid, methyl ester (109)
To a round bottom flask containing 107 (0.450 g,
1.28 mmol) dissolved in THF (10 mL), 10% Palladium
on carbon (0.120 g) was added. The reaction mixture
was then subject to an atmosphere of H2 gas, and stirred for 18 hours. Upon completion,
the H2 atmosphere was removed, and the reaction mixture was filtered through a pad of
Celite, with the pad washed with EtOAc (4 x 20 mL). Subsequent evaporation to
dryness of the filtrate resulted in the isolation of 109 as an off-white solid. (0.288 g,
86%), M.p. 41-42°C (Lit. 42-45°C).252 1H NMR (500 MHz, CDCl3) δ 5.17 (d, 1H,
J = 7.1 Hz, NH), 4.36 (m, 1H, Hα), 3.74 (s, 3H, OCH3), 2.52-2.35 (m, 1H, Hγ), 2.212.15 (m, 1H, Hβ), 2.01-1.90 (m, 1H, Hβ’), 1.43 (s, 9H, Boc-H).

13

C NMR (125 MHz,

CDCl3) δ 177.7 (C=O, COOH), 173.8 (C=O, COOCH3), 155.8 (C=O, NHBoc), 80.3
(C(CH3)3), 52.8 (Cα), 52.5 (OCH3), 30.1 (Cγ), 28.3 (C(CH3)3), 27.7 (Cβ). LRMS (ESI):
m/z 284 [M + Na]+ HRMS (ESI): m/z calculated for C11H19NO6Na [M + Na]+:
284.1110; Found 284.1124.
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Nα-(tert-Butoxycarbonyl)-Nγ-(6-azido-6-deoxy-1-amino-2,3,4-tri-O-acetyl-β-Dglucosyl)-L-aspartic acid, methyl ester (110)
103 (0.070 g, 0.17 mmol), Boc.Asp.OMe (108,
0.063 g, 0.254 mmol) and HBTU (0.0965 g,
0.254 mmol) were dissolved in DMF (1 mL),
and the solution was cooled to 0°C. DIPEA
(0.060 mL, 0.080 g, 0.625 mmol) was added dropwise to the solution, and the reaction
mixture was allowed to warm to room temperature and stirred for 24 hours. Upon
completion, the reaction mixture was filtered, and the filtrate was diluted with EtOAc
(10 mL), and extracted with H2O (2 x 1 mL). The organic phase was dried and
evaporated, and the resulting residue purified by flash column chromatography
(2:1 Hexane:EtOAc) to produce 110 as a clear oil. (0.066 g, 70%), Rf 0.30
(1:1 Hexane:EtOAc.).1H NMR (500 MHz, CDCl3) δ 6.54 (d, 1H, J = 9.0 Hz, NH), 5.68
(d, 1H, J = 9.0 Hz, NHBoc), 5.25 (d/t, 2H, J = 9.9 Hz, 9.0 Hz, H1/H3), 5.05 (t, 1H, J =
9.6 Hz, H4), 4.93 (t, 1H, J = 9.0 Hz, H2), 4.56 (m, 1H, Hα), 3.78 (m, 1H, H5), 3.74 (s,
3H, OCH3), 3.40 (dd, 1H, J = 5.4 Hz, 12.4 Hz, H6), 3.31 (dd, 1H, J = 2.1 Hz, 12.4 Hz,
H6’), 2.87 (dd, 1H, J = 4.2 Hz, 16.5 Hz, Hβ), 2.72 (dd, 1H, J = 4.2 Hz, 16.5 Hz, Hβ’),
2.09-2.02 (3s, 9H, CH3, 3 x OAc), 1.44 (s, 9H, Boc-H). 13C NMR (125 MHz, CDCl3) δ
171.7 (C=O, CONH2), 171.2 (C=O, COOCH3), 170.9 (C=O, OAc), 169.9 (C=O, OAc),
169.6 (C=O, OAc), 155.6 (C=O, Boc), 80.2 (C1), 77.9 (C(CH3)3), 74.6 (C5), 72.5 (C3),
70.4 (C2), 69.2 (C4), 52.7 (Cα), 50.6 (C6), 50.0 (OCH3) 38.0 (Cβ), 28.3 (C(CH3)3), 20.6
(CH3, OAc), 20.6 (CH3, OAc), 20.6 (CH3, OAc). LRMS (ESI): m/z 582 [M + Na]+
HRMS (ESI): m/z calculated for C22H33N5O12Na [M + Na]+: 582.2023; Found
582.2029.
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Nα-(tert-Butoxycarbonyl)-Nδ-(6-azido-6-deoxy-1-amino-2,3,4-tri-O-acetyl-β-Dglucosyl)-L-glutamic acid, methyl ester (111)
103 (0.071 g, 0.17 mmol), Boc.Glu.OMe
(109, 0.067 g, 0.254 mmol) and HBTU
(0.067 g, 0.255 mmol) were dissolved in
DMF (1 mL), and the solution was cooled to
0°C. DIPEA (0.060 mL, 0.080 g, 0.625 mmol) was added dropwise to the solution, and
the reaction mixture was allowed to warm to room temperature and stirred for 24 hours.
Upon completion, the reaction mixture was filtered, and the filtrate was diluted with
EtOAc (10 mL), and extracted with H2O (2 x 1 mL). The organic phase was dried and
evaporated, with the following residue purified by flash column chromatography
(2:1 Hexane: EtOAc) to produce 111 as a clear oil. (0.061 g, 62%), Rf 0.35
(1:1 Hexane:EtOAc.). 1H NMR (500 MHz, CDCl3) δ 6.85 (d, 1H, J = 9.0 Hz, NH), 5.28
(m, 3H, NHBoc, H1/H3), 5.06 (t, 1H, J = 9.6 Hz, H4), 4.94 (t, 1H, J = 9.0 Hz, H2), 4.26
(m, 1H, Hα), 3.81 (m, 1H, H5), 3.75 (s, 3H, OCH3), 3.43 (dd, 1H, J = 2.0 Hz, 13.0 Hz,
H6), 3.29 (dd, 1H, J = 4.5 Hz, 13.0 Hz, H6’), 2.31 (m, 2H, Hγ), 2.17 (m, 1H, Hβ), 2.042.01 (3s, 9H, CH3, 3 x OAc), 1.88 (m, 1H, Hβ), 1.44 (s, 9H, Boc-H).

13

C NMR

(125 MHz, CDCl3) δ 172.7 (C=O, CONH2), 172.5 (C=O, COOCH3), 170.7 (C=O,
OAc), 170.0 (C=O, OAc), 169.5 (C=O, OAc), 155.7 (C=O, Boc), 80.3 (C1), 78.0
(C(CH3)3), 74.5 (C5), 72.9 (C3), 70.4 (C2), 69.3 (C4), 52.7 (Cα), 52.4 (C6), 50.6 (C6),
32.3 (Cγ), 28.6 (Cβ), 28.3 (C(CH3)3), 20.6 (CH3, OAc), 20.6 (CH3, OAc), 20.6 (CH3,
OAc).

LRMS (ESI): m/z 596 [M + Na]+ HRMS (ESI): m/z calculated for

C25H35N5O12Na [M + Na]+: 596.2180; Found 596.2204.
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Nα-(tert-Butoxycarbonyl)-Nε-(6-(4’-(3”-hydroxypropyl)-1’,2’,3’-triazol-1’-yl)-6deoxy-1-amino-2,3,4-tri-O-acetyl -β-D-glucosyl)-L-aspartic acid, methyl ester (112)
To a round bottom flask containing 110
(0.061 g, 0.131 mmol), 4-pentyn-1-ol
(0.050 mL,

0.045

g,

0.54

mmol),

CuOAc2.H2O (0.005 g, 0.026 mmol)
and sodium ascorbate (0.010 g, 0.049
mmol) was added a 1:1 solution of nBuOH:H2O, (0.500 mL), with the solution stirred
vigorously under an atmosphere of nitrogen at room temperature for 24 hours. Upon
completion, the reaction mixture was diluted with CH2Cl2 (10 mL), and extracted with
H2O (1 mL), then brine (1 mL). Subsequent drying (MgSO4) of the organic phase, and
evaporation in vacuo resulted in a residue which was purified by flash column
chromatography (EtOAc.) to yield 112 as a clear oil (0.057 g, 70%), Rf 0.15 (1:3
Hexane:EtOAc.). 1H NMR (500 MHz, CDCl3) δ 7.54 (s, 1H, Triazole-H), 6.79 (d, 1H,
J = 8.9 Hz, NH), 5.77 (d, 1H, J = 9.0 Hz, NHBoc), 5.30 (t, 1H, J = 9.0 Hz, H1), 5.12 (t,
1H, J = 9.5 Hz, H3), 4.90 (t, 1H, J = 9.0 Hz, H2), 4.83 (t, 1H, J 9.6 Hz, H4), 4.51-4.64
(dd, 2H, J = 5.2 Hz, 11.5 Hz, H6/H6’), 4.30 (m, 1H, Hα), 3.88 (m, 1H, H5), 3.75 (s, 3H,
OCH3), 3.68 (m, 2H, CH2-CH2-CH2-OH), 3.31 (dd, 1H, J = 2.1 Hz, 12.4 Hz, H6’), 2.87
(m, 2H, CH2-CH2-CH2-OH), 2.78 (dd, 2H, J = 4.0 Hz, 16.4 Hz, Hβ’), 2.10-2.00 (3s, 9H,
CH3, 3 x OAc), 1.96 (m, 2H, CH2-CH2-CH2-OH), 1.46 (s, 9H, Boc-H). Exchangeable
OH not detected.

13

C NMR (125 MHz, CDCl3) δ 171.7 (C=O, CONH2), 171.3 (C=O,

COOCH3), 171.0 (C=O, OAc), 169.7 (C=O, OAc), 169.7 (C=O, OAc), 155.6 (C=O,
Boc), 147.9 (Triazole-C), 122.0 (Triazole-C), 80.5 (C1), 78.4 (C(CH3)3), 74.2 (C5),
72.3 (C3), 70.3 (C2), 69.4 (C4), 61.4 (CH2-CH2-CH2-OH), 52.8 (Cα), 50.5 (C6), 50.2
(OCH3), 38.2 (Cβ), 31.6 (CH2-CH2-CH2-OH), 28.3 (C(CH3)3), 21.9 (CH2-CH2-CH2-
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OH), 20.7 (CH3, OAc), 20.6 (CH3, OAc), 20.5 (CH3, OAc). LRMS (ESI): m/z 666
[M + Na]+ HRMS (ESI): m/z calculated for C27H41N5O13Na [M + Na]+: 666.2599;
Found 666.2621

Nα-(tert-Butoxycarbonyl)-Nε-(6-(4’-(3”-hydroxypropyl)-1’,2’,3’-triazol-1’-yl)-6deoxy-1-amino-2,3,4-tri-O-acetyl-β-D-glucosyl)-L-glutamic acid, methyl ester (113)
To a round bottom flask containing 111
(0.075 g, 0.131 mmol), 4-pentyn-1-ol
(0.050 mL,

0.045

g,

0.54

mmol),

CuOAc2.H2O (0.005 g, 0.026 mmol) and
sodium ascorbate (0.010 g, 0.049 mmol)
was added a 1:1 solution of nBuOH:H2O, (0.500 mL), with the solution stirred
vigorously under an atmosphere of nitrogen at room temperature for 24 hours. Upon
completion, the reaction mixture was diluted with CH2Cl2 (10 mL), and extracted with
H2O (1 mL), then brine (1 mL). Subsequent drying (MgSO4) of the organic phase, and
evaporation in vacuo resulted in a residue which was purified by flash column
chromatography (EtOAc.)

to yield 113 as a clear oil (0.053 g, 62%), Rf 0.26

(1:3 Hexane:EtOAc.). 1H NMR (500 MHz, CDCl3) δ 7.71 (bs,1H, Triazole-H), 7.16 (d,
1H, J = 8.7 Hz, NH), 5.35 (m, 2H, NHBoc/H1), 5.19 (t. 1H, J = 9.4 Hz, H3), 4.96 (t,
1H, J = 9.5 Hz, H4), 4.89 (t, 1H, J = 9.3 Hz, H2), 4.68 (m, 1H, H6), 4.37 (m, 2H,
Hα/H6’), 3.95 (m, 1H, H5), 3.79 (s, 3H, OCH3), 3.70 (m, 2H, CH2-CH2-CH2-OH), 2.86
(m, 2H, CH2-CH2-CH2-OH), 2.34 (m, 4H, Hγ/ CH2-CH2-CH2-OH),

(dd, 1H,

J = 2.0 Hz, 13.0 Hz, H6), 3.29 (dd, 1H, J = 4.5 Hz, 13.0 Hz, H6’), 2.20 (m, 1H, Hβ),
2.12-2.04 (3s, 9H, CH3, 3 x OAc), 1.95 (m, 1H, Hβ), 1.44 (s, 9H, Boc-H). Exchangeable
OH not detected.13C NMR (125 MHz, CDCl3) δ 173.3 (C=O, CONH2), 172.7 (C=O,
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COOCH3), 171.0 (C=O, OAc), 170.0 (C=O, OAc), 169.9 (C=O, OAc), 156.0 (C=O,
Boc), 147.4 (Triazole-C), 119.9 (Triazole-C), 80.7 (C1), 78.7 (C(CH3)3), 74.5 (C5), 72.9
(C3), 70.4 (C2), 69.3 (C4), 61.3 (CH2-CH2-CH2-OH), 52.8 (Cα), 50.7 (OCH3), 32.6
(Cγ), 31.1 (CH2-CH2-CH2-OH), 28.9 (Cβ), 28.5 (C(CH3)3), 22.9 (CH2-CH2-CH2-OH),
20.9 (CH3, OAc), 20.8 (CH3, OAc), 20.7 (CH3, OAc). LRMS (ESI): m/z 680 [M + Na]+
HRMS

(ESI):

m/z calculated for C28H43N5O13Na [M

+ Na]+:

680.2755;

Found 680.2793.

7.4 Chapter 4 Experimental Data:
6-p-Toluenesulfonyl-1,2,3,4-tetra-O-acetyl-D-glucose (114)
According to the method of Nishimura et al.,196 a round
bottom flask containing D-glucose (10.0 g, 55 mmol), pyridine
(150 mL) was added. The reaction mixture was cooled to 0°C,
and p-toluenesulfonyl chloride (11.00 g, 58 mmol) was added portionwise to the
reaction mixture, forming a yellow/green solution. The reaction mixture was slowly
brought to room temperature, and allowed to stir for 16 hours. Following this time,
acetic anhydride (40 mL) was added and the reaction mixture was stirred for an
additional 1 hour. Upon completion, the reaction mixture was evaporated, with the
resulting residue subject to recrystallization from ethanol, producing the desired product
114

as

a

white

solid.

(11.08

g,

40%),

M.p. 192-196°C

(decomp.),

Rf 0.71 (1:1 Hexane:EtOAc.). 1H NMR (500 MHz, CDCl3) δ 7.75 (d, 4H, J = 8.3 Hz,
Ar-H), 7.33 (d, 4H, J = 8.3 Hz, Ar-H), 5.71-5.63 (d, 2H, J = 8.2 Hz, H1α/β), 5.20-5.16
(m, 1H, H3α/β), 5.04-5.01 (m, 8H, H2α/β, H4α/β), 4.12-4.09 (m, 4H, H6α/β/H6’α/β),
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3.83 (d, 2H, J = 8.3 Hz, H5α/β), 2.44 (s, 6H, CH3-Ar), 2.09-1.97 (4s, 24H, CH3,
4 x OAc). 13C NMR (125 MHz, CDCl3) δ 170.1 (C=O, OAc), 169.3 (C=O, OAc), 169.1
(C=O, OAc), 168.8 (C=O, OAc), 145.2 (Ar-C1), 132.4 (Ar-C4), 129.9 (Ar-C2/C6),
128.2 (Ar-C3/C5), 91.7 (C1α), 91.5 (C1β), 72.6 (C5), 72.2 (C3), 70.0 (C2), 67.9 (C4),
66.8 (C6), 21.7 (ArCH3), 20.7 (Ar-CH3), 20.5 (OAc), 20.5 (OAc), 20.5 (OAc). LRMS
(ESI): m/z 525 [M + Na]+ HRMS (ESI): m/z calculated for C21H26O12SNa [M + Na]+:
525.1043; Found 525.1062.

6-p-Toluenesulfonyl-1,2,3-tri-O-acetyl-β,D-glucosyl azide (116)
A solution of 114 (2.25 g, 4.48 mmol) dissolved in dry CH2Cl2
(5 mL) was chilled to 0°C. 33% w/v HBr in AcOH (12 mL) was
added dropwise to the solution, and upon addition the reaction
mixture was allowed to gradually warm to room temperature under constant stirring.
After 3 hours, the reaction mixture was diluted with CH2Cl2 (50 mL), and washed with
H2O (10 mL), ice cold sat. NaHCO3 solution (2 x 10 mL) and brine (10 mL). The
organic phases were then dried and evaporated, producing the bromo intermediate 115
as a orange oil that was used without further purification. 115 was subsequently
dissolved in dry DMF (20 mL), and the solution was cooled to 0°C. NaN3 (1.166 g,
17.92 mmol) was added portion wise to the mixture, and allowed to stir at 0°C for 30
minutes, after which it was allowed to warm to room temperature. After 3 hours, the
reaction mixture was diluted with H2O (20 mL), with the aqueous phase extracted with
EtOAc (3 x 50 mL). The organic phase was dried and evaporated, with recrystallization
from EtOAc/Hexanes producing 116 as an off-white solid. (1.42 g, 65%), M.p.
137-138°C, Rf 0.76 (1:1 Hexane:EtOAc.). 1H NMR (500 MHz, CDCl3) δ 7.80 (d, 2H,
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J = 8.2 Hz, Ar-H), 7.36 (d, 2H, J = 8.2 Hz, Ar-H), 5.18 (t, 1H, J = 9.4 Hz, H3), 4.96 (t,
1H, J = 9.9 Hz, H2), 4.85 (t, 1H, J = 8.8 Hz, 9.4 Hz, H4), 4.56 (d, 1H, J = 9.8 Hz, H1),
4.15 (dd, 1H, J = 2.2 Hz, 11.0 Hz, H6), 4.09 (dd, 1H, J = 5.2 Hz, 11.0 Hz, H6’), 3.83
(m, 1H, H5), 2.46 (s, 3H, ArCH3), 2.06-1.99 (3s, 9H, CH3, 3 x OAc).

13

C NMR

(125 MHz, CDCl3) δ 170.0 (C=O, OAc), 169.3 (C=O, OAc), 169.1 (C=O, OAc), 145.3
(Ar-C1), 132.2 (Ar-C4), 129.9 (Ar-C2/C6), 128.1 (Ar-C3/C5), 87.7 (C1), 73.6 (C3),
72.3 (C2), 70.4 (C4), 68.1 (C5), 67.2 (C6), 21.7 (ArCH3), 20.5 (OAc), 20.5 (OAc), 20.5
(OAc). LRMS (ESI): m/z 508 [M + Na]+ HRMS (ESI): m/z calculated for
C19H23N3O10SNa [M + Na]+: 508.1002; Found 508.0997.

6-Iodo-6-deoxy-1,2,3-tri-O-acetyl-β,D-glucosyl azide (117)
To a round bottom flask containing 116 (1.01 g, 2.08 mmol) and
sodium iodide (1.25 g, 8.32 mmol), acetone (25 mL) was added.
The resulting suspension was heated under at reflux and stirred
for 48 hours. After completion, the reaction mixture was evaporated to dryness, with the
resulting residue suspended in ice cold H2O (100 mL). Filtration of the precipitate,
followed by recrystallization from ethanol resulted in the isolation of 117 as a white
solid. (0.572 g, 62%), M.p. 127-128°C Rf 0.81 (1:1 Hexane:EtOAc.). 1H NMR
(500 MHz, CDCl3) δ 5.22 (t, 1H, J = 9.5 Hz, H3), 4.97 (t overlapping, 2H, J = 9.5 Hz,
H2/4), 4.70 (d, 1H, J = 9.6 Hz, H1), 3.56 (dt, 1H, J = 2.5 Hz, 8.0 Hz, H5), 3.36-3.32
(dd, 1H, J = 7.1 Hz, 11.1 Hz, H6), 3.21-3.18 (dd, 1H, J = 7.2 Hz, 11.0 Hz, H6’),
2.07-2.01 (3s, 9H, CH3, 3 x OAc).

13

C NMR (125 MHz, CDCl3) δ 170.0 (C=O, OAc),

169.9 (C=O, OAc), 169.8, (C=O, OAc), 87.6 (C1), 72.2 (C3), 69.7 (C2), 69.6 (C4), 68.3
(C5), 20.1 (OAc), 19.0 (OAc), 18.9 (OAc), 3.6 (C6). LRMS (ESI): m/z 464 [M + Na]+

247 | P a g e

Chapter 7: Experimental
N,N-(tert-Butoxycarbonyl)-L-homocystine (118)
According to the method of Zhu et al.,197 a
round bottom flask containing L,L-homocystine
(2.68 g, 10.0 mmol) was added a 10% sodium
carbonate solution (90 mL) and 1,4-dioxane (80 mL). The resultant suspension was
cooled to 0°C and di-t-butyl dicarbonate (4.80 g, 22.2 mmol) was added. The reaction
mixture was allowed to warm to room temperature and stirred for 18 hours. Following
this time, 10% ascorbic acid was added to adjust the solution to pH 4, and the reaction
mixture was extracted with ethyl acetate (3 x 50 ml). The organic layers were then
combined, washed with brine (25 mL), dried (MgSO4) and evaporated in vacuo,
producing 118 as a white solid, (4.20 g, 90%), M.p. 162-164°C (decomp.)(Lit. 158159°C).178 1H NMR (500 MHz, CD3OD) δ 4.20 (m, 2H, Hα), 2.74 (m, 4H, Hγ), 2.20
(m, 2H, Hβ), 1.96 (m, 2H, Hβ’), 1.42 (s,18H, Boc-H). 13C NMR (125 MHz, CD3OD) δ
175.7 (COOH), 158.2 (C=O, Boc), 80.7 (C(CH3)3, 53.7 (Cα), 35.8 (Cγ), 32.5 (Cβ), 28.8
(C(CH3)3).

LRMS (ESI): m/z 491 [M + Na]+, HRMS (ESI): m/z calculated for

C18H32N2O8S2Na [M + Na]+: 491.1498; Found 491.1470.

N,N-(tert-Butoxycarbonyl)-L-homocystine ditert-butyl ester (119)
According to the method of Bourdier
et al., 178

a

solution

of

118

(0.895 g,

1.92 mmol) dissolved in CH2Cl2 (10 mL)
under argon was added tert-butyl-2,2,2-trichloroacetimidate (2.20 g, 9.55 mmol). The
reaction mixture was allowed to stir at room temperature for 18 hours, after which
evaporation in vacuo, followed by flash column chromatography (6:1 Hexane: EtOAc)
yielded the product 119 as a white solid.
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66-68°C),178 Rf 0.60 (4:1 Hexane:EtOAc.).1H NMR (500 MHz, CDCl3) δ 5.22 (m, 2H,
NH), 4.24 (m, 2H, Hα), 2.70 (m, 4H, Hγ), 2.19 (m, 2H, Hβ), 1.97 (m, 2H, Hβ’), 1.48 (s,
18H, tBu), 1.45 (s, 18H, Boc-H).

13

C NMR (125 MHz, CDCl3) δ 171.5 (C=O), 155.7

(C=O, Boc), 82.5 (C(CH3)3), 80.1 (Boc C-CH3), 53.6 (Cα), 34.9 (Cγ), 33.1 (Cβ), 28.7
(C(CH3)3), 28.3(Boc C-CH3).

LRMS (ESI): m/z 603 [M + Na]+ HRMS (ESI):

m/z calculated for C26H48N2O8S2Na [M + Na]+: 603.2750; Found 603.2771.

N-(Tert-butoxycarbonyl)-L-homocysetine tert-butyl ester (120)
According to the method of Bourdier et al.,178 a solution of 119
(0.321 g, 0.551 mmol) in DMF (5 mL) under argon, was added
H2O (0.500 mL) and tributylphosphine (0.160 mL, 0.131 g,
0.631 mmol). The reaction mixture was allowed to stir at room temperature for 18
hours, after which the reaction was quenched with H2O (50 mL). The aqueous phase
was washed with EtOAc (3 x 25 mL), which was subsequently washed with brine (25
mL), dried (MgSO4) and evaporated in vacuo. Purification by flash column
chromatography (6:1 Hexane: EtOAc) resulted in the isolation of 120 as a clear solid.
(0.274 g, 85%). M.p. 38-40°C, Rf 0.75 (4:1 Hexane:EtOAc.).1H NMR (500 MHz,
CDCl3) δ 5.17 (d, 1H, J = 6.9 Hz, NH), 4.29 (m, 1H, Hα), 2.56 (m, 2H, Hγ), 2.06 (m,
1H, Hβ), 1.95 (m, 1H, Hβ’), 1.55 (t, 1H, J = 5.2 Hz, SH), 1.48 (s, 9H, tBu), 1.45 (s, 9H,
Boc-H)

13

C NMR (125 MHz, CDCl3) δ 171.7 (C=O), 155.7 (C=O, Boc), 82.5

(C(CH3)3), 80.1 (Boc C-CH3), 53.3 (Cα), 38.0 (Cβ), 28.7 (C(CH3)3), 28.3(Boc C-CH3)
21.1 (Cγ). LRMS (ESI): m/z 314 [M + Na]+ HRMS (ESI): m/z calculated for
C13H25NO4SNa [M + Na]+: 314.1402; Found 314.1390
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Attempted synthesis of Nα-(tert-Butoxycarbonyl)-S-(1-azido-1-deoxy-2,3,4-tri-Oacetyl-6-thio-β-D-glucosyl)-L-homocysteine tert-butyl ester (124)

Method A: In a round bottom flask, 117 (0.100 g, 0.227 mmol) and Boc.HCys.OtBu
(120; 0.132 g, 0.454 mmol) was dissolved in THF (5 mL). NEt3 (0.065 mL, 0.047 g,
0.454 mmol) was added to the reaction mixture and allowed to stir at room temperature.
Periodic monitoring by TLC highlighted the formation of the side product 121, with the
desired product 124 not detected. After 48 hours, the reaction mixture was evaporated in
vacuo and dissolved in EtOAc (10 ml). After washing with H2O (5 mL) and brine (5
mL), the organic phases were then dried and evaporated in vacuo with the resulting
residue purified by flash column chromatography (3:1 Hexane: EtOAc), resulting in the
isolation of the side product 121 as a white solid. (0.054g, 39%)
Method B: In a round bottom flask, 117 (0.100 g, 0.227 mmol) and Boc.HCys.OtBu
(120; 0.132 g, 0.454 mmol) was dissolved in THF (5 mL). DBU (0.070 mL, 0.069 g,
0.454 mmol) was added to the reaction mixture and allowed to stir at room temperature.
Periodic monitoring by TLC highlighted the formation of the side product 121, with the
desired product 124 not detected. After 48 hours, the reaction mixture was evaporated in
vacuo and dissolved in EtOAc (5 ml). After washing with H2O (5 mL) and brine
(5 mL), the organic phases were then dried and evaporated in vacuo with the resulting
residue purified by flash column chromatography (3:1 Hexane: EtOAc), resulting in the
isolation of the side product 121 as a white solid. (0.066 g, 48%)
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Method C: In a round bottom flask, 117 (0.102 g, 0.228 mmol) and Boc.HCys.OtBu
(120; 0.130 g, 0.453 mmol) was dissolved in DMF (5 mL). Cs2CO3 (0.148 g,
0.454 mmol) was added to the reaction mixture and allowed to stir at room temperature.
Periodic monitoring by TLC highlighted the formation of the side product 121, with the
desired product 124 not detected. After 48 hours, the reaction mixture was diluted with
EtOAc (5 ml). After washing with H2O (5 mL) and brine (5 mL), the organic phases
were then dried and evaporated in vacuo with the resulting residue purified by flash
column chromatography (3:1 Hexane: EtOAc), resulting in the isolation of the side
product 121 as a white solid. (0.068 g, 49%)
Method D: In a round bottom flask, 117 (0.101 g, 0.227 mmol) and Boc.HCys.OtBu
(120; 0.131 g, 0.454 mmol) was dissolved in DMF (5 mL). Ag2O (0.210 g, 0.906 mmol)
was added to the reaction mixture the reaction glassware was covered in foil and
allowed to stir at room temperature in the dark for 4 days. Periodically monitored by
TLC, neither the formation of side product 121, or the desired product 124 were
detected. As a result, the reaction was terminated, and a work up was not performed.
Method E: In a round bottom flask, 117 (0.100 g, 0.227 mmol) and Boc.HCys.OtBu
(120; 0.130 g, 0.453 mmol) was dissolved in THF (5 mL). Ag20 (0.213 g, 0.908 mmol)
was added to the reaction mixture and allowed to stir at room temperature in the dark.
Periodical monitoring by TLC highlighted the formation of the side product 121, with
the desired product 124 not detected. After 8 days, the reaction mixture was evaporated
in vacuo and dissolved in EtOAc (5 ml). After washing with H2O (5 mL) and brine
(5 mL), the organic phases were then dried and evaporated. 1H NMR of the reaction
worked up displayed trace quantities of the side product 121. As a result, the reaction
mixture was discarded and no isolation of 121 was performed.
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Analytical data for (121): Rf 0.41 (1:1 Hexane EtOAc), M.p. 84-86°C. 1H NMR
(500 MHz, CDCl3) δ 5.50 (d, 1H, J = 7.6 Hz, H4), 5.08 (t, 1H, J = 7.8 Hz, H3), 4.96 (t,
1H, J = 7.9 Hz, H2), 4.90 (overlapping d, 2H, J = 7.5 Hz, H1/CH), 4.64 (m, 1H, CH),
2.10-2.02 (3s, 9H, CH3, 3 x OAc). 13C NMR (125 MHz, CDCl3) δ 169.9 (C=O, OAc),
169.4 (C=O, OAc), 169.3 (C=O, OAc), 150.8 (C5), 98.4, (C6) 88.3 (C1), 71.6 (C4),
70.9 (C3), 68.7 (C2), 20.9 (CH3, OAc), 20.8 (CH3, OAc), 20.8 (CH3, OAc). LRMS
(ESI): m/z 336 [M + Na]+ HRMS (ESI): m/z calculated for C12H15N3O7 [M + Na]+:
336.0808, Found 336.0820.

6-Azido-6-deoxy-1,2,3,4-tetra-O-acetyl--D-glucose (125)
To a round bottom flask containing 114 (4.00 g, 7.96 mmol)
was added NaN3 (1.55 g, 23.88 mmol) and DMF (20 mL).
The resulting suspension was heated to 50°C and stirred
under nitrogen for 24 hours, after which the solution was concentrated. The resulting
residue was suspended in H2O (10 mL), and subsequently washed with EtOAc
(3 x 50 mL). The organic phases were collected, dried and evaporated, with the
resulting residue subjected to flash column chromatography (3:1 Hexane: EtOAc).
Further recrystallization by EtOAc/Hexanes yielded 125 as a white solid present as a
1:1 mixture of α and β anomers. (1.71 g, 57%), M.p. 130-133°C, Rf 0.79 (1:1
Hexane:EtOAc.). 1H NMR (500 MHz, CDCl3) δ α-anomer: 6.36 (d, 1H, J = 8.2 Hz,
H1α), 5.43 (t, 1H, J = 9.2 Hz, H3α), 5.17-5.05 (m, 2H, H2/H4), 4.05 (dt, 1H,
J = 9.1 Hz, H5α), 3.36-3.32 (m, 2H, H6α/H6α’), 2.24-1.99 (4s, 12H, CH3, 4 x OAc). βanomer: 5.70 (d, 1H, J = 8.0 Hz, H1β), 5.22 (t, 1H, J = 8.4 Hz, H3β), 5.10 (m, 2H,
H2/H4), 3.80 (dt, 1H, J = 9.3 Hz, H5β), 3.36-3.32 (m, 2H, H6β/H6β’), 2.24-2.04 (4s,
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12H, CH3, 4 x OAc). 13C NMR (125 MHz, CDCl3) δ 170.1 (C=O, CH3), 169.6 (C=O,
CH3), 169.4 (C=O, CH3), 168.7 (C=O, CH3), 91.4 (C1β), 88.8 (C1α), 73.8 (C5), 72.5
(C3β), 70.8 (C3β), 70.1 (C2β), 69.7 (C5β), 69.1 (C4β), 68.9 (C4), 50.6 (C6), 20.8 (CH3,
OAc), 20.7 (CH3, OAc), 20.6 (CH3, OAc), 20.4 (CH3, OAc). LRMS (ESI): m/z 396
[M + Na]+ HRMS (ESI): m/z calculated for C14H19N3O9Na [M + Na]+: 396.1019;
Found 396.1019.

6-Azido-6-deoxy-1,2,3-tri-O-acetyl-α,D-glucosyl trichloroacetimidate (127)
To a round bottom flask containing 125 (1.80 g, 4.80 mmol)
DMF (40 mL) was added. The resultant was cooled to 0°C.
Hydrazine acetate (0.60 g, 7.20 mmol) was then added
portion wise to the reaction mixture, which was allowed to
gradually warm to room temperature and stir for 3 hours.
Upon completion, the reaction mixture was evaporated to dryness and subject to flash
column chromatography (1:1 Hexane: EtOAc), producing the lactol intermediate 126
(1.270 g, 80%). Subsequently, 126 was re-dissolved in dry CH2Cl2 (15 mL) under
argon with trichloroacetonitrile (3.00 mL, 4.32 g, 29.92 mmol). The mixture was cooled
to 0°C, and DBU (1.08 mL, 1.10 g, 7.23 mmol) was added to the mixture dropwise,
with the reaction warmed to room temperature and allowed to stir for a further 3 hours.
Upon completion, the reaction mixture was diluted with CH2Cl2, (15 mL) washed with
sat. NaHCO3 solution (25 mL) and brine (25 mL), dried (MgSO4) and evaporated in
vacuo. The resulting residue was subjected to flash column chromatography
(2:1 Hexane: EtOAc), yielding 127 as an off-white solid. (1.37 g, 75%), M.p. 76-78°C,
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Rf 0.55 (1:1 Hexane:EtOAc.). 1H NMR (500 MHz, CDCl3) δ 8.76 (s, 1H, NHCCl3),
6.63 (d, 1H, J = 3.7 Hz, H1), 5.51 (t, 1H, J = 9.5 Hz, H3), 5.19-5.16 (m, 2H, H2/H4),
4.22 (ddd, 1H, J = 10.2 Hz, H5), 3.46 (dd, 1H, J = 3.0 Hz, H6’), 3.36 (dd, 1H, J = 5.5
Hz, 13.5 Hz, H6), 2.10-2.05 (3s, 9H, CH3, 3 x OAc).

13

C NMR (125 MHz, CDCl3) δ

170.0, 169.8, 169.5 (C=O, OAc), 92.8 (C1), 71.1 (C5), 69.7 (C2), 69.6 (C3), 68.9 (C4),
50.6 (C6), 20.7 (CH3, OAc), 20.6 (CH3, OAc), 20.4 (CH3, OAc). LRMS (ESI): m/z
498 [M + Na]+.

L-Homocystine dimethyl ester dihydrochloride (128)
To

a

round

bottom

flask

containing

homocystine (0.786 g, 2.93 mmol) was added
methanol (10 mL). The resulting suspension
was cooled to 0°C, and thionyl chloride (0.240 mL, 0.383 g, 3.223 mmol) was added
dropwise. Upon addition, the reaction mixture was allowed to gradually warm to room
temperature, and was left to stir for 18 hours. Upon completion, the reaction solvents
were removed in vacuo, producing the dimethyl ester dihydrochloride salt 128 as a light
yellow oil. (1.076 g, 99%). 1H NMR (500 MHz, CDCl3) δ 4.17 (t, 2H, J = 6.6 Hz, Hα)
3.82 (s, 6H, NH3), 3.69 (s, 6H, OCH3), 2.81 (t, 4H, J = 7.3 Hz, Hγ), 2.37 (m, 4H, Hβ).
13

C NMR (125 MHz, D2O) δ 170.2 (C=O, COOCH3), 53.7 (Cα), 51.44 (OCH3),

32.0 (Cβ), 28.9 (Cγ). LRMS (ESI): m/z 297 [M +H]+
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N,N-(Fluorenylmethylcarbonyl)-L-homocystine dimethyl ester (129)
According to the method of Kelleman
et al.,203 a round bottom flask containing 128
(0.594 g, 1.61 mmol), was added solid
K2CO3 (1.02 g, 7.25 mmol). H2O (10 mL) and 1,4-dioxane (5 mL) were also added, and
the mixture was gently stirred at room temperature. Solid Fmoc-Cl (1.039 g, 4.03
mmol) was added to the reaction mixture portion wise, and the reaction mixture was
allowed to stir vigorously at room temperature for 18 hours. After this time, the reaction
mixture was subjected to sonication then filtered. The isolated solid was subjected to
flash column chromatography (4:1 Hexane: EtOAc), resulting in the isolation of 129 as
a light yellow solid. (0.884 g, 74%), M.p. 89-91°C, Rf 0.15 (4:1 Hexane:EtOAc.). 1H
NMR (500 MHz, CDCl3) δ 7.74 (d, 4H, J = 7.3 Hz, Fmoc-H) 7.57 (d, 4H, J = 7.3 Hz,
Fmoc-H), 7.39 (t, 4H, J = 7.3 Hz, Fmoc-H), 7.24 (t, 4H, J = 7.3 Hz, Fmoc-H), 5.51 (d,
2H, J = 8.0 Hz, NH), 4.48 (m, 2H, Hα), 4.40 (m, 4H, OCH2), 4.19 (t, 2H, J = 6.7 Hz),
3.75 (s, 6H, OCH3), 2.70 (t, 4H, J = 7.3 Hz, Hγ), 2.17 (m, 4H, Hβ).

13

C NMR (125

MHz, CDCl3) δ 172.4 (C=O, COOCH3), 155.9 (C=O, Fmoc), 143.8 (Fmoc Ar-C1),
143.4 (Fmoc Ar-C1), 141.3 (Fmoc Ar-C6), 127.7 (Fmoc Ar-C4), 127.1 (Fmoc Ar-C5),
125.0 (Fmoc Ar-C3), 120.0 (Fmoc Ar-C2), 67.0 (OCH2CH), 52.7, 52.6 (OCH3/Cα), 47.2
(OCH2CH), 34.5 (Cβ), 32.4 (Cγ). LRMS (ESI): m/z 763 [M + Na]+ HRMS (ESI): m/z
calculated for C40H40N2O8S2Na [M + Na]+: 763.2124; Found 763.2151.
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N-(Fluorenylmethylcarbonyl)-L-homocysteine methyl ester (130)
According to the method of Kelleman et al.,203

a round

bottom flask containing 129 (0.519 g, 0.700 mmol) under
argon, was added CH2Cl2 (20 mL) and MeOH (60 mL). To the
flask, zinc dust (0.250 g, 3.50 mmol) was added followed by TFA (2.20 mL, 3.278 g,
28.75 mmol) dropwise. Subsequently, the flask was again flushed with argon, and the
reaction mixture was allowed to stir at room temperature for 18 hours. Following this,
the reaction mixture was filtered and evaporated in vacuo, with the resulting residues
dissolved in EtOAc (50 mL). Subsequent washes with H2O (10 mL) and brine (10 mL),
followed by drying (MgSO4) and concentration, resulted in the isolation of 130 as a
light yellow solid. (0.370 g, 71%),
1

M.p. 87-90°C, Rf 0.42 (4:1 Hexane:EtOAc.).

H NMR (500 MHz, CDCl3) δ 7.74 (d, 2H, J = 7.3 Hz, Fmoc-H) 7.59 (d, 2H, J = 7.3

Hz, Fmoc-H), 7.39 (t, 2H, J = 7.3 Hz, Fmoc-H), 7.23 (t, 2H, J = 7.3 Hz, Fmoc-H), 5.34
(d, 1H, J = 8.0 Hz, NH), 4.54 (m, 1H, Hα), 4.44 (m, 2H, OCH2), 4.22 (t, 1H, J = 6.7
Hz), 3.76 (s, 3H, OCH3), 2.55 (t, 2H, J = 7.3 Hz, Hγ), 2.13 (m, 1H, Hβ), 1.97 (m, 1H,
Hβ’), 1.55 (t, 1H, J = 8.1 Hz, SH).

13

C NMR (125 MHz, CDCl3) δ 172.5 (COOCH3),

156.0 (C=O, Fmoc), 143.9 (Fmoc Ar-C1), 143.6 (Fmoc Ar-C1), 141.4 (Fmoc Ar-C6),
127.8 (Fmoc Ar-C4), 127.1 (Fmoc Ar-C5), 125.0 (Fmoc Ar-C3), 120.0 (Fmoc Ar-C2),
67.0 (OCH2CH), 52.7, 52.6 (OCH3/Cα), 47.2 (OCH2CH), 37.0 (Cβ), 20.6 (Cγ). LRMS
(ESI): m/z 394 [M + Na]+ HRMS (ESI): m/z calculated for C20H21NO4SNa [M + Na]+:
394.1089; Found 394.1082.
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Nα-(Fluorenylmethylcarbonyl)-S-(6-azido-6-deoxy-1-thio-2,3,4-tri-O-acetyl-Dglucosyl)-L-homocysteine methyl ester (131)
Method A: To a round bottom flask containing
125 (0.100 g, 0.268 mmol) and Fmoc.HCys.OMe
(130, 0.250 g, 0.670 mmol) under argon, was
added dry CH2Cl2 (5 mL). The mixture was
cooled to 0°C, and SnCl4 (0.020 ml, 0.045 g,
0.0171 mmol) was added to the solution. The reaction mixture was subsequently
allowed to warm to room temperature, and stirred overnight. Upon completion, the
reaction mixture was diluted with CH2Cl2 (10 mL) and quenched with sat. NaHCO3
solution (5 mL). The organic phases where then washed with H2O (5 mL) and brine (10
mL), dried (Na2SO4) and evaporated in vacuo with the resulting residues purified by
flash column chromatography (3.5:1 Hexane: EtOAc), producing 131 as an amorphous
solid present in a ~2:1 ratio of α and β-anomers. (0.094 g, 51%).
Method B: A round bottom flask containing 127 (0.127 g, 0.268 mmol),
Fmoc.HCys.OMe (128, 0.248 g, 0.669 mmol) and 4Å molecular sieves (0.100 g) was
dried under high vacuum overnight. Upon drying, the flask was immersed in an
atmosphere of argon and dry CH2Cl2 (2 mL) was added. The reaction mixture was
cooled to -20°C, and stirred at this temperature for 30 minutes. After this time, TMSOTf
(0.005 mL, 0.006 g, 0.027 mmol) was added to the reaction mixture dropwise, and the
flask was stirred vigorously for an additional 1 hour. Upon reaction completion, the
reaction mixture was diluted with CH2Cl2 (10 mL) and quenched with sat. NaHCO3
solution (1 mL). The organic phases where then washed with H2O (5 mL) and brine
(5 mL), dried (Na2SO4) and evaporated in vacuo with the resulting residues purified by
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flash column chromatography (3.5:1 Hexane: EtOAc), producing 131 as a white foam
present as a 1:1 mixture of α and β-anomers. (0.071 g, 38%).
α-anomer; Rf 0.30 (2:1 Hexane:EtOAc.). 1H NMR (500 MHz, CDCl3) δ 7.75 (m, 2H,
Fmoc-H), 7.57 (m, 2H, Fmoc-H), 7.37 (m, 2H, Fmoc-H), 7.29 (m, 2H, Fmoc-H), 6.36
(d, 2H, J = 4.0 Hz, H1), 5.47 (overlapping t, 2H, J = 9.9 Hz, NH/H3), 5.10 (m, 2H,
H2/H4), 4.48 (m, 1H, Hα), 4.39 (m, 2H, OCH2-CH), 4.19 (m, 1H, OCH2-CH), 4.08 (m,
1H, H5), 3.76 (s, 3H, OCH3), 3.39 (dd, 1H, J = 2.6, 13.6 Hz, H6), 3.30 (dd, 1H, J = 5.5;
13.4 Hz, H6’), 2.70 (m, 2H, Hγ), 2 24 (m, 1H, Hβ), 2.10 (m, 1H, Hβ), 2.02-2.06 (3s, 9H,
CH3, 3 x OAc).

13

C NMR (125 MHz, CDCl3) δ 172.5 (C=O, COOCH3), 170.4 (C=O,

OAc), 169.8 (C=O, OAc), 168.9 (C=O, OAc), 156.2 (C=O, Fmoc), 143.9 (Fmoc ArC1), 141.6 (Fmoc Ar-C6), 128.1 (Fmoc Ar-C4), 127.2 (Fmoc Ar-C5), 125.4 (Fmoc ArC3), 120.3 (Fmoc Ar-C2), 89.2 (C1), 71.2 (C5) 71.0 (C3), 69.9 (C2), 69.5 (C4), 67.3
(OCH2CH), 53.1 (Cα), 52.7 (OCH3), 51.0 (C6), 47.4 (OCH2CH), 34.7 (Cβ), 21.1 (Cγ),
20.8 (CH3, OAc), 20.7 (CH3, OAc), 20.6 (CH3, OAc).
β-anomer, Rf 0.23 (2:1 Hexane:EtOAc.). 1H NMR (500 MHz, CDCl3) δ 7.76 (m, 2H,
Fmoc-H), 7.61 (m, 2H, Fmoc-H), 7.40 (m, 2H, Fmoc-H), 7.32 (m, 2H, Fmoc-H), 5.45
(m, 1H, NH), 5.22 (t, 1H, J = 9.9 Hz, H3), 5.02 (m, 2H, H2/H4), 4.51 (d, 1H, J = 9.8
Hz, H1), 4.48 (m, 1H, Hα), 4.42 (d, 2H, J = 8.1 Hz, OCH2CH), 4.23 (t, 1H, J = 8.2 Hz,
OCH2CH), 3.77 (s, 2H, OCH3), 3.67 (m, 1H, H5), 3.32 (m, 2H, H6/H6’), 2.80 (m, 1H,
Hγ), 2.67 (m, 1H, Hγ’), 2.18 (m, 1H, Hβ), 2.07 (m, 1H, Hβ’), 2.01-2.05 (3s, 9H, CH3,
3 x OAc). 13C NMR (125 MHz, CDCl3) δ 172.3 (C=O, COOCH3), 170.1 (C=O, OAc),
169.4 (C=O, OAc), 169.4 (C=O, OAc), 155.9 (C=O, Fmoc), 143.8 (Fmoc Ar-C1), 141.3
(Fmoc Ar-C6), 127.7 (Fmoc Ar-C4), 127.1 (Fmoc Ar-C5), 125.1 (Fmoc Ar-C3), 120.0
(Fmoc Ar-C2), 83.4 (C1), 77.0 (C5), 73.6 (C3) 69.6 (C2), 69.4 (C4), 67.0 (OCH2CH),
53.0 (Cα), 52.6 (OCH3), 51.1 (C6), 47.2 (OCH2CH), 32.8 (Cβ), 21.0 (Cγ), 20.7 (CH3,
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OAc), 20.6 (CH3, OAc), 20.6 (CH3, OAc). LRMS (ESI): m/z 707 [M + Na]+ HRMS
(ESI): m/z calculated for C32H36N4O11SNa [M + Na]+: 707.1999; Found 707.2008

N-(tert-Butoxycarbonyl)ethylenediamine maleimide (134)
According to the method of Richter et al.,211 round bottom
flask containing N-Boc-ethylenediamine (133, 0.50 mL,
0.510 g, 3.20 mmol) and NEt3 (0.66 mL) was suspended in
Et2O (5 mL) and cooled to 0°C. Maleic anhydride (0.311 g, 3.20 mmol) dissolved in
Et2O (5 mL) was added dropwise to the reaction mixture, after which it was allowed to
stir for 4 hours gradually warming to room temperature. After this time, the reaction
mixture was concentrated, and the resulting residue was dissolved in acetone (15 mL).
NEt3 (1.0 mL) and Ac2O (0.500 mL) was added, and the mixture was heated to reflux
for a further 20 hours. Upon completion, solvent evaporation resulted in a brown
residue, which following flash column chromatography resulted in the isolation of the
desired product 134 as a white solid. (0.388 g. 50%). M.p. 126-128°C, Rf 0.80 (1:1
Hexane: EtOAc). 1H NMR (500 MHz, CDCl3) δ 6.70 (m, 2H, CH=CH), 4.78 (bs, 1H,
NH), 3.64 (m, 2H, CH2-CH3-NHBoc), 3.31 (m, 2H, CH2-CH3-NHBoc), 1.39 (s, 9H,
Boc-H)

13

C NMR (125 MHz, CDCl3) δ 170.8 (C=O, maleimide), 155.9 (C=O, Boc),

134.2 (CH=CH), 79.5 (C(CH3)3), 39.4 (CH2-CH2-NHBoc), 38.0 (CH2-CH2-NHBoc),
28.3 (C(CH3)3). LRMS (ESI): m/z 263 [M + Na]+ HRMS (ESI): m/z calculated for
C11H16N2O4Na [M + Na]+: 263.1008; Found 263.1061.
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N-Ethylenediamine maleimide trifluoroacetate (135)
According to the method of Richter et al.,211 a round bottom
flask containing 134 (0.150 g, 0.624 mmol) was added dry
CH2Cl2 (5 mL). The flask was cooled to 0°C, and TFA (2.50
mL, 3.725 g, 32.67 mmol) was added to the solution dropwise. Upon addition, the
reaction mixture was stirred for 1 hour, during which it was allowed to warm to room
temperature. Upon completion, the reaction mixture was evaporated to dryness, with
flushing of the mixture with ice-cold Et2O (5 mL) resulting in precipitation of
thedesired product. Trituration with additional Et2O (4 x 5 mL) followed by filtration
resulting in the isolation of 135 as a white solid. (0.141 g, 95%). M.p. 133-134°C.
1

H NMR (500 MHz, D2O) δ 6.95 (s, 2H, CH=CH), 3.88 (t, 2H, J = 5.7 Hz, CH2-CH2-

NHBoc), 3.28 (t, 2H, J = 5.7 Hz, CH2-CH2-NHBoc).

13

C NMR (125 MHz, D2O) δ

172.7 (C=O), 134.7 (CH=CH), 38.4 (CH2-CH2-NHBoc), 35.0 (CH2-CH2-NHBoc).
LRMS (ESI): m/z 141 [M – TFA +H]+

N-(1-Azido-2,3,4-tri-O-acetyl-β-D-glucuronoyl)-ethylenediamine maleimide (136)
135 (0.076 g, 0.322 mmol), 60 (0.075 g, 0.215 mmol), and
DCC (0.066 g, 0.321 mmol) were dissolved in ACN
(2 mL), and the solution was cooled to 0°C. HOBt
(0.043 g, 3.21 mmol) was added portionwise to the
reaction mixture, and allowed to warm to room temperature and stir for 8 hours. Upon
completion, the reaction mixture was filtered, and the filtrate was evaporated to dryness.
The resulting residue was subject to purification by flash column chromatography
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(1:1 Hexane: EtOAc), producing the desired compound 136 as a white solid (0.066 g,
66%). M.p. 196-198°C (Decomp.), Rf 0.20 (1:1 Hexane:EtOAc). 1H NMR (500 MHz,
CDCl3) δ 6.84 (m, 1H, NH), 6.74 (s, 2H, CH=CH), 5.27 (t, 1H, J = 9.5 Hz, H3), 5.12 (t,
1H, J = 9.6 Hz, H4), 4.95 (t, 1H, J = 9.0 Hz, H2), 4.73 (d, 1H, J = 8.8 Hz, H1), 3.71 (m,
2H, CH2-CH2-NH), 3.43 (m, 2H, CH2-CH2-NH), 2.08-2.01 (3s, 9H, CH3, 3 x OAc).
13

C NMR (125 MHz, CDCl3) δ 170.9 (C=O, maleimide), 169.9 (C=O, OAc), 169.6

(C=O, OAc), 169.2 (C=O, OAc), 166.4 (C=O, CONH), 134.3 (CH=CH), 87.8 (C1),
74.1 (C5), 71.9 (C2), 70.5 (C3), 69.0 (C4), 38.9 (CH2-CH2-NH), 37.0 (CH2-CH2-NH),
20.6 (CH3, OAc), 20.6 (CH3, OAc), 20.5 (CH3, OAc). LRMS (ESI): m/z 490 [M + Na]+
HRMS

(ESI):

m/z calculated for C18H21N5O10Na [M

+ Na]+:

490.1186;

Found 490.1204.

Nα-(Fluorenylmethylcarbonyl)-S-(N-(1-azido-2,3,4-tri-O-acetyl-β-D-glucuronoyl)ethylenediamine succinimido)-L-Homocysteine methyl ester (137)
To a round bottom flask containing 137
(0.020 g, 0.0428 mmol) and Fmoc.HCys.OMe
(130, 0.016 g, 0.0428 mmol) was added a
1:1 solution of ACN:H2O (0.5 mL). The
reaction mixture was left to stir at room
temperature for 3 hours, with periodic monitoring of product formation by LR-ESIMS.
Upon completion the reaction mixture was evaporated to dryness, with the resulting
residue purified by flash column chromatography (1:1 Hexane EtOAc) to yield the
desired product 137 as a light yellow oil, present as a mixture of diastereomers
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(0.022g, 62%). Rf 0.25 (1:1 Hexane: EtOAc) 1H NMR (500 MHz, CDCl3) δ 7.76 (d,
2H, J = 7.3 Hz, Fmoc-H), 7.62 (d, 2H, J = 7.2 Hz, Fmoc-H), 7.41 (t, 2H, J = 7.3 Hz,
Fmoc-H), 7.32 (t, 2H, J = 7.3 Hz, Fmoc-H), 6.82 (m,1H, CH2-CH2-NH), 5.67 (m, 1H,
Fmoc-NH), 5.27 (m, 1H, C3), 5.08 (m, 1H, C4), 4.94 (t, 1 H, J = 9.0 Hz, H2), 4.70 (t,
1H, J = 9 Hz, H1), 4.54 (m, 1H, Hα), 4.41 (m, 2H, OCH2-CH), 4.24 (t, 1H, J = 6.5 Hz,
OCH2CH), 3.96 (m, 1H, H5), 3.77 (m, 3.5H, Succinimide-CH/OCH3), 3.71 (m, 2H,
CH2-CH2-NH), 3.59 (m, 1H, CH2-CH2-NH), 3.36 (m, 1H, CH2-CH2-NH), 3.20-3.24 (m,
2H, Succinimide-CH2), 3.03 (m, 1H, Hγ), 2.75-2.87 (dm, 1H, Hγ), 2.49 (m, 0.5H,
Succinimide-CH), 2.10-2.25 (dm, 2H, Hβ), 2.00-2.08 (3s, 9H, CH3, 3 x OAc).
13

C NMR (125 MHz, CDCl3) δ 177.3 (C=O, Succinimide), 175.3 (C=O, Succinimide),

175.0 (C=O, Succinimide), 172.2 (C=O, CONH), 169.8 (C=O, OAc), 169.5 (C=O,
OAc), 169.5 (C=O, OAc), 166.5 (C=O, CO COOCH3), 156.1 (C=O, Fmoc), 143.8
(Fmoc Ar-C1), 141.3 (Fmoc Ar-C6), 127.8 (Fmoc Ar-C4), 127.1 (Fmoc Ar-C5), 125.1
(Fmoc Ar-C3), 120.0 (Fmoc Ar-C2), 87.8 (C1), 74.2 (C5), 71.8 (C3), 70.5 (C2), 69.1
(C4),

67.2

(OCH2CH),

52.9

(Cα),

52.7

(OCH3),

47.1

(OCH2CH),

39.2

(Succinimide-CH), 38.9 (Succinimide-CH), 38.6 (CH2-CH2-NH), 38.3 (CH2-CH2-NH),
35.8 (Succinimide-CH2), 32.0 (Cβ), 27.8 (Cγ), 20.7 (CH3, OAc), 20.5 (CH3, OAc), 20.5
(CH3, OAc). LRMS (ESI): m/z 861 [M + Na]+
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Nα-(Fluorenylmethylcarbonyl)-S-(N-(1-(4’-(3”-hydroxypropyl)-1’,2’,3’-triazol1’-yl)-2,3,4-tri-O-acetyl-β-D-glucuronoyl)-ethylenediamine succinimido)-Lhomocysteine methyl ester (138)
To a round bottom flask
containing
0.036 mmol),

137

(0.030 g,

4-pentyn-1-ol

(0.015 mL,

0.013 g,

0.143 mmol),

CuOAc2

(0.002 g, 0.010 mmol) and sodium ascorbate (0.003 g, 0.015 mmol) was added a
1:1 solution of n-BuOH:H2O, (0.250 mL), with the solution stirred vigorously under an
atmosphere of nitrogen at

room temperature for 24 hours. Upon completion, the

reaction mixture was diluted with CH2Cl2 (5 mL), and extracted with H2O (1 mL), then
brine (1 mL). Subsequent drying (MgSO4) of the organic phase, and evaporation in
vacuo resulted in a residue which was purified by flash column chromatography
(1:3 Hexane: EtoAc) to yield 138 as a light yellow oil. (0.025 g, 76%). Rf 0.15
(1:3 Hexane: EtOAc). 1H NMR (500 MHz, CD3CN) δ 7.87 (m, 3H, Fmoc-H/TriazoleH), 7.72 (m, 2H, Fmoc-H), 7.46 (t, 4H, J = 7.3 Hz, Fmoc-H), 7.38 (t, 4H, J = 7.3 Hz,
Fmoc-H), 7.01 (m, 1H, NH), 6.27 (m, 1H, Fmoc-NH), 6.05 (d, 1H, J = 8.5 Hz, H1),
5.51-5.60 (m, 2H, H3/H2), 5.33 (m, 1H, H4), 4.37 (m, 3H, Hα/OCH2CH). 4.29 (m, 2H,
OCH2CH/H5), 3.80 (m, 0.5H, Succinimide-H), 3.73 (s, 3H, OCH3) 3.49-3.62 (m, 4H,
CH2-CH2-NH/CH2-CH2-CH2-OH). 3.32 (m, 2H, CH2-CH2-NH), 3.10 (m, 2H,
Succinimide-H), 2.93 (m, 1H, Hγ), 2.81 (m, 1H, Hγ), 2.77 (t, 2H, J = 7.1 Hz, CH2-CH2CH2-OH), 2.46 (m, 0.5H, Succinimide-H), 2.27 (m, 2H, Hβ), 2.00-2.03 (2s, 6H, CH3, 2
x OAc), 1.98 (m, 2H, CH2-CH2-CH2-OH), 1.81 (s, 3H, CH3, OAc). Exchangeable OH
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not detected. 13C NMR (125 MHz, CD3CN) δ 177.2 (C=O, Succinimide), 175.3 (C=O,
Succinimide), 175.3 (C=O, Succinimide), 172.6 (C=O, CONH), 170.0 (C=O, OAc),
169.7 (C=O, OAc), 169.0 (C=O, OAc), 166.6 (C=O, CONH), 156.4 (C=O, Fmoc),
148.4 (Triazole-C), 144.4 (Fmoc Ar-C1), 141.4 (Fmoc Ar-C6), 127.8 (Fmoc Ar-C4),
127.3 (Fmoc Ar-C5), 125.4 (Fmoc Ar-C3), 120.8 (Triazole-C), 120.2 (Fmoc Ar-C2),
84.8 (C1), 74.6 (C5), 72.1 (C3), 70.3 (C2), 69.2 (C4), 66.6 (OCH2CH), 60.9 (CH2-CH2CH2-OH) 53.2 (Cα), 52.3 (OCH3), 47.3 (OCH2CH), 40.0 (Succinimide-CH), 39.7
(Succinimide-CH), 38.2 (CH2-CH2-NH), 36.7 (CH2-CH2-NH), 36.2 (Succinimide-CH2),
32.6 (CH2-CH2-CH2-OH), 32.2 (Cβ), 30.2 (CH2-CH2-CH2-OH), 27.8 (Cγ), 20.1 (CH3,
OAc), 20.0 (CH3, OAc), 19.6 (CH3, OAc). LRMS (ESI): m/z 945 [M + Na]+

7.5 Chapter 5 Experimental Data:
1,2,3,4,6-Penta-O-acetyl-D-glucopyranose (147)
To a round bottom flask containing D-glucose (2.54g,
14.1 mmol) was added pyridine (10 mL) and Ac2O (7.00 mL,
7.52 g, 73.7 mmol), with the reaction mixture allowed to stir at
room temperature for 72 hours. After which, the reaction mixture was diluted with
CH2Cl2 (30 mL) and washed with 1% CuSO4 solution (2 x 50 mL). The organic layers
were further washed with water, dried with Na2SO4 and concentrated, with the resultant
solid recrystallised from EtOAc to produce 147 as white crystals, present as a mixture
of α/β anomers. (5.42 g, 96%). Mp 96-97°C (Lit 100-102°C),222 Rf 0.65
(1:1 Hexane:EtOAc). 1H NMR (500 MHz, CDCl3) δ 6.31 (d, 1H, J = 3.9 Hz, H1α),
5.72 (d,1H, J = 8.2 Hz, H1β) 5.47 (m, 1H, J = 9.8 Hz, H3α) 5.26 (m, 1H, J = 9.6Hz,
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H3β) 5.16-5.10 (m, 4H, H2αβ/H4αβ) 4.30-4.25 (m, 2H) 4.14-4.09 (m, 3H, H5α/H6αβ ),
3.84 (m, 1H, H5), 2.18 (s, 3H, OAc), 2.11-2.02 (5s, 15H, CH3, 5 x OAc). 3C NMR
(CDCl3, 125 MHz): 170.4 (C=O, OAc), 170.1 (C=O, OAc), 169.5 (C=O, OAc), 169.3
(C=O, OAc), 168.6 (C=O, OAc), 92.0 (C1β), 89.4 (C1α), 73.2 (C3), 70.6 (C2α), 70.2
(C2β), 69.5 (C4), 68.2 (C5), 61.7 (C6), 21.0 (CH3, OAc), 20.9 (CH3, OAc),
20.8 (CH3, OAc), 20.7 (CH3, OAc). LRMS (ESI): m/z 413 [M + Na]+

2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl azide (148)
To a solution of 147 (1.17g, 2.99 mmol) in CH2Cl2 (30 mL)
under a nitrogen atmosphere, were added sequentially TMSN3
(0.500 mL, 0.458 g, 3.97 mmol) and SnCl4 (0.200 mL, 0.444 g,
1.71 mmol), with the reaction mixture allowed to stir at room temperature for 24 hours.
Upon completion, the reaction mixture was diluted further with DCM (50 mL), washed
with aq. NaHCO3 solution (50 mL) and H2O (50 mL), dried with Na2SO4 and
concentrated. The resultant solid was recrystallised from EtOH to produce 148 as a fine
white

powder.

(0.728 g, 65%).

Mp 128-130°C

(Lit.

128.5°C),254

Rf

0.75

(1:1 Hexane:EtOAc). 1H NMR (500 MHz, CDCl3) δ 5.22 (t, 1H, J = 9.4 Hz, H3 ) 5.10
(t, 1H, J = 9.1 Hz, H4 ) 4.96 (t, 1H, J = 9.4 Hz, 9.1 Hz, H2 ) 4.66 (d, 1H, J = 8.8 Hz,
H1) 4.27 (dd, 1H, J = 12.2 Hz, 4.8 Hz, H6) 4.16 (dd, 1H, J = 12.4 Hz, 2.5 Hz, H6’) 3.79
(m, 1H, H5) 2.10-2.01 (4s, 12H, CH3, 4 x OAc). 13C NMR (125 MHz, CDCl3) δ 170.6
(C=O, OAc), 170.1 (C=O, OAc), 169.3 (C=O, OAc), 169.2 (C=O, OAc), 87.9 (C1),
73.6 (C3), 72.5 (C2), 70.6 (C4), 67.8 (C5), 61.6 (C6), 20.7 (CH3, OAc), 20.6 (CH3,
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OAc), 20.5 (CH3, OAc), 20.5 (CH3, OAc). LRMS (ESI): m/z 396 [M + Na]+ HRMS
(ESI): m/z calculated for C17H19N3O9Na [M + Na]+: 396.1019; Found 396.1026.

4,6-Benzylidene-β-D-glucopyranosyl azide (150)
According to the method of D’Onofrio et al.,158 To a round
bottom flask containing 148 (0.351 g, 940 mmol) in MeOH
(9.50 mL) was added 0.500 mL of a 0.5M solution of
NaOCH3 in MeOH, with the reaction mixture allowed to stir at room temperature for
0.5 hours. The reaction mixture was neutralised with Dowex 50 x 4 [H+] resin, filtered
and concentrated to dryness. The resultant residue (149) was dissolved in dry DMF
(6 mL), treated with benzylidene dimethyl acetal (0.318 g, 0.320 mL, 2.09 mmol) and
dry p-TsOH (0.020 g, 0.116 mmol), and allowed to stir under aspirator vacuum pressure
at 60°C for 5 hours. Upon completion, the reaction mixture was concentrated, and
purified using flash column chromatography (1:9 Acetone: CH2Cl2) to yield 150 as an
amorphous white solid. (0.239 g, 87%) Mp 155-157°C (Lit. 152-153°C),225 Rf 0.27
(1:9 Acetone: CH2Cl2). 1H NMR (500 MHz, CD3OD) δ 7.48 (m, 2H, Ar-H), 7.37 (m,
3H, Ar-H), 5.55 (s, 1H, PhCH), 4.68 (d, 1H, J = 8.9 Hz, H1), 4.30 (dd, 1H, J = 4.8 Hz,
9.2 Hz, H6), 3.81 (m, 1H, H3/H6’), 3.56 (t, 1H, J = 9.2 Hz, 8.5 Hz, H4), 3.55 (m, 1H,
H5), 3.46 (t, 1H, J = 9.1 Hz, 8.8 Hz, H3), 3.25 (t, 1H, J = 8.8 Hz, 8.4 Hz, H2).13C NMR
(125 MHz, CDCl3) δ 137.1 (Ar-C1), 129.6 (Ar-C4), 128.6 (Ar-C3/5), 126.5 (Ar-C2/6),
102.2 (PhCH), 90.8 (C1), 80.4 (C4), 74.4 (C5), 73.8 (C3), 68.6 (C6), 68.6 (C2). LRMS
(ESI): m/z 328 [M + Cl]- HRMS (ESI): m/z calculated for C13H15N3O5Cl: 328.0700 [M
+ Cl]-; Found 328.0708.
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2,3-Di-O-p-methoxybenzyl-4,6-benzylidene-β-D-glucopyranosyl azide (151)
To a round bottom flask containing 150 (0.200 g, 0.682 mmol)
was added p-methoxybenzyl chloride (0.530 mL, 0.614 g,
3.92 mmol), tert-butylammonium iodide (150 g, 0.406 mmol)
and anhydrous DMF (10 mL). The reaction mixture was cooled to 0°C, before NaH –
60% dispersed in mineral oil (0.161 g, 3.93 mmol) was added portion wise. The reaction
mixture was then allowed to warm to room temperature, and was left to stir for
24 hours. Upon completion, the reaction mixture was diluted with NH3Cl and
evaporated in vacuo. The residue was dissolved in CHCl3 (20 mL), washed with water
(2 x 20 mL), dried with Na2SO4 and evaporated. The resultant residue was purified
using flash column chromatography (4:1 Hexane:EtOAc.), furnishing 151 as a fluffy
white solid. (0.264 g, 73%). M.p. 132-133°C Rf 0.61 (4:1 Hexane:EtOAc.) 1H NMR
(500 MHz, CDCl3) δ 7.48 (d, 2H, J = 7.6 Hz, PhH2/6), 7.36 (m, 3H, PhH3/4/5), 7.26
(dd, 4H, J= 3.1 Hz, 5.5 Hz, PMB-H3/5), 6.84 (dd, 4H, J= 8.5 Hz, 5.5 Hz, PMB-H2/6),
5.54 (s, 1H, Ph-CH), 4.84 (d, 1H, J = 11.0 Hz, CH2Ph), 4.74 (m, 2H, CH2Ph), 4.71 (d,
1H, J = 11.0 Hz, CH2Ph), 4.65 (d, 1H, J = 11.0 Hz, Ch2Ph), 4.34 (dd, 1H, J = 5.0 Hz,
10.5 Hz, H6), 3.76 (m, 7H, 2 x OCH3, H3), 3.73 (dd, 1H, J = 4.4 Hz, 10.3 Hz, H6’),
3.63 (t, 1H, J = 9.1 Hz, H4), 3.45 (m, 1H, H5), 3.34 (t, 1H, J = 8.5 Hz, H2). 13C NMR
(125 MHz, CDCl3) δ 159.8 (PMB-C4), 159.6 (PMB-C4’), 137.4 (Ph-C1), 130.7 (PMBC1/C1’), 130.2 (PMB-C2/C6), 130.0 (PMB-C2’/C6’), 129.3 (Ph-C4), 128.6 (PhC3/C5), 126.3(Ph-C2/C6), 114.2 (PMB-C3/C5), 114.1(PMB-C3’/C5’), 101.5 (Ph-C-O),
91.0 (C1), 81.5(C3), 81.3 (C2), 81.1 (C4), 75.5 (O-CH2Ph), 75.1 (O-CH2Ph), 68.7 (C5),
68.4 (C6), 55.5 (OCH3). LRMS (ESI): m/z 556 [M + Na]+

HRMS (ESI): m/z

calculated for C29H31N3O7Na [M + Na]+: 556.2060, Found: 556.2078.
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2,3-Di-O-benzoyl-4,6-benzylidene-β-D-glucopyranosyl azide (152)
To a round bottom flask containing 150 (1.63 g, 5.54 mmol)
was added pyridine (20 mL). The reaction mixture was cooled
to 0°C, and benzoyl chloride (1.55 mL, 1.98 g, 13.33 mmol)
was added dropwise to the solution. The reaction mixture was subsequently allowed to
warm to room temperature, and stirred for 3 hours. Upon completion, the reaction
mixture was concentrated in vacuo, with the resulting residue recrystallized from
EtOAc/Hexanes to produce 152 as a fine white solid. (2.79 g, 63%). M.p. 162-164°C
(decomp.), Rf 0.90 (1:1 Hexane:EtOAc.). 1H NMR (500 MHz, CDCl3) δ 7.96 (m, 4H,
Bz-H2/H6), 7.47-7.53 (m, 2H, Bz-C4). 7.31-7.40 (m, 9H, Ar-H), 5.81 (t, 1H, J = 9.5
Hz, H3), 5.56 (s, 1H, PhCH), 5.42 (t, 1H, J = 9.2 Hz, H4), 4.92 (d, 1H, J = 8.7 Hz, H1),
4.48 (m, 1H, H6), 3.88-3.97 (m, 2H, H2/H6’), 3.80 (m, 1H, H5). 13C NMR (125 MHz,
CD3OD) δ 165.5 (C=O), 165.2 (C=O), 136.5 (Ar-C1), 133.6 (Ar-C4), 133.3 (Ar-C4),
129.9 (Ar-C2/C6), 129.8 (Ar-C2/C6), 129.2 (Ar-C1), 128.7 (Ar-C4), 128.5 (Ar-C3/C5),
128.4 (Ar-C3/C5), 128.2 (Ar-C3/C5), 126.1 (Ar-C2/C6), 101.6 (PhCH), 88.9 (C1, 78.5
(C4), 71.9 (C3), 71.8 (C5), 68.9 (C2), 68.3 (C6). LRMS (ESI): m/z 540 [M + K]+
HRMS (ESI): m/z calculated for C27H23N3O7K [M + K]+: 540.1173 Found 540.1173.

2,3-Di-O-p-methoxybenzyl-β-D-glucopyranosyl azide (153)
To a round bottom flask containing 151 (0.169 g, 0. 318 mmol)
in MeOH: CHCl3 (5:1, 12 mL) was added dry p-TsOH (0.045 g,
0.261 mmol), with the reaction allowed to stir for 24 hours at
room temperature. Upon completion, solvent was removed and the resultant residue was
purified using flash column chromatography (1:1 Hexane:EtOAc) providing 153 as a
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waxy solid. (0.102 g, 72%), M.p 112-115°C Rf 0.31 (1:1 Hexane:EtOAc). 1H NMR
(500 MHz, CD3OD) δ 7.24 (m, 4H, J = 8.5 Hz, PMB-H3/H5), 6.84 (d, 4H, J = 8.5 Hz,
PMB-H2/H6), 4.84-4.61 (m, 5H, CH2-Ph, H1), 3.87(dd, 1H, J = 2.2 Hz, 12.1 Hz, H6),
3.77 (s, 6H, -OCH3), 3.68 (dd, 1H, J = 5.1 Hz, 12.2 Hz, H6’), 3.47-3.36 (m, 2H,
H3/H5), 3.30 (m, 1H, H4), 3.20 (t, 1H, J = 8.5 Hz, H2). 13C NMR (125 MHz, CD3OD)
δ 159.6 (PMB-C4), 159.5 (PMB-C4’), 130.9 (PMB-C1), 130.3 (PMB-C1’), 129.5
(PMB-C2/C6), 129.5 (PMB-C2’/C6’), 90.2 (C1), 84.6 (C3), 81.0 (C2), 78.8 (C4), 74.9
(CH2-Ph), 74.4 (CH2-Ph), 70.1 (C5), 61.1 (C6), 54.4 (OCH3). LRMS (ESI): m/z 479
[M + HCOO]-

2,3-Di-O-benzoyl-β-D-glucopyranosyl azide (154)
To a round bottom flask containing 152 (0.528 g, 1.054 mmol),
was added a solution of CH2Cl2 and CH3OH (1:4, 5 mL). The
resulting suspension was cooled to 0°C, and p-TsOH (0.091 g,
0.526 mmol) was added portionwise to the solution. The reaction mixture was then
allowed to warm to room temperature, and stirred for 3 hours. Subsequently, the
reaction mixture was quenched with sat. NaHCO3 solution (5 mL), and extracted with
CH2Cl2 (2 x 50 mL). The organic layers were pooled together, dried (MgSO4) and
concentrated in vacuo, with the resulting residue subject to flash column
chromatography (1:1 Hexane:EtOAc), producing 154 as a clear oil. (0.320 g, 73%).
Rf 0.25 (1:1 Hexane:EtOAc).

1

H NMR (500 MHz, CDCl3) δ 7.95 (t, 4H, 7.0 Hz, Ar-

H2/H6), 7.51 (m, 2H, Ar-H4), 7.35 (m, 4H, Ar-H3/H5), 5.51 (t, 1H, J = 9.5 Hz, H3),
5.34 (t, 1H, J = 9.0 Hz, H2), 4.87 (d, 1H, J = 8.9 Hz, H1), 3.98 (m, 2H, H4/H6), 3.91
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(dd, 1H, J = 3.0 Hz, 12.1 Hz, H6’), 3.90 (bs, 1H, OH), 3.69 (m, 1H, H5), 2.65 (bs, 1H,
OH). 13C NMR (125 MHz, CDCl3) δ 167.3 (C=O), 165.5 (C=O), 133.9 (Ar-C4), 133.8
(Ar-C4), 130.1 (Ar-C2/C6), 130.1 (Ar-C2/C6), 129.0 (Ar-C1), 128.7 (Ar-C3/C5), 128.7
(Ar-C3/C5), 88.4 (C1), 78.4 (C3), 76.6 (C2), 71.3 (C5), 69.4 (C4), 62.1 (C6). LRMS
(ESI): m/z 458 [M + HCOO]-

2,3-Di-O-p-methoxybenzyl-6-trityl-β-D-glucopyranosyl azide (155)
To a round bottom flask 153 (0.100 g, 0.145 mmol) was added
trityl chloride (0.061 g, 0.218 mmol) and pyridine (5 mL), with
the reaction allowed to stir at room temperature for 48 hours.
Upon completion, the reaction mixture was co-evaporated with toluene (2 x 25 mL).
The resultant residue was purified using flash column chromatography (4:1
Hexane:EtOAc), producing 155 as a white amorphous solid. (0.048 g, 31%) Rf 0.28 (4:1
Hexane:EtOAc). 1H NMR (500 MHz, CDCl3) δ 7.45 (d, 4H, J = 8.5 Hz, PMB-H3/H5),
7.30-7.20 (m, 15H, Ar-H), 6.86 (m, 4H, J = 8.5 Hz, PMB-H2/H6), 4.82 (m, 2H,
J = 11.1 Hz, CH2-Ph, H1), 4.70 (d, 1H, J = 5.7 Hz, CH2-Ph), 4.64 (d, 1H, J = 6.3 Hz,
CH2-Ph), 4.61 (d, 1H, J = 8.1 Hz, CH2-Ph), 3.79 (s, 3H, OCH3), 3.78 (s, 3H, OCH3),
3.67 (t, 1H, J = 5.5 Hz, H3), 3.45-3.30 (m, 5H, H2/H4/H5/H6/H6’).

13

C NMR (125

MHz, CDCl3) δ 159.8 (PMB-C4/C4’), 143.9 (Trt-C1), 130.8 (Ar-C), 130.3 (Ar-C),
130.2 (Ar-C), 130.0 (Ar-C), 129.0 (Ar-C), 128.2 (Ar-C), 127.5 (Ar-C), 114.3 (PMBC3/C5), 114.2 (Ar-C3’/C5’), 90.2 (C1), 87.2 (Ph-C), 84.3 (C3), 81.4 (C2), 76.6 (C4),
75.5 (CH2-Ph), 75.1 (CH2-Ph), 71.5 (C5), 63.8 (C6), 55.6 (OCH3). LRMS (ESI):
m/z 710 [M + Na]+

270 | P a g e

Chapter 7: Experimental
2,3-O-p-Methoxybenzyl-6-(p-methoxytrityl)-β-D-glucopyranosyl azide (156)
To a round bottom flask 153 (0.101 g, 0.146 mmole) was added
4-methoxytrityl chloride (0.068 g, 0.220 mmol) and pyridine
(5 mL), with the reaction allowed to stir at room temperature for
48 hours. Upon completion, the reaction mixture was co-evaporated with toluene
(2 x 25 mL). The resultant residue was purified using flash column chromatography
(4:1 Hexane: EtOAc) producing 156 as a white amorphous solid. (0.099 g, 61%),
Rf 0.35 (4:1 Hexane:EtOAc). 1H NMR (500 MHz, CDCl3) δ 7.45 (d, 6H, J = 8.5 Hz,
PMB-H3/H5), 7.20-7.34 (m, 10H, Ar-H), 6.82-6.88 (m, 6H, PMB-H2/H6), 4.81 (d, 2H,
CH2-Ph), 4.69 (m, 2H, CH2-Ph), 4.61 (d, 1H, J = 8.8 Hz, H1), 3.79 (3s, 9H, OCH3),
3.67 (t, 1H, J = 9.0 Hz, H3), 3.33-3.45 (m, 5H, H2/H4/H5/H6/H6’).

13

C NMR

(125 MHz, CDCl3) δ 159.5 (PMB-C4) 159.4 (PMB-C4’), 158.7 (PMB-Trt-C4), 144.2
(Trt-C1/C1’), 135.3 (PMB-Trt-C1), 130.4 (Ar-C), 130.1 (Ar-C), 129.9 (Ar-C),
129.7 (Ar-C), 128.4 (Ar-C), 127.9 (Ar-C), 127.1 (Ar-C), 114.0 (PMB-C3/C5), 113.9
(PMB-C3’/C5’), 113.3 (PMB-Trt-C3’/C5’), 90.0 (C1), 86.7 (Ph-C), 84.0 (C3), 81.1
(C2), 76.3 (C4), 75.2 (CH2-Ph), 74.8 (CH2-Ph), 71.4 (C5), 63.6 (C6), 55.3 (OCH3), 55.3
(OCH3), 55.2 (OCH3). LRMS (ESI): m/z 740 [M + Na]+

2,3-Di-O-benzoyl-1-azido-β-D-glucuronic acid (161)
According to the method of van den Bos et al.,

227

a round bottom

flask containing 154 (0.120 g, 0.29 mmol), was added a solution of
CH2Cl2 and H2O (2:1; 1.50 mL)). The biphasic solution was cooled
to 0°C, and TEMPO (0.010 g, 0.640 mmol) and PhIOAc2 (0.242 g, 0.751 mmol) was
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added to the reaction mixture portion wise, after which the reaction mixture was
warmed to room temperature, and stirred vigorously for 45 minutes. After this time, the
reaction was diluted with 10% sodium thiosulphate solution (5 mL), and extracted with
EtOAc (2 x 10 mL). The combined organic layers were washed with brine (5 mL), dried
(MgSO4) and evaporated in vacuo, with purification by flash column chromatography
(5% AcOH in 1:1 Hexane:EtOAc) yielding the product 161 as a light yellow oil. (0.109
g, 88%). Rf 0.28 (5% AcOH in 1:1 Hexane:EtOAc). 1H NMR (500 MHz, CD3OD) δ
7.91 (t, 2H, 7.0 Hz, Ar-H2/H6), 7.51 (m, 2H, Ar-H4), 7.37 (m, 4H, Ar-H3/H5), 5.61 (t,
1H, J = 9.3 Hz, H3), 5.25 (t, 1H, J = 9.0 Hz, H2), 5.16 (d, 1H, J = 8.7 Hz, H1), 4.24 (d,
1H,, J = 9.7 Hz, H5), 4.09 (t, 1H, J = 9.6 Hz, H4).

13

C NMR (125 MHz, CD3OD) δ

169.7 (C=O, COOH), 165.9 (C=O), 165.2 (C=O), 133.3 (Ar-C4), 133.1 (Ar-C4), 129.3
(Ar-C2/C6), 129.3 (Ar-C2/C6), 128.8 (Ar-C1), 128.2 (Ar-C3/C5), 128.1 (Ar-C3/C5),
87.9 (C1), 77.0 (C3), 75.0 (C2), 71.4 (C5), 69.7 (C4). LRMS (ESI): m/z 426 [M - H]HRMS (ESI): m/z calculated for C20H16N3O8 [M - H]-: 426.0937; Found 426.0946

2,3-Di-O-benzoyl-1-azido-β-D-glucuronic acid methyl ester (162)
To a round bottom flask containing 161 (0.109 g, 0.255 mmol) in
DMF (2 mL), was added K2CO3 (0.141 g, 1.02 mmol). The
solution was stirred for 5 minutes, before being brought down to
0°C. MeI (0.024 mL, 0.054 g, 0.382 mmol) was subsequently added to the stirring
solution dropwise, with the reaction mixture allowed to warm gradually to room
temperature and stir for an additional 16 hours. Following completion, the reaction was
diluted with H2O (5 mL), and extracted with EtOAc (10 mL). The organic layers were
collected, washed with brine (5 mL), dried (Na2SO4) and evaporated in vacuo, yielding
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a residue that following flash column chromatography (2:1 Hexane:EtOAc.) resulted in
the isolation of 162 as a clear oil. (0.072 g, 64%). Rf 0.35 (2:1 Hexane:EtOAc.).
1

H NMR (500 MHz, CDCl3) δ 7.95 (m, 4H, Ar-H2/H6), 7.50 (m, 2H, Ar-H4), 7.37 (m,

4H, Ar-H3/H5), 5.60 (m, 1H, H3), 5.38 (t, 1H, J = 9.5 Hz, H2), 4.91 (d, 1H, J = 8.7 Hz,
H1), 4.20 (m, 2H, H4/H5), 3.87 (s, 3H, OCH3), 3.51 (bs, 1H, OH).13C NMR (125 MHz,
CDCl3) 168.5 (C=O, COOCH3), 166.4 (C=O), 165.1 (C=O), 133.6 (Ar-C4), 133.6 (ArC4), 129.9 (Ar-C2/C6), 129.9 (Ar-C2/C6), 128.8 (Ar-C3/C5), 128.6 (Ar-C3/C5), 128.6
(Ar-C1), 128.5 (Ar-C1), 88.6 (C1), 76.2 (C3), 74.6 (C2), 70.5 (C5), 70.2 (C4), 53.1
(OCH3). LRMS (ESI): m/z 464 [M + Na]+ HRMS (ESI): m/z calculated for
C21H19N3O8Na [M + Na]+: 464.1070; Found 464.1092. Data gained in the production of
this compound was not consistent with that published elsewhere.226

L-Alanine methyl ester hydrochloride (163)
To a round bottom flask containing L-alanine (1.7 g, 19 mmol),
was added MeOH (20 mL) and placed under an atmosphere of
argon. The reaction mixture was cooled to 0°C, and thionyl
chloride (1.45 mL, 2.37 g, 20 mmol) was subsequently added to the reaction mixture
dropwise. After 30 minutes, the round bottom flask was allowed to warm to room
temperature, and the reaction mixture was stirred for an additional 18 hours. Upon
completion, the reaction mixture was concentrated in vacuo, producing 163 as an offwhite crystalline solid. (2.64 g, 99%). M.p. 104-106°C (Lit. 107-110°C)255 1H NMR
(500 MHz, DMSO-d6) δ 8.54 (bs, 1H, NH3), 4.05 (m, 1H, Hα), 3.73 (s, 3H, OCH3), 1.43
(d, 3H, J = 7.3 Hz, Hβ). 13C NMR (125 MHz, DMSO-d6) 170.4 (C=O, COOCH3), 52.7
(OCH3), 47.8 (Cα), 15.6 (Cβ). LRMS (ESI): m/z 104 [M –Cl + H]+
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N-(1-Azido-2,3-di-O-benzoyl-β-D-glucopyranuronoyl)-L-alanine methyl ester (164)
161 (0.100 g, 0.234 mmol), HBTU (0.178 g, 0.468 mmol) and
L-alanine methyl ester hydrochloride (163, 0.049 g, 0.351 mmol)
were placed in a round bottom flask. DMF (5 mL) was added to
the flask, and the resulting solution was cooled to 0°C. DIPEA
(0.045 mL, 0.033 g, 0.257 mmol) was then added, and the reaction mixture was allowed
to warm to room temperature, stirring for 24 hours. Upon completion, the reaction
mixture was diluted with H2O (5 mL), and the aqueous solution was washed with
EtOAc (20 mL). The organic phases were pooled together and washed with brine
(5 mL), dried (NaSO4) and evaporated in vacuo. The resulting residue was then
subjected to flash column chromatography (1:3 Hexane: EtOAc), resulting in the
isolation of 164 as a clear oil. (0.060 g, 50%). Rf 0.05 (1:1 Hexane:EtOAc.). 1H NMR
(500 MHz, CDCl3) δ 7.95 (m, 4H, Ar-H2/H6), 7.51 (m, 2H, Ar-H4), 7.37 (m, 4H,
Ar-H3/H5), 7.15 (d, 1H, J = 7.4 Hz, NH), 5.68 (t, 1H, J = 9.4 Hz, H3), 5.36 (t,
1H, J = 9.5 Hz, H2), 4.94 (d, 1H, J = 8.9 Hz, H1), 4.64 (m, 1H, Hα), 4.11 (m, 2H,
H4/H5), 3.80 (s, 3H, OCH3), 1.51 (d, 3H, J = 7.5 Hz, Hβ). 13C NMR (125 MHz, CDCl3)
172.5 (C=O, COOCH3), 168.9 (C=O, CONH), 165.7 (C=O), 165.1 (C=O), 133.6
(Ar-C4), 133.3 (Ar-C4), 129.9 (Ar-C2/H6), 129.8 (Ar-C2/H6), 129.0 (Ar-C1), 128.6
(Ar-C1), 128.5 (Ar-C3/C5), 128.3 (Ar-C3/C5), 88.3 (C1), 74.4 (C5), 73.9 (C3), 70.6
(C2), 70.4 (C4), 52.8 (OCH3), 47.9 (Cα), 18.1 (Cβ). LRMS (ESI): m/z 547 [M + Cl]-.
HRMS (ESI): m/z calculated for C24H24N4O9Cl [M + Cl]-: 547.1232; Found 547.1238.
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N-(1-Azido-2,3-di-O-benzoyl-4-t-butyldimethylsilyl-β-D-glucopyranuronoyl)-Lalanine methyl ester (165)
164 (0.105 g, 0.205 mmol) and imidazole (0.070 g, 1.03 mmol)
were dissolved in dry DMF (1 mL) in a round bottom flask. The
reaction mixture was cooled to 0°C, and t-butyldimethylsilyl
chloride (0.077 g, 0.511 mmol) was added portion wise. The
reaction mixture was then flushed with argon, warmed to room temperature and allowed
to stir for 18 hours. Upon completion, the reaction mixture was diluted with H2O (2 mL)
and extracted with EtOAc (10 mL). The organic layers were washed with brine (2 mL),
dried (Na2SO4) and evaporated in vacuo, with the resulting residue subjected to flash
column chromatography (1:1 Hexane: EtOAc), producing 165 as a clear oil. (0.046 g,
36%). Rf 0.55 (1:1 Hexane:EtOAc.). 1H NMR (500 MHz, CDCl3) δ 7.92 (m, 4H, ArH2/H6), 7.50 (m, 2H, Ar-H4), 7.37 (m, 4H, Ar-H3/H5), 6.87 (d, 1H, J = 7.4 Hz, NH),
5.48 (t, 1H, J = 9.4 Hz, H3), 5.29 (t, 1H, J = 9.5 Hz, H2), 5.09 (d, 1H, J = 8.9 Hz, H1),
4.53 (m, 1H, Hα), 4.38 (t, 1H, J = 9.4 Hz, H4), 4.17 (d, 1H, J = 6.5 Hz, H5), 3.76 (s, 3H,
OCH3), 1.39 (d, 3H, J = 7.0 Hz, Hβ), 0.79 (s, 9H, CH3, Si-t-Bu), 0.04 (s, 3H, SiCH3), -0.08 (s, 3H, Si-CH3).

13

C NMR (125 MHz, CDCl3) 172.9 (C=O, COOCH3),

166.5 (C=O, CONH), 165.3 (C=O), 165.1 (C=O), 133.5 (Ar-C4), 133.4 (Ar-C4), 129.9
(Ar-C2/H6), 129.8 (Ar-C2/H6), 129.3 (Ar-C1), 128.8 (Ar-C1), 128.4 (Ar-C3/C5), 128.4
(Ar-C3/C5), 87.6 (C1), 79.7 (C5), 74.9 (C3), 71.8 (C2), 70.4 (C4), 52.6 (OCH3), 48.1
(Cα), 30.9 (Si-C), 25.6 (C(CH3)3), 18.4 (Cβ), -4.6 (Si-C), -4.9 (Si-CH3). LRMS (ESI):
m/z 649 [M + Na]+. HRMS (ESI): m/z calculated for C30H38N4O9SiNa: 649.2306
[M + Na]+; Found 649.2302
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1,2,3,4-Tetra-O-acetyl-β-D-glucopyranuronic acid methyl ester (52)
According to the method of Graff von Roedern et al.,156
Glucuronolactone (51, 12.90 g, 72 mmol) was suspended in dry
MeOH (400 mL), and triethylamine (0.6 mL) was added. The
reaction mixture was stirred for 3 hours until the glucuronolactone was dissolved. The
solvent was evaporated and the resulting solid was used without further purification.
The solid was then suspended in Ac2O (63.0 mL, 67.8 g, 660 mmol) and NaOAc
(6.30 g, 72.0 mmol) were added, and the suspension was stirred for 8 days. The reaction
mixture was then poured onto ice water (300 mL) and stirred overnight. The resulting
white solid was isolated by filtration, washed with water (50 mL), and recrystallized
from EtOAc/Hexanes to afford the desired product 52 solely present as the β anomer.
(10.59 g, 38%) Mp 179-180 °C. (Lit.179-180°C).164 Rf 0.75 (1:1 Hexane:EtOAc).
1

H NMR (500 MHz, CDCl3) δ 6.02 (d, 1H, J = 8.1 Hz, H1), 5.51 (dd, 1H J = 9.4 Hz,

H3), 5.01 (t, 1H, J = 9.6 Hz, H4), 4.97 (t, 1H, J = 8.2 Hz, H2), 4.67 (d, 1H, J = 9.8 Hz,
H5), 3.63 (s, 3H, OCH3β), 2.08-1.97 (4s, 12H, OAc).

13

C NMR (125 MHz, CDCl3)

170.1 (C=O, OAc), 169.6 (C=O, OAc), 169.4 (C=O, OAc), 169.0 (C=O, OAc), 167.0
(C=O, COOCH3), 91.6 (C1), 73.2 (C5), 72.0 (C4), 70.4 (C3), 69.1 (C2), 53.2 (OCH3),
21.0 (CH3, OAc), 20.8 (CH3, OAc), 20.8 (CH3, OAc), 20.7 (CH3, OAc). LRMS (ESI):
m/z 399 [M + Na]+. HRMS (ESI): m/z calculated for C15H20O11Na [M + Na]+:
399.0903; Found 399.0917.

1-Azido-1-deoxy-2,3,4-tri-O-acetyl-β-D-glucuronic acid methyl ester (53)
To a solution of 52 (5.00g, 2.65 mmol) in CH2Cl2 (50 mL) under
a N2 atmosphere, were added sequentially TMS-N3 (2.50 mL,
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2.290 g, 19.85 mmol) and SnCl4 (1.00 mL, 2.22 g, 8.55 mmol), with the reaction
mixture allowed to stir at room temperature for 3 hours. Upon completion, the reaction
mixture was diluted further with CH2Cl2 (100 mL), washed with sat. NaHCO3 solution
(100 mL) and brine (100 mL), dried with Na2SO4 and concentrated. The resultant solid
was recrystallised from EtOAc/Hexanes to produce 53 as a fine white powder. (3.89 g,
81%) Mp 154-157 °C (Lit. 152-153°C),153 Rf 0.85 (1:1 Hexane:EtOAc). 1H NMR (500
MHz, CDCl3) δ 5.40 (dd, 1H, J = 9.6 Hz, H3), 5.19 (d, 1H, J = 8.8 Hz, H1), 5.05 (dd,
1H, J = 9.8 Hz, H4), 4.87 (dd, 1H, J = 9.2 Hz, H2), 4.57 (d,1H, J = 9.9 Hz, H5), 3.66
(s, 3H, OCH3), 2.04-1.98 (3s, 9H, OAc). ). 13C NMR (125 MHz, CDCl3) δ 170.2 (C=O,
OAc), 169.4 (C=O, OAc), 169.3 (C=O, OAc), 167.1 (C=O), 88.1 (C1), 74.3 (C5), 72.0
(C4), 70.5 (C2), 69.1 (C3), 53.2 (OCH3) 20.7 (CH3, OAc), 20.7 (CH3, OAc), 20.6 (CH3,
OAc). LRMS (ESI): m/z 382 [M + Na]+ HRMS (ESI): m/z calculated for
C13H17N3O9Na [M + Na]+: 382.0862; Found 382.0867.

2,4-Di-O-acetyl-β-D-glucopyranuronyl azide-3,6-lactone (166)
According to the method of Tosin et al.,157 To a round bottom flask
containing 53 (0.985 g, 2.74 mmol) was added a solution of LiOH
(0.3 M, 60 mL) at 0°C, with the resulting suspension allowed to stir for
3.5 hours. Following this time, the pH of the solution was adjusted to 2
using Amberlite IR-120 resin, the solution was filtered, and concentrated in vacuo,
before being subjected to lyophilisation overnight. The resulting white powder was
suspended in Ac2O (20.0 mL) and 4Å molecular sieves were added, with the reaction
mixture placed under argon and allowed to stir at 85°C for 2 hours. After this time,
filtration followed by concentration in vacuo and consecutive azeotropic distillation
with toluene, resulted in the isolation of 166 as yellow oil that was directly used in the

277 | P a g e

Chapter 7: Experimental
next step without further purification. (0.586 g, 75%), Rf 0.31 (1:1 Hexane:EtOAc.).
1

H NMR (500 MHz, CDCl3) δ 5.44 (m, 1H, H1), 5.07 (m, 1H, H3), 4.93 (m, 2H,

H2/H4), 4.36 (m, 1H, H5), 2.19 (s, 3H, CH3, OAc), 2.10 (s, 3H, CH3, OAc).
13

C NMR (125 MHz, CDCl3) δ 170.2 (C=O), 169.0 (C=O, OAc), 168.9 (C=O, OAc),

88.5 (C1), 71.4 (C5), 68.9 (C4), 68.6 (C3), 67.5 (C2), 20.7 (CH3, OAc), 20.7
(CH3, OAc).

N-(1-Azido-2,4-di-O-acetyl-β-D-glucopyranuronoyl)-L-alanine methyl ester (169)
To a round bottom flask containing 166 (0.586 g, 2.05 mmol), was
added L-alanine methyl ester hydrochloride (163, 0.430 g,
3.08 mmol) and dry CH2Cl2 (10 ml). The reaction mixture was
cooled to 0°C, and NEt3 (0.311 g, 0.430 mL, 3.08 mmol) was
added dropwise, with the resulting suspension allowed to warm to room temperature
and stirred for 18 hours. Upon completion, the reaction mixture was diluted with
CH2Cl2 (10 mL), and the organic phase was washed with H2O (5 mL) and brine (5 mL).
Drying (Na2SO4) and evaporation in vacuo, followed by flash column chromatography
resulted in the isolation of 169 as a white solid. (0.447 g, 56%), M.p. 162-163°C
(decomp.) Rf 0.25 (1:1 Hexane:EtOAc.). 1H NMR (500 MHz, CDCl3) δ 6.93 (d, 1H,
J = 7.1 Hz, NH), 5.04 (t, 1H, J = 9.6 Hz, H4), 4.87 (t, 1H, J = 8.9 Hz, H2), 4.69 (d, 1H,
J = 8.8 Hz, H1), 4.54 (m, 1H, Hα), 3.94 (d, 1H, J = 9.9 Hz, H5), 3.83 (t, 1H, J = 9.2 Hz,
H4), 3.76 (s, 3H, OCH3), 2.16 (s, 3H, CH3, OAc), 2.13 (s, 3H, CH3, OAc), 1.43 (d, 3H,
J = 7.1 Hz, Hβ). 13C NMR (125 MHz, CDCl3) 172.9 (C=O), 170.3 (C=O, OAc), 170.2
(C=O, OAc), 165.8 (C=O, CONH), 87.9 (C1), 74.4 (C5), 72.9 (C4), 72.8 (C2), 71.5
(C3), 52.6 (OCH3), 47.8 (Cα), 20.8 (CH3, OAc), 20.8 (CH3, OAc), 18.1 (Cβ).
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LRMS (ESI): m/z 411 [M + Na]+ HRMS (ESI): m/z calculated for C14H20N4O9Na
[M + Na]+: 411.1128; Found 411.1165.

N-(1-Azido-2,4-di-O-acetyl-3-t-butyldimethylsilyl-β-D-glucopyranuronoyl)-Lalanine methyl ester (170)
169 (0.400 g, 1.03 mmol) and imidazole (0.281 g, 4.12 mmol)
were dissolved in dry DMF (10 mL) in a round bottom flask. The
reaction mixture was cooled to 0°C, and t-butyldimethylsilyl
chloride (0.310 g, 2.06 mmol) was added portionwise. The
reaction mixture was then flushed with argon, warmed to room temperature and allowed
to stir for 18 hours. Upon completion, the reaction mixture was diluted with H2O
(10 mL) and extracted with EtOAc (2 x 25 mL). The organic layers were pooled and
washed with brine (10 mL), dried (Na2SO4) and evaporated in vacuo, with the resulting
residue subjected to flash column chromatography, producing 170 as a white solid.
(0.343 g, 66%), M.p. 152-153°C Rf 0.85 (1:1 Hexane:EtOAc.)

1

H NMR (500 MHz,

CDCl3) δ 6.94 (d, 1H, J = 7.1 Hz, NH), 5.01 (t, 1H, J = 9.6 Hz, H4), 4.93 (t, 1H,
J = 8.9 Hz, H2), 4.53 (m, 2H, H1/Hα), 3.88 (m, 2H, H4/H5), 3.75 (s, 3H, OCH3), 2.13
(s, 3H, CH3, OAc), 2.10 (s, 3H, CH3, OAc), 1.42 (d, 3H, J = 7.1 Hz, Hβ), 0.81 (s, 9H,
Si-tBu), 0.05 (s, 6H, 2 x Si-CH3).

13

C NMR (125 MHz, CDCl3) 173.0 (C=O), 169.9

(C=O, OAc), 169.4 (C=O, OAc), 166.1 (C=O, CONH), 88.2 (C1), 74.9 (C5), 73.0 (C4),
72.9 (C2), 72.0 (C3), 52.8 (OCH3), 47.9 (Cα), 25.6 (C(CH3)3), 21.3 (CH3, OAc), 21.2
(CH3, OAc), 18.3 (Cβ), 18.0 (C(CH3)3), -4.4 (Si-CH3). LRMS (ESI): m/z 525 [M + Na]+
HRMS (ESI): m/z calculated for C20H34N4O9SiNa [M + Na]+: 525.1993;
Found 525.2014.
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1-(4’-(3”-Fluoropropyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetyl-β-D-glucuronic
acid allyl ester (173)
To a round bottom flask containing 74 (0.101 g,
0.215 mmol) dissolved in ACN (5 mL), was
added

C4F9SO2F

(0.132 g,

0.080

mL,

0.433 mmol) NEt3.3HF (0.069 g, 0.070 mL,
0.430 mmol) and NEt3 (0.131 g, 0.180 mL, 1.30 mmol). Under an argon atmosphere,
the reaction mixture was stirred at room temperature for 24 hours. Upon completion, the
reaction mixture was filtered through a short silica plug. The resulting solution was then
evaporated in vacuo, with purification by flash column chromatography (1:1 Hexane:
EtOAc) producing the desired product 173 as a light yellow solid. (0.059 g, 58 %). Rf
0.15 (1:1 Hexane:EtOAc), M.p 114-116°C. 1H NMR (500 MHz, CDCl3) δ 7.65 (s, 1H,
Triazole-H),

5.94-5.81

(m,

2H,

H1/CH2=CH-CH2),

5.48-5.27

(m,

5H,

H4/H3/H2/CH2=CH-CH2), 4.65 (m, 2H, CH2=CH-CH2), 4.51-4.42 (dt, 2H, J = 6.1 Hz,
47 Hz, CH2-CH2-CH2-F), 4.36 (d,1H, J = 9.8 Hz, H5), 2.87 (m, 2H, CH2-CH2-CH2-F),
2.17 (m, 2H, CH2-CH2-CH2-F), 2.05 (2s, 6H, OAc), 1.88 (s, 3H, OAc). 13C NMR (125
MHz, CDCl3) δ 170.0 (C=O, OAc), 169.6 (C=O, OAc), 169.1 (C=O, OAc), 165.8
(C=O), 147.9 (Triazole C), 131.0 (CH2-CH=CH2), 120.1 (Triazole C), 119.7(CH2CH=CH2), 85.6 (C1), 83.8-82.4 (d, J = 164.9 Hz, CH2-CH2-CH2-F), 75.1 (C5), 72.1
(C4), 70.2 (C3), 69.2 (C2), 67.2 (CH2-CH=CH2), 30.0-29.8 (d, J = 20.1 Hz, CH2-CH2CH2-F), 21.5 (CH2-CH2-CH2-F), 20.7 (CH3, OAc), 20.7 (CH3, OAc), 20.3 (CH3, OAc).
LRMS (ESI): m/z 494 [M + Na]+ HRMS (ESI): m/z calculated for C20H26FN3O9Na
[M + Na]+: 494.1551; Found 494.1574.
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N-(1-(4’-(3”-Fluoropropyl)-1’,2’,3’-triazol-1’-yl)-2,3,4-tri-O-acetyl-β-Dglucuronoyl)-L-methionine methyl ester (174)
To a round bottom flask containing 86 (0.100 g,
0.174 mmol) dissolved in ACN (5 mL), was
added

C4F9SO2F

(0.105 g,

0.063

mL,

0.348 mmol) NEt3.3HF (0.059 g, 0.060 mL,
0.352 mmol) and NEt3 (0.105 g, 0.145 mL, 1.04 mmol). Under an argon atmosphere,
the reaction mixture was stirred at room temperature for 24 hours. Upon completion, the
reaction mixture was filtered through a short silica plug. The resulting solution was then
evaporated in vacuo, with purification of the residue by flash column chromatography
(1:1 Hexane: EtOAc) producing the desired product 174 as a white solid (0.049mg,
49%). Rf 0.35 (1:1 Hexane:EtOAc), M.p 198-199°C. 1H NMR (500 MHz, CDCl3) δ
7.63 (s, 1H, Triazole-H), 7.06 (d, 1H, J = 7.6 Hz, NH), 5.94 (d, 1H, J = 9.5 Hz, H1),
5.55 (t, 1H, J = 9.7 Hz, H3), 5.49 (t, 1H, J = 9.7 Hz, H4), 5.35 (t, 1H, J = 9.7 Hz, H2),
4.64 (m, 1H, Hα), 4.27-4.25 (dt, 2H, J = 5.8 Hz, 52.9 Hz, CH2-CH2-CH2-F), 4.25 (d,
1H, J = 10.0 Hz, H5), 3.73 (s, 3H, OCH3), 2.89 (t, 2H, J = 7.3 Hz, CH2-CH2-CH2-F),
2.51 (t, 1H, J = 7.2 Hz, Hγ), 2.17-2.15 (m, 2H, Hβ), 2.09-2.04 (2s, 9H, 3 x OAc), 2.041.99, (m, 2H, CH2-CH2-CH2-F), 1.89 (s, 3H, SCH3).

13

C NMR (125 MHz, CD3OD) δ

172.1 (COOCH3), 169.9 (C=O, OAc), 169.7 (C=O, OAc), 169.1 (C=O, OAc), 165.4
(C=O), 148.0 (Triazole-C), 119.9 (Triazole-C), 85.3 (C1), 83.7-82.4 (d, J = 164.6 Hz,
CH2-CH2-CH2-F), 75.4 (C5), 72.2 (C2), 70.2 (C4), 69.2 (C3), 52.9 (Cα), 51.6 (-OCH3),
31.2 (Cβ), 30.0 (Cγ), 30.0-29.8 (d, J = 20.5 Hz, CH2-CH2-CH2-F), 21.7 (CH2-CH2-CH2F), 20.8 (CH3, OAc), 20.7 (CH3, OAc), 20.3 (CH3, OAc), 15.5 (SCH3).
LRMS (ESI): m/z 599 [M + Na]+ HRMS (ESI): m/z calculated for C23H33FN4O10SNa
[M + Na]+: 599.1799; Found 599.1808.
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